,Sentence,ESG BERT Topic 1,ESG BERT Topic 2,ESG BERT Topic 3,Mapped Criteria Topic 1,Mapped Criteria Topic 2,Mapped Criteria Topic 3
Line 1,"2021 Performance Report Advancing Science  for LifePatient spotlight: Arnold Vargas Gonzalez Not long after joining Boston Scientific, Arnold Vargas Gonzalez sensed it would be  more than just a job.
","('Business_Model_Resilience', 0.12671920657157898)","('Access_And_Affordability', 0.10534004867076874)","('Ecological_Impacts', 0.10001260042190552)","('NON-ESG', 0.12671920657157898)","('NON-ESG', 0.10534004867076874)","('NON-ESG', 0.10001260042190552)"
Line 2,"“The Boston Scientific quality culture inspired me right away,”  says the 39-year-old, who is based in Coyol, Costa Rica.
","('Business_Model_Resilience', 0.2305557131767273)","('Employee_Engagement_Inclusion_And_Diversity', 0.09367507696151733)","('Ecological_Impacts', 0.08452889323234558)","('NON-ESG', 0.2305557131767273)","('NON-ESG', 0.09367507696151733)","('NON-ESG', 0.08452889323234558)"
Line 3,"Arnold worked hard to progress from product builder to quality inspector, and with encouragement and support  from his leaders and colleagues, he pursued a degree in industrial engineering to advance his career in quality.
","('Product_Design_And_Lifecycle_Management', 0.8499873280525208)","('Product_Quality_And_Safety', 0.04082116484642029)","('Supply_Chain_Management', 0.01393898669630289)","(['Product Stewardship'], 0.8499873280525208)","('NON-ESG', 0.04082116484642029)","('NON-ESG', 0.01393898669630289)"
Line 4,"After earning a promotion to quality engineer, Arnold suffered gallbladder complications, which led to a critical  surgery.
","('Employee_Health_And_Safety', 0.7485968470573425)","('Employee_Engagement_Inclusion_And_Diversity', 0.04560968652367592)","('Access_And_Affordability', 0.02085711620748043)","(['Operational Eco-Efficiency'], 0.7485968470573425)","('NON-ESG', 0.04560968652367592)","('NON-ESG', 0.02085711620748043)"
Line 5,"When doctors showed him the stent they were using, he knew he would make a full recovery.
","('Employee_Health_And_Safety', 0.6783872246742249)","('Employee_Engagement_Inclusion_And_Diversity', 0.03480149060487747)","('Access_And_Affordability', 0.028640814125537872)","(['Operational Eco-Efficiency'], 0.6783872246742249)","('NON-ESG', 0.03480149060487747)","('NON-ESG', 0.028640814125537872)"
Line 6,"“I saw the  Boston Scientific logo and it gave me such peace of mind.
","('Employee_Engagement_Inclusion_And_Diversity', 0.18551665544509888)","('Business_Model_Resilience', 0.11765573173761368)","('Product_Design_And_Lifecycle_Management', 0.10656513273715973)","('NON-ESG', 0.18551665544509888)","('NON-ESG', 0.11765573173761368)","('NON-ESG', 0.10656513273715973)"
Line 7,"I believed in the device because we built it.” Arnold was  soon back on the quality front lines and to his studies.
","('Product_Design_And_Lifecycle_Management', 0.37250322103500366)","('Business_Model_Resilience', 0.14469227194786072)","('Employee_Engagement_Inclusion_And_Diversity', 0.059557463973760605)","('NON-ESG', 0.37250322103500366)","('NON-ESG', 0.14469227194786072)","('NON-ESG', 0.059557463973760605)"
Line 8,"In 2021, amid global uncertainty, Arnold and his team   stood strong — along with 41,000 Boston Scientific  colleagues around the world.
","('GHG_Emissions', 0.1631609946489334)","('Competitive_Behavior', 0.1597166210412979)","('Management_Of_Legal_And_Regulatory_Framework', 0.10748074948787689)","('NON-ESG', 0.1631609946489334)","('NON-ESG', 0.1597166210412979)","('NON-ESG', 0.10748074948787689)"
Line 9,"Across the company,  our people innovated to improve patient outcomes,  stay connected with customers and deliver solutions  wherever they were needed.
","('Access_And_Affordability', 0.4940657615661621)","('Customer_Welfare', 0.08522424101829529)","('Product_Design_And_Lifecycle_Management', 0.0443183071911335)","('NON-ESG', 0.4940657615661621)","('NON-ESG', 0.08522424101829529)","('NON-ESG', 0.0443183071911335)"
Line 10,"The collective resolve of our global team accelerated  our progress as a business and as a corporate citizen.
","('Human_Rights_And_Community_Relations', 0.6514506340026855)","('Business_Model_Resilience', 0.06309188157320023)","('Employee_Health_And_Safety', 0.030835861340165138)","(['Community Relations'], 0.6514506340026855)","('NON-ESG', 0.06309188157320023)","('NON-ESG', 0.030835861340165138)"
Line 11,"We found new ways to support our communities,  protect the environment we all share and make care  more equitable.
","('Human_Rights_And_Community_Relations', 0.5614123940467834)","('Ecological_Impacts', 0.27098751068115234)","('Water_And_Wastewater_Management', 0.017549164593219757)","(['Community Relations'], 0.5614123940467834)","('NON-ESG', 0.27098751068115234)","('NON-ESG', 0.017549164593219757)"
Line 12,"Like Arnold, we believe — in the power of doing our part,  always working for a better future and advancing science  for life.
","('Access_And_Affordability', 0.19630233943462372)","('Product_Design_And_Lifecycle_Management', 0.11652208864688873)","('Ecological_Impacts', 0.09455664455890656)","('NON-ESG', 0.19630233943462372)","('NON-ESG', 0.11652208864688873)","('NON-ESG', 0.09455664455890656)"
Line 13,"Arnold Vargas Gonzalez engineer,  Quality Assurance   and Boston Scientific patient“ I knew my future would be here,  making our products — always with   the patient in mind.” Arnold and his wife Eimy, who also works in manufacturing  at our Coyol site, are inspired to make life better for patients  every day.
","('Product_Design_And_Lifecycle_Management', 0.9244052767753601)","('Product_Quality_And_Safety', 0.01673082821071148)","('Customer_Welfare', 0.010313247330486774)","(['Product Stewardship'], 0.9244052767753601)","('NON-ESG', 0.01673082821071148)","('NON-ESG', 0.010313247330486774)"
Line 14,"2021 Performance ReportIntroduction Patient spotlight Table of contents A message from   our Chairman and   Chief Executive Officer Our mission and values Boston Scientific:   2021 at a glance Our ESG strategy 2021 highlights Awards and recognition Transforming care Investing in   our people Accelerating   possibilities Protecting the  environment Creating value  responsibly Appendix This report has been prepared in reference to the Global  Reporting Initiative guidelines and the SASB standards  for the Medical Equipment & Supplies industry.
","('Management_Of_Legal_And_Regulatory_Framework', 0.3336941599845886)","('Access_And_Affordability', 0.2215932458639145)","('Product_Quality_And_Safety', 0.11531154066324234)","('NON-ESG', 0.3336941599845886)","('NON-ESG', 0.2215932458639145)","('NON-ESG', 0.11531154066324234)"
Line 15,"2021 Performance ReportIntroduction Patient spotlight Table of contents A message from   our Chairman and   Chief Executive Officer Our mission and values Boston Scientific:   2021 at a glance Our ESG strategy 2021 highlights Awards and recognition Transforming care Investing in   our people Accelerating   possibilities Protecting the  environment Creating value  responsibly Appendix This report has been prepared in reference to the Global  Reporting Initiative guidelines and the SASB standards  for the Medical Equipment & Supplies industry.
","('Supply_Chain_Management', 0.7354018092155457)","('Energy_Management', 0.055288225412368774)","('Waste_And_Hazardous_Materials_Management', 0.023727359250187874)","(['Supply Chain Management'], 0.7354018092155457)","('NON-ESG', 0.055288225412368774)","('NON-ESG', 0.023727359250187874)"
Line 16,"Unless  otherwise indicated, data in this 2021 Performance  Report and appendix are as of December 31, 2021, or  for the year ended December 31, 2021, as applicable.
","('Management_Of_Legal_And_Regulatory_Framework', 0.585196316242218)","('Physical_Impacts_Of_Climate_Change', 0.05050257593393326)","('Systemic_Risk_Management', 0.04853016510605812)","(['Corporate Governance'], 0.585196316242218)","('NON-ESG', 0.05050257593393326)","('NON-ESG', 0.04853016510605812)"
Line 17,"Please refer to the appendix for detailed metrics and  key definitions used within this report.
","('Management_Of_Legal_And_Regulatory_Framework', 0.6755912899971008)","('Systemic_Risk_Management', 0.038310810923576355)","('Access_And_Affordability', 0.037136513739824295)","(['Corporate Governance'], 0.6755912899971008)","('NON-ESG', 0.038310810923576355)","('NON-ESG', 0.037136513739824295)"
Line 18,"Reporting on  other matters specific to financial performance of the  company and its subsidiaries can be found in our  2021 Annual Report.Table of contents Patient spotlight: Arnold Vargas Gonzalez A message from our Chairman   and Chief Executive Officer Our mission and values  Boston Scientific: 2021 at a glance  Our ESG strategy: Advancing science for life  2021 highlights  Awards and recognition  Transforming care   Innovating to meet more patient needs   Ensuring quality, health and safety    Improving access and outcomes  through digital solutions  Investing in our people   Our diverse, equitable and inclusive workplace   Attracting, developing and retaining talent   Employee well-being, rewards and safety  Accelerating possibilities   Improving health equity and access   Confronting inequities   Supporting our communities  36Protecting the environment   Reducing our environmental impact   Managing climate risk    Advancing product stewardship   Creating value responsibly  48   Good governance reflects our values   Compliance, ethics and integrity    Protecting human rights across our   company and supply chain   Keeping our supply chain resilient and reliable   Risk management and global security   Keeping our products and patient data secure  Appendix   Stakeholder engagement   Metrics summary   Global Reporting Initiative (GRI) index   Sustainability Accounting Standards Board  (SASB) index   United Nations Sustainable Development  Goals (SDGs)  2021 Performance ReportIntroduction Patient spotlight Table of contents A message from   our Chairman and   Chief Executive Officer Our mission and values Boston Scientific:   2021 at a glance Our ESG strategy 2021 highlights Awards and recognition Transforming care Investing in   our people Accelerating   possibilities Protecting the  environment Creating value  responsibly Appendix A message from our   Chairman and Chief Executive Officer We remain confident in our progress and committed to  transforming care, investing in our people, accelerating  possibilities, protecting the environment and creating value  responsibly.
","('Product_Quality_And_Safety', 0.7010924220085144)","('Product_Design_And_Lifecycle_Management', 0.06746430695056915)","('Customer_Welfare', 0.043527934700250626)","(['Product Quality & Recall Management'], 0.7010924220085144)","('NON-ESG', 0.06746430695056915)","('NON-ESG', 0.043527934700250626)"
Line 19,"Reporting on  other matters specific to financial performance of the  company and its subsidiaries can be found in our  2021 Annual Report.Table of contents Patient spotlight: Arnold Vargas Gonzalez A message from our Chairman   and Chief Executive Officer Our mission and values  Boston Scientific: 2021 at a glance  Our ESG strategy: Advancing science for life  2021 highlights  Awards and recognition  Transforming care   Innovating to meet more patient needs   Ensuring quality, health and safety    Improving access and outcomes  through digital solutions  Investing in our people   Our diverse, equitable and inclusive workplace   Attracting, developing and retaining talent   Employee well-being, rewards and safety  Accelerating possibilities   Improving health equity and access   Confronting inequities   Supporting our communities  36Protecting the environment   Reducing our environmental impact   Managing climate risk    Advancing product stewardship   Creating value responsibly  48   Good governance reflects our values   Compliance, ethics and integrity    Protecting human rights across our   company and supply chain   Keeping our supply chain resilient and reliable   Risk management and global security   Keeping our products and patient data secure  Appendix   Stakeholder engagement   Metrics summary   Global Reporting Initiative (GRI) index   Sustainability Accounting Standards Board  (SASB) index   United Nations Sustainable Development  Goals (SDGs)  2021 Performance ReportIntroduction Patient spotlight Table of contents A message from   our Chairman and   Chief Executive Officer Our mission and values Boston Scientific:   2021 at a glance Our ESG strategy 2021 highlights Awards and recognition Transforming care Investing in   our people Accelerating   possibilities Protecting the  environment Creating value  responsibly Appendix A message from our   Chairman and Chief Executive Officer We remain confident in our progress and committed to  transforming care, investing in our people, accelerating  possibilities, protecting the environment and creating value  responsibly.
","('Employee_Engagement_Inclusion_And_Diversity', 0.7212581038475037)","('Human_Rights_And_Community_Relations', 0.09098558127880096)","('Access_And_Affordability', 0.04598716273903847)","(['Human Capital Development'], 0.7212581038475037)","('NON-ESG', 0.09098558127880096)","('NON-ESG', 0.04598716273903847)"
Line 20,"Reporting on  other matters specific to financial performance of the  company and its subsidiaries can be found in our  2021 Annual Report.Table of contents Patient spotlight: Arnold Vargas Gonzalez A message from our Chairman   and Chief Executive Officer Our mission and values  Boston Scientific: 2021 at a glance  Our ESG strategy: Advancing science for life  2021 highlights  Awards and recognition  Transforming care   Innovating to meet more patient needs   Ensuring quality, health and safety    Improving access and outcomes  through digital solutions  Investing in our people   Our diverse, equitable and inclusive workplace   Attracting, developing and retaining talent   Employee well-being, rewards and safety  Accelerating possibilities   Improving health equity and access   Confronting inequities   Supporting our communities  36Protecting the environment   Reducing our environmental impact   Managing climate risk    Advancing product stewardship   Creating value responsibly  48   Good governance reflects our values   Compliance, ethics and integrity    Protecting human rights across our   company and supply chain   Keeping our supply chain resilient and reliable   Risk management and global security   Keeping our products and patient data secure  Appendix   Stakeholder engagement   Metrics summary   Global Reporting Initiative (GRI) index   Sustainability Accounting Standards Board  (SASB) index   United Nations Sustainable Development  Goals (SDGs)  2021 Performance ReportIntroduction Patient spotlight Table of contents A message from   our Chairman and   Chief Executive Officer Our mission and values Boston Scientific:   2021 at a glance Our ESG strategy 2021 highlights Awards and recognition Transforming care Investing in   our people Accelerating   possibilities Protecting the  environment Creating value  responsibly Appendix A message from our   Chairman and Chief Executive Officer We remain confident in our progress and committed to  transforming care, investing in our people, accelerating  possibilities, protecting the environment and creating value  responsibly.
","('Supply_Chain_Management', 0.8981386423110962)","('Business_Model_Resilience', 0.020388567820191383)","('Product_Design_And_Lifecycle_Management', 0.016606392338871956)","(['Supply Chain Management'], 0.8981386423110962)","('NON-ESG', 0.020388567820191383)","('NON-ESG', 0.016606392338871956)"
Line 21,"Reporting on  other matters specific to financial performance of the  company and its subsidiaries can be found in our  2021 Annual Report.Table of contents Patient spotlight: Arnold Vargas Gonzalez A message from our Chairman   and Chief Executive Officer Our mission and values  Boston Scientific: 2021 at a glance  Our ESG strategy: Advancing science for life  2021 highlights  Awards and recognition  Transforming care   Innovating to meet more patient needs   Ensuring quality, health and safety    Improving access and outcomes  through digital solutions  Investing in our people   Our diverse, equitable and inclusive workplace   Attracting, developing and retaining talent   Employee well-being, rewards and safety  Accelerating possibilities   Improving health equity and access   Confronting inequities   Supporting our communities  36Protecting the environment   Reducing our environmental impact   Managing climate risk    Advancing product stewardship   Creating value responsibly  48   Good governance reflects our values   Compliance, ethics and integrity    Protecting human rights across our   company and supply chain   Keeping our supply chain resilient and reliable   Risk management and global security   Keeping our products and patient data secure  Appendix   Stakeholder engagement   Metrics summary   Global Reporting Initiative (GRI) index   Sustainability Accounting Standards Board  (SASB) index   United Nations Sustainable Development  Goals (SDGs)  2021 Performance ReportIntroduction Patient spotlight Table of contents A message from   our Chairman and   Chief Executive Officer Our mission and values Boston Scientific:   2021 at a glance Our ESG strategy 2021 highlights Awards and recognition Transforming care Investing in   our people Accelerating   possibilities Protecting the  environment Creating value  responsibly Appendix A message from our   Chairman and Chief Executive Officer We remain confident in our progress and committed to  transforming care, investing in our people, accelerating  possibilities, protecting the environment and creating value  responsibly.
","('Human_Rights_And_Community_Relations', 0.32575032114982605)","('Access_And_Affordability', 0.2459360957145691)","('Business_Model_Resilience', 0.06201187148690224)","('NON-ESG', 0.32575032114982605)","('NON-ESG', 0.2459360957145691)","('NON-ESG', 0.06201187148690224)"
Line 22,"Reporting on  other matters specific to financial performance of the  company and its subsidiaries can be found in our  2021 Annual Report.Table of contents Patient spotlight: Arnold Vargas Gonzalez A message from our Chairman   and Chief Executive Officer Our mission and values  Boston Scientific: 2021 at a glance  Our ESG strategy: Advancing science for life  2021 highlights  Awards and recognition  Transforming care   Innovating to meet more patient needs   Ensuring quality, health and safety    Improving access and outcomes  through digital solutions  Investing in our people   Our diverse, equitable and inclusive workplace   Attracting, developing and retaining talent   Employee well-being, rewards and safety  Accelerating possibilities   Improving health equity and access   Confronting inequities   Supporting our communities  36Protecting the environment   Reducing our environmental impact   Managing climate risk    Advancing product stewardship   Creating value responsibly  48   Good governance reflects our values   Compliance, ethics and integrity    Protecting human rights across our   company and supply chain   Keeping our supply chain resilient and reliable   Risk management and global security   Keeping our products and patient data secure  Appendix   Stakeholder engagement   Metrics summary   Global Reporting Initiative (GRI) index   Sustainability Accounting Standards Board  (SASB) index   United Nations Sustainable Development  Goals (SDGs)  2021 Performance ReportIntroduction Patient spotlight Table of contents A message from   our Chairman and   Chief Executive Officer Our mission and values Boston Scientific:   2021 at a glance Our ESG strategy 2021 highlights Awards and recognition Transforming care Investing in   our people Accelerating   possibilities Protecting the  environment Creating value  responsibly Appendix A message from our   Chairman and Chief Executive Officer We remain confident in our progress and committed to  transforming care, investing in our people, accelerating  possibilities, protecting the environment and creating value  responsibly.
","('Ecological_Impacts', 0.8981552124023438)","('Human_Rights_And_Community_Relations', 0.018045924603939056)","('Business_Model_Resilience', 0.01272647362202406)","(['Natural Capital'], 0.8981552124023438)","('NON-ESG', 0.018045924603939056)","('NON-ESG', 0.01272647362202406)"
Line 23,"Our 2021 performance report is one example  of our efforts to be transparent and accountable to the  public and our many stakeholders.
","('Management_Of_Legal_And_Regulatory_Framework', 0.7262593507766724)","('Business_Ethics', 0.12842735648155212)","('Human_Rights_And_Community_Relations', 0.027270076796412468)","(['Corporate Governance'], 0.7262593507766724)","('NON-ESG', 0.12842735648155212)","('NON-ESG', 0.027270076796412468)"
Line 24,"We are committed  to understanding and managing environmental, social  and governance (ESG) opportunities and risks in our  business practices.
","('Human_Rights_And_Community_Relations', 0.3733119070529938)","('Business_Model_Resilience', 0.18943080306053162)","('Physical_Impacts_Of_Climate_Change', 0.09364095330238342)","('NON-ESG', 0.3733119070529938)","('NON-ESG', 0.18943080306053162)","('NON-ESG', 0.09364095330238342)"
Line 25,"Overall, performance across Boston Scientific businesses  remains strong and our future is promising.
","('Business_Model_Resilience', 0.6605960726737976)","('Systemic_Risk_Management', 0.1563757210969925)","('Competitive_Behavior', 0.018063979223370552)","(['Codes of Business Conduct'], 0.6605960726737976)","('NON-ESG', 0.1563757210969925)","('NON-ESG', 0.018063979223370552)"
Line 26,"We’ve  accomplished a great deal as we learned to manage  through the pandemic.
","('Physical_Impacts_Of_Climate_Change', 0.4319419860839844)","('Air_Quality', 0.0970323458313942)","('Systemic_Risk_Management', 0.07453081756830215)","('NON-ESG', 0.4319419860839844)","('NON-ESG', 0.0970323458313942)","('NON-ESG', 0.07453081756830215)"
Line 27,"In 2021, we invested more than   $1 billion in research and development and launched  90 new products to advance patient care.
","('Product_Design_And_Lifecycle_Management', 0.8984161615371704)","('Customer_Welfare', 0.02368997409939766)","('Product_Quality_And_Safety', 0.015460705384612083)","(['Product Stewardship'], 0.8984161615371704)","('NON-ESG', 0.02368997409939766)","('NON-ESG', 0.015460705384612083)"
Line 28,"We strengthened  our digital capabilities to enhance patient engagement  to facilitate remote education and training for health care  providers.
","('Access_And_Affordability', 0.8577389717102051)","('Product_Quality_And_Safety', 0.013713388703763485)","('Employee_Engagement_Inclusion_And_Diversity', 0.01172338705509901)","(['Health Outcome Contribution'], 0.8577389717102051)","('NON-ESG', 0.013713388703763485)","('NON-ESG', 0.01172338705509901)"
Line 29,"Our teams conducted 145 global clinical trials and  received approximately 1,250 market approvals that expand  access to our technologies.
","('Competitive_Behavior', 0.17212456464767456)","('Access_And_Affordability', 0.1640079766511917)","('Customer_Welfare', 0.09323045611381531)","('NON-ESG', 0.17212456464767456)","('NON-ESG', 0.1640079766511917)","('NON-ESG', 0.09323045611381531)"
Line 30,"Above all, we improved the lives  of more than 30 million patients.At Boston Scientific, we have always been dedicated to advancing science for life.
","('Access_And_Affordability', 0.49430081248283386)","('Employee_Engagement_Inclusion_And_Diversity', 0.07981225103139877)","('Customer_Welfare', 0.05291401222348213)","('NON-ESG', 0.49430081248283386)","('NON-ESG', 0.07981225103139877)","('NON-ESG', 0.05291401222348213)"
Line 31,"Now more than ever — at a time when we face continued challenges and uncertainty  as a global community — we are hopeful and united by our mission and values to  create a healthier, brighter future for one another and for our planet.
","('Human_Rights_And_Community_Relations', 0.656920313835144)","('Business_Model_Resilience', 0.10734613984823227)","('Access_And_Affordability', 0.02560841292142868)","(['Community Relations'], 0.656920313835144)","('NON-ESG', 0.10734613984823227)","('NON-ESG', 0.02560841292142868)"
Line 32,"Mike Mahoney  Chairman and Chief Executive Officer,   Boston Scientific“ Working together, we can  continue to transform lives around  the world through innovative  medical solutions.” 2021 Performance ReportIntroduction Patient spotlight Table of contents A message from   our Chairman and   Chief Executive Officer Our mission and values Boston Scientific:   2021 at a glance Our ESG strategy 2021 highlights Awards and recognition Transforming care Investing in   our people Accelerating   possibilities Protecting the  environment Creating value  responsibly Appendix Addressing inequities in workplaces, communities   and health care systems  The inequities in our workplaces, communities and health care systems have been starkly  revealed over the last few years — by the pandemic, polarizing political environments,  racial and social injustice and economic uncertainty.
","('Access_And_Affordability', 0.32774633169174194)","('Business_Model_Resilience', 0.10695132613182068)","('Product_Design_And_Lifecycle_Management', 0.09332972764968872)","('NON-ESG', 0.32774633169174194)","('NON-ESG', 0.10695132613182068)","('NON-ESG', 0.09332972764968872)"
Line 33,"Mike Mahoney  Chairman and Chief Executive Officer,   Boston Scientific“ Working together, we can  continue to transform lives around  the world through innovative  medical solutions.” 2021 Performance ReportIntroduction Patient spotlight Table of contents A message from   our Chairman and   Chief Executive Officer Our mission and values Boston Scientific:   2021 at a glance Our ESG strategy 2021 highlights Awards and recognition Transforming care Investing in   our people Accelerating   possibilities Protecting the  environment Creating value  responsibly Appendix Addressing inequities in workplaces, communities   and health care systems  The inequities in our workplaces, communities and health care systems have been starkly  revealed over the last few years — by the pandemic, polarizing political environments,  racial and social injustice and economic uncertainty.
","('Human_Rights_And_Community_Relations', 0.8468159437179565)","('Employee_Health_And_Safety', 0.018661895766854286)","('Employee_Engagement_Inclusion_And_Diversity', 0.01851746253669262)","(['Community Relations'], 0.8468159437179565)","('NON-ESG', 0.018661895766854286)","('NON-ESG', 0.01851746253669262)"
Line 34,"We have committed to support  diversity, address health inequities and combat systemic racism and injustice both within  Boston Scientific and our communities.
","('Employee_Engagement_Inclusion_And_Diversity', 0.8908944725990295)","('Business_Ethics', 0.02546328492462635)","('Human_Rights_And_Community_Relations', 0.009456094354391098)","(['Human Capital Development'], 0.8908944725990295)","('NON-ESG', 0.02546328492462635)","('NON-ESG', 0.009456094354391098)"
Line 35,"In 2021, we made progress toward our goals by  taking the following actions: • Deepened our diversity programs aimed at eliminating bias, racism and other forms of  discrimination in our workplace as part of our 3Up by 2023 initiative, which is aimed at  increasing representation of women and multicultural talent at the management level.
","('Employee_Engagement_Inclusion_And_Diversity', 0.975913941860199)","('Employee_Health_And_Safety', 0.0018983212066814303)","('Human_Rights_And_Community_Relations', 0.0016551002627238631)","(['Human Capital Development'], 0.975913941860199)","('NON-ESG', 0.0018983212066814303)","('NON-ESG', 0.0016551002627238631)"
Line 36,"• Introduced a human capital scorecard as part of our 2021 annual bonus program to  hold ourselves accountable for building a more diverse and inclusive workplace and  achieving our environmental goals.
","('Employee_Engagement_Inclusion_And_Diversity', 0.9438930749893188)","('Human_Rights_And_Community_Relations', 0.012172484770417213)","('Business_Model_Resilience', 0.004022091161459684)","(['Human Capital Development'], 0.9438930749893188)","('NON-ESG', 0.012172484770417213)","('NON-ESG', 0.004022091161459684)"
Line 37,"• Expanded relationships with certified companies that share our dedication to  improving customer and patient care, which included investing more than   $865 million in small and diverse suppliers to help us meet our business objectives  through external collaborations.
","('Supply_Chain_Management', 0.3426873981952667)","('Product_Design_And_Lifecycle_Management', 0.15781520307064056)","('Customer_Welfare', 0.15573053061962128)","('NON-ESG', 0.3426873981952667)","('NON-ESG', 0.15781520307064056)","('NON-ESG', 0.15573053061962128)"
Line 38,"• Extended our advocacy across 28 national and local organizations as part of the second  year of a $3.5 million multiyear strategy to combat inequity, systemic racism and  injustice in the U.S.  • Increased diversity in medical research and partnered with community health care  providers to expand awareness of health disparities and address them through our  Close the Gap health equity initiative.
","('Employee_Engagement_Inclusion_And_Diversity', 0.8879621028900146)","('Business_Ethics', 0.01670009270310402)","('Employee_Health_And_Safety', 0.011242011561989784)","(['Human Capital Development'], 0.8879621028900146)","('NON-ESG', 0.01670009270310402)","('NON-ESG', 0.011242011561989784)"
Line 39,"• Contributed more than $75 million in corporate donations to fund medical research,  fellowships, education and charitable organizations globally.Taking action for a healthier planet By protecting the planet’s health, we protect human health.
","('Employee_Health_And_Safety', 0.4257619082927704)","('Access_And_Affordability', 0.2470104694366455)","('Critical_Incident_Risk_Management', 0.04346046224236488)","('NON-ESG', 0.4257619082927704)","('NON-ESG', 0.2470104694366455)","('NON-ESG', 0.04346046224236488)"
Line 40,"That’s why sustainable and inclusive  business practices are central to our work to transform lives.
","('Employee_Engagement_Inclusion_And_Diversity', 0.3854118287563324)","('Human_Rights_And_Community_Relations', 0.20092938840389252)","('Business_Model_Resilience', 0.09609530121088028)","('NON-ESG', 0.3854118287563324)","('NON-ESG', 0.20092938840389252)","('NON-ESG', 0.09609530121088028)"
Line 41,"We are on track to achieve carbon neutrality by 2030 in all manufacturing and key distribution  sites.
","('Energy_Management', 0.3147638142108917)","('GHG_Emissions', 0.27743199467658997)","('Management_Of_Legal_And_Regulatory_Framework', 0.08394133299589157)","('NON-ESG', 0.3147638142108917)","('NON-ESG', 0.27743199467658997)","('NON-ESG', 0.08394133299589157)"
Line 42,"In 2021, we committed to setting new science-based targets and reaching net-zero carbon  emissions across our entire value chain by 2050.
","('GHG_Emissions', 0.8434963226318359)","('Air_Quality', 0.03844190761446953)","('Energy_Management', 0.03579343855381012)","(['Climate Change'], 0.8434963226318359)","('NON-ESG', 0.03844190761446953)","('NON-ESG', 0.03579343855381012)"
Line 43,"So far, we’ve cut our energy usage by investing in and increasing energy efficiency at all of  our sites.
","('Energy_Management', 0.9804052114486694)","('Air_Quality', 0.0022847631480544806)","('Critical_Incident_Risk_Management', 0.0015883600572124124)","(['Operational Eco-Efficiency'], 0.9804052114486694)","('NON-ESG', 0.0022847631480544806)","('NON-ESG', 0.0015883600572124124)"
Line 44,"This includes new construction that meets the highest climate standards.
","('Physical_Impacts_Of_Climate_Change', 0.7707058787345886)","('Business_Model_Resilience', 0.04716583341360092)","('GHG_Emissions', 0.03758227080106735)","(['Climate Change'], 0.7707058787345886)","('NON-ESG', 0.04716583341360092)","('NON-ESG', 0.03758227080106735)"
Line 45,"Nearly half  of Boston Scientific real estate — more than 4 million global square feet — currently meets  International Organization for Standardization (ISO) and Leadership in Energy and Environmental  Design (LEED) energy and environmental standards.
","('Energy_Management', 0.7467328310012817)","('Product_Design_And_Lifecycle_Management', 0.09174662083387375)","('Product_Quality_And_Safety', 0.02313324436545372)","(['Operational Eco-Efficiency'], 0.7467328310012817)","('NON-ESG', 0.09174662083387375)","('NON-ESG', 0.02313324436545372)"
Line 46,"We are also converting to renewable  energy.
","('Energy_Management', 0.9549130201339722)","('Management_Of_Legal_And_Regulatory_Framework', 0.01115464512258768)","('Product_Design_And_Lifecycle_Management', 0.003689291886985302)","(['Operational Eco-Efficiency'], 0.9549130201339722)","('NON-ESG', 0.01115464512258768)","('NON-ESG', 0.003689291886985302)"
Line 47,"In 2021, 73% of our electricity came from renewable sources (exceeding our interim  goal of 50% by 2021) and we aim to source or generate 100% of our electricity from renewable  sources by 2024.1,2 We are also pursuing efforts to better manage or reduce waste, conserve  water and increase medical device recycling to minimize environmental impact of our products  and packaging.
","('Product_Design_And_Lifecycle_Management', 0.9389822483062744)","('Waste_And_Hazardous_Materials_Management', 0.009291434660553932)","('Energy_Management', 0.009148858487606049)","(['Product Stewardship'], 0.9389822483062744)","('NON-ESG', 0.009291434660553932)","('NON-ESG', 0.009148858487606049)"
Line 48,"To better protect our business and customers from climate-related disruption,  our climate risk approach entails oversight, risk management and mitigation efforts throughout  our business.
","('Physical_Impacts_Of_Climate_Change', 0.953671932220459)","('Business_Model_Resilience', 0.010063286870718002)","('GHG_Emissions', 0.0037556535098701715)","(['Climate Change'], 0.953671932220459)","('NON-ESG', 0.010063286870718002)","('NON-ESG', 0.0037556535098701715)"
Line 49,"Creating a healthier, more equitable future We have much work to do but we are making meaningful progress.
","('Human_Rights_And_Community_Relations', 0.200748473405838)","('Access_And_Affordability', 0.18576085567474365)","('Business_Model_Resilience', 0.11041171103715897)","('NON-ESG', 0.200748473405838)","('NON-ESG', 0.18576085567474365)","('NON-ESG', 0.11041171103715897)"
Line 50,"The spirit and commitment  of our global team has enabled us to succeed during uncertain times.
","('Business_Model_Resilience', 0.2857350707054138)","('Human_Rights_And_Community_Relations', 0.20303644239902496)","('Employee_Engagement_Inclusion_And_Diversity', 0.11135482043027878)","('NON-ESG', 0.2857350707054138)","('NON-ESG', 0.20303644239902496)","('NON-ESG', 0.11135482043027878)"
Line 51,"We have a robust portfolio  and pipeline, ambitious research and development, the highest quality standards and a deeply  talented global team.
","('Access_And_Affordability', 0.14993321895599365)","('Employee_Engagement_Inclusion_And_Diversity', 0.14733247458934784)","('Business_Model_Resilience', 0.09196890145540237)","('NON-ESG', 0.14993321895599365)","('NON-ESG', 0.14733247458934784)","('NON-ESG', 0.09196890145540237)"
Line 52,"Working together, we can continue to transform lives around the world  through innovative medical solutions.
","('Product_Design_And_Lifecycle_Management', 0.3965831696987152)","('Access_And_Affordability', 0.14611010253429413)","('Customer_Welfare', 0.07505578547716141)","('NON-ESG', 0.3965831696987152)","('NON-ESG', 0.14611010253429413)","('NON-ESG', 0.07505578547716141)"
Line 53,"Mike Mahoney  Chairman and Chief Executive Officer,   Boston Scientific   1 Inclusive of all manufacturing and key distribution sites only.
","('Supply_Chain_Management', 0.2690931260585785)","('Product_Design_And_Lifecycle_Management', 0.22978739440441132)","('Customer_Welfare', 0.08930209279060364)","('NON-ESG', 0.2690931260585785)","('NON-ESG', 0.22978739440441132)","('NON-ESG', 0.08930209279060364)"
Line 54,"2 Reflects adjustments to previously reported figure of 72% renewable electricity   in our 2022 Annual Proxy Statement, based on subsequent internal audit.
","('Energy_Management', 0.7197604179382324)","('Management_Of_Legal_And_Regulatory_Framework', 0.20667418837547302)","('GHG_Emissions', 0.008425294421613216)","(['Operational Eco-Efficiency'], 0.7197604179382324)","('NON-ESG', 0.20667418837547302)","('NON-ESG', 0.008425294421613216)"
Line 55,"2021 Performance ReportIntroduction Patient spotlight Table of contents A message from   our Chairman and   Chief Executive Officer Our mission and values Boston Scientific:   2021 at a glance Our ESG strategy 2021 highlights Awards and recognition Transforming care Investing in   our people Accelerating   possibilities Protecting the  environment Creating value  responsibly Appendix Our mission  and values Boston Scientific is dedicated to  transforming lives through innovative  medical solutions that improve the  health of patients around the world.
","('Access_And_Affordability', 0.3333435356616974)","('Product_Design_And_Lifecycle_Management', 0.11017037183046341)","('Customer_Welfare', 0.09877719730138779)","('NON-ESG', 0.3333435356616974)","('NON-ESG', 0.11017037183046341)","('NON-ESG', 0.09877719730138779)"
Line 56,"2021 Performance ReportIntroduction Patient spotlight Table of contents A message from   our Chairman and   Chief Executive Officer Our mission and values Boston Scientific:   2021 at a glance Our ESG strategy 2021 highlights Awards and recognition Transforming care Investing in   our people Accelerating   possibilities Protecting the  environment Creating value  responsibly Appendix Our mission  and values Boston Scientific is dedicated to  transforming lives through innovative  medical solutions that improve the  health of patients around the world.
","('Employee_Health_And_Safety', 0.23707149922847748)","('Access_And_Affordability', 0.23086902499198914)","('Customer_Welfare', 0.06307346373796463)","('NON-ESG', 0.23707149922847748)","('NON-ESG', 0.23086902499198914)","('NON-ESG', 0.06307346373796463)"
Line 57,"Our work is guided by core values that  define the Boston Scientific culture  and empower our employees.Meaningful innovation We foster an environment of creativity to transform new  ideas into breakthrough services and solutions that create  value for patients, customers and employees.
","('Product_Design_And_Lifecycle_Management', 0.28280362486839294)","('Business_Model_Resilience', 0.24250569939613342)","('Employee_Engagement_Inclusion_And_Diversity', 0.0938216969370842)","('NON-ESG', 0.28280362486839294)","('NON-ESG', 0.24250569939613342)","('NON-ESG', 0.0938216969370842)"
Line 58,"Diversity We embrace diversity and value the unique  talents, ideas and experiences of our employees.High performance We strive for high performance to benefit  our patients, clinicians and shareholders.
","('Employee_Engagement_Inclusion_And_Diversity', 0.9735345840454102)","('Employee_Health_And_Safety', 0.002682833932340145)","('Human_Rights_And_Community_Relations', 0.0016615359345450997)","(['Human Capital Development'], 0.9735345840454102)","('NON-ESG', 0.002682833932340145)","('NON-ESG', 0.0016615359345450997)"
Line 59,"Winning spirit We adapt to change and act with speed, agility  and accountability to further improve patient care.Caring We act with integrity and compassion to support  patients, customers, our communities and each other.
","('Human_Rights_And_Community_Relations', 0.5446312427520752)","('Access_And_Affordability', 0.1656891405582428)","('Business_Ethics', 0.04290805011987686)","(['Community Relations'], 0.5446312427520752)","('NON-ESG', 0.1656891405582428)","('NON-ESG', 0.04290805011987686)"
Line 60,"Global collaboration We work collaboratively to pursue global opportunities  that extend the reach of our medical solutions.
","('Access_And_Affordability', 0.28935107588768005)","('Human_Rights_And_Community_Relations', 0.08261740952730179)","('Business_Model_Resilience', 0.06724892556667328)","('NON-ESG', 0.28935107588768005)","('NON-ESG', 0.08261740952730179)","('NON-ESG', 0.06724892556667328)"
Line 61,"2021 Performance ReportIntroduction Patient spotlight Table of contents A message from   our Chairman and   Chief Executive Officer Our mission and values Boston Scientific:   2021 at a glance Our ESG strategy 2021 highlights Awards and recognition Transforming care Investing in   our people Accelerating   possibilities Protecting the  environment Creating value  responsibly Appendix U.S. $6,EMEA (Europe, Middle East and Africa) $2,APAC (Asia-Pacific) $2,LACA (Latin America and Canada) $Medical Devices1 $11,Specialty Pharmaceuticals2 $Net Sales $11,888Boston Scientific: 2021 at a glance Boston Scientific transforms lives through innovative medical solutions that improve the health of patients around the world.
","('Access_And_Affordability', 0.2175096869468689)","('Business_Model_Resilience', 0.1550396978855133)","('Management_Of_Legal_And_Regulatory_Framework', 0.09517843276262283)","('NON-ESG', 0.2175096869468689)","('NON-ESG', 0.1550396978855133)","('NON-ESG', 0.09517843276262283)"
Line 62,"2021 Performance ReportIntroduction Patient spotlight Table of contents A message from   our Chairman and   Chief Executive Officer Our mission and values Boston Scientific:   2021 at a glance Our ESG strategy 2021 highlights Awards and recognition Transforming care Investing in   our people Accelerating   possibilities Protecting the  environment Creating value  responsibly Appendix U.S. $6,EMEA (Europe, Middle East and Africa) $2,APAC (Asia-Pacific) $2,LACA (Latin America and Canada) $Medical Devices1 $11,Specialty Pharmaceuticals2 $Net Sales $11,888Boston Scientific: 2021 at a glance Boston Scientific transforms lives through innovative medical solutions that improve the health of patients around the world.
","('Product_Design_And_Lifecycle_Management', 0.2915022075176239)","('Customer_Welfare', 0.23478570580482483)","('Access_And_Affordability', 0.08872058987617493)","('NON-ESG', 0.2915022075176239)","('NON-ESG', 0.23478570580482483)","('NON-ESG', 0.08872058987617493)"
Line 63,"As a global medical technology leader for more than  40 years, we advance science for life by providing a broad range of high-performance solutions that address unmet patient needs and reduce the cost of health care.
","('Energy_Management', 0.2465939074754715)","('Access_And_Affordability', 0.2022417038679123)","('Product_Design_And_Lifecycle_Management', 0.11001111567020416)","('NON-ESG', 0.2465939074754715)","('NON-ESG', 0.2022417038679123)","('NON-ESG', 0.11001111567020416)"
Line 64,"2021 net sales by region  (dollars in millions)2021 net sales by business  (dollars in millions) 1  We have three historical reportable segments comprised of Medical Surgical (MedSurg), Rhythm and Neuro, and Cardiovascular, which  represent an aggregation of our operating segments that generate revenues from the sale of medical devices.
","('Customer_Welfare', 0.3411700129508972)","('Product_Design_And_Lifecycle_Management', 0.23315127193927765)","('Energy_Management', 0.07524611055850983)","('NON-ESG', 0.3411700129508972)","('NON-ESG', 0.23315127193927765)","('NON-ESG', 0.07524611055850983)"
Line 65,"In the first quarter of  2022, we reorganized our operational structure in order to strengthen our category leadership in the markets we serve and, in particular,  benefit our Cardiology customers and patients.
","('Business_Model_Resilience', 0.442442923784256)","('Customer_Welfare', 0.0792958214879036)","('Employee_Engagement_Inclusion_And_Diversity', 0.07522010058164597)","('NON-ESG', 0.442442923784256)","('NON-ESG', 0.0792958214879036)","('NON-ESG', 0.07522010058164597)"
Line 66,"Following the reorganization, we have aggregated our core businesses, into two  reportable segments: MedSurg and Cardiovascular, each of which generates revenues from the sale of medical devices.
","('Customer_Welfare', 0.2892044186592102)","('Product_Design_And_Lifecycle_Management', 0.2273208498954773)","('Competitive_Behavior', 0.07946554571390152)","('NON-ESG', 0.2892044186592102)","('NON-ESG', 0.2273208498954773)","('NON-ESG', 0.07946554571390152)"
Line 67,"2  On March 1, 2021, we completed the sale of the Specialty Pharmaceuticals business.
","('Customer_Welfare', 0.2515302896499634)","('Selling_Practices_And_Product_Labeling', 0.1447698324918747)","('Competitive_Behavior', 0.13620242476463318)","('NON-ESG', 0.2515302896499634)","('NON-ESG', 0.1447698324918747)","('NON-ESG', 0.13620242476463318)"
Line 68,"Our consolidated net sales include Specialty  Pharmaceuticals up to the date of the closing of the transaction.
","('Competitive_Behavior', 0.2862759530544281)","('Business_Model_Resilience', 0.15082333981990814)","('Systemic_Risk_Management', 0.12144146114587784)","('NON-ESG', 0.2862759530544281)","('NON-ESG', 0.15082333981990814)","('NON-ESG', 0.12144146114587784)"
Line 69,"Specialty Pharmaceuticals net sales were substantially U.S. based  and presented as a stand-alone operating segment alongside our Medical Device reportable segments.
","('Competitive_Behavior', 0.3561374247074127)","('Customer_Welfare', 0.24282017350196838)","('Systemic_Risk_Management', 0.06373447924852371)","('NON-ESG', 0.3561374247074127)","('NON-ESG', 0.24282017350196838)","('NON-ESG', 0.06373447924852371)"
Line 70,"$11,million To learn more about our category leadership strategy and growth  opportunities, visit our Investor Relations website.Minimally invasive  devices for diagnosing  and treating  gastrointestinal and  airway conditionsSolutions for urological  diseases including stone  disease, men’s health  and women’s healthGroundbreaking  technologies that treat  irregular heart rhythms  and heart failure and  help protect against  sudden cardiac arrestA broad range of  mapping and treatment  technologies for  diagnosing and treating  heart rhythm disordersElectronic implantable  technologies that  help patients manage  debilitating chronic  pain and neurological  conditionsMinimally invasive  innovations that help  improve the lives of  patients living with heart  and vascular conditionsLeading devices for  diagnosis and minimally  invasive treatments  of peripheral vascular  disease and cancer$2,141 $1,583 $2,019 $365 $909 $3,038 $1,Rhythm and Neuro MedSurg Endoscopy Electrophysiology Neuromodulation Cardiac Rhythm  Management Urology and  Pelvic Health Cardiovascular Interventional   Cardiology  Peripheral   Interventions 2021 Performance ReportIntroduction Patient spotlight Table of contents A message from   our Chairman and   Chief Executive Officer Our mission and values Boston Scientific:   2021 at a glance Our ESG strategy 2021 highlights Awards and recognition Transforming care Investing in   our people Accelerating   possibilities Protecting the  environment Creating value  responsibly Appendix Linking compensation to ESG performance We introduced a human capital scorecard as part of our 2021 annual bonus program for all eligible employees.
","('Employee_Health_And_Safety', 0.4797128438949585)","('Access_And_Affordability', 0.0924127846956253)","('Critical_Incident_Risk_Management', 0.06562891602516174)","('NON-ESG', 0.4797128438949585)","('NON-ESG', 0.0924127846956253)","('NON-ESG', 0.06562891602516174)"
Line 71,"$11,million To learn more about our category leadership strategy and growth  opportunities, visit our Investor Relations website.Minimally invasive  devices for diagnosing  and treating  gastrointestinal and  airway conditionsSolutions for urological  diseases including stone  disease, men’s health  and women’s healthGroundbreaking  technologies that treat  irregular heart rhythms  and heart failure and  help protect against  sudden cardiac arrestA broad range of  mapping and treatment  technologies for  diagnosing and treating  heart rhythm disordersElectronic implantable  technologies that  help patients manage  debilitating chronic  pain and neurological  conditionsMinimally invasive  innovations that help  improve the lives of  patients living with heart  and vascular conditionsLeading devices for  diagnosis and minimally  invasive treatments  of peripheral vascular  disease and cancer$2,141 $1,583 $2,019 $365 $909 $3,038 $1,Rhythm and Neuro MedSurg Endoscopy Electrophysiology Neuromodulation Cardiac Rhythm  Management Urology and  Pelvic Health Cardiovascular Interventional   Cardiology  Peripheral   Interventions 2021 Performance ReportIntroduction Patient spotlight Table of contents A message from   our Chairman and   Chief Executive Officer Our mission and values Boston Scientific:   2021 at a glance Our ESG strategy 2021 highlights Awards and recognition Transforming care Investing in   our people Accelerating   possibilities Protecting the  environment Creating value  responsibly Appendix Linking compensation to ESG performance We introduced a human capital scorecard as part of our 2021 annual bonus program for all eligible employees.
","('Employee_Health_And_Safety', 0.6582297682762146)","('Access_And_Affordability', 0.07585716247558594)","('Product_Quality_And_Safety', 0.0346628837287426)","(['Operational Eco-Efficiency'], 0.6582297682762146)","('NON-ESG', 0.07585716247558594)","('NON-ESG', 0.0346628837287426)"
Line 72,"$11,million To learn more about our category leadership strategy and growth  opportunities, visit our Investor Relations website.Minimally invasive  devices for diagnosing  and treating  gastrointestinal and  airway conditionsSolutions for urological  diseases including stone  disease, men’s health  and women’s healthGroundbreaking  technologies that treat  irregular heart rhythms  and heart failure and  help protect against  sudden cardiac arrestA broad range of  mapping and treatment  technologies for  diagnosing and treating  heart rhythm disordersElectronic implantable  technologies that  help patients manage  debilitating chronic  pain and neurological  conditionsMinimally invasive  innovations that help  improve the lives of  patients living with heart  and vascular conditionsLeading devices for  diagnosis and minimally  invasive treatments  of peripheral vascular  disease and cancer$2,141 $1,583 $2,019 $365 $909 $3,038 $1,Rhythm and Neuro MedSurg Endoscopy Electrophysiology Neuromodulation Cardiac Rhythm  Management Urology and  Pelvic Health Cardiovascular Interventional   Cardiology  Peripheral   Interventions 2021 Performance ReportIntroduction Patient spotlight Table of contents A message from   our Chairman and   Chief Executive Officer Our mission and values Boston Scientific:   2021 at a glance Our ESG strategy 2021 highlights Awards and recognition Transforming care Investing in   our people Accelerating   possibilities Protecting the  environment Creating value  responsibly Appendix Linking compensation to ESG performance We introduced a human capital scorecard as part of our 2021 annual bonus program for all eligible employees.
","('Employee_Health_And_Safety', 0.37434032559394836)","('Access_And_Affordability', 0.3369147479534149)","('Employee_Engagement_Inclusion_And_Diversity', 0.03649846464395523)","('NON-ESG', 0.37434032559394836)","('NON-ESG', 0.3369147479534149)","('NON-ESG', 0.03649846464395523)"
Line 73,"$11,million To learn more about our category leadership strategy and growth  opportunities, visit our Investor Relations website.Minimally invasive  devices for diagnosing  and treating  gastrointestinal and  airway conditionsSolutions for urological  diseases including stone  disease, men’s health  and women’s healthGroundbreaking  technologies that treat  irregular heart rhythms  and heart failure and  help protect against  sudden cardiac arrestA broad range of  mapping and treatment  technologies for  diagnosing and treating  heart rhythm disordersElectronic implantable  technologies that  help patients manage  debilitating chronic  pain and neurological  conditionsMinimally invasive  innovations that help  improve the lives of  patients living with heart  and vascular conditionsLeading devices for  diagnosis and minimally  invasive treatments  of peripheral vascular  disease and cancer$2,141 $1,583 $2,019 $365 $909 $3,038 $1,Rhythm and Neuro MedSurg Endoscopy Electrophysiology Neuromodulation Cardiac Rhythm  Management Urology and  Pelvic Health Cardiovascular Interventional   Cardiology  Peripheral   Interventions 2021 Performance ReportIntroduction Patient spotlight Table of contents A message from   our Chairman and   Chief Executive Officer Our mission and values Boston Scientific:   2021 at a glance Our ESG strategy 2021 highlights Awards and recognition Transforming care Investing in   our people Accelerating   possibilities Protecting the  environment Creating value  responsibly Appendix Linking compensation to ESG performance We introduced a human capital scorecard as part of our 2021 annual bonus program for all eligible employees.
","('Management_Of_Legal_And_Regulatory_Framework', 0.12231983244419098)","('Systemic_Risk_Management', 0.12149305641651154)","('Labor_Practices', 0.09726275503635406)","('NON-ESG', 0.12231983244419098)","('NON-ESG', 0.12149305641651154)","('NON-ESG', 0.09726275503635406)"
Line 74,"This is  intended to reinforce our ESG focus and hold ourselves accountable to our goals in a measurable way.
","('Business_Model_Resilience', 0.4027293026447296)","('Human_Rights_And_Community_Relations', 0.20460113883018494)","('Management_Of_Legal_And_Regulatory_Framework', 0.06090328097343445)","('NON-ESG', 0.4027293026447296)","('NON-ESG', 0.20460113883018494)","('NON-ESG', 0.06090328097343445)"
Line 75,"The human capital  scorecard is weighted at 15% of our total bonus pool funding and equally divided among three ESG performance metrics.
","('Systemic_Risk_Management', 0.2918991446495056)","('Business_Model_Resilience', 0.19366484880447388)","('Management_Of_Legal_And_Regulatory_Framework', 0.12302646040916443)","('NON-ESG', 0.2918991446495056)","('NON-ESG', 0.19366484880447388)","('NON-ESG', 0.12302646040916443)"
Line 76,"Performance metric 2021 results Diversity, equity  and inclusion (DE&I) • Increased representation of women in supervisor and manager roles globally to 41.1%  and multicultural employees in the U.S. and Puerto Rico to 21.6%.
","('Employee_Engagement_Inclusion_And_Diversity', 0.9762335419654846)","('Employee_Health_And_Safety', 0.001684044487774372)","('Human_Rights_And_Community_Relations', 0.0015989375533536077)","(['Human Capital Development'], 0.9762335419654846)","('NON-ESG', 0.001684044487774372)","('NON-ESG', 0.0015989375533536077)"
Line 77,"Our 2021 goals were  41.5% and 22.2%, respectively.
","('Management_Of_Legal_And_Regulatory_Framework', 0.23694951832294464)","('Business_Model_Resilience', 0.15358157455921173)","('Human_Rights_And_Community_Relations', 0.1341983526945114)","('NON-ESG', 0.23694951832294464)","('NON-ESG', 0.15358157455921173)","('NON-ESG', 0.1341983526945114)"
Line 78,"Employee engagement  and retention• Conducted an employee engagement survey and executed against our multi‐year  enterprise action plan.
","('Employee_Engagement_Inclusion_And_Diversity', 0.9635059237480164)","('Employee_Health_And_Safety', 0.005232730880379677)","('Labor_Practices', 0.0035532533656805754)","(['Human Capital Development'], 0.9635059237480164)","('NON-ESG', 0.005232730880379677)","('NON-ESG', 0.0035532533656805754)"
Line 79,"• Met key employee retention rate goals.
","('Employee_Engagement_Inclusion_And_Diversity', 0.9522123336791992)","('Labor_Practices', 0.006046237424015999)","('Employee_Health_And_Safety', 0.005418827291578054)","(['Human Capital Development'], 0.9522123336791992)","('NON-ESG', 0.006046237424015999)","('NON-ESG', 0.005418827291578054)"
Line 80,"Environmental • Increased renewable electricity use to 73% and decreased carbon footprint to  52.3k metric tons.1,2 Our 2021 goals were 70% and 55.0k metric tons, respectively.Human capital scorecard Learn more about our stakeholder engagement in the Appendix.For more information on our compensation programs,  including the human capital scorecard, please see the  Compensation Discussion and Analysis section of the  company’s 2022 Proxy Statement.1 Inclusive of all manufacturing and key distribution sites only.
","('Business_Model_Resilience', 0.26371100544929504)","('Competitive_Behavior', 0.16515086591243744)","('Systemic_Risk_Management', 0.15203629434108734)","('NON-ESG', 0.26371100544929504)","('NON-ESG', 0.16515086591243744)","('NON-ESG', 0.15203629434108734)"
Line 81,"Environmental • Increased renewable electricity use to 73% and decreased carbon footprint to  52.3k metric tons.1,2 Our 2021 goals were 70% and 55.0k metric tons, respectively.Human capital scorecard Learn more about our stakeholder engagement in the Appendix.For more information on our compensation programs,  including the human capital scorecard, please see the  Compensation Discussion and Analysis section of the  company’s 2022 Proxy Statement.1 Inclusive of all manufacturing and key distribution sites only.
","('Management_Of_Legal_And_Regulatory_Framework', 0.17461489140987396)","('GHG_Emissions', 0.11553029716014862)","('Systemic_Risk_Management', 0.08295390009880066)","('NON-ESG', 0.17461489140987396)","('NON-ESG', 0.11553029716014862)","('NON-ESG', 0.08295390009880066)"
Line 82,"2 Reflects adjustments to previously reported figures of 72%  renewable electricity and 53.7k metric tons CO2 in our 2022  Annual Proxy Statement, based on subsequent internal audit.
","('Energy_Management', 0.8546456694602966)","('Management_Of_Legal_And_Regulatory_Framework', 0.07459311932325363)","('GHG_Emissions', 0.01657232828438282)","(['Operational Eco-Efficiency'], 0.8546456694602966)","('NON-ESG', 0.07459311932325363)","('NON-ESG', 0.01657232828438282)"
Line 83,"2021 Performance ReportIntroduction Patient spotlight Table of contents A message from   our Chairman and   Chief Executive Officer Our mission and values Boston Scientific:   2021 at a glance Our ESG strategy 2021 highlights Awards and recognition Transforming care Investing in   our people Accelerating   possibilities Protecting the  environment Creating value  responsibly Appendix Our ESG strategy:  Advancing science  for life We believe in the life-changing potential of science for  health care providers, their patients and communities.
","('Access_And_Affordability', 0.1995866298675537)","('Product_Design_And_Lifecycle_Management', 0.18429335951805115)","('Business_Model_Resilience', 0.13411229848861694)","('NON-ESG', 0.1995866298675537)","('NON-ESG', 0.18429335951805115)","('NON-ESG', 0.13411229848861694)"
Line 84,"2021 Performance ReportIntroduction Patient spotlight Table of contents A message from   our Chairman and   Chief Executive Officer Our mission and values Boston Scientific:   2021 at a glance Our ESG strategy 2021 highlights Awards and recognition Transforming care Investing in   our people Accelerating   possibilities Protecting the  environment Creating value  responsibly Appendix Our ESG strategy:  Advancing science  for life We believe in the life-changing potential of science for  health care providers, their patients and communities.
","('Human_Rights_And_Community_Relations', 0.7009709477424622)","('Access_And_Affordability', 0.08923719823360443)","('Critical_Incident_Risk_Management', 0.026766225695610046)","(['Community Relations'], 0.7009709477424622)","('NON-ESG', 0.08923719823360443)","('NON-ESG', 0.026766225695610046)"
Line 85,"Our focus on improving patient health comes with a  responsibility to have a positive impact on the world we  share.
","('Access_And_Affordability', 0.4869583249092102)","('Employee_Health_And_Safety', 0.19847697019577026)","('Human_Rights_And_Community_Relations', 0.06805925071239471)","('NON-ESG', 0.4869583249092102)","('NON-ESG', 0.19847697019577026)","('NON-ESG', 0.06805925071239471)"
Line 86,"We are committed to understanding, managing  and integrating environmental, social and governance  (ESG) risks and opportunities into our business practices.
","('Human_Rights_And_Community_Relations', 0.37841612100601196)","('Business_Model_Resilience', 0.18676885962486267)","('Systemic_Risk_Management', 0.07812981307506561)","('NON-ESG', 0.37841612100601196)","('NON-ESG', 0.18676885962486267)","('NON-ESG', 0.07812981307506561)"
Line 87,"Guided by these insights and our values, we are making  measurable progress.
","('Human_Rights_And_Community_Relations', 0.2876526713371277)","('Business_Ethics', 0.12538550794124603)","('Business_Model_Resilience', 0.09808771312236786)","('NON-ESG', 0.2876526713371277)","('NON-ESG', 0.12538550794124603)","('NON-ESG', 0.09808771312236786)"
Line 88,"Our people in approximately 115 countries are the driving  force behind our initiatives aimed at addressing the  world’s most pressing challenges, including inequity,  economic disparity, climate change and environmental  protection.
","('Physical_Impacts_Of_Climate_Change', 0.9417316317558289)","('Business_Model_Resilience', 0.015702256932854652)","('GHG_Emissions', 0.0049139936454594135)","(['Climate Change'], 0.9417316317558289)","('NON-ESG', 0.015702256932854652)","('NON-ESG', 0.0049139936454594135)"
Line 89,"Subject matter experts from across the  company serve on our global ESG council and champion  our ESG priorities.
","('Business_Model_Resilience', 0.4078434407711029)","('Management_Of_Legal_And_Regulatory_Framework', 0.108709916472435)","('Systemic_Risk_Management', 0.10503259301185608)","('NON-ESG', 0.4078434407711029)","('NON-ESG', 0.108709916472435)","('NON-ESG', 0.10503259301185608)"
Line 90,"The council’s efforts are directed by  our ESG steering committee, composed of senior leaders  and led by a member of our executive committee.
","('Director_Removal', 0.3980669677257538)","('Management_Of_Legal_And_Regulatory_Framework', 0.12141555547714233)","('Business_Model_Resilience', 0.09290368854999542)","('NON-ESG', 0.3980669677257538)","('NON-ESG', 0.12141555547714233)","('NON-ESG', 0.09290368854999542)"
Line 91,"These members help shape our enterprise strategy  and provide regular updates to our board of directors  and its Nominating and Governance Committee,  which has responsibility to monitor developments and  oversee the company’s practices and policies related  to environmental and social issues, and other matters  impacting our standing as a responsible corporate citizen.
","('Human_Rights_And_Community_Relations', 0.9092291593551636)","('Management_Of_Legal_And_Regulatory_Framework', 0.014569434337317944)","('Business_Model_Resilience', 0.00731297442689538)","(['Community Relations'], 0.9092291593551636)","('NON-ESG', 0.014569434337317944)","('NON-ESG', 0.00731297442689538)"
Line 92,"Within this framework, everyone in the organization has  responsibility for and contributes to ESG progress.Stakeholder engagement for ESG progress Our ESG strategy, priorities and practices are informed by conversations with diverse stakeholders inside and outside the  company — locally, nationally and globally.
","('Human_Rights_And_Community_Relations', 0.3861885666847229)","('Business_Model_Resilience', 0.2427636981010437)","('Management_Of_Legal_And_Regulatory_Framework', 0.0448584109544754)","('NON-ESG', 0.3861885666847229)","('NON-ESG', 0.2427636981010437)","('NON-ESG', 0.0448584109544754)"
Line 93,"In our collaborations and other business relationships, we work with organizations  that share our commitment to better understand and improve environmental, social and economic progress.
","('Human_Rights_And_Community_Relations', 0.9381877779960632)","('Management_Of_Legal_And_Regulatory_Framework', 0.0068100024946033955)","('Ecological_Impacts', 0.006005723960697651)","(['Community Relations'], 0.9381877779960632)","('NON-ESG', 0.0068100024946033955)","('NON-ESG', 0.006005723960697651)"
Line 94,"Importance to stakeholdersOur ESG materiality matrix Human capital attraction  and developmentEmployee well-being,  engagement and safety Corporate governancePatient outcomes Product quality and customer  health and safety Diversity, equity and  inclusion/anti-racism Greenhouse gas emissions/energySupply chain managementHealth equity and access Climate risk managementProduct stewardship ComplianceTransparency Data securityInnovation for patient needs Corporate philanthropy, community outreach and volunteerism Other air and water emissions Customer relationship management Ethics in research and development /animal testing Public policy and lobbyingBiodiversityRisk and crisis managementLabor and compensationAnti-corruption and  anti-competitive behaviorHuman rights Impact on economy, environment and societyhigh criticalcritical Key MaterialImportantAssessing our ESG priorities We can better focus our efforts to reduce risk and drive  positive impact when we fully understand the ESG topics  most important to our stakeholders and our business.
","('GHG_Emissions', 0.9400179982185364)","('Physical_Impacts_Of_Climate_Change', 0.008143940940499306)","('Ecological_Impacts', 0.005893161986023188)","(['Climate Change'], 0.9400179982185364)","('NON-ESG', 0.008143940940499306)","('NON-ESG', 0.005893161986023188)"
Line 95,"Importance to stakeholdersOur ESG materiality matrix Human capital attraction  and developmentEmployee well-being,  engagement and safety Corporate governancePatient outcomes Product quality and customer  health and safety Diversity, equity and  inclusion/anti-racism Greenhouse gas emissions/energySupply chain managementHealth equity and access Climate risk managementProduct stewardship ComplianceTransparency Data securityInnovation for patient needs Corporate philanthropy, community outreach and volunteerism Other air and water emissions Customer relationship management Ethics in research and development /animal testing Public policy and lobbyingBiodiversityRisk and crisis managementLabor and compensationAnti-corruption and  anti-competitive behaviorHuman rights Impact on economy, environment and societyhigh criticalcritical Key MaterialImportantAssessing our ESG priorities We can better focus our efforts to reduce risk and drive  positive impact when we fully understand the ESG topics  most important to our stakeholders and our business.
","('Systemic_Risk_Management', 0.24266169965267181)","('Air_Quality', 0.1916670948266983)","('Business_Ethics', 0.15745039284229279)","('NON-ESG', 0.24266169965267181)","('NON-ESG', 0.1916670948266983)","('NON-ESG', 0.15745039284229279)"
Line 96,"Importance to stakeholdersOur ESG materiality matrix Human capital attraction  and developmentEmployee well-being,  engagement and safety Corporate governancePatient outcomes Product quality and customer  health and safety Diversity, equity and  inclusion/anti-racism Greenhouse gas emissions/energySupply chain managementHealth equity and access Climate risk managementProduct stewardship ComplianceTransparency Data securityInnovation for patient needs Corporate philanthropy, community outreach and volunteerism Other air and water emissions Customer relationship management Ethics in research and development /animal testing Public policy and lobbyingBiodiversityRisk and crisis managementLabor and compensationAnti-corruption and  anti-competitive behaviorHuman rights Impact on economy, environment and societyhigh criticalcritical Key MaterialImportantAssessing our ESG priorities We can better focus our efforts to reduce risk and drive  positive impact when we fully understand the ESG topics  most important to our stakeholders and our business.
","('Human_Rights_And_Community_Relations', 0.45705464482307434)","('Business_Model_Resilience', 0.1366051435470581)","('Customer_Privacy', 0.05492619797587395)","('NON-ESG', 0.45705464482307434)","('NON-ESG', 0.1366051435470581)","('NON-ESG', 0.05492619797587395)"
Line 97,"In 2021, we engaged with an independent third-party  consulting firm to update our materiality1 assessment.
","('Management_Of_Legal_And_Regulatory_Framework', 0.42829832434654236)","('Systemic_Risk_Management', 0.1463489532470703)","('Business_Ethics', 0.06148453801870346)","('NON-ESG', 0.42829832434654236)","('NON-ESG', 0.1463489532470703)","('NON-ESG', 0.06148453801870346)"
Line 98,"The work to examine our priority topics involved in-depth  interviews, peer benchmarking and guidance from  internationally recognized sustainability frameworks and  standards.
","('Management_Of_Legal_And_Regulatory_Framework', 0.5530054569244385)","('Product_Quality_And_Safety', 0.17841410636901855)","('Business_Ethics', 0.03231728821992874)","(['Corporate Governance'], 0.5530054569244385)","('NON-ESG', 0.17841410636901855)","('NON-ESG', 0.03231728821992874)"
Line 99,"After consulting with internal subject matter  experts on the topics identified by the assessment, the  Boston Scientific ESG Steering Committee, Executive  Committee and Board of Directors reviewed the findings.
","('Management_Of_Legal_And_Regulatory_Framework', 0.6762978434562683)","('Ecological_Impacts', 0.0677119717001915)","('GHG_Emissions', 0.03379623219370842)","(['Corporate Governance'], 0.6762978434562683)","('NON-ESG', 0.0677119717001915)","('NON-ESG', 0.03379623219370842)"
Line 100,"Taking direction from our stakeholders We worked with our outside experts to assess research and  benchmarking results and distill more than 100 potential  material topics to 31.
","('Management_Of_Legal_And_Regulatory_Framework', 0.5389595031738281)","('Competitive_Behavior', 0.06520865857601166)","('Access_And_Affordability', 0.05353127792477608)","(['Corporate Governance'], 0.5389595031738281)","('NON-ESG', 0.06520865857601166)","('NON-ESG', 0.05353127792477608)"
Line 101,"Based on this process and input  gathered from stakeholder outreach, we scored potential  topics on two dimensions: importance to stakeholders  and impact on the economy, environment and society.
","('Human_Rights_And_Community_Relations', 0.5694699883460999)","('Management_Of_Legal_And_Regulatory_Framework', 0.10540647804737091)","('Ecological_Impacts', 0.09936100244522095)","(['Community Relations'], 0.5694699883460999)","('NON-ESG', 0.10540647804737091)","('NON-ESG', 0.09936100244522095)"
Line 102,"Informed by our materiality assessment and our values,  we prioritized 15 material topics that would have the  greatest impact.
","('Business_Model_Resilience', 0.4151957631111145)","('Management_Of_Legal_And_Regulatory_Framework', 0.09872259944677353)","('Ecological_Impacts', 0.058851733803749084)","('NON-ESG', 0.4151957631111145)","('NON-ESG', 0.09872259944677353)","('NON-ESG', 0.058851733803749084)"
Line 103,"Our teams will be working to further  prioritize and integrate these findings into our ESG  strategy.
","('Business_Model_Resilience', 0.7658756971359253)","('Systemic_Risk_Management', 0.049117136746644974)","('Employee_Engagement_Inclusion_And_Diversity', 0.021113436669111252)","(['Codes of Business Conduct'], 0.7658756971359253)","('NON-ESG', 0.049117136746644974)","('NON-ESG', 0.021113436669111252)"
Line 104,"We will continue to regularly monitor and assess  progress to ensure we remain focused on the issues of  greatest importance to our stakeholders.
","('Human_Rights_And_Community_Relations', 0.597994863986969)","('Management_Of_Legal_And_Regulatory_Framework', 0.12661772966384888)","('Business_Model_Resilience', 0.04035333916544914)","(['Community Relations'], 0.597994863986969)","('NON-ESG', 0.12661772966384888)","('NON-ESG', 0.04035333916544914)"
Line 105,"1  Throughout this report, we use the Global Reporting Initiative Standards  definition of materiality in order to identify and prioritize ESG topics for  the company.
","('Systemic_Risk_Management', 0.38844117522239685)","('Business_Model_Resilience', 0.20606280863285065)","('Management_Of_Legal_And_Regulatory_Framework', 0.12115288525819778)","('NON-ESG', 0.38844117522239685)","('NON-ESG', 0.20606280863285065)","('NON-ESG', 0.12115288525819778)"
Line 106,"This standard is different from the definition and concept  of materiality within the securities laws that we use to assess, among  other things, required disclosure in Securities and Exchange Commission  filings.
","('Management_Of_Legal_And_Regulatory_Framework', 0.9656346440315247)","('Business_Ethics', 0.004031960852444172)","('Competitive_Behavior', 0.002532459795475006)","(['Corporate Governance'], 0.9656346440315247)","('NON-ESG', 0.004031960852444172)","('NON-ESG', 0.002532459795475006)"
Line 107,"ESG topics identified as “material” for purposes of this report may  not be considered material to the Company as a whole, including for  SEC reporting purposes.
","('Business_Model_Resilience', 0.30018267035484314)","('Systemic_Risk_Management', 0.1036774218082428)","('Management_Of_Legal_And_Regulatory_Framework', 0.09643308073282242)","('NON-ESG', 0.30018267035484314)","('NON-ESG', 0.1036774218082428)","('NON-ESG', 0.09643308073282242)"
Line 108,"2021 Performance ReportIntroduction Patient spotlight Table of contents A message from   our Chairman and   Chief Executive Officer Our mission and values Boston Scientific:   2021 at a glance Our ESG strategy 2021 highlights Awards and recognition Transforming care Investing in   our people Accelerating   possibilities Protecting the  environment Creating value  responsibly Appendix Our ESG framework We have organized our areas of focus under five pillars  that reflect our ongoing dedication to ESG as we pursue  our commitment to advance science for life.
","('Business_Model_Resilience', 0.5668681859970093)","('Human_Rights_And_Community_Relations', 0.0692346841096878)","('Employee_Engagement_Inclusion_And_Diversity', 0.04098759964108467)","(['Codes of Business Conduct'], 0.5668681859970093)","('NON-ESG', 0.0692346841096878)","('NON-ESG', 0.04098759964108467)"
Line 109,"2021 Performance ReportIntroduction Patient spotlight Table of contents A message from   our Chairman and   Chief Executive Officer Our mission and values Boston Scientific:   2021 at a glance Our ESG strategy 2021 highlights Awards and recognition Transforming care Investing in   our people Accelerating   possibilities Protecting the  environment Creating value  responsibly Appendix Our ESG framework We have organized our areas of focus under five pillars  that reflect our ongoing dedication to ESG as we pursue  our commitment to advance science for life.
","('Access_And_Affordability', 0.28086790442466736)","('Product_Design_And_Lifecycle_Management', 0.14935371279716492)","('Ecological_Impacts', 0.07598631829023361)","('NON-ESG', 0.28086790442466736)","('NON-ESG', 0.14935371279716492)","('NON-ESG', 0.07598631829023361)"
Line 110,"In some  cases, they overlap across our pillars, which is represented  in the graphic to the right: Protecting the  environmentInvesting in   our peopleCreating value  responsiblyTransforming care Product quality  and customer  health and safety Diversity, equity  and inclusion Greenhouse gas  emissions and energyAccelerating  possibilitiesProduct stewardshipSupply chain  managementHealth equity   and access Patient  outcomesInnovation for  patient needs Climate risk  management Corporate  governanceTransparency Data securityCompliance Employee well-being,  engagement and safety Human capital attraction  and development 2021 Performance ReportIntroduction Patient spotlight Table of contents A message from   our Chairman and   Chief Executive Officer Our mission and values Boston Scientific:   2021 at a glance Our ESG strategy 2021 highlights Awards and recognition Transforming care Investing in   our people Accelerating   possibilities Protecting the  environment Creating value  responsibly Appendix 2021 highlights Transforming   care Protecting   the environmentAccelerating  possibilities Creating value  responsibly Investing in   our people $1+ billion invested in R&D for  products to advance  patient care41.1% of supervisor and manager  roles held by women globally;  21.6% by multicultural  employees in the U.S.  and Puerto Ricohospitals and providers  acted to address inequities  in specialty care through  Close the Gap partnerships68% reduction in greenhouse gas  emissions since 2009   (Scope 1 and 2)1~35 million products delivered 99%+ pay equity$75+ million in contributions for medical  research, fellowships,  education and charitable  organizations globally73% of electricity consumed  generated from renewable  sources, surpassing our  interim goal of 50% by 20211, 2$865+ million spent on small and   diverse suppliers30+ million patients served 1 Inclusive of all manufacturing and key distribution sites only.
","('Product_Design_And_Lifecycle_Management', 0.4439746141433716)","('Product_Quality_And_Safety', 0.15424023568630219)","('GHG_Emissions', 0.07007050514221191)","('NON-ESG', 0.4439746141433716)","('NON-ESG', 0.15424023568630219)","('NON-ESG', 0.07007050514221191)"
Line 111,"In some  cases, they overlap across our pillars, which is represented  in the graphic to the right: Protecting the  environmentInvesting in   our peopleCreating value  responsiblyTransforming care Product quality  and customer  health and safety Diversity, equity  and inclusion Greenhouse gas  emissions and energyAccelerating  possibilitiesProduct stewardshipSupply chain  managementHealth equity   and access Patient  outcomesInnovation for  patient needs Climate risk  management Corporate  governanceTransparency Data securityCompliance Employee well-being,  engagement and safety Human capital attraction  and development 2021 Performance ReportIntroduction Patient spotlight Table of contents A message from   our Chairman and   Chief Executive Officer Our mission and values Boston Scientific:   2021 at a glance Our ESG strategy 2021 highlights Awards and recognition Transforming care Investing in   our people Accelerating   possibilities Protecting the  environment Creating value  responsibly Appendix 2021 highlights Transforming   care Protecting   the environmentAccelerating  possibilities Creating value  responsibly Investing in   our people $1+ billion invested in R&D for  products to advance  patient care41.1% of supervisor and manager  roles held by women globally;  21.6% by multicultural  employees in the U.S.  and Puerto Ricohospitals and providers  acted to address inequities  in specialty care through  Close the Gap partnerships68% reduction in greenhouse gas  emissions since 2009   (Scope 1 and 2)1~35 million products delivered 99%+ pay equity$75+ million in contributions for medical  research, fellowships,  education and charitable  organizations globally73% of electricity consumed  generated from renewable  sources, surpassing our  interim goal of 50% by 20211, 2$865+ million spent on small and   diverse suppliers30+ million patients served 1 Inclusive of all manufacturing and key distribution sites only.
","('Employee_Health_And_Safety', 0.27918896079063416)","('Human_Rights_And_Community_Relations', 0.19369706511497498)","('Access_And_Affordability', 0.08208957314491272)","('NON-ESG', 0.27918896079063416)","('NON-ESG', 0.19369706511497498)","('NON-ESG', 0.08208957314491272)"
Line 112,"In some  cases, they overlap across our pillars, which is represented  in the graphic to the right: Protecting the  environmentInvesting in   our peopleCreating value  responsiblyTransforming care Product quality  and customer  health and safety Diversity, equity  and inclusion Greenhouse gas  emissions and energyAccelerating  possibilitiesProduct stewardshipSupply chain  managementHealth equity   and access Patient  outcomesInnovation for  patient needs Climate risk  management Corporate  governanceTransparency Data securityCompliance Employee well-being,  engagement and safety Human capital attraction  and development 2021 Performance ReportIntroduction Patient spotlight Table of contents A message from   our Chairman and   Chief Executive Officer Our mission and values Boston Scientific:   2021 at a glance Our ESG strategy 2021 highlights Awards and recognition Transforming care Investing in   our people Accelerating   possibilities Protecting the  environment Creating value  responsibly Appendix 2021 highlights Transforming   care Protecting   the environmentAccelerating  possibilities Creating value  responsibly Investing in   our people $1+ billion invested in R&D for  products to advance  patient care41.1% of supervisor and manager  roles held by women globally;  21.6% by multicultural  employees in the U.S.  and Puerto Ricohospitals and providers  acted to address inequities  in specialty care through  Close the Gap partnerships68% reduction in greenhouse gas  emissions since 2009   (Scope 1 and 2)1~35 million products delivered 99%+ pay equity$75+ million in contributions for medical  research, fellowships,  education and charitable  organizations globally73% of electricity consumed  generated from renewable  sources, surpassing our  interim goal of 50% by 20211, 2$865+ million spent on small and   diverse suppliers30+ million patients served 1 Inclusive of all manufacturing and key distribution sites only.
","('GHG_Emissions', 0.9614051580429077)","('Air_Quality', 0.00551991630345583)","('Physical_Impacts_Of_Climate_Change', 0.0045067197643220425)","(['Climate Change'], 0.9614051580429077)","('NON-ESG', 0.00551991630345583)","('NON-ESG', 0.0045067197643220425)"
Line 113,"In some  cases, they overlap across our pillars, which is represented  in the graphic to the right: Protecting the  environmentInvesting in   our peopleCreating value  responsiblyTransforming care Product quality  and customer  health and safety Diversity, equity  and inclusion Greenhouse gas  emissions and energyAccelerating  possibilitiesProduct stewardshipSupply chain  managementHealth equity   and access Patient  outcomesInnovation for  patient needs Climate risk  management Corporate  governanceTransparency Data securityCompliance Employee well-being,  engagement and safety Human capital attraction  and development 2021 Performance ReportIntroduction Patient spotlight Table of contents A message from   our Chairman and   Chief Executive Officer Our mission and values Boston Scientific:   2021 at a glance Our ESG strategy 2021 highlights Awards and recognition Transforming care Investing in   our people Accelerating   possibilities Protecting the  environment Creating value  responsibly Appendix 2021 highlights Transforming   care Protecting   the environmentAccelerating  possibilities Creating value  responsibly Investing in   our people $1+ billion invested in R&D for  products to advance  patient care41.1% of supervisor and manager  roles held by women globally;  21.6% by multicultural  employees in the U.S.  and Puerto Ricohospitals and providers  acted to address inequities  in specialty care through  Close the Gap partnerships68% reduction in greenhouse gas  emissions since 2009   (Scope 1 and 2)1~35 million products delivered 99%+ pay equity$75+ million in contributions for medical  research, fellowships,  education and charitable  organizations globally73% of electricity consumed  generated from renewable  sources, surpassing our  interim goal of 50% by 20211, 2$865+ million spent on small and   diverse suppliers30+ million patients served 1 Inclusive of all manufacturing and key distribution sites only.
","('Energy_Management', 0.8464064002037048)","('Product_Design_And_Lifecycle_Management', 0.07446593791246414)","('Access_And_Affordability', 0.00900317169725895)","(['Operational Eco-Efficiency'], 0.8464064002037048)","('NON-ESG', 0.07446593791246414)","('NON-ESG', 0.00900317169725895)"
Line 114,"2 Reflects adjustments to previously reported figure of 72% renewable electricity in our 2022 Annual Proxy Statement, based on subsequent internal audit.
","('Energy_Management', 0.7197604179382324)","('Management_Of_Legal_And_Regulatory_Framework', 0.20667418837547302)","('GHG_Emissions', 0.008425294421613216)","(['Operational Eco-Efficiency'], 0.7197604179382324)","('NON-ESG', 0.20667418837547302)","('NON-ESG', 0.008425294421613216)"
Line 115,"2021 Performance ReportIntroduction Patient spotlight Table of contents A message from   our Chairman and   Chief Executive Officer Our mission and values Boston Scientific:   2021 at a glance Our ESG strategy 2021 highlights Awards and recognition Transforming care Investing in   our people Accelerating   possibilities Protecting the  environment Creating value  responsibly Appendix Awards and recognition Newsweek   America’s Most   Responsible Companies   (2020, 2021)Forbes   Best Employers for Diversity   (2018 – 2022) Clarivate Analytics   Top 100 Global Innovators   (2017 – 2021)  Glassdoor   Employees’ Choice Best  Places to Work   (2018, 2019, 2022)  FTSE4Good Index   (2016 – 2021)Fast Company    Best Workplaces for Innovators   (2020, 2021)  Newsweek   America’s Most Loved Workplaces   (2021) Catalyst Award   (2022)Disability Equality Index (DEI)   Best Place to Work for   Disability Inclusion   (2016 – 2021)   Forbes   World’s Top Female   Friendly Companies   (2021) Seramount Inclusion Index  Leading Company   (2021)Human Rights Campaign (HRC)   Best Places to Work for   LGBTQ Equality   (2015 – 2022) Bloomberg   Gender-Equality Index (GEI)   (2019 – 2022) Dow Jones Sustainability  Index North America   (2020, 2021)  FORTUNE    World’s Most Admired Companies   (2016 – 2022)  JUST Capital and CNBC’s   America’s Most JUST Companies   (2020 – 2022)  Visit our website for more information on our recent awards and recognitions.
","('Employee_Engagement_Inclusion_And_Diversity', 0.9435421824455261)","('Human_Rights_And_Community_Relations', 0.0070776427164673805)","('Access_And_Affordability', 0.00551042053848505)","(['Human Capital Development'], 0.9435421824455261)","('NON-ESG', 0.0070776427164673805)","('NON-ESG', 0.00551042053848505)"
Line 116,"2021 Performance ReportIntroduction Patient spotlight Table of contents A message from   our Chairman and   Chief Executive Officer Our mission and values Boston Scientific:   2021 at a glance Our ESG strategy 2021 highlights Awards and recognition Transforming care Investing in   our people Accelerating   possibilities Protecting the  environment Creating value  responsibly Appendix Awards and recognition Newsweek   America’s Most   Responsible Companies   (2020, 2021)Forbes   Best Employers for Diversity   (2018 – 2022) Clarivate Analytics   Top 100 Global Innovators   (2017 – 2021)  Glassdoor   Employees’ Choice Best  Places to Work   (2018, 2019, 2022)  FTSE4Good Index   (2016 – 2021)Fast Company    Best Workplaces for Innovators   (2020, 2021)  Newsweek   America’s Most Loved Workplaces   (2021) Catalyst Award   (2022)Disability Equality Index (DEI)   Best Place to Work for   Disability Inclusion   (2016 – 2021)   Forbes   World’s Top Female   Friendly Companies   (2021) Seramount Inclusion Index  Leading Company   (2021)Human Rights Campaign (HRC)   Best Places to Work for   LGBTQ Equality   (2015 – 2022) Bloomberg   Gender-Equality Index (GEI)   (2019 – 2022) Dow Jones Sustainability  Index North America   (2020, 2021)  FORTUNE    World’s Most Admired Companies   (2016 – 2022)  JUST Capital and CNBC’s   America’s Most JUST Companies   (2020 – 2022)  Visit our website for more information on our recent awards and recognitions.
","('Employee_Engagement_Inclusion_And_Diversity', 0.9163849353790283)","('Employee_Health_And_Safety', 0.026621419936418533)","('Human_Rights_And_Community_Relations', 0.00683610001578927)","(['Human Capital Development'], 0.9163849353790283)","('NON-ESG', 0.026621419936418533)","('NON-ESG', 0.00683610001578927)"
Line 117,"2021 Performance ReportIntroduction Patient spotlight Table of contents A message from   our Chairman and   Chief Executive Officer Our mission and values Boston Scientific:   2021 at a glance Our ESG strategy 2021 highlights Awards and recognition Transforming care Investing in   our people Accelerating   possibilities Protecting the  environment Creating value  responsibly Appendix Awards and recognition Newsweek   America’s Most   Responsible Companies   (2020, 2021)Forbes   Best Employers for Diversity   (2018 – 2022) Clarivate Analytics   Top 100 Global Innovators   (2017 – 2021)  Glassdoor   Employees’ Choice Best  Places to Work   (2018, 2019, 2022)  FTSE4Good Index   (2016 – 2021)Fast Company    Best Workplaces for Innovators   (2020, 2021)  Newsweek   America’s Most Loved Workplaces   (2021) Catalyst Award   (2022)Disability Equality Index (DEI)   Best Place to Work for   Disability Inclusion   (2016 – 2021)   Forbes   World’s Top Female   Friendly Companies   (2021) Seramount Inclusion Index  Leading Company   (2021)Human Rights Campaign (HRC)   Best Places to Work for   LGBTQ Equality   (2015 – 2022) Bloomberg   Gender-Equality Index (GEI)   (2019 – 2022) Dow Jones Sustainability  Index North America   (2020, 2021)  FORTUNE    World’s Most Admired Companies   (2016 – 2022)  JUST Capital and CNBC’s   America’s Most JUST Companies   (2020 – 2022)  Visit our website for more information on our recent awards and recognitions.
","('Employee_Engagement_Inclusion_And_Diversity', 0.7166519165039062)","('Human_Rights_And_Community_Relations', 0.12356483936309814)","('Employee_Health_And_Safety', 0.03719038516283035)","(['Human Capital Development'], 0.7166519165039062)","('NON-ESG', 0.12356483936309814)","('NON-ESG', 0.03719038516283035)"
Line 118,"2021 Performance ReportIntroduction Patient spotlight Table of contents A message from   our Chairman and   Chief Executive Officer Our mission and values Boston Scientific:   2021 at a glance Our ESG strategy 2021 highlights Awards and recognition Transforming care Investing in   our people Accelerating   possibilities Protecting the  environment Creating value  responsibly Appendix Transforming  care Our work in health care is about addressing patients’ critical  needs, expanding access to care and helping improve outcomes  so people can lead longer, better lives.When we challenge the status quo, we advance  breakthrough ideas to transform lives.
","('Access_And_Affordability', 0.8314808011054993)","('Human_Rights_And_Community_Relations', 0.016412856057286263)","('Customer_Welfare', 0.015151649713516235)","(['Health Outcome Contribution'], 0.8314808011054993)","('NON-ESG', 0.016412856057286263)","('NON-ESG', 0.015151649713516235)"
Line 119,"2021 Performance ReportIntroduction Patient spotlight Table of contents A message from   our Chairman and   Chief Executive Officer Our mission and values Boston Scientific:   2021 at a glance Our ESG strategy 2021 highlights Awards and recognition Transforming care Investing in   our people Accelerating   possibilities Protecting the  environment Creating value  responsibly Appendix Transforming  care Our work in health care is about addressing patients’ critical  needs, expanding access to care and helping improve outcomes  so people can lead longer, better lives.When we challenge the status quo, we advance  breakthrough ideas to transform lives.
","('Access_And_Affordability', 0.4831548035144806)","('Human_Rights_And_Community_Relations', 0.12107306718826294)","('Employee_Engagement_Inclusion_And_Diversity', 0.08329739421606064)","('NON-ESG', 0.4831548035144806)","('NON-ESG', 0.12107306718826294)","('NON-ESG', 0.08329739421606064)"
Line 120,"$1+ billion invested in R&D for products  to advance patient care30+ million patients served 2021 Performance ReportIntroduction Transforming care Overview and   2021 highlights Innovating to meet   more patient needs Ensuring quality,   health and safety Improving access   and outcomes through  digital solutions Investing in   our people Accelerating   possibilities Protecting the  environment Creating value  responsibly Appendix Overview and 2021 highlights Amid significant disruption and uncertainty in a prolonged pandemic, our teams challenged what was possible.
","('Access_And_Affordability', 0.4794265031814575)","('Employee_Health_And_Safety', 0.14691895246505737)","('Product_Quality_And_Safety', 0.11065390706062317)","('NON-ESG', 0.4794265031814575)","('NON-ESG', 0.14691895246505737)","('NON-ESG', 0.11065390706062317)"
Line 121,"$1+ billion invested in R&D for products  to advance patient care30+ million patients served 2021 Performance ReportIntroduction Transforming care Overview and   2021 highlights Innovating to meet   more patient needs Ensuring quality,   health and safety Improving access   and outcomes through  digital solutions Investing in   our people Accelerating   possibilities Protecting the  environment Creating value  responsibly Appendix Overview and 2021 highlights Amid significant disruption and uncertainty in a prolonged pandemic, our teams challenged what was possible.
","('Physical_Impacts_Of_Climate_Change', 0.3343566656112671)","('Critical_Incident_Risk_Management', 0.15221688151359558)","('Air_Quality', 0.13748979568481445)","('NON-ESG', 0.3343566656112671)","('NON-ESG', 0.15221688151359558)","('NON-ESG', 0.13748979568481445)"
Line 122,"We developed new capabilities and adapted to stay connected with customers who were frequently faced with treating  patients in challenging settings.
","('Access_And_Affordability', 0.8035719394683838)","('Critical_Incident_Risk_Management', 0.02187739871442318)","('Customer_Welfare', 0.019410014152526855)","(['Health Outcome Contribution'], 0.8035719394683838)","('NON-ESG', 0.02187739871442318)","('NON-ESG', 0.019410014152526855)"
Line 123,"Our people upheld rigorous quality processes, delivered market-leading solutions  around the world and collaborated with providers and communities to expand health care access.
","('Access_And_Affordability', 0.8821189403533936)","('Critical_Incident_Risk_Management', 0.011894541792571545)","('Human_Rights_And_Community_Relations', 0.011790689080953598)","(['Health Outcome Contribution'], 0.8821189403533936)","('NON-ESG', 0.011894541792571545)","('NON-ESG', 0.011790689080953598)"
Line 124,"To increase the impact  of our work, we enhanced our digital platforms that support our products and help keep us engaged with physicians  and their patients.
","('Product_Design_And_Lifecycle_Management', 0.5744544863700867)","('Customer_Welfare', 0.12987419962882996)","('Competitive_Behavior', 0.038650061935186386)","(['Product Stewardship'], 0.5744544863700867)","('NON-ESG', 0.12987419962882996)","('NON-ESG', 0.038650061935186386)"
Line 125,"Innovating to meet more patient needs Our teams are always reaching for breakthrough solutions that will make a meaningful difference for patients and  health care providers.
","('Access_And_Affordability', 0.46874290704727173)","('Customer_Welfare', 0.08583708107471466)","('Product_Design_And_Lifecycle_Management', 0.06189290061593056)","('NON-ESG', 0.46874290704727173)","('NON-ESG', 0.08583708107471466)","('NON-ESG', 0.06189290061593056)"
Line 126,"Our products help physicians diagnose and treat complex cardiovascular, vascular, digestive,  oncological, neurological, urological and pelvic health diseases and conditions.
","('Employee_Health_And_Safety', 0.6778431534767151)","('Access_And_Affordability', 0.06615065783262253)","('Product_Quality_And_Safety', 0.03741859644651413)","(['Operational Eco-Efficiency'], 0.6778431534767151)","('NON-ESG', 0.06615065783262253)","('NON-ESG', 0.03741859644651413)"
Line 127,"We work across the company and  with trusted experts and providers to deepen our portfolio in these areas and continue to create value for patients,  physicians and payers.
","('Access_And_Affordability', 0.22986845672130585)","('Management_Of_Legal_And_Regulatory_Framework', 0.15609385073184967)","('Competitive_Behavior', 0.08965840935707092)","('NON-ESG', 0.22986845672130585)","('NON-ESG', 0.15609385073184967)","('NON-ESG', 0.08965840935707092)"
Line 128,"Our innovations are the result of organic research, collaborations, tuck-in acquisitions,  investments in emerging technologies and strategic partnerships.
","('Business_Model_Resilience', 0.20124392211437225)","('Management_Of_Legal_And_Regulatory_Framework', 0.16240428388118744)","('Product_Design_And_Lifecycle_Management', 0.07641170918941498)","('NON-ESG', 0.20124392211437225)","('NON-ESG', 0.16240428388118744)","('NON-ESG', 0.07641170918941498)"
Line 129,"Research and development (R&D)  to advance innovative care We pursue scientific advances through a uniform, global  approach that combines business, technical and quality  processes.
","('Access_And_Affordability', 0.22303906083106995)","('Ecological_Impacts', 0.08456438034772873)","('Management_Of_Legal_And_Regulatory_Framework', 0.08196983486413956)","('NON-ESG', 0.22303906083106995)","('NON-ESG', 0.08456438034772873)","('NON-ESG', 0.08196983486413956)"
Line 130,"This allows us to monitor products over their  life cycles, from concept and commercialization through  next-generation designs.
","('Product_Design_And_Lifecycle_Management', 0.9675558805465698)","('Business_Model_Resilience', 0.0029055725317448378)","('Customer_Welfare', 0.0028437450528144836)","(['Product Stewardship'], 0.9675558805465698)","('NON-ESG', 0.0029055725317448378)","('NON-ESG', 0.0028437450528144836)"
Line 131,"The data we gather and analyze  help us develop solutions to address unmet customer and  patient needs.
","('Access_And_Affordability', 0.43797677755355835)","('Business_Model_Resilience', 0.06129281222820282)","('Supply_Chain_Management', 0.05593965947628021)","('NON-ESG', 0.43797677755355835)","('NON-ESG', 0.06129281222820282)","('NON-ESG', 0.05593965947628021)"
Line 132,"In 2021, we invested more than $1 billion in  R&D and launched 90 new products to advance patient care.
","('Product_Design_And_Lifecycle_Management', 0.8854961395263672)","('Customer_Welfare', 0.026842888444662094)","('Product_Quality_And_Safety', 0.0176809374243021)","(['Product Stewardship'], 0.8854961395263672)","('NON-ESG', 0.026842888444662094)","('NON-ESG', 0.0176809374243021)"
Line 133,"Thirty-five percent of total company revenue flowed from  products released between 2019 and 2021, which we believe  represents a strong pace of innovation.We have research and development sites in the United  States, the European Union, Costa Rica, India and China.
","('Product_Design_And_Lifecycle_Management', 0.9548243880271912)","('Product_Quality_And_Safety', 0.005761774256825447)","('Customer_Welfare', 0.005540378391742706)","(['Product Stewardship'], 0.9548243880271912)","('NON-ESG', 0.005761774256825447)","('NON-ESG', 0.005540378391742706)"
Line 134,"Some of the sites also serve as R&D Centers of Excellence  where we identify successful practices and share them  across the company to strengthen our overall R&D  capability.
","('Business_Model_Resilience', 0.5029066205024719)","('Supply_Chain_Management', 0.07994068413972855)","('Systemic_Risk_Management', 0.06485012918710709)","(['Codes of Business Conduct'], 0.5029066205024719)","('NON-ESG', 0.07994068413972855)","('NON-ESG', 0.06485012918710709)"
Line 135,"One example of how these R&D Centers of  Excellence teams work together to inspire continuous  innovation is our growing line of drug-eluting devices.
","('Competitive_Behavior', 0.19037069380283356)","('Business_Model_Resilience', 0.19002029299736023)","('Product_Design_And_Lifecycle_Management', 0.16610389947891235)","('NON-ESG', 0.19037069380283356)","('NON-ESG', 0.19002029299736023)","('NON-ESG', 0.16610389947891235)"
Line 136,"Since introducing drug-eluting coronary stents in the  early 2000s, our teams have advanced the technology  and developed new devices to address a broader  range of conditions.
","('Customer_Welfare', 0.3884824216365814)","('Competitive_Behavior', 0.12840647995471954)","('Product_Design_And_Lifecycle_Management', 0.096295066177845)","('NON-ESG', 0.3884824216365814)","('NON-ESG', 0.12840647995471954)","('NON-ESG', 0.096295066177845)"
Line 137,"We offer our customers both a  drug-coated balloon and a drug-eluting stent, providing  a comprehensive set of therapies to treat patients with  peripheral artery disease in major markets.Randy Schiestl  vice president, R&D,   Global Technology“ Since our founding, creating  something new that  makes a difference in  patients’ lives is at the  heart of how we innovate.”$1+ billion invested in R&D 10.1%  R&D spend as percent of sales 90  new products 35%  sales generated from new products   launched over the last three years 2021 innovation results 2021 Performance ReportIntroduction Transforming care Overview and   2021 highlights Innovating to meet   more patient needs Ensuring quality,   health and safety Improving access   and outcomes through  digital solutions Investing in   our people Accelerating   possibilities Protecting the  environment Creating value  responsibly Appendix Seeking new opportunities to  deliver breakthrough solutions Through our venture portfolio and strategic  acquisitions, we invest in early-stage and  commercial-stage companies to identify technologies  that expand our ability to diagnose and treat complex  diseases and conditions.
","('Product_Design_And_Lifecycle_Management', 0.7785969376564026)","('Customer_Welfare', 0.07509225606918335)","('Product_Quality_And_Safety', 0.03077268786728382)","(['Product Stewardship'], 0.7785969376564026)","('NON-ESG', 0.07509225606918335)","('NON-ESG', 0.03077268786728382)"
Line 138,"We offer our customers both a  drug-coated balloon and a drug-eluting stent, providing  a comprehensive set of therapies to treat patients with  peripheral artery disease in major markets.Randy Schiestl  vice president, R&D,   Global Technology“ Since our founding, creating  something new that  makes a difference in  patients’ lives is at the  heart of how we innovate.”$1+ billion invested in R&D 10.1%  R&D spend as percent of sales 90  new products 35%  sales generated from new products   launched over the last three years 2021 innovation results 2021 Performance ReportIntroduction Transforming care Overview and   2021 highlights Innovating to meet   more patient needs Ensuring quality,   health and safety Improving access   and outcomes through  digital solutions Investing in   our people Accelerating   possibilities Protecting the  environment Creating value  responsibly Appendix Seeking new opportunities to  deliver breakthrough solutions Through our venture portfolio and strategic  acquisitions, we invest in early-stage and  commercial-stage companies to identify technologies  that expand our ability to diagnose and treat complex  diseases and conditions.
","('Employee_Health_And_Safety', 0.3936588168144226)","('Access_And_Affordability', 0.2805357277393341)","('Product_Quality_And_Safety', 0.09635303914546967)","('NON-ESG', 0.3936588168144226)","('NON-ESG', 0.2805357277393341)","('NON-ESG', 0.09635303914546967)"
Line 139,"We offer our customers both a  drug-coated balloon and a drug-eluting stent, providing  a comprehensive set of therapies to treat patients with  peripheral artery disease in major markets.Randy Schiestl  vice president, R&D,   Global Technology“ Since our founding, creating  something new that  makes a difference in  patients’ lives is at the  heart of how we innovate.”$1+ billion invested in R&D 10.1%  R&D spend as percent of sales 90  new products 35%  sales generated from new products   launched over the last three years 2021 innovation results 2021 Performance ReportIntroduction Transforming care Overview and   2021 highlights Innovating to meet   more patient needs Ensuring quality,   health and safety Improving access   and outcomes through  digital solutions Investing in   our people Accelerating   possibilities Protecting the  environment Creating value  responsibly Appendix Seeking new opportunities to  deliver breakthrough solutions Through our venture portfolio and strategic  acquisitions, we invest in early-stage and  commercial-stage companies to identify technologies  that expand our ability to diagnose and treat complex  diseases and conditions.
","('Employee_Health_And_Safety', 0.26215022802352905)","('Product_Quality_And_Safety', 0.1347547024488449)","('Access_And_Affordability', 0.09763472527265549)","('NON-ESG', 0.26215022802352905)","('NON-ESG', 0.1347547024488449)","('NON-ESG', 0.09763472527265549)"
Line 140,"In 2021, Boston Scientific  announced five acquisitions that we anticipate  will help us advance outcomes and strengthen  our pipeline.
","('Business_Model_Resilience', 0.33859968185424805)","('Management_Of_Legal_And_Regulatory_Framework', 0.1322435438632965)","('Competitive_Behavior', 0.08308807015419006)","('NON-ESG', 0.33859968185424805)","('NON-ESG', 0.1322435438632965)","('NON-ESG', 0.08308807015419006)"
Line 141,"Learn more about each acquisition  on our website .
","('Systemic_Risk_Management', 0.2395649403333664)","('Business_Model_Resilience', 0.23566894233226776)","('Competitive_Behavior', 0.09436806291341782)","('NON-ESG', 0.2395649403333664)","('NON-ESG', 0.23566894233226776)","('NON-ESG', 0.09436806291341782)"
Line 142,"Partnering to accelerate   scientific progress Our teams work closely with external research  organizations, academic institutions and practitioners  to evaluate ideas, develop medical device designs and  conduct feasibility studies.
","('Management_Of_Legal_And_Regulatory_Framework', 0.2519949972629547)","('Access_And_Affordability', 0.1335388422012329)","('GHG_Emissions', 0.08208829909563065)","('NON-ESG', 0.2519949972629547)","('NON-ESG', 0.1335388422012329)","('NON-ESG', 0.08208829909563065)"
Line 143,"For instance, through our  Motion Medical joint innovation accelerator with the  Mayo Clinic, engineers from Boston Scientific work with  physicians to develop prototypes and treatments for  conditions that impede quality and longevity of life.
","('Employee_Health_And_Safety', 0.44304949045181274)","('Employee_Engagement_Inclusion_And_Diversity', 0.0829431340098381)","('Access_And_Affordability', 0.08147499710321426)","('NON-ESG', 0.44304949045181274)","('NON-ESG', 0.0829431340098381)","('NON-ESG', 0.08147499710321426)"
Line 144,"Here are some highlights from our collaborations.
","('Competitive_Behavior', 0.14293372631072998)","('Business_Model_Resilience', 0.11185409128665924)","('Employee_Engagement_Inclusion_And_Diversity', 0.07183723896741867)","('NON-ESG', 0.14293372631072998)","('NON-ESG', 0.11185409128665924)","('NON-ESG', 0.07183723896741867)"
Line 145,"gBETA MedTech Black Founder Accelerator: The first  gBETA MedTech program specifically for early-stage  Black-owned businesses announced its initial cohort   of five health care start-ups.
","('Business_Model_Resilience', 0.27243828773498535)","('Systemic_Risk_Management', 0.11311440914869308)","('Supply_Chain_Management', 0.10480667650699615)","('NON-ESG', 0.27243828773498535)","('NON-ESG', 0.11311440914869308)","('NON-ESG', 0.10480667650699615)"
Line 146,"PracticePoint Alliance: Our engineers worked with  Worcester Polytechnic Institute (WPI) faculty and students  to develop robotics concepts and test endoscopy and  urology prototypes.
","('Employee_Health_And_Safety', 0.20214517414569855)","('Employee_Engagement_Inclusion_And_Diversity', 0.1883203685283661)","('Ecological_Impacts', 0.10103316605091095)","('NON-ESG', 0.20214517414569855)","('NON-ESG', 0.1883203685283661)","('NON-ESG', 0.10103316605091095)"
Line 147,"MEDX Xelerator: The medical device and digital health- focused incubator announced its first million-dollar  challenge for physicians and engineers pursuing novel  ways to meet health care needs.~$1 billion  invested in venture portfolio  over the past decade ~35  active venture investments in 3 out of 5   of our 2021 acquisitions announced  came from our venture portfolio 2021 Performance ReportIntroduction Transforming care Overview and   2021 highlights Innovating to meet   more patient needs Ensuring quality,   health and safety Improving access   and outcomes through  digital solutions Investing in   our people Accelerating   possibilities Protecting the  environment Creating value  responsibly Appendix Jenifer Levinson  vice president,   Global Health Economics  and Market AccessAddressing health economics   to improve market access To increase patient access to needed medical therapies  globally, our Health Economics and Market Access (HEMA)  team studies the health economics associated with using  our devices.
","('Access_And_Affordability', 0.2778366208076477)","('Customer_Welfare', 0.15145151317119598)","('Product_Design_And_Lifecycle_Management', 0.1291520893573761)","('NON-ESG', 0.2778366208076477)","('NON-ESG', 0.15145151317119598)","('NON-ESG', 0.1291520893573761)"
Line 148,"MEDX Xelerator: The medical device and digital health- focused incubator announced its first million-dollar  challenge for physicians and engineers pursuing novel  ways to meet health care needs.~$1 billion  invested in venture portfolio  over the past decade ~35  active venture investments in 3 out of 5   of our 2021 acquisitions announced  came from our venture portfolio 2021 Performance ReportIntroduction Transforming care Overview and   2021 highlights Innovating to meet   more patient needs Ensuring quality,   health and safety Improving access   and outcomes through  digital solutions Investing in   our people Accelerating   possibilities Protecting the  environment Creating value  responsibly Appendix Jenifer Levinson  vice president,   Global Health Economics  and Market AccessAddressing health economics   to improve market access To increase patient access to needed medical therapies  globally, our Health Economics and Market Access (HEMA)  team studies the health economics associated with using  our devices.
","('Access_And_Affordability', 0.7695381045341492)","('Product_Quality_And_Safety', 0.03721639886498451)","('Management_Of_Legal_And_Regulatory_Framework', 0.01851186901330948)","(['Health Outcome Contribution'], 0.7695381045341492)","('NON-ESG', 0.03721639886498451)","('NON-ESG', 0.01851186901330948)"
Line 149,"MEDX Xelerator: The medical device and digital health- focused incubator announced its first million-dollar  challenge for physicians and engineers pursuing novel  ways to meet health care needs.~$1 billion  invested in venture portfolio  over the past decade ~35  active venture investments in 3 out of 5   of our 2021 acquisitions announced  came from our venture portfolio 2021 Performance ReportIntroduction Transforming care Overview and   2021 highlights Innovating to meet   more patient needs Ensuring quality,   health and safety Improving access   and outcomes through  digital solutions Investing in   our people Accelerating   possibilities Protecting the  environment Creating value  responsibly Appendix Jenifer Levinson  vice president,   Global Health Economics  and Market AccessAddressing health economics   to improve market access To increase patient access to needed medical therapies  globally, our Health Economics and Market Access (HEMA)  team studies the health economics associated with using  our devices.
","('Product_Design_And_Lifecycle_Management', 0.26267048716545105)","('Data_Security', 0.2006315141916275)","('Customer_Privacy', 0.09673376381397247)","('NON-ESG', 0.26267048716545105)","('NON-ESG', 0.2006315141916275)","('NON-ESG', 0.09673376381397247)"
Line 150,"HEMA economists use clinical outcomes and  real-world data to demonstrate the economic value of our  medical solutions and share that clinical and economic  evidence to support payer and provider decision-making.
","('Access_And_Affordability', 0.21693366765975952)","('Customer_Welfare', 0.11037687957286835)","('Competitive_Behavior', 0.0883868932723999)","('NON-ESG', 0.21693366765975952)","('NON-ESG', 0.11037687957286835)","('NON-ESG', 0.0883868932723999)"
Line 151,"The HEMA team worked closely with our Close the Gap  initiative in 2021, using health disparity analytics to engage  providers and advocate for clinical trial reimbursement policies  that support more diverse representation.
","('Management_Of_Legal_And_Regulatory_Framework', 0.2789265811443329)","('Competitive_Behavior', 0.18741726875305176)","('Employee_Engagement_Inclusion_And_Diversity', 0.17952711880207062)","('NON-ESG', 0.2789265811443329)","('NON-ESG', 0.18741726875305176)","('NON-ESG', 0.17952711880207062)"
Line 152,"As a result of the HEMA team’s efforts in 2021, we made the  following advances to improve patient access to treatment: “ It’s all about access.
","('Access_And_Affordability', 0.8963969349861145)","('Product_Quality_And_Safety', 0.012003423646092415)","('Human_Rights_And_Community_Relations', 0.007736736908555031)","(['Health Outcome Contribution'], 0.8963969349861145)","('NON-ESG', 0.012003423646092415)","('NON-ESG', 0.007736736908555031)"
Line 153,"If a health care  provider believes their patient is going  to benefit from a procedure, we want to  make sure it is affordable and covered  by the payer so the patient receives the  care they need.”Access in the U.S. Most insurance plans in the U.S. now cover approved use of  the WATCHMAN FLX™ left atrial appendage closure device.
","('Access_And_Affordability', 0.8067729473114014)","('Energy_Management', 0.01984291709959507)","('Product_Quality_And_Safety', 0.016362255439162254)","(['Health Outcome Contribution'], 0.8067729473114014)","('NON-ESG', 0.01984291709959507)","('NON-ESG', 0.016362255439162254)"
Line 154,"The U.S. Centers for Medicare & Medicaid Services granted  new payment terms for single-use duodenoscopes,  including the Boston Scientific EXALT™ Model D, increasing  patient access to medical technology that substantially  improves diagnosis and treatment.
","('Access_And_Affordability', 0.6686366200447083)","('Customer_Welfare', 0.04150119051337242)","('Product_Quality_And_Safety', 0.03224276378750801)","(['Health Outcome Contribution'], 0.6686366200447083)","('NON-ESG', 0.04150119051337242)","('NON-ESG', 0.03224276378750801)"
Line 155,"Providers now have  access to a device for the 40% of Medicare patients who  need treatment for problems in the liver, gallbladder, bile  ducts and pancreas.
","('Access_And_Affordability', 0.4322046935558319)","('Employee_Health_And_Safety', 0.10449820011854172)","('Customer_Welfare', 0.061358287930488586)","('NON-ESG', 0.4322046935558319)","('NON-ESG', 0.10449820011854172)","('NON-ESG', 0.061358287930488586)"
Line 156,"Access in South Africa Nearly 3 million patients now have access to procedures  utilizing the AXIOS™ Stent and Delivery System, which  enables physicians to treat patients endoscopically  instead of surgically.Access in Korea In Korea, patients now have access to procedures  involving the SpyGlass™ DS direct visualization  system and TheraSphere™ therapy for hepatocellular  carcinoma (HCC).
","('Access_And_Affordability', 0.5696161389350891)","('Employee_Health_And_Safety', 0.0899582952260971)","('Product_Quality_And_Safety', 0.04637033864855766)","(['Health Outcome Contribution'], 0.5696161389350891)","('NON-ESG', 0.0899582952260971)","('NON-ESG', 0.04637033864855766)"
Line 157,"Global evidence generation The HEMA team published eight peer-reviewed health  economics manuscripts and 24 peer-reviewed abstracts  to contribute to the global evidence base for payer and  other purchasing decision-makers.
","('Management_Of_Legal_And_Regulatory_Framework', 0.6005349159240723)","('Competitive_Behavior', 0.12716048955917358)","('Access_And_Affordability', 0.0538000613451004)","(['Corporate Governance'], 0.6005349159240723)","('NON-ESG', 0.12716048955917358)","('NON-ESG', 0.0538000613451004)"
Line 158,"Pre-clinical science and clinical trials Before Boston Scientific products proceed to human  clinical trials, we use stringent pre-clinical standards to  conduct extensive research into new devices.
","('Competitive_Behavior', 0.36817046999931335)","('Product_Quality_And_Safety', 0.13400717079639435)","('Management_Of_Legal_And_Regulatory_Framework', 0.12811735272407532)","('NON-ESG', 0.36817046999931335)","('NON-ESG', 0.13400717079639435)","('NON-ESG', 0.12811735272407532)"
Line 159,"After clinical  trials generate safety and efficacy data, we publicly report  the outcomes.
","('Product_Quality_And_Safety', 0.6345086097717285)","('Selling_Practices_And_Product_Labeling', 0.06941469013690948)","('Customer_Welfare', 0.052194323390722275)","(['Product Quality & Recall Management'], 0.6345086097717285)","('NON-ESG', 0.06941469013690948)","('NON-ESG', 0.052194323390722275)"
Line 160,"In 2021, we continued to strengthen and  refine our operating procedures to ensure we met or  exceeded all European Union Medical Device Regulation  (EU MDR) requirements.
","('Management_Of_Legal_And_Regulatory_Framework', 0.9585115313529968)","('Product_Quality_And_Safety', 0.004342239815741777)","('Access_And_Affordability', 0.003312034299597144)","(['Corporate Governance'], 0.9585115313529968)","('NON-ESG', 0.004342239815741777)","('NON-ESG', 0.003312034299597144)"
Line 161,"To learn more about progress we have made  advancing diversity in clinical trials, go to   Accelerating possibilities.
","('Employee_Engagement_Inclusion_And_Diversity', 0.25199389457702637)","('Competitive_Behavior', 0.13399407267570496)","('Customer_Welfare', 0.11872095614671707)","('NON-ESG', 0.25199389457702637)","('NON-ESG', 0.13399407267570496)","('NON-ESG', 0.11872095614671707)"
Line 162,"145   active clinical trials with  14,000 patients enrolled globally Active clinical trials 2021 Performance ReportIntroduction Transforming care Overview and   2021 highlights Innovating to meet   more patient needs Ensuring quality,   health and safety Improving access   and outcomes through  digital solutions Investing in   our people Accelerating   possibilities Protecting the  environment Creating value  responsibly Appendix Everyone makes an impact Our quality culture is reinforced through annual  Everyone Makes an Impact (EMAI) virtual events  where patients and caregivers share how Boston  Scientific devices improved their lives.Ensuring quality, health and safety Health care providers and their patients deserve transparency about the quality of our solutions.
","('Access_And_Affordability', 0.32282692193984985)","('Product_Quality_And_Safety', 0.2837386727333069)","('Employee_Health_And_Safety', 0.10354268550872803)","('NON-ESG', 0.32282692193984985)","('NON-ESG', 0.2837386727333069)","('NON-ESG', 0.10354268550872803)"
Line 163,"145   active clinical trials with  14,000 patients enrolled globally Active clinical trials 2021 Performance ReportIntroduction Transforming care Overview and   2021 highlights Innovating to meet   more patient needs Ensuring quality,   health and safety Improving access   and outcomes through  digital solutions Investing in   our people Accelerating   possibilities Protecting the  environment Creating value  responsibly Appendix Everyone makes an impact Our quality culture is reinforced through annual  Everyone Makes an Impact (EMAI) virtual events  where patients and caregivers share how Boston  Scientific devices improved their lives.Ensuring quality, health and safety Health care providers and their patients deserve transparency about the quality of our solutions.
","('Employee_Health_And_Safety', 0.25395500659942627)","('Product_Quality_And_Safety', 0.20303592085838318)","('Business_Ethics', 0.14360381662845612)","('NON-ESG', 0.25395500659942627)","('NON-ESG', 0.20303592085838318)","('NON-ESG', 0.14360381662845612)"
Line 164,"That is why a  comprehensive quality infrastructure guides our work through the life cycle of each Boston Scientific product.
","('Product_Design_And_Lifecycle_Management', 0.9591221809387207)","('Product_Quality_And_Safety', 0.006148581393063068)","('Customer_Welfare', 0.003418303094804287)","(['Product Stewardship'], 0.9591221809387207)","('NON-ESG', 0.006148581393063068)","('NON-ESG', 0.003418303094804287)"
Line 165,"Our  global quality and safety teams diligently oversee the processes and systems for everything we do — from research,  development and design to product building, supply chain operations and distribution.
","('Product_Design_And_Lifecycle_Management', 0.7734254598617554)","('Supply_Chain_Management', 0.09133324772119522)","('Product_Quality_And_Safety', 0.02802870236337185)","(['Product Stewardship'], 0.7734254598617554)","('NON-ESG', 0.09133324772119522)","('NON-ESG', 0.02802870236337185)"
Line 166,"Our annual bonus plan includes  a quality metrics modifier, which allows the Executive Compensation and Human Resources Committee of the Board to  reduce annual bonus plan funding for failure to meet quality goals and to reinforce accountability across the company.
","('Labor_Practices', 0.22815269231796265)","('Employee_Engagement_Inclusion_And_Diversity', 0.19187869131565094)","('Management_Of_Legal_And_Regulatory_Framework', 0.14251559972763062)","('NON-ESG', 0.22815269231796265)","('NON-ESG', 0.19187869131565094)","('NON-ESG', 0.14251559972763062)"
Line 167,"• The Boston Scientific Best4 strategy is the framework  our teams follow to deliver industry-leading quality  through a patient-centric culture, agile quality  processes, a relentless focus on product performance  and global regulatory compliance.
","('Management_Of_Legal_And_Regulatory_Framework', 0.3428129553794861)","('Product_Quality_And_Safety', 0.307643324136734)","('Business_Ethics', 0.0818599984049797)","('NON-ESG', 0.3428129553794861)","('NON-ESG', 0.307643324136734)","('NON-ESG', 0.0818599984049797)"
Line 168,"• Our global quality system continuously integrates  customer feedback and enables us to adapt to  changing global regulatory requirements.
","('Management_Of_Legal_And_Regulatory_Framework', 0.954098641872406)","('Competitive_Behavior', 0.007209125440567732)","('Business_Ethics', 0.005285386927425861)","(['Corporate Governance'], 0.954098641872406)","('NON-ESG', 0.007209125440567732)","('NON-ESG', 0.005285386927425861)"
Line 169,"• Quality improvement projects are prioritized  companywide to ensure that our products meet the  highest performance and safety standards and achieve  excellent patient outcomes.
","('Product_Quality_And_Safety', 0.9254445433616638)","('Employee_Health_And_Safety', 0.009043070487678051)","('Product_Design_And_Lifecycle_Management', 0.007359109353274107)","(['Product Quality & Recall Management'], 0.9254445433616638)","('NON-ESG', 0.009043070487678051)","('NON-ESG', 0.007359109353274107)"
Line 170,"• Boston Scientific quality system training is mandatory  for all employees and compliance is monitored through  quality management oversight.
","('Management_Of_Legal_And_Regulatory_Framework', 0.47917482256889343)","('Business_Ethics', 0.32685962319374084)","('Product_Quality_And_Safety', 0.035488311201334)","('NON-ESG', 0.47917482256889343)","('NON-ESG', 0.32685962319374084)","('NON-ESG', 0.035488311201334)"
Line 171,"At EMAI 2021, Brooke Thomas discussed how receiving an  implantable cardioverter defibrillator (ICD) changed her life.
","('Employee_Health_And_Safety', 0.6647801399230957)","('Employee_Engagement_Inclusion_And_Diversity', 0.04842435568571091)","('Product_Design_And_Lifecycle_Management', 0.03600035980343819)","(['Operational Eco-Efficiency'], 0.6647801399230957)","('NON-ESG', 0.04842435568571091)","('NON-ESG', 0.03600035980343819)"
Line 172,"Boston Scientific Quality teams collaborated with  Human Resources to reinforce our quality focus through  companywide incentives.
","('Management_Of_Legal_And_Regulatory_Framework', 0.36612626910209656)","('Business_Ethics', 0.20089609920978546)","('Product_Quality_And_Safety', 0.07663337886333466)","('NON-ESG', 0.36612626910209656)","('NON-ESG', 0.20089609920978546)","('NON-ESG', 0.07663337886333466)"
Line 173,"For example, we launched the  Quality Catch recognition program for product builders  at all manufacturing sites.
","('Product_Design_And_Lifecycle_Management', 0.7515549659729004)","('Product_Quality_And_Safety', 0.1381521224975586)","('Customer_Welfare', 0.011309715919196606)","(['Product Stewardship'], 0.7515549659729004)","('NON-ESG', 0.1381521224975586)","('NON-ESG', 0.011309715919196606)"
Line 174,"Employees who raise system  or process concerns that lead to quality improvements  are recognized by supervisors and peers for contributions  such as “Eagle Eye” and “Raise Your Hand” catches.
","('Business_Ethics', 0.2701345682144165)","('Human_Rights_And_Community_Relations', 0.13032317161560059)","('Labor_Practices', 0.08408248424530029)","('NON-ESG', 0.2701345682144165)","('NON-ESG', 0.13032317161560059)","('NON-ESG', 0.08408248424530029)"
Line 175,"To learn more, visit our newsroom.
","('Customer_Privacy', 0.11375757306814194)","('Business_Model_Resilience', 0.09091608971357346)","('Data_Security', 0.0868338942527771)","('NON-ESG', 0.11375757306814194)","('NON-ESG', 0.09091608971357346)","('NON-ESG', 0.0868338942527771)"
Line 176,"2021 Performance ReportIntroduction Transforming care Overview and   2021 highlights Innovating to meet   more patient needs Ensuring quality,   health and safety Improving access   and outcomes through  digital solutions Investing in   our people Accelerating   possibilities Protecting the  environment Creating value  responsibly Appendix Successfully implemented all process and  system requirements for EU MDR compliance  by May 26, Zero findings resulting in action following  more than 400 external audit daysCompliance Adhering to Global Quality System  compliance excellence and executing EU  MDR Quality Management System (QMS)Performance   Driving continuous improvement  in product performance,  patient experience7% reduction in overall complaint rate in  2021 compared to 2020, with a 39% overall  reduction in complaint rate since 98%+ effectiveness in CAPA metrics   and on-time approvalsAgility  Removing complexity,  improving systems$39 million in cost avoidance through  quality system improvements Implemented Quality System structure  for remote case supportThe “Best4” strategy — which includes a focus on culture, agility, performance and compliance — is the companywide  framework for our patient-centric quality culture.
","('Employee_Health_And_Safety', 0.4991304576396942)","('Access_And_Affordability', 0.26014935970306396)","('Product_Quality_And_Safety', 0.06668999046087265)","('NON-ESG', 0.4991304576396942)","('NON-ESG', 0.26014935970306396)","('NON-ESG', 0.06668999046087265)"
Line 177,"2021 Performance ReportIntroduction Transforming care Overview and   2021 highlights Innovating to meet   more patient needs Ensuring quality,   health and safety Improving access   and outcomes through  digital solutions Investing in   our people Accelerating   possibilities Protecting the  environment Creating value  responsibly Appendix Successfully implemented all process and  system requirements for EU MDR compliance  by May 26, Zero findings resulting in action following  more than 400 external audit daysCompliance Adhering to Global Quality System  compliance excellence and executing EU  MDR Quality Management System (QMS)Performance   Driving continuous improvement  in product performance,  patient experience7% reduction in overall complaint rate in  2021 compared to 2020, with a 39% overall  reduction in complaint rate since 98%+ effectiveness in CAPA metrics   and on-time approvalsAgility  Removing complexity,  improving systems$39 million in cost avoidance through  quality system improvements Implemented Quality System structure  for remote case supportThe “Best4” strategy — which includes a focus on culture, agility, performance and compliance — is the companywide  framework for our patient-centric quality culture.
","('Product_Quality_And_Safety', 0.5482630133628845)","('Business_Ethics', 0.1121208593249321)","('Product_Design_And_Lifecycle_Management', 0.06109410524368286)","(['Product Quality & Recall Management'], 0.5482630133628845)","('NON-ESG', 0.1121208593249321)","('NON-ESG', 0.06109410524368286)"
Line 178,"2021 Performance ReportIntroduction Transforming care Overview and   2021 highlights Innovating to meet   more patient needs Ensuring quality,   health and safety Improving access   and outcomes through  digital solutions Investing in   our people Accelerating   possibilities Protecting the  environment Creating value  responsibly Appendix Successfully implemented all process and  system requirements for EU MDR compliance  by May 26, Zero findings resulting in action following  more than 400 external audit daysCompliance Adhering to Global Quality System  compliance excellence and executing EU  MDR Quality Management System (QMS)Performance   Driving continuous improvement  in product performance,  patient experience7% reduction in overall complaint rate in  2021 compared to 2020, with a 39% overall  reduction in complaint rate since 98%+ effectiveness in CAPA metrics   and on-time approvalsAgility  Removing complexity,  improving systems$39 million in cost avoidance through  quality system improvements Implemented Quality System structure  for remote case supportThe “Best4” strategy — which includes a focus on culture, agility, performance and compliance — is the companywide  framework for our patient-centric quality culture.
","('Business_Ethics', 0.39414912462234497)","('Systemic_Risk_Management', 0.11506440490484238)","('Product_Quality_And_Safety', 0.09069608151912689)","('NON-ESG', 0.39414912462234497)","('NON-ESG', 0.11506440490484238)","('NON-ESG', 0.09069608151912689)"
Line 179,"It is a key pillar in our Delivering Excellence strategy to uphold cohesive  quality across our global supply chain.
","('Supply_Chain_Management', 0.9382380247116089)","('Product_Design_And_Lifecycle_Management', 0.010153714567422867)","('Labor_Practices', 0.003925731871277094)","(['Supply Chain Management'], 0.9382380247116089)","('NON-ESG', 0.010153714567422867)","('NON-ESG', 0.003925731871277094)"
Line 180,"All Boston Scientific manufacturing and distribution sites use a shared set of metrics  to ensure the highest quality standards are met throughout the company’s operations and supply chain.
","('Supply_Chain_Management', 0.9294373393058777)","('Product_Design_And_Lifecycle_Management', 0.007762429770082235)","('Product_Quality_And_Safety', 0.006133270915597677)","(['Supply Chain Management'], 0.9294373393058777)","('NON-ESG', 0.007762429770082235)","('NON-ESG', 0.006133270915597677)"
Line 181,"Best4 Taking a comprehensive   quality approach Our Corrective and preventative action (CAPA) efforts  in 2021 included investing in systems, training and  processes focused on preventative action.
","('Critical_Incident_Risk_Management', 0.6871259212493896)","('Employee_Health_And_Safety', 0.08830784261226654)","('Human_Rights_And_Community_Relations', 0.06717314571142197)","(['Risk & Crisis Management'], 0.6871259212493896)","('NON-ESG', 0.08830784261226654)","('NON-ESG', 0.06717314571142197)"
Line 182,"We also made  measurable progress identifying and reducing risks  through a combination of corrective actions and process  improvements.
","('Systemic_Risk_Management', 0.7215076088905334)","('Physical_Impacts_Of_Climate_Change', 0.07794992625713348)","('Business_Model_Resilience', 0.0392557755112648)","(['Risk & Crisis Management'], 0.7215076088905334)","('NON-ESG', 0.07794992625713348)","('NON-ESG', 0.0392557755112648)"
Line 183,"Our practice of conducting limited market  releases for key products demonstrates how we are  adapting our processes to further support the responsible  development and expansion of new markets.
","('Product_Design_And_Lifecycle_Management', 0.9644501209259033)","('Product_Quality_And_Safety', 0.0035684960894286633)","('Customer_Welfare', 0.0035471811424940825)","(['Product Stewardship'], 0.9644501209259033)","('NON-ESG', 0.0035684960894286633)","('NON-ESG', 0.0035471811424940825)"
Line 184,"For  example, with the launch of the EXALT™ Model B device  in the United States and Europe, this approach allowed us  to closely monitor and evaluate device use and adjust for  any additional training needs prior to the full launch.
","('Product_Quality_And_Safety', 0.19596391916275024)","('Product_Design_And_Lifecycle_Management', 0.14590702950954437)","('Access_And_Affordability', 0.09115015715360641)","('NON-ESG', 0.19596391916275024)","('NON-ESG', 0.14590702950954437)","('NON-ESG', 0.09115015715360641)"
Line 185,"The company increased post-market surveillance  activities across our product portfolio and participated  in more than 400 days of external quality system audits  involving the U.S. Food and Drug Administration, EU MDR  bodies such as DEKRA, the British Standards Institute  (BSI) and TÜV SÜD as well as several country-specific  regulators.
","('Product_Quality_And_Safety', 0.7102975845336914)","('Business_Ethics', 0.038809455931186676)","('Selling_Practices_And_Product_Labeling', 0.03538394346833229)","(['Product Quality & Recall Management'], 0.7102975845336914)","('NON-ESG', 0.038809455931186676)","('NON-ESG', 0.03538394346833229)"
Line 186,"Since 2017, Boston Scientific has recorded a  39% year-over-year complaint rate reduction.
","('Management_Of_Legal_And_Regulatory_Framework', 0.4069909155368805)","('Systemic_Risk_Management', 0.14491789042949677)","('Business_Ethics', 0.1095823273062706)","('NON-ESG', 0.4069909155368805)","('NON-ESG', 0.14491789042949677)","('NON-ESG', 0.1095823273062706)"
Line 187,"In the rare  event that we do detect an issue, we act swiftly and with  patient safety in mind.
","('Employee_Health_And_Safety', 0.851574182510376)","('Product_Quality_And_Safety', 0.06312616914510727)","('Critical_Incident_Risk_Management', 0.013154416345059872)","(['Operational Eco-Efficiency'], 0.851574182510376)","('NON-ESG', 0.06312616914510727)","('NON-ESG', 0.013154416345059872)"
Line 188,"2021 recalls: • Class I recalls: • Class II recalls: 8Metric Results Culture Establishing a preventative quality culture26% of CAPAs considered preventativequality strategy  Best4quality results 2021 Performance ReportIntroduction Transforming care Overview and   2021 highlights Innovating to meet   more patient needs Ensuring quality,   health and safety Improving access   and outcomes through  digital solutions Investing in   our people Accelerating   possibilities Protecting the  environment Creating value  responsibly Appendix Additional details on product quality and safety   data are available in our Appendix.Connected patient challenge The sixth Boston Scientific Connected Patient  Challenge featured telehealth solutions to improve  patient care and connectivity while also addressing  the gap in treatment disparities.
","('Employee_Health_And_Safety', 0.7288462519645691)","('Product_Quality_And_Safety', 0.08959538489580154)","('Access_And_Affordability', 0.0347863994538784)","(['Operational Eco-Efficiency'], 0.7288462519645691)","('NON-ESG', 0.08959538489580154)","('NON-ESG', 0.0347863994538784)"
Line 189,"2021 recalls: • Class I recalls: • Class II recalls: 8Metric Results Culture Establishing a preventative quality culture26% of CAPAs considered preventativequality strategy  Best4quality results 2021 Performance ReportIntroduction Transforming care Overview and   2021 highlights Innovating to meet   more patient needs Ensuring quality,   health and safety Improving access   and outcomes through  digital solutions Investing in   our people Accelerating   possibilities Protecting the  environment Creating value  responsibly Appendix Additional details on product quality and safety   data are available in our Appendix.Connected patient challenge The sixth Boston Scientific Connected Patient  Challenge featured telehealth solutions to improve  patient care and connectivity while also addressing  the gap in treatment disparities.
","('Product_Quality_And_Safety', 0.8875054121017456)","('Selling_Practices_And_Product_Labeling', 0.018424145877361298)","('Product_Design_And_Lifecycle_Management', 0.018316682428121567)","(['Product Quality & Recall Management'], 0.8875054121017456)","('NON-ESG', 0.018424145877361298)","('NON-ESG', 0.018316682428121567)"
Line 190,"After receiving  a record number of submissions, first place went  to Kalia Health for KAL-PDx, a home-based early  detection test for preeclampsia.
","('Employee_Health_And_Safety', 0.18688642978668213)","('Product_Quality_And_Safety', 0.11568671464920044)","('Competitive_Behavior', 0.11524724215269089)","('NON-ESG', 0.18688642978668213)","('NON-ESG', 0.11568671464920044)","('NON-ESG', 0.11524724215269089)"
Line 191,"Improving access and outcomes   through digital solutions    For a health care solution to make a meaningful difference, it must reach the patients who need treatment.
","('Access_And_Affordability', 0.914174497127533)","('Critical_Incident_Risk_Management', 0.007554850075393915)","('Product_Quality_And_Safety', 0.007421738468110561)","(['Health Outcome Contribution'], 0.914174497127533)","('NON-ESG', 0.007554850075393915)","('NON-ESG', 0.007421738468110561)"
Line 192,"In 2021,  we made significant investments in physician digital education and engagement.
","('Access_And_Affordability', 0.5307549238204956)","('Employee_Engagement_Inclusion_And_Diversity', 0.14916926622390747)","('Human_Rights_And_Community_Relations', 0.03499649465084076)","(['Health Outcome Contribution'], 0.5307549238204956)","('NON-ESG', 0.14916926622390747)","('NON-ESG', 0.03499649465084076)"
Line 193,"Approximately 20,000 providers  accessed the Boston Scientific EDUCARE platform for on-demand learning modules, interactive training tools, clinical  overviews and case studies.
","('Access_And_Affordability', 0.31090542674064636)","('Customer_Welfare', 0.11243323981761932)","('Management_Of_Legal_And_Regulatory_Framework', 0.087532639503479)","('NON-ESG', 0.31090542674064636)","('NON-ESG', 0.11243323981761932)","('NON-ESG', 0.087532639503479)"
Line 194,"The platform includes medical education and training courses that support health care  professionals in the delivery of patient care around the globe and is the primary access point to the company’s  professional education for health care professionals.
","('Access_And_Affordability', 0.7924006581306458)","('Product_Quality_And_Safety', 0.023101214319467545)","('Employee_Engagement_Inclusion_And_Diversity', 0.02146845869719982)","(['Health Outcome Contribution'], 0.7924006581306458)","('NON-ESG', 0.023101214319467545)","('NON-ESG', 0.02146845869719982)"
Line 195,"To address treatment inequities, inconsistent outcomes and  COVID-19 safety concerns, we also introduced targeted technologies for improving patient care.Protecting product data   and patient privacy We continued to invest in heightened data security and  privacy.
","('Data_Security', 0.32389089465141296)","('Product_Quality_And_Safety', 0.2338074892759323)","('Customer_Privacy', 0.18160511553287506)","('NON-ESG', 0.32389089465141296)","('NON-ESG', 0.2338074892759323)","('NON-ESG', 0.18160511553287506)"
Line 196,"Our data security experts took action to mitigate  potential vulnerabilities, expand cybersecurity monitoring  and strengthen mandatory employee training.
","('Data_Security', 0.9439210295677185)","('Systemic_Risk_Management', 0.009734914638102055)","('Business_Ethics', 0.004847597796469927)","(['Information Security/Cybersecurity & System Availability'], 0.9439210295677185)","('NON-ESG', 0.009734914638102055)","('NON-ESG', 0.004847597796469927)"
Line 197,"For network- connected Boston Scientific systems, we implemented  advanced security testing to discover vulnerabilities and  quickly address them, along with a robust security risk  assessment process.
","('Data_Security', 0.9561207890510559)","('Systemic_Risk_Management', 0.006085778586566448)","('Business_Ethics', 0.003100043162703514)","(['Information Security/Cybersecurity & System Availability'], 0.9561207890510559)","('NON-ESG', 0.006085778586566448)","('NON-ESG', 0.003100043162703514)"
Line 198,"Safe, secure remote assistance The MyLATITUDE™ app enables  patients with Boston Scientific  pacemakers and defibrillators  to stay connected with their  providers through LATITUDE™  in-home monitoring.
","('Employee_Health_And_Safety', 0.30601173639297485)","('Access_And_Affordability', 0.17018020153045654)","('Critical_Incident_Risk_Management', 0.11900223791599274)","('NON-ESG', 0.30601173639297485)","('NON-ESG', 0.17018020153045654)","('NON-ESG', 0.11900223791599274)"
Line 199,"In 2021, data  from the ISO 27001 and 27018  certified LATITUDE system helped  providers safely and remotely  monitor approximately 1 million  patients with implanted devices,  to quickly detect and treat certain  heart conditions.SpaceOAR certification for  physicians in Hong Kong Our Asia Pacific digital team  developed a compliant virtual  certification program for  physicians using our SpaceOAR™  Hydrogel.
","('Employee_Health_And_Safety', 0.3270762264728546)","('Product_Quality_And_Safety', 0.16275791823863983)","('Access_And_Affordability', 0.14924825727939606)","('NON-ESG', 0.3270762264728546)","('NON-ESG', 0.16275791823863983)","('NON-ESG', 0.14924825727939606)"
Line 200,"The pilot program  for providers treating patients  undergoing prostate cancer  radiation therapy will serve as a  prototype for virtual certification  programs in other medical fields.Measuring chronic pain with  artificial intelligence (AI) As the opioid epidemic amplified  the need for reliable pain  measurement — especially in  telehealth settings — we work  with IBM Research on technology  to objectively measure pain.
","('Employee_Health_And_Safety', 0.9293683767318726)","('Critical_Incident_Risk_Management', 0.006158481352031231)","('Employee_Engagement_Inclusion_And_Diversity', 0.005946572870016098)","(['Operational Eco-Efficiency'], 0.9293683767318726)","('NON-ESG', 0.006158481352031231)","('NON-ESG', 0.005946572870016098)"
Line 201,"Our collective team of scientists,  engineers, device designers and  clinicians are using a custom AI  and cloud platform to discover  new biomarkers that will help  clinicians assess patients and offer  personalized chronic pain care.For more on our work to safeguard patient data  and product security, see  Creating value responsibly .
","('Data_Security', 0.8659656047821045)","('Customer_Privacy', 0.02119961380958557)","('Business_Ethics', 0.01131381094455719)","(['Information Security/Cybersecurity & System Availability'], 0.8659656047821045)","('NON-ESG', 0.02119961380958557)","('NON-ESG', 0.01131381094455719)"
Line 202,"2021 Performance ReportIntroduction Transforming care Overview and   2021 highlights Innovating to meet   more patient needs Ensuring quality,   health and safety Improving access   and outcomes through  digital solutions Investing in   our people Accelerating   possibilities Protecting the  environment Creating value  responsibly Appendix Investing in  our people As a business and as a global citizen, Boston Scientific is defined by  the talent and collective passion of our people.
","('Access_And_Affordability', 0.5085680484771729)","('Employee_Health_And_Safety', 0.22184789180755615)","('Product_Quality_And_Safety', 0.05238308385014534)","(['Health Outcome Contribution'], 0.5085680484771729)","('NON-ESG', 0.22184789180755615)","('NON-ESG', 0.05238308385014534)"
Line 203,"We strive to make  our company a place where employees are valued and feel they  belong — and where diversity of thought, skills and life experience  leads to breakthroughs.When we challenge ourselves to embrace  differences, we advance innovation.
","('Employee_Engagement_Inclusion_And_Diversity', 0.970328152179718)","('Human_Rights_And_Community_Relations', 0.002346715424209833)","('Employee_Health_And_Safety', 0.0022796622943133116)","(['Human Capital Development'], 0.970328152179718)","('NON-ESG', 0.002346715424209833)","('NON-ESG', 0.0022796622943133116)"
Line 204,"41.1% of supervisor and manager roles held by women globally;  21.6% by multicultural employees in the U.S. and Puerto Rico99%+  pay equity for employees across gender globally  and for multicultural talent in the U.S. and Puerto Rico 2021 Performance ReportIntroduction Transforming care Investing in   our people Overview and   2021 highlights Our diverse, equitable   and inclusive workplace Attracting, developing   and retaining talent Employee well-being,  rewards and safety Accelerating   possibilities Protecting the  environment Creating value  responsibly Appendix Overview and 2021 highlights Our people continued to address unmet clinical needs with innovative medical technology.
","('Employee_Engagement_Inclusion_And_Diversity', 0.9755792617797852)","('Employee_Health_And_Safety', 0.002439339878037572)","('Human_Rights_And_Community_Relations', 0.0019555753096938133)","(['Human Capital Development'], 0.9755792617797852)","('NON-ESG', 0.002439339878037572)","('NON-ESG', 0.0019555753096938133)"
Line 205,"41.1% of supervisor and manager roles held by women globally;  21.6% by multicultural employees in the U.S. and Puerto Rico99%+  pay equity for employees across gender globally  and for multicultural talent in the U.S. and Puerto Rico 2021 Performance ReportIntroduction Transforming care Investing in   our people Overview and   2021 highlights Our diverse, equitable   and inclusive workplace Attracting, developing   and retaining talent Employee well-being,  rewards and safety Accelerating   possibilities Protecting the  environment Creating value  responsibly Appendix Overview and 2021 highlights Our people continued to address unmet clinical needs with innovative medical technology.
","('Product_Design_And_Lifecycle_Management', 0.3285931348800659)","('Business_Model_Resilience', 0.15974101424217224)","('Customer_Welfare', 0.14615730941295624)","('NON-ESG', 0.3285931348800659)","('NON-ESG', 0.15974101424217224)","('NON-ESG', 0.14615730941295624)"
Line 206,"Teams across Boston  Scientific adapted to new ways of working to deliver on our commitments to providers and patients around the world.
","('Access_And_Affordability', 0.8166855573654175)","('Human_Rights_And_Community_Relations', 0.017885038629174232)","('Critical_Incident_Risk_Management', 0.017284691333770752)","(['Health Outcome Contribution'], 0.8166855573654175)","('NON-ESG', 0.017885038629174232)","('NON-ESG', 0.017284691333770752)"
Line 207,"We prioritized a diverse and inclusive workplace where employees learn and grow, have access to resources to support  their well-being and receive equitable rewards for their contributions.
","('Employee_Engagement_Inclusion_And_Diversity', 0.9053181409835815)","('Human_Rights_And_Community_Relations', 0.017861375585198402)","('Access_And_Affordability', 0.015925349667668343)","(['Human Capital Development'], 0.9053181409835815)","('NON-ESG', 0.017861375585198402)","('NON-ESG', 0.015925349667668343)"
Line 208,"Our diverse, equitable and inclusive workplace At Boston Scientific, we know diverse insights lead to new and better answers.
","('Employee_Engagement_Inclusion_And_Diversity', 0.9687831401824951)","('Human_Rights_And_Community_Relations', 0.002554934937506914)","('Business_Model_Resilience', 0.002309210831299424)","(['Human Capital Development'], 0.9687831401824951)","('NON-ESG', 0.002554934937506914)","('NON-ESG', 0.002309210831299424)"
Line 209,"That’s why we work to create an  inclusive, open and equitable culture for all employees no matter where they sit or what role they hold.
","('Employee_Engagement_Inclusion_And_Diversity', 0.9146435856819153)","('Human_Rights_And_Community_Relations', 0.016747839748859406)","('Labor_Practices', 0.00735100731253624)","(['Human Capital Development'], 0.9146435856819153)","('NON-ESG', 0.016747839748859406)","('NON-ESG', 0.00735100731253624)"
Line 210,"Our people  collaborate in ways that foster new approaches to tough problems, demonstrate our core values and reflect our  commitment to diversity, equity and inclusion (DE&I).
","('Employee_Engagement_Inclusion_And_Diversity', 0.9740987420082092)","('Human_Rights_And_Community_Relations', 0.0026675837580114603)","('Employee_Health_And_Safety', 0.0020927994046360254)","(['Human Capital Development'], 0.9740987420082092)","('NON-ESG', 0.0026675837580114603)","('NON-ESG', 0.0020927994046360254)"
Line 211,"The result is innovation that helps improve patient care.
","('Access_And_Affordability', 0.7321791052818298)","('Customer_Welfare', 0.02601342648267746)","('Energy_Management', 0.02533269114792347)","(['Health Outcome Contribution'], 0.7321791052818298)","('NON-ESG', 0.02601342648267746)","('NON-ESG', 0.02533269114792347)"
Line 212,"To achieve DE&I that endures, our aspirations and progress must be transparent and measurable.
","('Human_Rights_And_Community_Relations', 0.7168114185333252)","('Business_Model_Resilience', 0.03542133420705795)","('Management_Of_Legal_And_Regulatory_Framework', 0.032510317862033844)","(['Community Relations'], 0.7168114185333252)","('NON-ESG', 0.03542133420705795)","('NON-ESG', 0.032510317862033844)"
Line 213,"Our 3Up by 2023   goals aim to increase the representation of women and multicultural talent in our workforce through policies and  practices that give everyone equitable opportunities for career growth.
","('Employee_Engagement_Inclusion_And_Diversity', 0.9756597280502319)","('Employee_Health_And_Safety', 0.0017321388004347682)","('Human_Rights_And_Community_Relations', 0.0016298791160807014)","(['Human Capital Development'], 0.9756597280502319)","('NON-ESG', 0.0017321388004347682)","('NON-ESG', 0.0016298791160807014)"
Line 214,"Wendy Carruthers  executive vice president, Human Resources“ When we create a workplace where all  employees feel they belong, are valued  and have opportunities to   grow, we will advance   health care to many   more patients.”Boston Scientific wins premier Catalyst Award   for DE&I excellence We have been honored with a 2022 Catalyst Award, the premier award for DE&I  initiatives that improve gender representation across ranks and advance women  and other underrepresented groups.
","('Employee_Engagement_Inclusion_And_Diversity', 0.9678689241409302)","('Labor_Practices', 0.003517900360748172)","('Employee_Health_And_Safety', 0.0029845386743545532)","(['Human Capital Development'], 0.9678689241409302)","('NON-ESG', 0.003517900360748172)","('NON-ESG', 0.0029845386743545532)"
Line 215,"Boston Scientific was recognized for its multi- year, global initiative to address barriers women and diverse employees may face  in the workplace.
","('Employee_Engagement_Inclusion_And_Diversity', 0.9668827652931213)","('Labor_Practices', 0.004127573687583208)","('Human_Rights_And_Community_Relations', 0.0038745207712054253)","(['Human Capital Development'], 0.9668827652931213)","('NON-ESG', 0.004127573687583208)","('NON-ESG', 0.0038745207712054253)"
Line 216,"The effort accelerated a cultural shift within Boston Scientific.
","('Employee_Engagement_Inclusion_And_Diversity', 0.35212957859039307)","('Human_Rights_And_Community_Relations', 0.08898153156042099)","('Competitive_Behavior', 0.06349538266658783)","('NON-ESG', 0.35212957859039307)","('NON-ESG', 0.08898153156042099)","('NON-ESG', 0.06349538266658783)"
Line 217,"“We applaud Boston Scientific for its commitment to diversity, equity and inclusion  and to fostering career advancement for women and everyone,” said Lorraine  Hariton, president and chief executive officer, Catalyst.
","('Employee_Engagement_Inclusion_And_Diversity', 0.9736598134040833)","('Human_Rights_And_Community_Relations', 0.002188100479543209)","('Employee_Health_And_Safety', 0.0019658126402646303)","(['Human Capital Development'], 0.9736598134040833)","('NON-ESG', 0.002188100479543209)","('NON-ESG', 0.0019658126402646303)"
Line 218,"Increase our goal for representation of women at the  supervisor and manager level by 3 percentage points  or more, to at least 43% globally Increase our goal for representation of multicultural  talent at the supervisor and manager level by  3 percentage points or more, to at least 23% in  the U.S. and Puerto Rico Continue to be a top 10% globally recognized leader  for workplace inclusion  2021 Performance ReportIntroduction Transforming care Investing in   our people Overview and   2021 highlights Our diverse, equitable   and inclusive workplace Attracting, developing   and retaining talent Employee well-being,  rewards and safety Accelerating   possibilities Protecting the  environment Creating value  responsibly Appendix Board of director representationAccelerating our DE&I progress Unconscious bias training is required for all Boston  Scientific employees.
","('Employee_Engagement_Inclusion_And_Diversity', 0.9674995541572571)","('Employee_Health_And_Safety', 0.004325662739574909)","('Human_Rights_And_Community_Relations', 0.002685509156435728)","(['Human Capital Development'], 0.9674995541572571)","('NON-ESG', 0.004325662739574909)","('NON-ESG', 0.002685509156435728)"
Line 219,"Increase our goal for representation of women at the  supervisor and manager level by 3 percentage points  or more, to at least 43% globally Increase our goal for representation of multicultural  talent at the supervisor and manager level by  3 percentage points or more, to at least 23% in  the U.S. and Puerto Rico Continue to be a top 10% globally recognized leader  for workplace inclusion  2021 Performance ReportIntroduction Transforming care Investing in   our people Overview and   2021 highlights Our diverse, equitable   and inclusive workplace Attracting, developing   and retaining talent Employee well-being,  rewards and safety Accelerating   possibilities Protecting the  environment Creating value  responsibly Appendix Board of director representationAccelerating our DE&I progress Unconscious bias training is required for all Boston  Scientific employees.
","('Employee_Engagement_Inclusion_And_Diversity', 0.8941851854324341)","('Employee_Health_And_Safety', 0.02412969432771206)","('Human_Rights_And_Community_Relations', 0.016594333574175835)","(['Human Capital Development'], 0.8941851854324341)","('NON-ESG', 0.02412969432771206)","('NON-ESG', 0.016594333574175835)"
Line 220,"We expanded initiatives to support  equitable opportunities for growth, including diverse  hiring practices and development programs for women  and multicultural leaders.
","('Employee_Engagement_Inclusion_And_Diversity', 0.973181426525116)","('Human_Rights_And_Community_Relations', 0.002027281327173114)","('Access_And_Affordability', 0.0018006303580477834)","(['Human Capital Development'], 0.973181426525116)","('NON-ESG', 0.002027281327173114)","('NON-ESG', 0.0018006303580477834)"
Line 221,"To equip employees with  additional skills and tools to recognize and address  systemic racism, bias and prejudice, we introduced  Anti-Racism & Cultural History (ARCH) training in the  United States.
","('Employee_Engagement_Inclusion_And_Diversity', 0.7066000699996948)","('Business_Ethics', 0.1274116039276123)","('Employee_Health_And_Safety', 0.023020034655928612)","(['Human Capital Development'], 0.7066000699996948)","('NON-ESG', 0.1274116039276123)","('NON-ESG', 0.023020034655928612)"
Line 222,"The ARCH curriculum advances workplace  understanding of race, culture and identity through three  learning paths customized for individual contributors,  people leaders and senior leaders.
","('Employee_Engagement_Inclusion_And_Diversity', 0.9619787931442261)","('Human_Rights_And_Community_Relations', 0.0059068212285637856)","('Employee_Health_And_Safety', 0.0031617330387234688)","(['Human Capital Development'], 0.9619787931442261)","('NON-ESG', 0.0059068212285637856)","('NON-ESG', 0.0031617330387234688)"
Line 223,"The program is  required for people leaders and recommended for  individual contributors.
","('Employee_Engagement_Inclusion_And_Diversity', 0.2609780430793762)","('Human_Rights_And_Community_Relations', 0.14818023145198822)","('Director_Removal', 0.11446131020784378)","('NON-ESG', 0.2609780430793762)","('NON-ESG', 0.14818023145198822)","('NON-ESG', 0.11446131020784378)"
Line 224,"ARCH training will be adapted  and made available in all regions starting in 2023.“ I have been promoted eight times  in my career with Boston Scientific,  and I have never felt held back from  obtaining my goals.
","('Employee_Engagement_Inclusion_And_Diversity', 0.4092906415462494)","('Product_Quality_And_Safety', 0.07969018071889877)","('Management_Of_Legal_And_Regulatory_Framework', 0.05292961001396179)","('NON-ESG', 0.4092906415462494)","('NON-ESG', 0.07969018071889877)","('NON-ESG', 0.05292961001396179)"
Line 225,"My company’s  focus on increasing women in  leadership has created a culture that  has accelerated career opportunities  for all genders.” Becky Knutson  director,   Research and Development       Supervisor and manager level representation1Representation at all levels Women (global)2Women (global)2Multicultural  (U.S. and Puerto Rico)3Multicultural  (U.S. and Puerto Rico)2018 2019 2020 202146.5%47.0%47.4%48.3% 2018 2019 2020 202138.4% 38.1%39.9%41.1% 2018 2019 2020 202131.7%33.2%34.0%35.7% 2018 2019 2020 202119.6%20.8%21.4% 21.6%30%  of board of director members self- identify as women, 30% self-identify  as ethnically diverse 1 Supervisors and managers: includes all levels that are supervisor, manager I and manager II.
","('Employee_Engagement_Inclusion_And_Diversity', 0.9485629796981812)","('Business_Model_Resilience', 0.005618883762508631)","('Director_Removal', 0.003760757390409708)","(['Human Capital Development'], 0.9485629796981812)","('NON-ESG', 0.005618883762508631)","('NON-ESG', 0.003760757390409708)"
Line 226,"My company’s  focus on increasing women in  leadership has created a culture that  has accelerated career opportunities  for all genders.” Becky Knutson  director,   Research and Development       Supervisor and manager level representation1Representation at all levels Women (global)2Women (global)2Multicultural  (U.S. and Puerto Rico)3Multicultural  (U.S. and Puerto Rico)2018 2019 2020 202146.5%47.0%47.4%48.3% 2018 2019 2020 202138.4% 38.1%39.9%41.1% 2018 2019 2020 202131.7%33.2%34.0%35.7% 2018 2019 2020 202119.6%20.8%21.4% 21.6%30%  of board of director members self- identify as women, 30% self-identify  as ethnically diverse 1 Supervisors and managers: includes all levels that are supervisor, manager I and manager II.
","('Employee_Engagement_Inclusion_And_Diversity', 0.9733662009239197)","('Human_Rights_And_Community_Relations', 0.001803888357244432)","('Employee_Health_And_Safety', 0.00179887970443815)","(['Human Capital Development'], 0.9733662009239197)","('NON-ESG', 0.001803888357244432)","('NON-ESG', 0.00179887970443815)"
Line 227,"2 Gender: includes all employees globally where gender is identified.
","('Employee_Engagement_Inclusion_And_Diversity', 0.8954712152481079)","('Labor_Practices', 0.03545735403895378)","('Employee_Health_And_Safety', 0.00857766717672348)","(['Human Capital Development'], 0.8954712152481079)","('NON-ESG', 0.03545735403895378)","('NON-ESG', 0.00857766717672348)"
Line 228,"Excludes any employees where gender is ""undeclared"" and ""unknown."" 3 Multicultural talent: in the U.S. and Puerto Rico, defined as African American/Black, Asian, Hispanic/Latino, American Indian/Alaska Native, Native Hawaiian/Other Pacific Islander, and two or more races.
","('Employee_Engagement_Inclusion_And_Diversity', 0.9740831255912781)","('Labor_Practices', 0.0022194397170096636)","('Employee_Health_And_Safety', 0.002018955070525408)","(['Human Capital Development'], 0.9740831255912781)","('NON-ESG', 0.0022194397170096636)","('NON-ESG', 0.002018955070525408)"
Line 229,"Excludes any employees who choose not to self-identify.For detailed definitions and additional diversity  data, please visit the Appendix.
","('Employee_Engagement_Inclusion_And_Diversity', 0.9684572219848633)","('Customer_Privacy', 0.0023186083417385817)","('Human_Rights_And_Community_Relations', 0.0021810773760080338)","(['Human Capital Development'], 0.9684572219848633)","('NON-ESG', 0.0023186083417385817)","('NON-ESG', 0.0021810773760080338)"
Line 230,"2021 Performance ReportIntroduction Transforming care Investing in   our people Overview and   2021 highlights Our diverse, equitable   and inclusive workplace Attracting, developing   and retaining talent Employee well-being,  rewards and safety Accelerating   possibilities Protecting the  environment Creating value  responsibly Appendix Building capabilities with diverse talent In 2021 we broadened existing development programs  and introduced new initiatives to increase opportunities  for women and multicultural talent, strengthen retention  efforts and offer additional pathways to leadership.
","('Employee_Engagement_Inclusion_And_Diversity', 0.9688946008682251)","('Employee_Health_And_Safety', 0.003942539915442467)","('Human_Rights_And_Community_Relations', 0.0023100711405277252)","(['Human Capital Development'], 0.9688946008682251)","('NON-ESG', 0.003942539915442467)","('NON-ESG', 0.0023100711405277252)"
Line 231,"2021 Performance ReportIntroduction Transforming care Investing in   our people Overview and   2021 highlights Our diverse, equitable   and inclusive workplace Attracting, developing   and retaining talent Employee well-being,  rewards and safety Accelerating   possibilities Protecting the  environment Creating value  responsibly Appendix Building capabilities with diverse talent In 2021 we broadened existing development programs  and introduced new initiatives to increase opportunities  for women and multicultural talent, strengthen retention  efforts and offer additional pathways to leadership.
","('Employee_Engagement_Inclusion_And_Diversity', 0.9669399261474609)","('Employee_Health_And_Safety', 0.002711425768211484)","('Business_Model_Resilience', 0.0022432049736380577)","(['Human Capital Development'], 0.9669399261474609)","('NON-ESG', 0.002711425768211484)","('NON-ESG', 0.0022432049736380577)"
Line 232,"GROW.
","('Product_Design_And_Lifecycle_Management', 0.15588803589344025)","('Business_Model_Resilience', 0.12524588406085968)","('Ecological_Impacts', 0.09143392741680145)","('NON-ESG', 0.15588803589344025)","('NON-ESG', 0.12524588406085968)","('NON-ESG', 0.09143392741680145)"
Line 233,"We expanded GROW — Give Real Opportunities  for Valuable Work Experience — after talking with Black,  Hispanic and Latinx employees who build our medical  devices and are interested in furthering their careers  in business roles at Boston Scientific.
","('Employee_Engagement_Inclusion_And_Diversity', 0.9696657061576843)","('Employee_Health_And_Safety', 0.0030548772774636745)","('Business_Model_Resilience', 0.002039877697825432)","(['Human Capital Development'], 0.9696657061576843)","('NON-ESG', 0.0030548772774636745)","('NON-ESG', 0.002039877697825432)"
Line 234,"The program,  initially conceived in Cork, Ireland, enlists people leaders  to mentor participants through a series of classroom  and hands-on training sessions.
","('Access_And_Affordability', 0.3250916600227356)","('Employee_Engagement_Inclusion_And_Diversity', 0.31262215971946716)","('Human_Rights_And_Community_Relations', 0.08256042748689651)","('NON-ESG', 0.3250916600227356)","('NON-ESG', 0.31262215971946716)","('NON-ESG', 0.08256042748689651)"
Line 235,"After piloting GROW in  Maple Grove, Minnesota, we extended the opportunity  to product builders based in Arden Hills, Minnesota  and expect to expand the program to more sites in 2022.
","('Product_Design_And_Lifecycle_Management', 0.4996912479400635)","('Customer_Welfare', 0.12039096653461456)","('Business_Model_Resilience', 0.10569193959236145)","('NON-ESG', 0.4996912479400635)","('NON-ESG', 0.12039096653461456)","('NON-ESG', 0.10569193959236145)"
Line 236,"Accelerated Diverse Talent (ADT).
","('Employee_Engagement_Inclusion_And_Diversity', 0.9612157940864563)","('Employee_Health_And_Safety', 0.0033027410972863436)","('Human_Rights_And_Community_Relations', 0.002629694063216448)","(['Human Capital Development'], 0.9612157940864563)","('NON-ESG', 0.0033027410972863436)","('NON-ESG', 0.002629694063216448)"
Line 237,"Boston Scientific  launched the ADT program to support the development  of women and multicultural talent with the potential  for advancing to more senior leadership roles.
","('Employee_Engagement_Inclusion_And_Diversity', 0.9723848104476929)","('Human_Rights_And_Community_Relations', 0.0020294853020459414)","('Employee_Health_And_Safety', 0.0019044033251702785)","(['Human Capital Development'], 0.9723848104476929)","('NON-ESG', 0.0020294853020459414)","('NON-ESG', 0.0019044033251702785)"
Line 238,"Through  coaching and mentoring, development assignments and  executive sponsorships, the program is helping us build  a robust and diverse leadership pipeline.
","('Employee_Engagement_Inclusion_And_Diversity', 0.9575884342193604)","('Human_Rights_And_Community_Relations', 0.004642577841877937)","('Access_And_Affordability', 0.0035068336874246597)","(['Human Capital Development'], 0.9575884342193604)","('NON-ESG', 0.004642577841877937)","('NON-ESG', 0.0035068336874246597)"
Line 239,"Out of nearly  80 employees who participated in ADT in 2021, more than  half have moved to a different role or been promoted.
","('Employee_Engagement_Inclusion_And_Diversity', 0.35913893580436707)","('Director_Removal', 0.24016502499580383)","('Labor_Practices', 0.11958825588226318)","('NON-ESG', 0.35913893580436707)","('NON-ESG', 0.24016502499580383)","('NON-ESG', 0.11958825588226318)"
Line 240,"Nearly 30% of those who were promoted moved up to  vice president or director-level roles.Spanish-speaking manufacturing program.
","('Employee_Engagement_Inclusion_And_Diversity', 0.8594592213630676)","('Director_Removal', 0.01651902310550213)","('Business_Model_Resilience', 0.013869783841073513)","(['Human Capital Development'], 0.8594592213630676)","('NON-ESG', 0.01651902310550213)","('NON-ESG', 0.013869783841073513)"
Line 241,"In Spencer,  Indiana, we collaborated with our Hispanic Organization  for Leadership and Achievement (HOLA) employee  resource group to introduce an all- Spanish language  manufacturing shift to recruit product builders regardless  of their proficiency in English.
","('Employee_Engagement_Inclusion_And_Diversity', 0.9055567979812622)","('Customer_Welfare', 0.007992447353899479)","('Access_And_Affordability', 0.006966803688555956)","(['Human Capital Development'], 0.9055567979812622)","('NON-ESG', 0.007992447353899479)","('NON-ESG', 0.006966803688555956)"
Line 242,"The program grew to  support multiple shifts and manufacturing areas, and  helped mitigate pandemic-related unemployment and  labor shortages in the area and the language obstacle  faced by a growing Hispanic and Latinx community.
","('Labor_Practices', 0.5570918917655945)","('Employee_Engagement_Inclusion_And_Diversity', 0.30510053038597107)","('Employee_Health_And_Safety', 0.02557552047073841)","(['Labor Practice Indicators'], 0.5570918917655945)","('NON-ESG', 0.30510053038597107)","('NON-ESG', 0.02557552047073841)"
Line 243,"The company offers Spanish-speaking employees  the opportunity to learn English at no cost, and it also  offers their English-speaking colleagues comparable  opportunities to learn Spanish.
","('Employee_Engagement_Inclusion_And_Diversity', 0.906504213809967)","('Customer_Welfare', 0.008217539638280869)","('Employee_Health_And_Safety', 0.008058901876211166)","(['Human Capital Development'], 0.906504213809967)","('NON-ESG', 0.008217539638280869)","('NON-ESG', 0.008058901876211166)"
Line 244,"“ We decided to invest in this project to attract employees who are going to be with our company  for many, many years,” said project manager Marco Lopez, who pitched the idea for a Spanish- language work shift.
","('Employee_Engagement_Inclusion_And_Diversity', 0.7710323929786682)","('Labor_Practices', 0.052332885563373566)","('Employee_Health_And_Safety', 0.041561175137758255)","(['Human Capital Development'], 0.7710323929786682)","('NON-ESG', 0.052332885563373566)","('NON-ESG', 0.041561175137758255)"
Line 245,"Lopez worked for Boston Scientific in Costa Rica before transferring to our  Indiana site in 2016.
","('Business_Model_Resilience', 0.16350005567073822)","('GHG_Emissions', 0.10607830435037613)","('Ecological_Impacts', 0.09946014732122421)","('NON-ESG', 0.16350005567073822)","('NON-ESG', 0.10607830435037613)","('NON-ESG', 0.09946014732122421)"
Line 246,"In 2021, our Maple Grove, Minnesota site graduated its inaugural GROW class of participants.
","('Business_Model_Resilience', 0.1704707145690918)","('Employee_Engagement_Inclusion_And_Diversity', 0.17025797069072723)","('Product_Design_And_Lifecycle_Management', 0.08905601501464844)","('NON-ESG', 0.1704707145690918)","('NON-ESG', 0.17025797069072723)","('NON-ESG', 0.08905601501464844)"
Line 247,"All seven graduates have since progressed in their careers.
","('Employee_Engagement_Inclusion_And_Diversity', 0.5588608980178833)","('Director_Removal', 0.056596752256155014)","('Business_Ethics', 0.05587441474199295)","(['Human Capital Development'], 0.5588608980178833)","('NON-ESG', 0.056596752256155014)","('NON-ESG', 0.05587441474199295)"
Line 248,"2021 Performance ReportIntroduction Transforming care Investing in   our people Overview and   2021 highlights Our diverse, equitable   and inclusive workplace Attracting, developing   and retaining talent Employee well-being,  rewards and safety Accelerating   possibilities Protecting the  environment Creating value  responsibly Appendix Mia Bischoff  senior specialist,   Quality Learning and Development, and 2021 global co-lead,  Pacific East Asian Resources in Leadership (PEARL)“ I’m an Asian-American, and even though I was born in  the U.S., I still felt like I was different from others.
","('Employee_Engagement_Inclusion_And_Diversity', 0.965920627117157)","('Employee_Health_And_Safety', 0.003765178145840764)","('Human_Rights_And_Community_Relations', 0.0033359171357005835)","(['Human Capital Development'], 0.965920627117157)","('NON-ESG', 0.003765178145840764)","('NON-ESG', 0.0033359171357005835)"
Line 249,"2021 Performance ReportIntroduction Transforming care Investing in   our people Overview and   2021 highlights Our diverse, equitable   and inclusive workplace Attracting, developing   and retaining talent Employee well-being,  rewards and safety Accelerating   possibilities Protecting the  environment Creating value  responsibly Appendix Mia Bischoff  senior specialist,   Quality Learning and Development, and 2021 global co-lead,  Pacific East Asian Resources in Leadership (PEARL)“ I’m an Asian-American, and even though I was born in  the U.S., I still felt like I was different from others.
","('Employee_Engagement_Inclusion_And_Diversity', 0.44768252968788147)","('Business_Model_Resilience', 0.1012994721531868)","('Product_Design_And_Lifecycle_Management', 0.0717584565281868)","('NON-ESG', 0.44768252968788147)","('NON-ESG', 0.1012994721531868)","('NON-ESG', 0.0717584565281868)"
Line 250,"With  PEARL, I loved that I was surrounded by people with  similar backgrounds and experiences.”  Recruiting with purpose Boston Scientific collaborates with leading organizations  that advocate for the advancement of individuals from  underrepresented groups.
","('Employee_Engagement_Inclusion_And_Diversity', 0.963450014591217)","('Human_Rights_And_Community_Relations', 0.0031916245352476835)","('Employee_Health_And_Safety', 0.0030230579432100058)","(['Human Capital Development'], 0.963450014591217)","('NON-ESG', 0.0031916245352476835)","('NON-ESG', 0.0030230579432100058)"
Line 251,"Since 2014, we have partnered  with historically black college and university (HBCU)  engineering schools to support scholarships, research and  advisory board partnerships.
","('Employee_Engagement_Inclusion_And_Diversity', 0.5790200233459473)","('Access_And_Affordability', 0.11241912841796875)","('Management_Of_Legal_And_Regulatory_Framework', 0.05253955349326134)","(['Human Capital Development'], 0.5790200233459473)","('NON-ESG', 0.11241912841796875)","('NON-ESG', 0.05253955349326134)"
Line 252,"We also sponsor initiatives  for Black and HBCU students, such as events organized by  Advancement of Minority Interest in Engineering (AMIE),  Career Communications Group (CCG), National Action  Council for Minorities in Engineering (NACME) and the  National Society of Black Engineers (NSBE).
","('Employee_Engagement_Inclusion_And_Diversity', 0.9732750654220581)","('Employee_Health_And_Safety', 0.002202165313065052)","('Human_Rights_And_Community_Relations', 0.0018198809120804071)","(['Human Capital Development'], 0.9732750654220581)","('NON-ESG', 0.002202165313065052)","('NON-ESG', 0.0018198809120804071)"
Line 253,"In 2021, Boston  Scientific was voted a “Top Supporter of HBCUs” by U.S.  Black Engineer & Information Technology magazine for  the second consecutive year.Elevating employee voices through  employee resource groups (ERGs) Our voluntary, company-sponsored ERGs are essential  to our inclusive culture.
","('Employee_Engagement_Inclusion_And_Diversity', 0.9459318518638611)","('Employee_Health_And_Safety', 0.010139737278223038)","('Human_Rights_And_Community_Relations', 0.004147578030824661)","(['Human Capital Development'], 0.9459318518638611)","('NON-ESG', 0.010139737278223038)","('NON-ESG', 0.004147578030824661)"
Line 254,"While these groups are typically  formed around a specific affinity such as gender, race,  veteran status, sexual orientation or life stage, all  employees are welcome and encouraged to join and  participate in any ERG.
","('Employee_Engagement_Inclusion_And_Diversity', 0.9757100939750671)","('Employee_Health_And_Safety', 0.001896328991279006)","('Human_Rights_And_Community_Relations', 0.0017932949122041464)","(['Human Capital Development'], 0.9757100939750671)","('NON-ESG', 0.001896328991279006)","('NON-ESG', 0.0017932949122041464)"
Line 255,"Each ERG has an executive sponsor  and creates opportunities for members to network,  develop career skills and contribute to our communities.
","('Employee_Engagement_Inclusion_And_Diversity', 0.8763566017150879)","('Human_Rights_And_Community_Relations', 0.017803940922021866)","('Access_And_Affordability', 0.010603555478155613)","(['Human Capital Development'], 0.8763566017150879)","('NON-ESG', 0.017803940922021866)","('NON-ESG', 0.010603555478155613)"
Line 256,"Our Global Council for Inclusion (GCI) supports their  efforts and meets quarterly to discuss ERG progress.
","('Employee_Engagement_Inclusion_And_Diversity', 0.9326807260513306)","('Human_Rights_And_Community_Relations', 0.014317376539111137)","('Access_And_Affordability', 0.005795129109174013)","(['Human Capital Development'], 0.9326807260513306)","('NON-ESG', 0.014317376539111137)","('NON-ESG', 0.005795129109174013)"
Line 257,"The GCI is co-chaired by our chief financial officer and  executive vice president of Human Resources and also  includes our chairman and CEO, the executive committee,  DE&I team members and all nine global ERG leaders.
","('Business_Model_Resilience', 0.312380313873291)","('Employee_Engagement_Inclusion_And_Diversity', 0.12977179884910583)","('Systemic_Risk_Management', 0.09138309210538864)","('NON-ESG', 0.312380313873291)","('NON-ESG', 0.12977179884910583)","('NON-ESG', 0.09138309210538864)"
Line 258,"Global DE&I Summit speaks   to inclusion through adversity More than 2,400 Boston Scientific leaders and  employees participated in our second annual ERG  summit.
","('Employee_Engagement_Inclusion_And_Diversity', 0.9098812341690063)","('Human_Rights_And_Community_Relations', 0.01516684889793396)","('Access_And_Affordability', 0.010648256167769432)","(['Human Capital Development'], 0.9098812341690063)","('NON-ESG', 0.01516684889793396)","('NON-ESG', 0.010648256167769432)"
Line 259,"The 20-hour virtual event featured two days  of presentations and discussions on how to foster  inclusion in times of adversity.ERGs foster collaboration 8,000+   employees across nine ERGs 115  chapters globally 44  chapters outside the U.S. 15  virtual chaptersLearn about how we are partnering to promote   and support the development of talent from  underrepresented groups.
","('Employee_Engagement_Inclusion_And_Diversity', 0.9605436325073242)","('Employee_Health_And_Safety', 0.0041776723228394985)","('Access_And_Affordability', 0.002647391054779291)","(['Human Capital Development'], 0.9605436325073242)","('NON-ESG', 0.0041776723228394985)","('NON-ESG', 0.002647391054779291)"
Line 260,"2021 Performance ReportIntroduction Transforming care Investing in   our people Overview and   2021 highlights Our diverse, equitable   and inclusive workplace Attracting, developing   and retaining talent Employee well-being,  rewards and safety Accelerating   possibilities Protecting the  environment Creating value  responsibly Appendix Attracting, developing and retaining talent Boston Scientific is a company where everyone’s ideas, ambitions and careers matter.
","('Employee_Engagement_Inclusion_And_Diversity', 0.9618602395057678)","('Employee_Health_And_Safety', 0.0059397220611572266)","('Human_Rights_And_Community_Relations', 0.0034474488347768784)","(['Human Capital Development'], 0.9618602395057678)","('NON-ESG', 0.0059397220611572266)","('NON-ESG', 0.0034474488347768784)"
Line 261,"We want all employees to have  work that means something to them, in roles where they have opportunities to learn and advance.
","('Employee_Engagement_Inclusion_And_Diversity', 0.6578264832496643)","('Employee_Health_And_Safety', 0.07622107118368149)","('Human_Rights_And_Community_Relations', 0.03982297331094742)","(['Human Capital Development'], 0.6578264832496643)","('NON-ESG', 0.07622107118368149)","('NON-ESG', 0.03982297331094742)"
Line 262,"This means ensuring  that people at every level of the organization have access to continuous learning initiatives and tailored development  programs.
","('Access_And_Affordability', 0.7168246507644653)","('Employee_Engagement_Inclusion_And_Diversity', 0.0702398270368576)","('Human_Rights_And_Community_Relations', 0.030335618183016777)","(['Health Outcome Contribution'], 0.7168246507644653)","('NON-ESG', 0.0702398270368576)","('NON-ESG', 0.030335618183016777)"
Line 263,"It also means providing advancement opportunities for women and multicultural talent.
","('Employee_Engagement_Inclusion_And_Diversity', 0.9683559536933899)","('Access_And_Affordability', 0.0028177297208458185)","('Human_Rights_And_Community_Relations', 0.002480711555108428)","(['Human Capital Development'], 0.9683559536933899)","('NON-ESG', 0.0028177297208458185)","('NON-ESG', 0.002480711555108428)"
Line 264,"Our 2021 investments  reinforced our objectives for talent planning, manager development and engagement and retention.
","('Employee_Engagement_Inclusion_And_Diversity', 0.9610199928283691)","('Employee_Health_And_Safety', 0.003263385035097599)","('Business_Model_Resilience', 0.0027133929543197155)","(['Human Capital Development'], 0.9610199928283691)","('NON-ESG', 0.003263385035097599)","('NON-ESG', 0.0027133929543197155)"
Line 265,"Hiring and developing talent   to meet business needs Our talent planning approach relies on diverse representation  and cultivating capabilities to address business needs.
","('Employee_Engagement_Inclusion_And_Diversity', 0.9689583778381348)","('Employee_Health_And_Safety', 0.002681937301531434)","('Business_Model_Resilience', 0.002078332705423236)","(['Human Capital Development'], 0.9689583778381348)","('NON-ESG', 0.002681937301531434)","('NON-ESG', 0.002078332705423236)"
Line 266,"We  do this by developing internal talent and recruiting top talent  globally.
","('Employee_Engagement_Inclusion_And_Diversity', 0.9156646728515625)","('Competitive_Behavior', 0.0077699925750494)","('Employee_Health_And_Safety', 0.006566791329532862)","(['Human Capital Development'], 0.9156646728515625)","('NON-ESG', 0.0077699925750494)","('NON-ESG', 0.006566791329532862)"
Line 267,"In 2021, remote work offered opportunities for us to  recruit from new talent pools while preparing and promoting  people within the business.
","('Employee_Engagement_Inclusion_And_Diversity', 0.9351386427879333)","('Business_Model_Resilience', 0.00629637623205781)","('Human_Rights_And_Community_Relations', 0.004560520872473717)","(['Human Capital Development'], 0.9351386427879333)","('NON-ESG', 0.00629637623205781)","('NON-ESG', 0.004560520872473717)"
Line 268,"We also innovated with recruiting  approaches, including a Medical Sales College scholarship  program for students with high potential for becoming part  of a salesforce that mirrors the diversity of our customers and  their patients.
","('Employee_Engagement_Inclusion_And_Diversity', 0.9598551392555237)","('Business_Model_Resilience', 0.003397272899746895)","('Customer_Welfare', 0.003141673281788826)","(['Human Capital Development'], 0.9598551392555237)","('NON-ESG', 0.003397272899746895)","('NON-ESG', 0.003141673281788826)"
Line 269,"We tracked workforce analytics and implemented ways to  develop more skills internally.
","('Employee_Engagement_Inclusion_And_Diversity', 0.9563747644424438)","('Employee_Health_And_Safety', 0.006023237481713295)","('Labor_Practices', 0.004205984529107809)","(['Human Capital Development'], 0.9563747644424438)","('NON-ESG', 0.006023237481713295)","('NON-ESG', 0.004205984529107809)"
Line 270,"In tandem with these efforts,  leaders used digital dashboards to assess organizational  trends and improve hiring, advancement and engagement  practices.
","('Employee_Engagement_Inclusion_And_Diversity', 0.946510910987854)","('Business_Model_Resilience', 0.006366838701069355)","('Human_Rights_And_Community_Relations', 0.004442706238478422)","(['Human Capital Development'], 0.946510910987854)","('NON-ESG', 0.006366838701069355)","('NON-ESG', 0.004442706238478422)"
Line 271,"These insights helped us tailor our internal  development efforts and refine our recruiting outreach.
","('Employee_Engagement_Inclusion_And_Diversity', 0.6156153678894043)","('Competitive_Behavior', 0.07744884490966797)","('Access_And_Affordability', 0.03944619745016098)","(['Human Capital Development'], 0.6156153678894043)","('NON-ESG', 0.07744884490966797)","('NON-ESG', 0.03944619745016098)"
Line 272,"As a  result, Boston Scientific had more than 8,300 new hires and  filled 22% of our open positions with internal candidates.
","('Employee_Engagement_Inclusion_And_Diversity', 0.41922488808631897)","('Director_Removal', 0.19697949290275574)","('Labor_Practices', 0.10186096280813217)","('NON-ESG', 0.41922488808631897)","('NON-ESG', 0.19697949290275574)","('NON-ESG', 0.10186096280813217)"
Line 273,"2021 recruitment and hiring 8,300+   new hires 69%   of director level and above open  positions hired from within“ I have been in the talent attraction space for more than  26 years and have never seen a workplace culture like  ours.
","('Employee_Engagement_Inclusion_And_Diversity', 0.962340772151947)","('Employee_Health_And_Safety', 0.003359450027346611)","('Labor_Practices', 0.0031434770207852125)","(['Human Capital Development'], 0.962340772151947)","('NON-ESG', 0.003359450027346611)","('NON-ESG', 0.0031434770207852125)"
Line 274,"This is the first time in my career I can authentically  be who I am at work and it has been a game changer  for me.
","('Employee_Engagement_Inclusion_And_Diversity', 0.40050074458122253)","('Business_Model_Resilience', 0.1293710321187973)","('Human_Rights_And_Community_Relations', 0.07079310715198517)","('NON-ESG', 0.40050074458122253)","('NON-ESG', 0.1293710321187973)","('NON-ESG', 0.07079310715198517)"
Line 275,"The way Boston Scientific holistically cares about  employees resonates with me and so many others.” Erica Henry director, Global Talent Acquisition 2021 Performance ReportIntroduction Transforming care Investing in   our people Overview and   2021 highlights Our diverse, equitable   and inclusive workplace Attracting, developing   and retaining talent Employee well-being,  rewards and safety Accelerating   possibilities Protecting the  environment Creating value  responsibly Appendix Listening and learning Our best ideas come from our people.
","('Employee_Engagement_Inclusion_And_Diversity', 0.9531237483024597)","('Employee_Health_And_Safety', 0.006533279083669186)","('Human_Rights_And_Community_Relations', 0.005382563453167677)","(['Human Capital Development'], 0.9531237483024597)","('NON-ESG', 0.006533279083669186)","('NON-ESG', 0.005382563453167677)"
Line 276,"The way Boston Scientific holistically cares about  employees resonates with me and so many others.” Erica Henry director, Global Talent Acquisition 2021 Performance ReportIntroduction Transforming care Investing in   our people Overview and   2021 highlights Our diverse, equitable   and inclusive workplace Attracting, developing   and retaining talent Employee well-being,  rewards and safety Accelerating   possibilities Protecting the  environment Creating value  responsibly Appendix Listening and learning Our best ideas come from our people.
","('Human_Rights_And_Community_Relations', 0.563525378704071)","('Business_Model_Resilience', 0.05358128249645233)","('Employee_Engagement_Inclusion_And_Diversity', 0.04754478111863136)","(['Community Relations'], 0.563525378704071)","('NON-ESG', 0.05358128249645233)","('NON-ESG', 0.04754478111863136)"
Line 277,"We devote resources  to support ongoing feedback between employees and  managers and communications channels for employees   to share their valued perspectives.
","('Employee_Engagement_Inclusion_And_Diversity', 0.8355584144592285)","('Human_Rights_And_Community_Relations', 0.026672108098864555)","('Labor_Practices', 0.019518891349434853)","(['Human Capital Development'], 0.8355584144592285)","('NON-ESG', 0.026672108098864555)","('NON-ESG', 0.019518891349434853)"
Line 278,"Employee engagement survey We conducted a companywide engagement survey that  provided valuable feedback from employees about their  jobs, leadership, development opportunities and our work  environment.
","('Employee_Engagement_Inclusion_And_Diversity', 0.9516886472702026)","('Employee_Health_And_Safety', 0.007107831072062254)","('Human_Rights_And_Community_Relations', 0.006021781824529171)","(['Human Capital Development'], 0.9516886472702026)","('NON-ESG', 0.007107831072062254)","('NON-ESG', 0.006021781824529171)"
Line 279,"Boston Scientific made tablets available at  manufacturing facilities to increase employee access to  the survey and encourage strong response rates.
","('Employee_Engagement_Inclusion_And_Diversity', 0.27306607365608215)","('Access_And_Affordability', 0.26231980323791504)","('Labor_Practices', 0.10010555386543274)","('NON-ESG', 0.27306607365608215)","('NON-ESG', 0.26231980323791504)","('NON-ESG', 0.10010555386543274)"
Line 280,"With  more than 31,000 employees participating, we recorded  scores of 80% or higher for the key indices to the right.
","('Labor_Practices', 0.3319013714790344)","('Employee_Engagement_Inclusion_And_Diversity', 0.18166252970695496)","('Director_Removal', 0.07906003296375275)","('NON-ESG', 0.3319013714790344)","('NON-ESG', 0.18166252970695496)","('NON-ESG', 0.07906003296375275)"
Line 281,"We used engagement survey results to develop a  multi‐year action plan focused on career pathways for  all employees, supporting our teams through change  and equity and inclusion initiatives for women and  multicultural talent.
","('Employee_Engagement_Inclusion_And_Diversity', 0.9748558402061462)","('Employee_Health_And_Safety', 0.001937458640895784)","('Access_And_Affordability', 0.0017811033176258206)","(['Human Capital Development'], 0.9748558402061462)","('NON-ESG', 0.001937458640895784)","('NON-ESG', 0.0017811033176258206)"
Line 282,"To make progress in 2021, we  conducted focus groups and interviews with existing  talent to help promote retention, expanded leadership  training and retention resources, and provided tools for  employees as they adjusted to new ways of working.
","('Employee_Engagement_Inclusion_And_Diversity', 0.9734143018722534)","('Employee_Health_And_Safety', 0.0028380833100527525)","('Customer_Welfare', 0.0015243744710460305)","(['Human Capital Development'], 0.9734143018722534)","('NON-ESG', 0.0028380833100527525)","('NON-ESG', 0.0015243744710460305)"
Line 283,"Spark Survey.
","('Data_Security', 0.19783034920692444)","('Business_Model_Resilience', 0.18730898201465607)","('Product_Design_And_Lifecycle_Management', 0.07669545710086823)","('NON-ESG', 0.19783034920692444)","('NON-ESG', 0.18730898201465607)","('NON-ESG', 0.07669545710086823)"
Line 284,"Our Spark Survey solicits feedback about  our people leaders from their direct reports.
","('Business_Model_Resilience', 0.3197811245918274)","('Employee_Engagement_Inclusion_And_Diversity', 0.13662460446357727)","('Director_Removal', 0.10500465333461761)","('NON-ESG', 0.3197811245918274)","('NON-ESG', 0.13662460446357727)","('NON-ESG', 0.10500465333461761)"
Line 285,"The brief  digital format asks employees to rate their managers on  leadership attributes and is available in 14 languages.
","('Employee_Engagement_Inclusion_And_Diversity', 0.9014846086502075)","('Human_Rights_And_Community_Relations', 0.01658947579562664)","('Employee_Health_And_Safety', 0.00846103485673666)","(['Human Capital Development'], 0.9014846086502075)","('NON-ESG', 0.01658947579562664)","('NON-ESG', 0.00846103485673666)"
Line 286,"The survey is an important developmental tool for people  managers and assists us with identifying enterprise  people leadership strengths and opportunities.
","('Employee_Engagement_Inclusion_And_Diversity', 0.8238335251808167)","('Human_Rights_And_Community_Relations', 0.03261445835232735)","('Business_Model_Resilience', 0.024873405694961548)","(['Human Capital Development'], 0.8238335251808167)","('NON-ESG', 0.03261445835232735)","('NON-ESG', 0.024873405694961548)"
Line 287,"In 2021,  more than 21,000 employees were invited to evaluate  approximately 5,000 leaders.
","('Employee_Engagement_Inclusion_And_Diversity', 0.6781384348869324)","('Director_Removal', 0.06208401173353195)","('Business_Ethics', 0.030224230140447617)","(['Human Capital Development'], 0.6781384348869324)","('NON-ESG', 0.06208401173353195)","('NON-ESG', 0.030224230140447617)"
Line 288,"We had a response rate  of 74%, and 95% of people leaders, as well as their  supervisors, received a feedback report.Career growth and development initiatives Boston Scientific provides tools and training for  continuous learning so every employee can envision  greater possibilities no matter where they are in their  careers.
","('Employee_Engagement_Inclusion_And_Diversity', 0.8521244525909424)","('Employee_Health_And_Safety', 0.02181049808859825)","('Access_And_Affordability', 0.012365862727165222)","(['Human Capital Development'], 0.8521244525909424)","('NON-ESG', 0.02181049808859825)","('NON-ESG', 0.012365862727165222)"
Line 289,"We offer more than 150 professional and  technical courses, including on-the-job training, skills- based education and programs for employees who have  the potential to hold leadership positions.
","('Employee_Engagement_Inclusion_And_Diversity', 0.9064264893531799)","('Labor_Practices', 0.012183872982859612)","('Employee_Health_And_Safety', 0.009200001135468483)","(['Human Capital Development'], 0.9064264893531799)","('NON-ESG', 0.012183872982859612)","('NON-ESG', 0.009200001135468483)"
Line 290,"In 2021, we launched a global Learning Leaders Council  composed of cross-functional leaders who helped define  and accelerate our vision for creating an agile, continuous  learning organization.
","('Employee_Engagement_Inclusion_And_Diversity', 0.5692110657691956)","('Business_Model_Resilience', 0.10445831716060638)","('Systemic_Risk_Management', 0.0352177619934082)","(['Human Capital Development'], 0.5692110657691956)","('NON-ESG', 0.10445831716060638)","('NON-ESG', 0.0352177619934082)"
Line 291,"They identified ways to further  connect learning to our business strategy, embed it in the  daily flow of work, and prioritize learning for leaders and  their teams.
","('Business_Model_Resilience', 0.2917376458644867)","('Employee_Engagement_Inclusion_And_Diversity', 0.18900570273399353)","('Human_Rights_And_Community_Relations', 0.09987782686948776)","('NON-ESG', 0.2917376458644867)","('NON-ESG', 0.18900570273399353)","('NON-ESG', 0.09987782686948776)"
Line 292,"80% of employees   report that they are  actively engaged82% of employees feel  enabled to do their  jobs well80% of employees feel that  our workplace culture  is inclusiveEngagement   IndexEnablement   IndexInclusive Culture   Index2021 employee engagement survey results 2021 Performance ReportIntroduction Transforming care Investing in   our people Overview and   2021 highlights Our diverse, equitable   and inclusive workplace Attracting, developing   and retaining talent Employee well-being,  rewards and safety Accelerating   possibilities Protecting the  environment Creating value  responsibly Appendix Investing in our people leaders  The skills needed to be a successful people leader are  constantly changing.
","('Employee_Engagement_Inclusion_And_Diversity', 0.9607818126678467)","('Human_Rights_And_Community_Relations', 0.004748206585645676)","('Employee_Health_And_Safety', 0.004411813337355852)","(['Human Capital Development'], 0.9607818126678467)","('NON-ESG', 0.004748206585645676)","('NON-ESG', 0.004411813337355852)"
Line 293,"80% of employees   report that they are  actively engaged82% of employees feel  enabled to do their  jobs well80% of employees feel that  our workplace culture  is inclusiveEngagement   IndexEnablement   IndexInclusive Culture   Index2021 employee engagement survey results 2021 Performance ReportIntroduction Transforming care Investing in   our people Overview and   2021 highlights Our diverse, equitable   and inclusive workplace Attracting, developing   and retaining talent Employee well-being,  rewards and safety Accelerating   possibilities Protecting the  environment Creating value  responsibly Appendix Investing in our people leaders  The skills needed to be a successful people leader are  constantly changing.
","('Human_Rights_And_Community_Relations', 0.7497981190681458)","('Employee_Health_And_Safety', 0.03729936107993126)","('Business_Model_Resilience', 0.02716963179409504)","(['Community Relations'], 0.7497981190681458)","('NON-ESG', 0.03729936107993126)","('NON-ESG', 0.02716963179409504)"
Line 294,"We rolled out more resources to  help managers develop as strategic leaders, create a work  environment built on trust and help employees achieve  their career goals.
","('Employee_Engagement_Inclusion_And_Diversity', 0.722899854183197)","('Business_Model_Resilience', 0.044324133545160294)","('Human_Rights_And_Community_Relations', 0.04044583812355995)","(['Human Capital Development'], 0.722899854183197)","('NON-ESG', 0.044324133545160294)","('NON-ESG', 0.04044583812355995)"
Line 295,"Our development work included  these programs: • Manager Pathways.
","('Access_And_Affordability', 0.41657042503356934)","('Employee_Engagement_Inclusion_And_Diversity', 0.13290654122829437)","('Human_Rights_And_Community_Relations', 0.0534980446100235)","('NON-ESG', 0.41657042503356934)","('NON-ESG', 0.13290654122829437)","('NON-ESG', 0.0534980446100235)"
Line 296,"This program focuses on building  leadership skills among our people leaders, including  how to be inclusive and coach with empathy.
","('Employee_Engagement_Inclusion_And_Diversity', 0.8624927401542664)","('Human_Rights_And_Community_Relations', 0.03320637345314026)","('Employee_Health_And_Safety', 0.012395140714943409)","(['Human Capital Development'], 0.8624927401542664)","('NON-ESG', 0.03320637345314026)","('NON-ESG', 0.012395140714943409)"
Line 297,"• People Leaders Experience (PLE).
","('Employee_Engagement_Inclusion_And_Diversity', 0.6230255365371704)","('Business_Model_Resilience', 0.059709515422582626)","('Human_Rights_And_Community_Relations', 0.05882681906223297)","(['Human Capital Development'], 0.6230255365371704)","('NON-ESG', 0.059709515422582626)","('NON-ESG', 0.05882681906223297)"
Line 298,"This one-year  opportunity for new people leaders addresses  core leadership skills such as hiring, coaching and  providing feedback.
","('Employee_Engagement_Inclusion_And_Diversity', 0.9171528220176697)","('Business_Model_Resilience', 0.008464010432362556)","('Human_Rights_And_Community_Relations', 0.007831970229744911)","(['Human Capital Development'], 0.9171528220176697)","('NON-ESG', 0.008464010432362556)","('NON-ESG', 0.007831970229744911)"
Line 299,"• Advanced Manager Experience.
","('Product_Design_And_Lifecycle_Management', 0.22475920617580414)","('Business_Model_Resilience', 0.17875811457633972)","('Data_Security', 0.11835917830467224)","('NON-ESG', 0.22475920617580414)","('NON-ESG', 0.17875811457633972)","('NON-ESG', 0.11835917830467224)"
Line 300,"This eight-month  opportunity for succession-ready senior managers  emphasizes capabilities such as business acumen,  strategic thinking and inclusive leadership.
","('Employee_Engagement_Inclusion_And_Diversity', 0.7319117188453674)","('Business_Model_Resilience', 0.06858886778354645)","('Human_Rights_And_Community_Relations', 0.022191010415554047)","(['Human Capital Development'], 0.7319117188453674)","('NON-ESG', 0.06858886778354645)","('NON-ESG', 0.022191010415554047)"
Line 301,"• ExecOnline.
","('Business_Model_Resilience', 0.25568339228630066)","('Data_Security', 0.10279207676649094)","('Supply_Chain_Management', 0.07835455983877182)","('NON-ESG', 0.25568339228630066)","('NON-ESG', 0.10279207676649094)","('NON-ESG', 0.07835455983877182)"
Line 302,"These courses for leaders at or above  the director level include content developed at  top business schools and real-time projects that  participants incorporate into their day-to-day jobs.
","('Employee_Engagement_Inclusion_And_Diversity', 0.3871094286441803)","('Labor_Practices', 0.07786807417869568)","('Access_And_Affordability', 0.0685027614235878)","('NON-ESG', 0.3871094286441803)","('NON-ESG', 0.07786807417869568)","('NON-ESG', 0.0685027614235878)"
Line 303,"Virtual learning and development   for our hybrid workforce We expanded our virtual learning offerings to include  more topics and opportunities for all employees,  including self-development courses, a coaching portal  and self-directed mentoring programs.
","('Employee_Engagement_Inclusion_And_Diversity', 0.5217211842536926)","('Access_And_Affordability', 0.2132590115070343)","('Employee_Health_And_Safety', 0.04592368006706238)","(['Human Capital Development'], 0.5217211842536926)","('NON-ESG', 0.2132590115070343)","('NON-ESG', 0.04592368006706238)"
Line 304,"In addition,  we designed and hosted our first virtual leadership  conference, a three-day event for people leaders.
","('Employee_Engagement_Inclusion_And_Diversity', 0.5347713828086853)","('Business_Model_Resilience', 0.12676773965358734)","('Human_Rights_And_Community_Relations', 0.03887993469834328)","(['Human Capital Development'], 0.5347713828086853)","('NON-ESG', 0.12676773965358734)","('NON-ESG', 0.03887993469834328)"
Line 305,"• Virtual Learning Site employee views totaled 9,700+,  including 4,500+ unique new views.
","('Data_Security', 0.37748292088508606)","('Customer_Privacy', 0.08615590631961823)","('Competitive_Behavior', 0.05798574537038803)","('NON-ESG', 0.37748292088508606)","('NON-ESG', 0.08615590631961823)","('NON-ESG', 0.05798574537038803)"
Line 306,"• Virtual Leadership Summit 2021:   3 days > 6,600 attendees > 50+ speakers   > 4.5 (out of 5) average satisfaction score Talent review and succession planning Succession planning at Boston Scientific is a key  component of our business processes.
","('Business_Model_Resilience', 0.5236518979072571)","('Employee_Engagement_Inclusion_And_Diversity', 0.1203514039516449)","('Product_Design_And_Lifecycle_Management', 0.046466533094644547)","(['Codes of Business Conduct'], 0.5236518979072571)","('NON-ESG', 0.1203514039516449)","('NON-ESG', 0.046466533094644547)"
Line 307,"Our Executive  Committee annually conducts talent reviews to  understand insights about our succession plans, identify  areas of opportunity and ensure we are developing  the necessary bench strength.
","('Employee_Engagement_Inclusion_And_Diversity', 0.888342559337616)","('Business_Model_Resilience', 0.01385521050542593)","('Systemic_Risk_Management', 0.008335461840033531)","(['Human Capital Development'], 0.888342559337616)","('NON-ESG', 0.01385521050542593)","('NON-ESG', 0.008335461840033531)"
Line 308,"The reviews result in a succession strategy for all executive and critical business  roles.
","('Director_Removal', 0.4024047255516052)","('Business_Model_Resilience', 0.1724018156528473)","('Employee_Engagement_Inclusion_And_Diversity', 0.08927420526742935)","('NON-ESG', 0.4024047255516052)","('NON-ESG', 0.1724018156528473)","('NON-ESG', 0.08927420526742935)"
Line 309,"Succession plans for the CEO are reviewed annually  by the company’s board of directors and its Nominating  and Governance committee.
","('Director_Removal', 0.7110429406166077)","('Management_Of_Legal_And_Regulatory_Framework', 0.07374697923660278)","('Employee_Engagement_Inclusion_And_Diversity', 0.024585384875535965)","(['Anti-Crime Policy & Measures'], 0.7110429406166077)","('NON-ESG', 0.07374697923660278)","('NON-ESG', 0.024585384875535965)"
Line 310,"Succession planning takes  place for employees at every level when leaders gather  annually to assess the performance of their teams and  development plans.
","('Business_Model_Resilience', 0.2187000811100006)","('Employee_Engagement_Inclusion_And_Diversity', 0.1597529798746109)","('Human_Rights_And_Community_Relations', 0.15198558568954468)","('NON-ESG', 0.2187000811100006)","('NON-ESG', 0.1597529798746109)","('NON-ESG', 0.15198558568954468)"
Line 311,"These review sessions help to ensure  a strong pipeline of emerging leaders.
","('Business_Model_Resilience', 0.3236975371837616)","('Competitive_Behavior', 0.12708599865436554)","('Systemic_Risk_Management', 0.10068411380052567)","('NON-ESG', 0.3236975371837616)","('NON-ESG', 0.12708599865436554)","('NON-ESG', 0.10068411380052567)"
Line 312,"Throughout our talent review and succession planning  processes, we continue to strengthen our commitment to  advancing our diverse talent into leadership roles.
","('Employee_Engagement_Inclusion_And_Diversity', 0.9649435877799988)","('Employee_Health_And_Safety', 0.003254715818911791)","('Business_Model_Resilience', 0.0026320694014430046)","(['Human Capital Development'], 0.9649435877799988)","('NON-ESG', 0.003254715818911791)","('NON-ESG', 0.0026320694014430046)"
Line 313,"In 2021  we evolved the annual review to include highlights on key  diverse talent.
","('Employee_Engagement_Inclusion_And_Diversity', 0.9548428058624268)","('Human_Rights_And_Community_Relations', 0.003419087268412113)","('Employee_Health_And_Safety', 0.0029822492506355047)","(['Human Capital Development'], 0.9548428058624268)","('NON-ESG', 0.003419087268412113)","('NON-ESG', 0.0029822492506355047)"
Line 314,"This provided visibility and a commitment  to actions to accelerate development and readiness for  next roles.
","('Business_Model_Resilience', 0.39337316155433655)","('Human_Rights_And_Community_Relations', 0.0896647721529007)","('Management_Of_Legal_And_Regulatory_Framework', 0.08297306299209595)","('NON-ESG', 0.39337316155433655)","('NON-ESG', 0.0896647721529007)","('NON-ESG', 0.08297306299209595)"
Line 315,"Key talent actions are monitored throughout  the year.
","('Employee_Engagement_Inclusion_And_Diversity', 0.8525921106338501)","('Business_Ethics', 0.014728323556482792)","('Employee_Health_And_Safety', 0.01339561678469181)","(['Human Capital Development'], 0.8525921106338501)","('NON-ESG', 0.014728323556482792)","('NON-ESG', 0.01339561678469181)"
Line 316,"~700k   total hours spent in on-demand  virtual and classroom training1Continuous learning to build   a workforce for the future 1 Inclusive of global indirect labor employees only.
","('Labor_Practices', 0.9586570858955383)","('Employee_Engagement_Inclusion_And_Diversity', 0.009035222232341766)","('Employee_Health_And_Safety', 0.0038909234572201967)","(['Labor Practice Indicators'], 0.9586570858955383)","('NON-ESG', 0.009035222232341766)","('NON-ESG', 0.0038909234572201967)"
Line 317,"2021 Performance ReportIntroduction Transforming care Investing in   our people Overview and   2021 highlights Our diverse, equitable   and inclusive workplace Attracting, developing   and retaining talent Employee well-being,  rewards and safety Accelerating   possibilities Protecting the  environment Creating value  responsibly Appendix Employee well-being, rewards and safety At Boston Scientific, we prioritize the well-being, health and safety of our employees and their families.
","('Employee_Health_And_Safety', 0.9582831859588623)","('Employee_Engagement_Inclusion_And_Diversity', 0.008849067613482475)","('Human_Rights_And_Community_Relations', 0.004549616016447544)","(['Operational Eco-Efficiency'], 0.9582831859588623)","('NON-ESG', 0.008849067613482475)","('NON-ESG', 0.004549616016447544)"
Line 318,"We strive to  be flexible about where and when employees perform their work and to offer benefits that are valued by our people,  promote well-being and support life-work integration.
","('Human_Rights_And_Community_Relations', 0.34625765681266785)","('Employee_Health_And_Safety', 0.234364852309227)","('Employee_Engagement_Inclusion_And_Diversity', 0.1717158555984497)","('NON-ESG', 0.34625765681266785)","('NON-ESG', 0.234364852309227)","('NON-ESG', 0.1717158555984497)"
Line 319,"Adapting to new ways of working In the wake of the pandemic, the company reassessed its physical space and modified onsite protocols to support  employees as they adopted new work modes.
","('Employee_Health_And_Safety', 0.4169616401195526)","('Labor_Practices', 0.34539636969566345)","('Employee_Engagement_Inclusion_And_Diversity', 0.021278155967593193)","('NON-ESG', 0.4169616401195526)","('NON-ESG', 0.34539636969566345)","('NON-ESG', 0.021278155967593193)"
Line 320,"This involved workplace modifications to meet health and safety guidelines,  conference room upgrades, new ordering systems for home office equipment, and training to help employees succeed in  hybrid, onsite and remote settings.
","('Employee_Health_And_Safety', 0.9790979623794556)","('Employee_Engagement_Inclusion_And_Diversity', 0.003131655277684331)","('Product_Quality_And_Safety', 0.0023474539630115032)","(['Operational Eco-Efficiency'], 0.9790979623794556)","('NON-ESG', 0.003131655277684331)","('NON-ESG', 0.0023474539630115032)"
Line 321,"By the end of 202,1 as employees adapted to our culture of greater flexibility, 42% of our  people worked onsite, 41% adopted hybrid work modes and 17% worked primarily from remote locations.
","('Labor_Practices', 0.6412861943244934)","('Employee_Health_And_Safety', 0.11990439146757126)","('Employee_Engagement_Inclusion_And_Diversity', 0.05813218653202057)","(['Labor Practice Indicators'], 0.6412861943244934)","('NON-ESG', 0.11990439146757126)","('NON-ESG', 0.05813218653202057)"
Line 322,"Our return-to-site  resources included employee toolkits, onsite amenities, leader resources and safe onsite workspaces for collaboration.Benefits that meet employee needs Boston Scientific benefit programs support the well-being  and health of our people while providing flexibility to meet  their unique needs and expectations.
","('Employee_Health_And_Safety', 0.46062758564949036)","('Employee_Engagement_Inclusion_And_Diversity', 0.17360831797122955)","('Access_And_Affordability', 0.08555500954389572)","('NON-ESG', 0.46062758564949036)","('NON-ESG', 0.17360831797122955)","('NON-ESG', 0.08555500954389572)"
Line 323,"Employee eligibility  for benefits follows local regulations and practices.
","('Labor_Practices', 0.4611968994140625)","('Employee_Engagement_Inclusion_And_Diversity', 0.28810688853263855)","('Employee_Health_And_Safety', 0.11516677588224411)","('NON-ESG', 0.4611968994140625)","('NON-ESG', 0.28810688853263855)","('NON-ESG', 0.11516677588224411)"
Line 324,"In  most countries, this means we offer benefits to full-time  employees and part-time employees working more than  a certain number of hours.
","('Labor_Practices', 0.9602744579315186)","('Employee_Engagement_Inclusion_And_Diversity', 0.005177693907171488)","('Employee_Health_And_Safety', 0.0036802550312131643)","(['Labor Practice Indicators'], 0.9602744579315186)","('NON-ESG', 0.005177693907171488)","('NON-ESG', 0.0036802550312131643)"
Line 325,"We typically provide benefit  programs that are above and beyond government  requirements and offer a portfolio of additional benefits  that support our diverse population and the individual  needs of our employees.
","('Employee_Engagement_Inclusion_And_Diversity', 0.9460636377334595)","('Access_And_Affordability', 0.007663560565561056)","('Human_Rights_And_Community_Relations', 0.00643064035102725)","(['Human Capital Development'], 0.9460636377334595)","('NON-ESG', 0.007663560565561056)","('NON-ESG', 0.00643064035102725)"
Line 326,"Embracing life-work needs  Our Global Benefits to Fit Your Life program is designed  to make life-work integration easier for all employees at  any stage of life.
","('Employee_Health_And_Safety', 0.40170201659202576)","('Employee_Engagement_Inclusion_And_Diversity', 0.12853309512138367)","('Human_Rights_And_Community_Relations', 0.08587850630283356)","('NON-ESG', 0.40170201659202576)","('NON-ESG', 0.12853309512138367)","('NON-ESG', 0.08587850630283356)"
Line 327,"It provides the flexibility and benefits and  services our employees want to be happy, productive and  engaged in their roles.
","('Labor_Practices', 0.3125036656856537)","('Employee_Engagement_Inclusion_And_Diversity', 0.26904234290122986)","('Employee_Health_And_Safety', 0.10385072976350784)","('NON-ESG', 0.3125036656856537)","('NON-ESG', 0.26904234290122986)","('NON-ESG', 0.10385072976350784)"
Line 328,"In applicable countries, our life-work  offerings include telehealth services, childcare and parental  care benefits, college and financial planning, fertility and  surrogacy benefits, a breast milk shipping service, domestic  partner benefits, tuition support, a meal-planning service  and sabbaticals for employees with more than seven years  of service.
","('Access_And_Affordability', 0.8808251619338989)","('Employee_Health_And_Safety', 0.013749426230788231)","('Human_Rights_And_Community_Relations', 0.013192382641136646)","(['Health Outcome Contribution'], 0.8808251619338989)","('NON-ESG', 0.013749426230788231)","('NON-ESG', 0.013192382641136646)"
Line 329,"2021 Performance ReportIntroduction Transforming care Investing in   our people Overview and   2021 highlights Our diverse, equitable   and inclusive workplace Attracting, developing   and retaining talent Employee well-being,  rewards and safety Accelerating   possibilities Protecting the  environment Creating value  responsibly Appendix To learn more about our global benefit programs  and services, visit BenefitsConnect.Our approach to compensation  and pay equity We believe strongly in rewarding people for their  contributions to our high performance.
","('Employee_Engagement_Inclusion_And_Diversity', 0.923719584941864)","('Employee_Health_And_Safety', 0.019458679482340813)","('Human_Rights_And_Community_Relations', 0.009057322517037392)","(['Human Capital Development'], 0.923719584941864)","('NON-ESG', 0.019458679482340813)","('NON-ESG', 0.009057322517037392)"
Line 330,"2021 Performance ReportIntroduction Transforming care Investing in   our people Overview and   2021 highlights Our diverse, equitable   and inclusive workplace Attracting, developing   and retaining talent Employee well-being,  rewards and safety Accelerating   possibilities Protecting the  environment Creating value  responsibly Appendix To learn more about our global benefit programs  and services, visit BenefitsConnect.Our approach to compensation  and pay equity We believe strongly in rewarding people for their  contributions to our high performance.
","('Human_Rights_And_Community_Relations', 0.2244408130645752)","('Business_Model_Resilience', 0.1940106451511383)","('Ecological_Impacts', 0.06931707262992859)","('NON-ESG', 0.2244408130645752)","('NON-ESG', 0.1940106451511383)","('NON-ESG', 0.06931707262992859)"
Line 331,"Where it is  relevant to an employee’s responsibilities and follows  local and national labor standards, we strive to offer  both a base and a variable component to employee pay.
","('Labor_Practices', 0.9766770601272583)","('Director_Removal', 0.002398722805082798)","('Employee_Health_And_Safety', 0.001914029591716826)","(['Labor Practice Indicators'], 0.9766770601272583)","('NON-ESG', 0.002398722805082798)","('NON-ESG', 0.001914029591716826)"
Line 332,"Variable components include annual bonus programs,  long-term incentive stock awards and performance  rewards issued on a one-time basis, on-the-spot bonuses  for highly successful projects and recognition awards for  breakthrough performance.In 2021, we acknowledged the extraordinary efforts and  resiliency of our teams during the pandemic with a one-time  employee appreciation award for all employees.
","('Business_Model_Resilience', 0.5628054738044739)","('Systemic_Risk_Management', 0.06860802322626114)","('Employee_Engagement_Inclusion_And_Diversity', 0.054084714502096176)","(['Codes of Business Conduct'], 0.5628054738044739)","('NON-ESG', 0.06860802322626114)","('NON-ESG', 0.054084714502096176)"
Line 333,"In addition,  we expanded eligibility for the Boston Scientific Annual  Bonus Plan to include even more employees in 2022.
","('Labor_Practices', 0.8883752822875977)","('Employee_Engagement_Inclusion_And_Diversity', 0.037859074771404266)","('Director_Removal', 0.012014896608889103)","(['Labor Practice Indicators'], 0.8883752822875977)","('NON-ESG', 0.037859074771404266)","('NON-ESG', 0.012014896608889103)"
Line 334,"Paying people equally for equal work is foundational  to our inclusive culture.
","('Employee_Engagement_Inclusion_And_Diversity', 0.7256710529327393)","('Labor_Practices', 0.11789747327566147)","('Human_Rights_And_Community_Relations', 0.04913637414574623)","(['Human Capital Development'], 0.7256710529327393)","('NON-ESG', 0.11789747327566147)","('NON-ESG', 0.04913637414574623)"
Line 335,"Our most recent assessment  again reported 99% or greater pay equity for employees  across gender globally and for multicultural talent in the  United States and Puerto Rico.
","('Employee_Engagement_Inclusion_And_Diversity', 0.9444584250450134)","('Labor_Practices', 0.016182320192456245)","('Employee_Health_And_Safety', 0.004297340754419565)","(['Human Capital Development'], 0.9444584250450134)","('NON-ESG', 0.016182320192456245)","('NON-ESG', 0.004297340754419565)"
Line 336,"Our compensation experts  regularly benchmark salaries and conduct companywide  and external parity audits.
","('Labor_Practices', 0.6829001903533936)","('Management_Of_Legal_And_Regulatory_Framework', 0.0857435017824173)","('Business_Ethics', 0.08026547729969025)","(['Labor Practice Indicators'], 0.6829001903533936)","('NON-ESG', 0.0857435017824173)","('NON-ESG', 0.08026547729969025)"
Line 337,"We contract with an independent third party to assess pay  equity for all positions using regression analysis.
","('Management_Of_Legal_And_Regulatory_Framework', 0.2896031141281128)","('Competitive_Behavior', 0.19486619532108307)","('Business_Ethics', 0.17345581948757172)","('NON-ESG', 0.2896031141281128)","('NON-ESG', 0.19486619532108307)","('NON-ESG', 0.17345581948757172)"
Line 338,"This   data-driven approach controls for variables that appropriately influence compensation such as job position,  tenure, years of experience and location.
","('Labor_Practices', 0.48235923051834106)","('Employee_Engagement_Inclusion_And_Diversity', 0.3943975567817688)","('Employee_Health_And_Safety', 0.02052871137857437)","('NON-ESG', 0.48235923051834106)","('NON-ESG', 0.3943975567817688)","('NON-ESG', 0.02052871137857437)"
Line 339,"We use the  results to identify any potential pay disparities and address  them accordingly.
","('Labor_Practices', 0.8093501329421997)","('Business_Ethics', 0.03865489363670349)","('Competitive_Behavior', 0.02336612530052662)","(['Labor Practice Indicators'], 0.8093501329421997)","('NON-ESG', 0.03865489363670349)","('NON-ESG', 0.02336612530052662)"
Line 340,"99%+ pay equity for employees across gender globally and for multicultural talent in the U.S. and Puerto RicoMore mental health and well-being resources As ways of working changed for our people everywhere,  we enhanced mental health and well-being resources  to support employees in meeting their work and  family commitments.
","('Employee_Health_And_Safety', 0.5995316505432129)","('Employee_Engagement_Inclusion_And_Diversity', 0.13698431849479675)","('Access_And_Affordability', 0.09697622060775757)","(['Operational Eco-Efficiency'], 0.5995316505432129)","('NON-ESG', 0.13698431849479675)","('NON-ESG', 0.09697622060775757)"
Line 341,"• Webinars.
","('Competitive_Behavior', 0.12963993847370148)","('Business_Model_Resilience', 0.07607513666152954)","('Management_Of_Legal_And_Regulatory_Framework', 0.07050000876188278)","('NON-ESG', 0.12963993847370148)","('NON-ESG', 0.07607513666152954)","('NON-ESG', 0.07050000876188278)"
Line 342,"We offered more than 50 health and  well-being webinars led by caregiving specialists and  licensed clinicians.
","('Access_And_Affordability', 0.815794825553894)","('Employee_Health_And_Safety', 0.05729985982179642)","('Critical_Incident_Risk_Management', 0.020755978301167488)","(['Health Outcome Contribution'], 0.815794825553894)","('NON-ESG', 0.05729985982179642)","('NON-ESG', 0.020755978301167488)"
Line 343,"• Employee network.
","('Employee_Engagement_Inclusion_And_Diversity', 0.3017488718032837)","('Employee_Health_And_Safety', 0.15846341848373413)","('Labor_Practices', 0.09112284332513809)","('NON-ESG', 0.3017488718032837)","('NON-ESG', 0.15846341848373413)","('NON-ESG', 0.09112284332513809)"
Line 344,"We created a resource-rich virtual  community that facilitates information sharing on  topics such as parenting and well-being.
","('Access_And_Affordability', 0.7667333483695984)","('Human_Rights_And_Community_Relations', 0.05417812988162041)","('Employee_Health_And_Safety', 0.05343972146511078)","(['Health Outcome Contribution'], 0.7667333483695984)","('NON-ESG', 0.05417812988162041)","('NON-ESG', 0.05343972146511078)"
Line 345,"• Virtual support.
","('Data_Security', 0.4895915687084198)","('Product_Design_And_Lifecycle_Management', 0.09498068690299988)","('Customer_Privacy', 0.04820271208882332)","('NON-ESG', 0.4895915687084198)","('NON-ESG', 0.09498068690299988)","('NON-ESG', 0.04820271208882332)"
Line 346,"We expanded internal well-being  circles to provide forums for employees to connect  over shared circumstances and concerns.
","('Human_Rights_And_Community_Relations', 0.5155428647994995)","('Access_And_Affordability', 0.13261784613132477)","('Employee_Health_And_Safety', 0.12896126508712769)","(['Community Relations'], 0.5155428647994995)","('NON-ESG', 0.13261784613132477)","('NON-ESG', 0.12896126508712769)"
Line 347,"• Global Employee Assistance Program (EAP).
","('Employee_Health_And_Safety', 0.4986996054649353)","('Employee_Engagement_Inclusion_And_Diversity', 0.17401479184627533)","('Labor_Practices', 0.13200007379055023)","('NON-ESG', 0.4986996054649353)","('NON-ESG', 0.17401479184627533)","('NON-ESG', 0.13200007379055023)"
Line 348,"We  increased education on how to use our global network  of well-being and mental health resources.
","('Access_And_Affordability', 0.6985775828361511)","('Employee_Health_And_Safety', 0.11670553684234619)","('Human_Rights_And_Community_Relations', 0.027868319302797318)","(['Health Outcome Contribution'], 0.6985775828361511)","('NON-ESG', 0.11670553684234619)","('NON-ESG', 0.027868319302797318)"
Line 349,"• Access to care.
","('Access_And_Affordability', 0.8900944590568542)","('Critical_Incident_Risk_Management', 0.00938863679766655)","('Employee_Engagement_Inclusion_And_Diversity', 0.009137650951743126)","(['Health Outcome Contribution'], 0.8900944590568542)","('NON-ESG', 0.00938863679766655)","('NON-ESG', 0.009137650951743126)"
Line 350,"In the U.S., we increased telehealth  mental health care options and waived all co-pays  for mental health visits to ensure cost would not be a  barrier to care.
","('Access_And_Affordability', 0.6173012852668762)","('Employee_Health_And_Safety', 0.17273090779781342)","('Product_Quality_And_Safety', 0.03258952870965004)","(['Health Outcome Contribution'], 0.6173012852668762)","('NON-ESG', 0.17273090779781342)","('NON-ESG', 0.03258952870965004)"
Line 351,"Global pay equity 2021 Performance ReportIntroduction Transforming care Investing in   our people Overview and   2021 highlights Our diverse, equitable   and inclusive workplace Attracting, developing   and retaining talent Employee well-being,  rewards and safety Accelerating   possibilities Protecting the  environment Creating value  responsibly Appendix Keeping our employees healthy and safe  Boston Scientific takes a comprehensive approach to  managing and monitoring employee health and safety  at all offices and facilities globally.
","('Employee_Health_And_Safety', 0.9817478060722351)","('Employee_Engagement_Inclusion_And_Diversity', 0.0025943538639694452)","('Critical_Incident_Risk_Management', 0.00167722103651613)","(['Operational Eco-Efficiency'], 0.9817478060722351)","('NON-ESG', 0.0025943538639694452)","('NON-ESG', 0.00167722103651613)"
Line 352,"Global pay equity 2021 Performance ReportIntroduction Transforming care Investing in   our people Overview and   2021 highlights Our diverse, equitable   and inclusive workplace Attracting, developing   and retaining talent Employee well-being,  rewards and safety Accelerating   possibilities Protecting the  environment Creating value  responsibly Appendix Keeping our employees healthy and safe  Boston Scientific takes a comprehensive approach to  managing and monitoring employee health and safety  at all offices and facilities globally.
","('Business_Ethics', 0.193918377161026)","('Access_And_Affordability', 0.15753865242004395)","('Customer_Welfare', 0.06274320185184479)","('NON-ESG', 0.193918377161026)","('NON-ESG', 0.15753865242004395)","('NON-ESG', 0.06274320185184479)"
Line 353,"In the United States  in 2021, our occupational health nurse program and  standards of practice earned national recognition from  the American Board for Occupational Health Nurses  (ABOHN).
","('Employee_Health_And_Safety', 0.9763619303703308)","('Product_Quality_And_Safety', 0.0024275192990899086)","('Labor_Practices', 0.002363399602472782)","(['Operational Eco-Efficiency'], 0.9763619303703308)","('NON-ESG', 0.0024275192990899086)","('NON-ESG', 0.002363399602472782)"
Line 354,"Globally, we enhanced COVID-19 processes   and protocols to keep employees safe.
","('Employee_Health_And_Safety', 0.9099173545837402)","('Critical_Incident_Risk_Management', 0.035418130457401276)","('Air_Quality', 0.005249824840575457)","(['Operational Eco-Efficiency'], 0.9099173545837402)","('NON-ESG', 0.035418130457401276)","('NON-ESG', 0.005249824840575457)"
Line 355,"Employee safety initiatives we supported included: • Maximizing opportunities for people to work from  home to reduce potential for disease transmission.
","('Employee_Health_And_Safety', 0.9768468737602234)","('Employee_Engagement_Inclusion_And_Diversity', 0.0030232758726924658)","('Product_Quality_And_Safety', 0.0028293265495449305)","(['Operational Eco-Efficiency'], 0.9768468737602234)","('NON-ESG', 0.0030232758726924658)","('NON-ESG', 0.0028293265495449305)"
Line 356,"• Providing advice and equipment for at-home testing.
","('Product_Design_And_Lifecycle_Management', 0.2657797634601593)","('Energy_Management', 0.18817108869552612)","('Access_And_Affordability', 0.06725835055112839)","('NON-ESG', 0.2657797634601593)","('NON-ESG', 0.18817108869552612)","('NON-ESG', 0.06725835055112839)"
Line 357,"• Issuing personal protective equipment free of charge.
","('Employee_Health_And_Safety', 0.7451078295707703)","('Product_Design_And_Lifecycle_Management', 0.03909687697887421)","('Customer_Privacy', 0.03866307809948921)","(['Operational Eco-Efficiency'], 0.7451078295707703)","('NON-ESG', 0.03909687697887421)","('NON-ESG', 0.03866307809948921)"
Line 358,"• Offering an occupational health support call service.
","('Employee_Health_And_Safety', 0.9798513054847717)","('Critical_Incident_Risk_Management', 0.0026188527699559927)","('Employee_Engagement_Inclusion_And_Diversity', 0.0020905325654894114)","(['Operational Eco-Efficiency'], 0.9798513054847717)","('NON-ESG', 0.0026188527699559927)","('NON-ESG', 0.0020905325654894114)"
Line 359,"• Establishing a confidential employee vaccine register.
","('Customer_Privacy', 0.5142003893852234)","('Data_Security', 0.2100692242383957)","('Business_Ethics', 0.07058756053447723)","(['Privacy Protection'], 0.5142003893852234)","('NON-ESG', 0.2100692242383957)","('NON-ESG', 0.07058756053447723)"
Line 360,"We set health and safety goals called Total Recordable  Incident Rate (TRIR) targets and have a 2030 goal of  0.25 TRIR per 100 employees.
","('Employee_Health_And_Safety', 0.9823498725891113)","('Critical_Incident_Risk_Management', 0.0035303481854498386)","('Employee_Engagement_Inclusion_And_Diversity', 0.0013834669953212142)","(['Operational Eco-Efficiency'], 0.9823498725891113)","('NON-ESG', 0.0035303481854498386)","('NON-ESG', 0.0013834669953212142)"
Line 361,"Our global Employee  Health and Safety (EHS) Operations Council reviews  site TRIR performance monthly to discuss risks, trends  and opportunities for improvement.
","('Employee_Health_And_Safety', 0.9828632473945618)","('Employee_Engagement_Inclusion_And_Diversity', 0.0019656026270240545)","('Critical_Incident_Risk_Management', 0.0016714769881218672)","(['Operational Eco-Efficiency'], 0.9828632473945618)","('NON-ESG', 0.0019656026270240545)","('NON-ESG', 0.0016714769881218672)"
Line 362,"We expanded the  employee coverage in our TRIR calculation to incorporate  98% of our employee population in 2021, up from 67%  in 2020.
","('Employee_Engagement_Inclusion_And_Diversity', 0.8526911735534668)","('Labor_Practices', 0.051890838891267776)","('Employee_Health_And_Safety', 0.021855471655726433)","(['Human Capital Development'], 0.8526911735534668)","('NON-ESG', 0.051890838891267776)","('NON-ESG', 0.021855471655726433)"
Line 363,"As a result, our TRIR performance now reflects  incident rates for all global supply chain teams as well as  the majority of commercial staff who work primarily in  remote and office settings.In accordance with the Boston Scientific Environment,  Health and Safety Policy , we integrate health and  safety metrics across our global monitoring systems.
","('Employee_Health_And_Safety', 0.8678549528121948)","('Product_Quality_And_Safety', 0.027388283982872963)","('Supply_Chain_Management', 0.021154966205358505)","(['Operational Eco-Efficiency'], 0.8678549528121948)","('NON-ESG', 0.027388283982872963)","('NON-ESG', 0.021154966205358505)"
Line 364,"Our workplace guidelines support this policy and set  specific expectations for health- and safety-related  programs.
","('Employee_Health_And_Safety', 0.9828201532363892)","('Employee_Engagement_Inclusion_And_Diversity', 0.002017401624470949)","('Critical_Incident_Risk_Management', 0.0019333892269060016)","(['Operational Eco-Efficiency'], 0.9828201532363892)","('NON-ESG', 0.002017401624470949)","('NON-ESG', 0.0019333892269060016)"
Line 365,"We have met International Organization  for Standardization (ISO) requirements to achieve ISO  45001:2018 Occupational Health and Safety Management  System certification at four company locations.
","('Employee_Health_And_Safety', 0.9782342314720154)","('Product_Quality_And_Safety', 0.0030511640943586826)","('Employee_Engagement_Inclusion_And_Diversity', 0.002720100339502096)","(['Operational Eco-Efficiency'], 0.9782342314720154)","('NON-ESG', 0.0030511640943586826)","('NON-ESG', 0.002720100339502096)"
Line 366,"Our agile safety approach: 2021  COVID response team in India When a devastating COVID-19 surge struck India,   we acted quickly to protect more than 550 employees  and 140 contractors across the country.
","('Employee_Health_And_Safety', 0.9391841888427734)","('Critical_Incident_Risk_Management', 0.029818203300237656)","('Product_Quality_And_Safety', 0.002599315717816353)","(['Operational Eco-Efficiency'], 0.9391841888427734)","('NON-ESG', 0.029818203300237656)","('NON-ESG', 0.002599315717816353)"
Line 367,"Our team  of cross-functional experts organized testing and  medical services, financial assistance and vaccination  drives and secured life-saving supplies such as  oxygen concentrators.
","('Employee_Health_And_Safety', 0.2798192501068115)","('Access_And_Affordability', 0.19418391585350037)","('Critical_Incident_Risk_Management', 0.15588316321372986)","('NON-ESG', 0.2798192501068115)","('NON-ESG', 0.19418391585350037)","('NON-ESG', 0.15588316321372986)"
Line 368,"With contingency processes  in place, we prevented infection among employees,  helped their families and avoided business disruption.
","('Employee_Health_And_Safety', 0.8680914640426636)","('Critical_Incident_Risk_Management', 0.028041807934641838)","('Business_Ethics', 0.02036586031317711)","(['Operational Eco-Efficiency'], 0.8680914640426636)","('NON-ESG', 0.028041807934641838)","('NON-ESG', 0.02036586031317711)"
Line 369,"Boston Scientific is a Great Place to Work-CertifiedTM  organization in India and is recognized among India’s  Great Mid-size Workplaces 2021.
","('Employee_Engagement_Inclusion_And_Diversity', 0.3100358843803406)","('Labor_Practices', 0.21207939088344574)","('Employee_Health_And_Safety', 0.1682099848985672)","('NON-ESG', 0.3100358843803406)","('NON-ESG', 0.21207939088344574)","('NON-ESG', 0.1682099848985672)"
Line 370,"Total Recordable Incident Rate (TRIR): 2021:  0.42 TRIR (0.42 injuries per 100 employees) 2030 Goal:  0.25 (0.25 injuries per 100 employees) 2021 Performance ReportIntroduction Transforming care Investing in   our people Overview and   2021 highlights Our diverse, equitable   and inclusive workplace Attracting, developing   and retaining talent Employee well-being,  rewards and safety Accelerating   possibilities Protecting the  environment Creating value  responsibly Appendix Accelerating  possibilities When we challenge inequities, we advance health  care possibilities for people and communities.
","('Employee_Health_And_Safety', 0.9827410578727722)","('Critical_Incident_Risk_Management', 0.0027600987814366817)","('Employee_Engagement_Inclusion_And_Diversity', 0.001928033190779388)","(['Operational Eco-Efficiency'], 0.9827410578727722)","('NON-ESG', 0.0027600987814366817)","('NON-ESG', 0.001928033190779388)"
Line 371,"Total Recordable Incident Rate (TRIR): 2021:  0.42 TRIR (0.42 injuries per 100 employees) 2030 Goal:  0.25 (0.25 injuries per 100 employees) 2021 Performance ReportIntroduction Transforming care Investing in   our people Overview and   2021 highlights Our diverse, equitable   and inclusive workplace Attracting, developing   and retaining talent Employee well-being,  rewards and safety Accelerating   possibilities Protecting the  environment Creating value  responsibly Appendix Accelerating  possibilities When we challenge inequities, we advance health  care possibilities for people and communities.
","('Access_And_Affordability', 0.674483597278595)","('Human_Rights_And_Community_Relations', 0.14299064874649048)","('Employee_Health_And_Safety', 0.027919037267565727)","(['Health Outcome Contribution'], 0.674483597278595)","('NON-ESG', 0.14299064874649048)","('NON-ESG', 0.027919037267565727)"
Line 372,"Our commitment to improving patient outcomes inspires us to  address global health disparities.
","('Access_And_Affordability', 0.5377358198165894)","('Employee_Health_And_Safety', 0.16019761562347412)","('Human_Rights_And_Community_Relations', 0.03273266926407814)","(['Health Outcome Contribution'], 0.5377358198165894)","('NON-ESG', 0.16019761562347412)","('NON-ESG', 0.03273266926407814)"
Line 373,"We collaborate with partners  outside the company to expand community education, increase  health care provider outreach and break down barriers to care.
","('Access_And_Affordability', 0.9036415219306946)","('Human_Rights_And_Community_Relations', 0.014905293472111225)","('Employee_Health_And_Safety', 0.008714036084711552)","(['Health Outcome Contribution'], 0.9036415219306946)","('NON-ESG', 0.014905293472111225)","('NON-ESG', 0.008714036084711552)"
Line 374,"hospitals and providers acted to address inequities  in specialty care through Close the Gap partnerships$75+ million  in contributions for medical research, fellowships,  education and charitable organizations globally 2021 Performance ReportIntroduction Transforming care Investing in   our people Accelerating   possibilities Overview and   2021 highlights Improving health   equity and access Confronting inequities Supporting our  communities Protecting the  environment Creating value  responsibly Appendix Overview and   2021 highlights In 2021, Boston Scientific collaborated with providers  and nonprofit and local community organizations  to confront persistent health care inequities in  underrepresented populations.
","('Access_And_Affordability', 0.8355615735054016)","('Human_Rights_And_Community_Relations', 0.02212408371269703)","('Employee_Engagement_Inclusion_And_Diversity', 0.01378873735666275)","(['Health Outcome Contribution'], 0.8355615735054016)","('NON-ESG', 0.02212408371269703)","('NON-ESG', 0.01378873735666275)"
Line 375,"hospitals and providers acted to address inequities  in specialty care through Close the Gap partnerships$75+ million  in contributions for medical research, fellowships,  education and charitable organizations globally 2021 Performance ReportIntroduction Transforming care Investing in   our people Accelerating   possibilities Overview and   2021 highlights Improving health   equity and access Confronting inequities Supporting our  communities Protecting the  environment Creating value  responsibly Appendix Overview and   2021 highlights In 2021, Boston Scientific collaborated with providers  and nonprofit and local community organizations  to confront persistent health care inequities in  underrepresented populations.
","('Access_And_Affordability', 0.7582091689109802)","('Human_Rights_And_Community_Relations', 0.03093283623456955)","('Customer_Welfare', 0.020135655999183655)","(['Health Outcome Contribution'], 0.7582091689109802)","('NON-ESG', 0.03093283623456955)","('NON-ESG', 0.020135655999183655)"
Line 376,"Our teams worked to  improve treatment access and increase diversity in  medical research for women and individuals in Black,  Hispanic and Latinx communities.
","('Employee_Engagement_Inclusion_And_Diversity', 0.9746617674827576)","('Human_Rights_And_Community_Relations', 0.0020534347277134657)","('Employee_Health_And_Safety', 0.0017573223449289799)","(['Human Capital Development'], 0.9746617674827576)","('NON-ESG', 0.0020534347277134657)","('NON-ESG', 0.0017573223449289799)"
Line 377,"We also invested in  initiatives to support our communities, including science,  technology, engineering and math (STEM) education in  underserved communities.
","('Access_And_Affordability', 0.9415225386619568)","('Product_Quality_And_Safety', 0.00560538936406374)","('Ecological_Impacts', 0.004720499273389578)","(['Health Outcome Contribution'], 0.9415225386619568)","('NON-ESG', 0.00560538936406374)","('NON-ESG', 0.004720499273389578)"
Line 378,"Improving health  equity and access Social and economic factors — education, employment  status, income level, zip code, gender and ethnicity — can  have a significant impact on people’s ability to live long,  healthy lives.
","('Employee_Engagement_Inclusion_And_Diversity', 0.941310703754425)","('Access_And_Affordability', 0.010810541920363903)","('Human_Rights_And_Community_Relations', 0.008288471959531307)","(['Human Capital Development'], 0.941310703754425)","('NON-ESG', 0.010810541920363903)","('NON-ESG', 0.008288471959531307)"
Line 379,"Because health care inequities are rooted  in a broad range of injustices, our approach to mitigate  those inequities is far-reaching.
","('Systemic_Risk_Management', 0.8932734727859497)","('Business_Model_Resilience', 0.01900346949696541)","('Supply_Chain_Management', 0.01599823869764805)","(['Risk & Crisis Management'], 0.8932734727859497)","('NON-ESG', 0.01900346949696541)","('NON-ESG', 0.01599823869764805)"
Line 380,"Ralph Redd, MD  vascular surgeon,   Montgomery, Alabama“ Close the Gap’s disparity data helped us identify health  needs within our local community — as a result, we set up  a rural health clinic to evaluate patients for coronary artery  and peripheral artery disease.
","('Access_And_Affordability', 0.3812727630138397)","('Employee_Health_And_Safety', 0.23692923784255981)","('Critical_Incident_Risk_Management', 0.055782996118068695)","('NON-ESG', 0.3812727630138397)","('NON-ESG', 0.23692923784255981)","('NON-ESG', 0.055782996118068695)"
Line 381,"This program is closing the  treatment gap and helping patients receive the medical  interventions they need.” 2021 Performance ReportIntroduction Transforming care Investing in   our people Accelerating   possibilities Overview and   2021 highlights Improving health   equity and access Confronting inequities Supporting our  communities Protecting the  environment Creating value  responsibly Appendix Our Close the Gap initiative  to combat health inequities Close the Gap is our top initiative to address health care  gaps in underserved communities in the United States.
","('Access_And_Affordability', 0.8426510691642761)","('Employee_Health_And_Safety', 0.023184383288025856)","('Human_Rights_And_Community_Relations', 0.021588308736681938)","(['Health Outcome Contribution'], 0.8426510691642761)","('NON-ESG', 0.023184383288025856)","('NON-ESG', 0.021588308736681938)"
Line 382,"This program is closing the  treatment gap and helping patients receive the medical  interventions they need.” 2021 Performance ReportIntroduction Transforming care Investing in   our people Accelerating   possibilities Overview and   2021 highlights Improving health   equity and access Confronting inequities Supporting our  communities Protecting the  environment Creating value  responsibly Appendix Our Close the Gap initiative  to combat health inequities Close the Gap is our top initiative to address health care  gaps in underserved communities in the United States.
","('Access_And_Affordability', 0.9466403722763062)","('Critical_Incident_Risk_Management', 0.004883202724158764)","('Human_Rights_And_Community_Relations', 0.0045752618461847305)","(['Health Outcome Contribution'], 0.9466403722763062)","('NON-ESG', 0.004883202724158764)","('NON-ESG', 0.0045752618461847305)"
Line 383,"Over the course of 18 years, we have expanded its reach  to identify and address systemic and emerging treatment  gaps.
","('Systemic_Risk_Management', 0.945742666721344)","('Business_Model_Resilience', 0.008196287788450718)","('Supply_Chain_Management', 0.006381647661328316)","(['Risk & Crisis Management'], 0.945742666721344)","('NON-ESG', 0.008196287788450718)","('NON-ESG', 0.006381647661328316)"
Line 384,"Our vision is a world where all patients understand  their medical conditions and have access to care.In 2021, as the COVID-19 pandemic continued to expose  and worsen severe care disparities, we took the following  measures to advance equitable care:  • Educating providers.
","('Access_And_Affordability', 0.779162585735321)","('Employee_Health_And_Safety', 0.04601682350039482)","('Product_Quality_And_Safety', 0.02354539930820465)","(['Health Outcome Contribution'], 0.779162585735321)","('NON-ESG', 0.04601682350039482)","('NON-ESG', 0.02354539930820465)"
Line 385,"We partnered with community  providers to generate local disparity index data on  disease prevalence and treatment inequities, identifying  72,000 women and people of color who were not  receiving equitable specialty care.
","('Employee_Engagement_Inclusion_And_Diversity', 0.7490893602371216)","('Access_And_Affordability', 0.07899422198534012)","('Employee_Health_And_Safety', 0.0316777341067791)","(['Human Capital Development'], 0.7490893602371216)","('NON-ESG', 0.07899422198534012)","('NON-ESG', 0.0316777341067791)"
Line 386,"• Educating patients.
","('Access_And_Affordability', 0.686430037021637)","('Critical_Incident_Risk_Management', 0.03545629605650902)","('Employee_Engagement_Inclusion_And_Diversity', 0.028573714196681976)","(['Health Outcome Contribution'], 0.686430037021637)","('NON-ESG', 0.03545629605650902)","('NON-ESG', 0.028573714196681976)"
Line 387,"More than 10,000 patients  visited KnowYourHealth.com for resources such as a  personalized heart risk assessment and a find a doctor  tool.
","('Employee_Health_And_Safety', 0.3159583508968353)","('Access_And_Affordability', 0.11114469170570374)","('Product_Quality_And_Safety', 0.09177057445049286)","('NON-ESG', 0.3159583508968353)","('NON-ESG', 0.11114469170570374)","('NON-ESG', 0.09177057445049286)"
Line 388,"Approximately 2,100 patients attended virtual  health summits organized by Close the Gap in 2021.
","('Access_And_Affordability', 0.5370867252349854)","('Product_Quality_And_Safety', 0.048294972628355026)","('Systemic_Risk_Management', 0.04214104637503624)","(['Health Outcome Contribution'], 0.5370867252349854)","('NON-ESG', 0.048294972628355026)","('NON-ESG', 0.04214104637503624)"
Line 389,"Close the Gap 2021:   Empowering providers to act  72,women and people of color identified  as missing equitable specialty care of hospitals and providers acted to  address inequities in specialty care 50+ health care providers participated in  Black Health Matters events sponsored  by Close the Gap Learn more about inequities in access to health  care, and how our Close the Gap initiative was  created to address these gaps on our website .
","('Access_And_Affordability', 0.4503178298473358)","('Employee_Engagement_Inclusion_And_Diversity', 0.26548248529434204)","('Customer_Welfare', 0.03522137552499771)","('NON-ESG', 0.4503178298473358)","('NON-ESG', 0.26548248529434204)","('NON-ESG', 0.03522137552499771)"
Line 390,"We collaborate with health care providers to expand awareness of health inequities through community outreach   and educational resources.
","('Access_And_Affordability', 0.8720638751983643)","('Human_Rights_And_Community_Relations', 0.01995578221976757)","('Employee_Health_And_Safety', 0.016565561294555664)","(['Health Outcome Contribution'], 0.8720638751983643)","('NON-ESG', 0.01995578221976757)","('NON-ESG', 0.016565561294555664)"
Line 391,"Learn more by watching the full Close the Gap educational video .
","('Access_And_Affordability', 0.5043368935585022)","('Employee_Engagement_Inclusion_And_Diversity', 0.06521423161029816)","('Product_Quality_And_Safety', 0.046690575778484344)","(['Health Outcome Contribution'], 0.5043368935585022)","('NON-ESG', 0.06521423161029816)","('NON-ESG', 0.046690575778484344)"
Line 392,"2021 Performance ReportIntroduction Transforming care Investing in   our people Accelerating   possibilities Overview and   2021 highlights Improving health   equity and access Confronting inequities Supporting our  communities Protecting the  environment Creating value  responsibly Appendix Increasing diversity in medical research Diversity in medical research is essential to ensuring  everyone can benefit from treatments and therapies.
","('Employee_Engagement_Inclusion_And_Diversity', 0.9639230966567993)","('Access_And_Affordability', 0.003146988805383444)","('Employee_Health_And_Safety', 0.0029518259689211845)","(['Human Capital Development'], 0.9639230966567993)","('NON-ESG', 0.003146988805383444)","('NON-ESG', 0.0029518259689211845)"
Line 393,"We partner with providers and patient advocacy  organizations to improve representation in clinical  research.
","('Management_Of_Legal_And_Regulatory_Framework', 0.2439681887626648)","('Access_And_Affordability', 0.15236583352088928)","('Competitive_Behavior', 0.1274416297674179)","('NON-ESG', 0.2439681887626648)","('NON-ESG', 0.15236583352088928)","('NON-ESG', 0.1274416297674179)"
Line 394,"For example, approximately 200 million people  globally are affected by peripheral artery disease (PAD),  a common circulatory problem that disproportionately  affects Black men and women.
","('Employee_Health_And_Safety', 0.38445615768432617)","('Access_And_Affordability', 0.16303348541259766)","('Employee_Engagement_Inclusion_And_Diversity', 0.12475290149450302)","('NON-ESG', 0.38445615768432617)","('NON-ESG', 0.16303348541259766)","('NON-ESG', 0.12475290149450302)"
Line 395,"Yet, typically these groups  are underrepresented in PAD clinical trials.
","('Competitive_Behavior', 0.3985372483730316)","('Customer_Welfare', 0.08412765711545944)","('GHG_Emissions', 0.0724545419216156)","('NON-ESG', 0.3985372483730316)","('NON-ESG', 0.08412765711545944)","('NON-ESG', 0.0724545419216156)"
Line 396,"To expand the  body of clinical evidence on the outcomes of patients  diagnosed with PAD — particularly women and people of  color — we launched ELEGANCE, a global patient registry  and post-market study whose goal is to enroll no less  than 40% women and 40% underrepresented minorities.
","('Employee_Engagement_Inclusion_And_Diversity', 0.9730578064918518)","('Access_And_Affordability', 0.0020518568344414234)","('Human_Rights_And_Community_Relations', 0.0020026499405503273)","(['Human Capital Development'], 0.9730578064918518)","('NON-ESG', 0.0020518568344414234)","('NON-ESG', 0.0020026499405503273)"
Line 397,"The registry is also groundbreaking for the diversity of its  principal investigators, more than half of whom identify  as women and/or people of color.
","('Employee_Engagement_Inclusion_And_Diversity', 0.9757713675498962)","('Human_Rights_And_Community_Relations', 0.0016851592808961868)","('Employee_Health_And_Safety', 0.001393286045640707)","(['Human Capital Development'], 0.9757713675498962)","('NON-ESG', 0.0016851592808961868)","('NON-ESG', 0.001393286045640707)"
Line 398,"“ Increasing diversity in medical research is a critical step to ensure that  everyone can benefit from treatments and therapies.
","('Employee_Engagement_Inclusion_And_Diversity', 0.9329599738121033)","('Customer_Welfare', 0.005774495657533407)","('Access_And_Affordability', 0.005715725943446159)","(['Human Capital Development'], 0.9329599738121033)","('NON-ESG', 0.005774495657533407)","('NON-ESG', 0.005715725943446159)"
Line 399,"Now is the time  to eliminate disparities in health care — once and for all.” Michael R.
","('Systemic_Risk_Management', 0.17195875942707062)","('Employee_Engagement_Inclusion_And_Diversity', 0.1627906858921051)","('Access_And_Affordability', 0.08895670622587204)","('NON-ESG', 0.17195875942707062)","('NON-ESG', 0.1627906858921051)","('NON-ESG', 0.08895670622587204)"
Line 400,"Jaff, DO chief medical officer and vice president,  Clinical Affairs, Technology & Intervention,  Peripheral Interventions ELEGANCE breaks new ground   in diversifying clinical studies 40% Objective: Enroll at least  40% women and 40% people  of color 50% Principal investigator diversity:  50% women and people of color 2021 Performance ReportIntroduction Transforming care Investing in   our people Accelerating   possibilities Overview and   2021 highlights Improving health   equity and access Confronting inequities Supporting our  communities Protecting the  environment Creating value  responsibly Appendix Combating racism in the United States In the second year of our $3.5 million multiyear strategy to  combat racism, we expanded our advocacy across five pillars of  investment that we identified in collaboration with 28 national  and local organizations, such as The New Commonwealth  Racial Equity and Social Justice Fund in Massachusetts,  Advancing Minorities' Interest in Engineering and Nexus  Community Partners.
","('Employee_Engagement_Inclusion_And_Diversity', 0.9550731182098389)","('Access_And_Affordability', 0.006721742916852236)","('Employee_Health_And_Safety', 0.0039993636310100555)","(['Human Capital Development'], 0.9550731182098389)","('NON-ESG', 0.006721742916852236)","('NON-ESG', 0.0039993636310100555)"
Line 401,"Jaff, DO chief medical officer and vice president,  Clinical Affairs, Technology & Intervention,  Peripheral Interventions ELEGANCE breaks new ground   in diversifying clinical studies 40% Objective: Enroll at least  40% women and 40% people  of color 50% Principal investigator diversity:  50% women and people of color 2021 Performance ReportIntroduction Transforming care Investing in   our people Accelerating   possibilities Overview and   2021 highlights Improving health   equity and access Confronting inequities Supporting our  communities Protecting the  environment Creating value  responsibly Appendix Combating racism in the United States In the second year of our $3.5 million multiyear strategy to  combat racism, we expanded our advocacy across five pillars of  investment that we identified in collaboration with 28 national  and local organizations, such as The New Commonwealth  Racial Equity and Social Justice Fund in Massachusetts,  Advancing Minorities' Interest in Engineering and Nexus  Community Partners.
","('Employee_Engagement_Inclusion_And_Diversity', 0.8461889028549194)","('Human_Rights_And_Community_Relations', 0.06021999940276146)","('Employee_Health_And_Safety', 0.012465780600905418)","(['Human Capital Development'], 0.8461889028549194)","('NON-ESG', 0.06021999940276146)","('NON-ESG', 0.012465780600905418)"
Line 402,"Jaff, DO chief medical officer and vice president,  Clinical Affairs, Technology & Intervention,  Peripheral Interventions ELEGANCE breaks new ground   in diversifying clinical studies 40% Objective: Enroll at least  40% women and 40% people  of color 50% Principal investigator diversity:  50% women and people of color 2021 Performance ReportIntroduction Transforming care Investing in   our people Accelerating   possibilities Overview and   2021 highlights Improving health   equity and access Confronting inequities Supporting our  communities Protecting the  environment Creating value  responsibly Appendix Combating racism in the United States In the second year of our $3.5 million multiyear strategy to  combat racism, we expanded our advocacy across five pillars of  investment that we identified in collaboration with 28 national  and local organizations, such as The New Commonwealth  Racial Equity and Social Justice Fund in Massachusetts,  Advancing Minorities' Interest in Engineering and Nexus  Community Partners.
","('Management_Of_Legal_And_Regulatory_Framework', 0.4125540256500244)","('Business_Ethics', 0.07758299261331558)","('Competitive_Behavior', 0.07028970122337341)","('NON-ESG', 0.4125540256500244)","('NON-ESG', 0.07758299261331558)","('NON-ESG', 0.07028970122337341)"
Line 403,"More than 100 employees volunteered  alongside company leaders with these organizations to launch  initiatives primarily supporting the Black community.
","('Employee_Engagement_Inclusion_And_Diversity', 0.676207959651947)","('Human_Rights_And_Community_Relations', 0.1089710220694542)","('Labor_Practices', 0.056254949420690536)","(['Human Capital Development'], 0.676207959651947)","('NON-ESG', 0.1089710220694542)","('NON-ESG', 0.056254949420690536)"
Line 404,"Community Provided financial support for 200 Black,  indigenous and people of color-owned  businesses in Minnesota.
","('Employee_Engagement_Inclusion_And_Diversity', 0.637590765953064)","('Human_Rights_And_Community_Relations', 0.22919565439224243)","('Access_And_Affordability', 0.02416081726551056)","(['Human Capital Development'], 0.637590765953064)","('NON-ESG', 0.22919565439224243)","('NON-ESG', 0.02416081726551056)"
Line 405,"Education Funded scholarships for more than 45 Historically  Black Colleges and Universities students and  graduate-level health care students of color.
","('Employee_Engagement_Inclusion_And_Diversity', 0.9341967105865479)","('Access_And_Affordability', 0.010183269158005714)","('Human_Rights_And_Community_Relations', 0.004374111536890268)","(['Human Capital Development'], 0.9341967105865479)","('NON-ESG', 0.010183269158005714)","('NON-ESG', 0.004374111536890268)"
Line 406,"Health care Funded a mobile health clinic for The Family Van  to provide free health screenings and coaching  for underserved Boston-area communities.
","('Access_And_Affordability', 0.9447236061096191)","('Critical_Incident_Risk_Management', 0.005910187028348446)","('Product_Quality_And_Safety', 0.004558557644486427)","(['Health Outcome Contribution'], 0.9447236061096191)","('NON-ESG', 0.005910187028348446)","('NON-ESG', 0.004558557644486427)"
Line 407,"Economic empowerment Launched a mentorship program to increase the  number of Black-owned businesses and train  Black entrepreneurs to work with companies like  Boston Scientific.
","('Employee_Engagement_Inclusion_And_Diversity', 0.6386348605155945)","('Human_Rights_And_Community_Relations', 0.12467049807310104)","('Access_And_Affordability', 0.06495684385299683)","(['Human Capital Development'], 0.6386348605155945)","('NON-ESG', 0.12467049807310104)","('NON-ESG', 0.06495684385299683)"
Line 408,"Government / policies Sponsored a congressional Black Caucus  Foundation fellowship.
","('Management_Of_Legal_And_Regulatory_Framework', 0.918137788772583)","('Human_Rights_And_Community_Relations', 0.01171173807233572)","('Director_Removal', 0.006696129217743874)","(['Corporate Governance'], 0.918137788772583)","('NON-ESG', 0.01171173807233572)","('NON-ESG', 0.006696129217743874)"
Line 409,"Confronting inequities We have a responsibility to uphold our values in all that we  do.
","('Business_Model_Resilience', 0.2874528467655182)","('Management_Of_Legal_And_Regulatory_Framework', 0.1411905437707901)","('Systemic_Risk_Management', 0.12601377069950104)","('NON-ESG', 0.2874528467655182)","('NON-ESG', 0.1411905437707901)","('NON-ESG', 0.12601377069950104)"
Line 410,"In 2021, we continued to take decisive actions to confront  racism and intolerance.
","('Employee_Engagement_Inclusion_And_Diversity', 0.5328709483146667)","('Business_Ethics', 0.1837458312511444)","('Human_Rights_And_Community_Relations', 0.049127332866191864)","(['Human Capital Development'], 0.5328709483146667)","('NON-ESG', 0.1837458312511444)","('NON-ESG', 0.049127332866191864)"
Line 411,"In the face of pandemic-fueled hate  crimes targeting the Asian community, we spoke out against  xenophobia and stood in solidarity with our colleagues.
","('Employee_Engagement_Inclusion_And_Diversity', 0.852185070514679)","('Labor_Practices', 0.018877679482102394)","('Human_Rights_And_Community_Relations', 0.0158471018075943)","(['Human Capital Development'], 0.852185070514679)","('NON-ESG', 0.018877679482102394)","('NON-ESG', 0.0158471018075943)"
Line 412,"We organized listening forums and offered resources to  employees, including access to bystander intervention  training and expanded leadership inclusion training.
","('Employee_Engagement_Inclusion_And_Diversity', 0.8606582880020142)","('Access_And_Affordability', 0.034178152680397034)","('Employee_Health_And_Safety', 0.01254270225763321)","(['Human Capital Development'], 0.8606582880020142)","('NON-ESG', 0.034178152680397034)","('NON-ESG', 0.01254270225763321)"
Line 413,"In  March 2021, we joined a coalition of organizations and   allies who share support for Stop AAPI Hate by hosting  virtual events and reporting on hate incidents using Stop  AAPI Hate data.
","('Business_Ethics', 0.46325501799583435)","('Data_Security', 0.19118881225585938)","('Labor_Practices', 0.04142893850803375)","('NON-ESG', 0.46325501799583435)","('NON-ESG', 0.19118881225585938)","('NON-ESG', 0.04142893850803375)"
Line 414,"Our commitment to confronting discrimination and  injustice compelled us to take additional action in 2021.
","('Employee_Engagement_Inclusion_And_Diversity', 0.5552650094032288)","('Business_Ethics', 0.09995093941688538)","('Labor_Practices', 0.0832250788807869)","(['Human Capital Development'], 0.5552650094032288)","('NON-ESG', 0.09995093941688538)","('NON-ESG', 0.0832250788807869)"
Line 415,"Boston Scientific introduced Anti-Racism & Cultural  History (ARCH) training for U.S. employees to advance  our collective understanding of race, culture and identity  and its impact in the workplace and beyond.CEO action for racial equity Boston Scientific stepped up its commitment to   CEO Action for Diversity & Inclusion with support for the  CEO Action for Racial Equity Fellowship , an initiative to  advance policy change at the federal, state and local  levels.
","('Employee_Engagement_Inclusion_And_Diversity', 0.9762699007987976)","('Employee_Health_And_Safety', 0.002401878824457526)","('Human_Rights_And_Community_Relations', 0.0018268113490194082)","(['Human Capital Development'], 0.9762699007987976)","('NON-ESG', 0.002401878824457526)","('NON-ESG', 0.0018268113490194082)"
Line 416,"Boston Scientific CEO Mike Mahoney was among  the first signatories of the CEO Action for Diversity &  Inclusion Pledge shortly after its formation.
","('Employee_Engagement_Inclusion_And_Diversity', 0.9721599817276001)","('Employee_Health_And_Safety', 0.0024636469315737486)","('Human_Rights_And_Community_Relations', 0.0023528067395091057)","(['Human Capital Development'], 0.9721599817276001)","('NON-ESG', 0.0024636469315737486)","('NON-ESG', 0.0023528067395091057)"
Line 417,"Iñaki Martin Cossio senior health equity consultant,  Close the GapFor more on ARCH training, see the   Investing in our people section of this report.Here are some examples of our contributions since 2020: "" Volunteering as part of our combating  racism strategy has been an exciting  and fulfilling project.
","('Employee_Health_And_Safety', 0.41907283663749695)","('Human_Rights_And_Community_Relations', 0.16630294919013977)","('Employee_Engagement_Inclusion_And_Diversity', 0.12596012651920319)","('NON-ESG', 0.41907283663749695)","('NON-ESG', 0.16630294919013977)","('NON-ESG', 0.12596012651920319)"
Line 418,"Boston Scientific  has empowered me to make a difference  in so many ways for Black communities  across the United States."" 2021 Performance ReportIntroduction Transforming care Investing in   our people Accelerating   possibilities Overview and   2021 highlights Improving health   equity and access Confronting inequities Supporting our  communities Protecting the  environment Creating value  responsibly Appendix Supporting our communities Caring about human life is the basis for everything we do at Boston Scientific, including how we engage with the communities  where we work and live.
","('Human_Rights_And_Community_Relations', 0.7548190355300903)","('Access_And_Affordability', 0.11274135857820511)","('Employee_Health_And_Safety', 0.022675493732094765)","(['Community Relations'], 0.7548190355300903)","('NON-ESG', 0.11274135857820511)","('NON-ESG', 0.022675493732094765)"
Line 419,"Boston Scientific  has empowered me to make a difference  in so many ways for Black communities  across the United States."" 2021 Performance ReportIntroduction Transforming care Investing in   our people Accelerating   possibilities Overview and   2021 highlights Improving health   equity and access Confronting inequities Supporting our  communities Protecting the  environment Creating value  responsibly Appendix Supporting our communities Caring about human life is the basis for everything we do at Boston Scientific, including how we engage with the communities  where we work and live.
","('Human_Rights_And_Community_Relations', 0.9420385956764221)","('Access_And_Affordability', 0.005552499555051327)","('Employee_Engagement_Inclusion_And_Diversity', 0.005323652643710375)","(['Community Relations'], 0.9420385956764221)","('NON-ESG', 0.005552499555051327)","('NON-ESG', 0.005323652643710375)"
Line 420,"Employees in more than 50 countries participated in STEM outreach to local students, helped raise  awareness of chronic health conditions and contributed time and money to support those in need.
","('Employee_Health_And_Safety', 0.8778602480888367)","('Access_And_Affordability', 0.036698367446660995)","('Product_Quality_And_Safety', 0.010866752825677395)","(['Operational Eco-Efficiency'], 0.8778602480888367)","('NON-ESG', 0.036698367446660995)","('NON-ESG', 0.010866752825677395)"
Line 421,"The company also donated  more than $75 million to fund medical research, fellowships, education and charitable organizations globally.
","('Access_And_Affordability', 0.4416052997112274)","('Management_Of_Legal_And_Regulatory_Framework', 0.2935086786746979)","('Ecological_Impacts', 0.0349050797522068)","('NON-ESG', 0.4416052997112274)","('NON-ESG', 0.2935086786746979)","('NON-ESG', 0.0349050797522068)"
Line 422,"And in the United  States, the Boston Scientific Foundation awarded more than $1 million in grants and scholarships.
","('Management_Of_Legal_And_Regulatory_Framework', 0.6500884890556335)","('Access_And_Affordability', 0.1275804042816162)","('Ecological_Impacts', 0.044601038098335266)","(['Corporate Governance'], 0.6500884890556335)","('NON-ESG', 0.1275804042816162)","('NON-ESG', 0.044601038098335266)"
Line 423,"Our priorities for supporting communities are: 2021 contributions   and engagement 50,000+  volunteer hours in 50+ countries  where our employees contribute   to their communities $75+ million in contributions for medical research,  fellowships, education and charitable  organizations globally 3,500+  nonprofits we support with donations,  grant funding and in-kind contributions $1+ million in Boston Scientific Foundation   contributionsAdvancing health We work to reduce health  disparities and chronic disease  risk in underserved populations by  increasing access to screenings and  qualified health care professionals.
","('Employee_Health_And_Safety', 0.7507274150848389)","('Access_And_Affordability', 0.06830745935440063)","('Product_Quality_And_Safety', 0.02297709323465824)","(['Operational Eco-Efficiency'], 0.7507274150848389)","('NON-ESG', 0.06830745935440063)","('NON-ESG', 0.02297709323465824)"
Line 424,"Our priorities for supporting communities are: 2021 contributions   and engagement 50,000+  volunteer hours in 50+ countries  where our employees contribute   to their communities $75+ million in contributions for medical research,  fellowships, education and charitable  organizations globally 3,500+  nonprofits we support with donations,  grant funding and in-kind contributions $1+ million in Boston Scientific Foundation   contributionsAdvancing health We work to reduce health  disparities and chronic disease  risk in underserved populations by  increasing access to screenings and  qualified health care professionals.
","('Access_And_Affordability', 0.9472834467887878)","('Critical_Incident_Risk_Management', 0.004757882561534643)","('Product_Quality_And_Safety', 0.0045546069741249084)","(['Health Outcome Contribution'], 0.9472834467887878)","('NON-ESG', 0.004757882561534643)","('NON-ESG', 0.0045546069741249084)"
Line 425,"In China, we collaborated to support  a rural health clinic for children.
","('Access_And_Affordability', 0.7667678594589233)","('Employee_Health_And_Safety', 0.05027490481734276)","('Critical_Incident_Risk_Management', 0.04774567112326622)","(['Health Outcome Contribution'], 0.7667678594589233)","('NON-ESG', 0.05027490481734276)","('NON-ESG', 0.04774567112326622)"
Line 426,"Advancing community We empower our employees to  improve life in their communities  by donating their talent and  resources through our matching  gifts and volunteer programs.
","('Employee_Engagement_Inclusion_And_Diversity', 0.3754436671733856)","('Human_Rights_And_Community_Relations', 0.1900474578142166)","('Access_And_Affordability', 0.1628350019454956)","('NON-ESG', 0.3754436671733856)","('NON-ESG', 0.1900474578142166)","('NON-ESG', 0.1628350019454956)"
Line 427,"In Malaysia, we donated care kits to  children undergoing cancer treatment.
","('Access_And_Affordability', 0.6154786348342896)","('Employee_Health_And_Safety', 0.07772540301084518)","('Product_Quality_And_Safety', 0.06626404076814651)","(['Health Outcome Contribution'], 0.6154786348342896)","('NON-ESG', 0.07772540301084518)","('NON-ESG', 0.06626404076814651)"
Line 428,"Advancing education We support STEM programming  for underserved students  around the world to develop  the next generation of health  care innovators.
","('Access_And_Affordability', 0.9448138475418091)","('Critical_Incident_Risk_Management', 0.005087542347609997)","('Product_Quality_And_Safety', 0.0043875910341739655)","(['Health Outcome Contribution'], 0.9448138475418091)","('NON-ESG', 0.005087542347609997)","('NON-ESG', 0.0043875910341739655)"
Line 429,"In Costa Rica, we mentored STEM students  participating in a robotics program.
","('Access_And_Affordability', 0.4814258813858032)","('Employee_Engagement_Inclusion_And_Diversity', 0.21788239479064941)","('Management_Of_Legal_And_Regulatory_Framework', 0.024948863312602043)","('NON-ESG', 0.4814258813858032)","('NON-ESG', 0.21788239479064941)","('NON-ESG', 0.024948863312602043)"
Line 430,"2021 Performance ReportIntroduction Transforming care Investing in   our people Accelerating   possibilities Overview and   2021 highlights Improving health   equity and access Confronting inequities Supporting our  communities Protecting the  environment Creating value  responsibly Appendix Virtually assisted care in Colombia We partnered with local telecommunications  companies to offer our Clinical Eye virtual tool to health  professionals.
","('Access_And_Affordability', 0.8322051763534546)","('Human_Rights_And_Community_Relations', 0.028492944315075874)","('Employee_Health_And_Safety', 0.021205762401223183)","(['Health Outcome Contribution'], 0.8322051763534546)","('NON-ESG', 0.028492944315075874)","('NON-ESG', 0.021205762401223183)"
Line 431,"Providers in the region used the system’s  assisted reality glasses to treat 746 remote and at-risk  patients, including 336 in COVID isolation.Advancing health: Global Signature Health Grant Program The World Health Organization estimates a shortage of 18 million health care workers in low- and middle- income countries by 2030.
","('Access_And_Affordability', 0.41730156540870667)","('Employee_Health_And_Safety', 0.2698175311088562)","('Critical_Incident_Risk_Management', 0.04112252593040466)","('NON-ESG', 0.41730156540870667)","('NON-ESG', 0.2698175311088562)","('NON-ESG', 0.04112252593040466)"
Line 432,"We collaborate with nonprofit organizations to address this crisis by increasing  the number of trained health care workers and improving the quality and availability of chronic disease  screenings.
","('Employee_Health_And_Safety', 0.9139580130577087)","('Access_And_Affordability', 0.01725584827363491)","('Critical_Incident_Risk_Management', 0.010748310945928097)","(['Operational Eco-Efficiency'], 0.9139580130577087)","('NON-ESG', 0.01725584827363491)","('NON-ESG', 0.010748310945928097)"
Line 433,"Since 2016, our Global Signature Health Grant Program has helped train nearly 5,000 community health workers  in five countries and provided screenings for more than 23,000 individuals.
","('Employee_Health_And_Safety', 0.790621817111969)","('Human_Rights_And_Community_Relations', 0.05299888923764229)","('Access_And_Affordability', 0.04495559260249138)","(['Operational Eco-Efficiency'], 0.790621817111969)","('NON-ESG', 0.05299888923764229)","('NON-ESG', 0.04495559260249138)"
Line 434,"Training health care workers   in vulnerable communities 5,community health workers trained  in 5 countries 23,000+ health screenings provided since In Colombia, we partnered with Project Hope and  local health departments, hospitals and universities  to train more than 400 community health care  workers to help treat nearly 700,000 patients with  chronic diseases in small, rural clinics along the  Venezuelan border.Colombia   Since Learn about more of our digital solutions   in the Transforming care section of this report.
","('Access_And_Affordability', 0.5368390083312988)","('Employee_Health_And_Safety', 0.141121044754982)","('Human_Rights_And_Community_Relations', 0.13162118196487427)","(['Health Outcome Contribution'], 0.5368390083312988)","('NON-ESG', 0.141121044754982)","('NON-ESG', 0.13162118196487427)"
Line 435,"Training health care workers   in vulnerable communities 5,community health workers trained  in 5 countries 23,000+ health screenings provided since In Colombia, we partnered with Project Hope and  local health departments, hospitals and universities  to train more than 400 community health care  workers to help treat nearly 700,000 patients with  chronic diseases in small, rural clinics along the  Venezuelan border.Colombia   Since Learn about more of our digital solutions   in the Transforming care section of this report.
","('Management_Of_Legal_And_Regulatory_Framework', 0.7240120768547058)","('Business_Ethics', 0.037358105182647705)","('Human_Rights_And_Community_Relations', 0.02336280420422554)","(['Corporate Governance'], 0.7240120768547058)","('NON-ESG', 0.037358105182647705)","('NON-ESG', 0.02336280420422554)"
Line 436,"2021 Performance ReportIntroduction Transforming care Investing in   our people Accelerating   possibilities Overview and   2021 highlights Improving health   equity and access Confronting inequities Supporting our  communities Protecting the  environment Creating value  responsibly Appendix In Ireland, Boston Scientific STEM teams sponsored the 2021  SciFest National Final, which featured nearly 600 projects by  more than 1,000 students from 130 schools.In Costa Rica, we hosted a virtual open house where our employees  showcased careers in health care for 200 students and guided them  through STEM experiments.Advancing education:   STEM outreach By supporting STEM programming for K-12  students, we are helping develop diverse  talent who will contribute to health care innovations for  generations to come.
","('Access_And_Affordability', 0.8458272218704224)","('Human_Rights_And_Community_Relations', 0.027038129046559334)","('Employee_Health_And_Safety', 0.014461216516792774)","(['Health Outcome Contribution'], 0.8458272218704224)","('NON-ESG', 0.027038129046559334)","('NON-ESG', 0.014461216516792774)"
Line 437,"2021 Performance ReportIntroduction Transforming care Investing in   our people Accelerating   possibilities Overview and   2021 highlights Improving health   equity and access Confronting inequities Supporting our  communities Protecting the  environment Creating value  responsibly Appendix In Ireland, Boston Scientific STEM teams sponsored the 2021  SciFest National Final, which featured nearly 600 projects by  more than 1,000 students from 130 schools.In Costa Rica, we hosted a virtual open house where our employees  showcased careers in health care for 200 students and guided them  through STEM experiments.Advancing education:   STEM outreach By supporting STEM programming for K-12  students, we are helping develop diverse  talent who will contribute to health care innovations for  generations to come.
","('Employee_Engagement_Inclusion_And_Diversity', 0.7875714898109436)","('Access_And_Affordability', 0.0715978592634201)","('Customer_Welfare', 0.01533527858555317)","(['Human Capital Development'], 0.7875714898109436)","('NON-ESG', 0.0715978592634201)","('NON-ESG', 0.01533527858555317)"
Line 438,"We launched partnerships with  online platforms so our U.S. STEM employee teams could  make classroom presentations, provide one-on-one  tutoring and teach students about careers in STEM and  medical devices.
","('Employee_Engagement_Inclusion_And_Diversity', 0.7841530442237854)","('Access_And_Affordability', 0.02885105088353157)","('Employee_Health_And_Safety', 0.025176923722028732)","(['Human Capital Development'], 0.7841530442237854)","('NON-ESG', 0.02885105088353157)","('NON-ESG', 0.025176923722028732)"
Line 439,"teams focused on STEM outreach globally 35,000+ students reached by our programs 340+ organizations supported through  STEM outreach or donationsAdvancing community: Relief  efforts and COVID-19 action When a natural disaster or other traumatic  event strikes one of our communities, Boston  Scientific has three priorities: keep employees and their  families safe, assess the event’s impact and determine how  to support relief efforts in the area.
","('Critical_Incident_Risk_Management', 0.9539331793785095)","('Employee_Health_And_Safety', 0.014690112322568893)","('Access_And_Affordability', 0.0038848768454045057)","(['Risk & Crisis Management'], 0.9539331793785095)","('NON-ESG', 0.014690112322568893)","('NON-ESG', 0.0038848768454045057)"
Line 440,"In 2021, the company  coordinated and encouraged employee donations to help  people affected by COVID-19, the earthquake in Haiti and  wildfires in the United States and Europe.
","('Critical_Incident_Risk_Management', 0.7314338684082031)","('Physical_Impacts_Of_Climate_Change', 0.11300212144851685)","('Human_Rights_And_Community_Relations', 0.0335887111723423)","(['Risk & Crisis Management'], 0.7314338684082031)","('NON-ESG', 0.11300212144851685)","('NON-ESG', 0.0335887111723423)"
Line 441,"Employees who  donated to these efforts received a matching contribution  from the company.
","('Labor_Practices', 0.2795352041721344)","('Human_Rights_And_Community_Relations', 0.1545216292142868)","('Management_Of_Legal_And_Regulatory_Framework', 0.1355481743812561)","('NON-ESG', 0.2795352041721344)","('NON-ESG', 0.1545216292142868)","('NON-ESG', 0.1355481743812561)"
Line 442,"Vaccine availability led to stabilized COVID-19 rates in  some parts of the world, while other areas with less  access faced devastating surges.
","('Access_And_Affordability', 0.5079770684242249)","('Product_Quality_And_Safety', 0.08071833103895187)","('Customer_Welfare', 0.06782755255699158)","(['Health Outcome Contribution'], 0.5079770684242249)","('NON-ESG', 0.08071833103895187)","('NON-ESG', 0.06782755255699158)"
Line 443,"Boston Scientific made  additional financial contributions to assist with critical  medical care, including vaccines and COVID-19 testing in  India, Brazil and other countries where resources were  needed.
","('Access_And_Affordability', 0.6668274402618408)","('Customer_Welfare', 0.04587562754750252)","('Selling_Practices_And_Product_Labeling', 0.03400634974241257)","(['Health Outcome Contribution'], 0.6668274402618408)","('NON-ESG', 0.04587562754750252)","('NON-ESG', 0.03400634974241257)"
Line 444,"We also took the following steps to support our  employees, their families and communities: • Extended employee COVID-19 insurance support,  financial assistance, vaccine reimbursement and  telehealth services.
","('Employee_Health_And_Safety', 0.21350595355033875)","('Human_Rights_And_Community_Relations', 0.1603809893131256)","('Labor_Practices', 0.15250253677368164)","('NON-ESG', 0.21350595355033875)","('NON-ESG', 0.1603809893131256)","('NON-ESG', 0.15250253677368164)"
Line 445,"• Provided employees with supplies such as personal  protective equipment, COVID-19 care kits and  oxygen concentrators.
","('Employee_Health_And_Safety', 0.9242706298828125)","('Critical_Incident_Risk_Management', 0.010197477415204048)","('Product_Design_And_Lifecycle_Management', 0.009278159588575363)","(['Operational Eco-Efficiency'], 0.9242706298828125)","('NON-ESG', 0.010197477415204048)","('NON-ESG', 0.009278159588575363)"
Line 446,"• Secured lodging for employees and family members  with asymptomatic, mild or moderate COVID-19 so  they could quarantine away from home.
","('Employee_Health_And_Safety', 0.7968400716781616)","('Critical_Incident_Risk_Management', 0.042059436440467834)","('Access_And_Affordability', 0.03836950659751892)","(['Operational Eco-Efficiency'], 0.7968400716781616)","('NON-ESG', 0.042059436440467834)","('NON-ESG', 0.03836950659751892)"
Line 447,"For more information about our benefits and how  we support employees globally during difficult  times, see the Investing in our people section of   this report.2021 STEM outreach 2021 Performance ReportIntroduction Transforming care Investing in   our people Accelerating   possibilities Overview and   2021 highlights Improving health   equity and access Confronting inequities Supporting our  communities Protecting the  environment Creating value  responsibly Appendix Protecting the  environment When we challenge our impact on the  environment, we advance ways to protect it.
","('Human_Rights_And_Community_Relations', 0.7518631219863892)","('Access_And_Affordability', 0.08820343762636185)","('Ecological_Impacts', 0.03126577287912369)","(['Community Relations'], 0.7518631219863892)","('NON-ESG', 0.08820343762636185)","('NON-ESG', 0.03126577287912369)"
Line 448,"For more information about our benefits and how  we support employees globally during difficult  times, see the Investing in our people section of   this report.2021 STEM outreach 2021 Performance ReportIntroduction Transforming care Investing in   our people Accelerating   possibilities Overview and   2021 highlights Improving health   equity and access Confronting inequities Supporting our  communities Protecting the  environment Creating value  responsibly Appendix Protecting the  environment When we challenge our impact on the  environment, we advance ways to protect it.
","('Ecological_Impacts', 0.9256631135940552)","('Human_Rights_And_Community_Relations', 0.012482485733926296)","('GHG_Emissions', 0.011205754242837429)","(['Natural Capital'], 0.9256631135940552)","('NON-ESG', 0.012482485733926296)","('NON-ESG', 0.011205754242837429)"
Line 449,"Our commitment to improving the lives of patients calls for protecting  the planet we all share.
","('Human_Rights_And_Community_Relations', 0.39542120695114136)","('Access_And_Affordability', 0.22555290162563324)","('Ecological_Impacts', 0.10279981046915054)","('NON-ESG', 0.39542120695114136)","('NON-ESG', 0.22555290162563324)","('NON-ESG', 0.10279981046915054)"
Line 450,"That means confronting climate change and  challenging ourselves to meet ambitious environmental goals.
","('Physical_Impacts_Of_Climate_Change', 0.9527493119239807)","('Business_Model_Resilience', 0.00870351493358612)","('GHG_Emissions', 0.004732603207230568)","(['Climate Change'], 0.9527493119239807)","('NON-ESG', 0.00870351493358612)","('NON-ESG', 0.004732603207230568)"
Line 451,"68% reduction in greenhouse gas  emissions since 2009 (Scope 1 and 2)173%  of electricity consumed generated from renewable  sources, surpassing our interim goal of 50% by 20211, 1 Inclusive of all manufacturing and key distribution sites only.
","('GHG_Emissions', 0.9688106775283813)","('Air_Quality', 0.0038624026346951723)","('Ecological_Impacts', 0.003416153835132718)","(['Climate Change'], 0.9688106775283813)","('NON-ESG', 0.0038624026346951723)","('NON-ESG', 0.003416153835132718)"
Line 452,"2 Reflects adjustments to previously reported figure of 72% renewable electricity in our 2022 Annual Proxy Statement, based on subsequent internal audit.
","('Energy_Management', 0.7197604179382324)","('Management_Of_Legal_And_Regulatory_Framework', 0.20667418837547302)","('GHG_Emissions', 0.008425294421613216)","(['Operational Eco-Efficiency'], 0.7197604179382324)","('NON-ESG', 0.20667418837547302)","('NON-ESG', 0.008425294421613216)"
Line 453,"2021 Performance ReportIntroduction Transforming care Investing in   our people Accelerating   possibilities Protecting the  environment Overview and   2021 highlights Reducing our  environmental impact Managing climate risk Advancing product  stewardship Creating value  responsibly Appendix Overview and   2021 highlights Boston Scientific took action for a healthier world by  further reducing our environmental impact, addressing  supply chain sustainability and working to mitigate  material climate risks to the business.
","('Supply_Chain_Management', 0.5184682011604309)","('Product_Design_And_Lifecycle_Management', 0.3094765245914459)","('Business_Model_Resilience', 0.035753317177295685)","(['Supply Chain Management'], 0.5184682011604309)","('NON-ESG', 0.3094765245914459)","('NON-ESG', 0.035753317177295685)"
Line 454,"2021 Performance ReportIntroduction Transforming care Investing in   our people Accelerating   possibilities Protecting the  environment Overview and   2021 highlights Reducing our  environmental impact Managing climate risk Advancing product  stewardship Creating value  responsibly Appendix Overview and   2021 highlights Boston Scientific took action for a healthier world by  further reducing our environmental impact, addressing  supply chain sustainability and working to mitigate  material climate risks to the business.
","('Competitive_Behavior', 0.3238140642642975)","('Business_Ethics', 0.09973688423633575)","('Systemic_Risk_Management', 0.06261975318193436)","('NON-ESG', 0.3238140642642975)","('NON-ESG', 0.09973688423633575)","('NON-ESG', 0.06261975318193436)"
Line 455,"We exceeded  our target of 50% renewable electricity use by 2021,  stayed on course for carbon neutrality in all of our  manufacturing and key distribution sites by 2030 and  committed to setting science-based targets and reaching  net-zero carbon emissions across our entire value chain  by 2050.
","('Energy_Management', 0.5965613126754761)","('GHG_Emissions', 0.2152881622314453)","('Management_Of_Legal_And_Regulatory_Framework', 0.04547465965151787)","(['Operational Eco-Efficiency'], 0.5965613126754761)","('NON-ESG', 0.2152881622314453)","('NON-ESG', 0.04547465965151787)"
Line 456,"Our teams also made progress monitoring  the business risks associated with climate change and  advancing product stewardship and waste management.
","('Waste_And_Hazardous_Materials_Management', 0.5536482334136963)","('Product_Design_And_Lifecycle_Management', 0.19796325266361237)","('Supply_Chain_Management', 0.05232532322406769)","(['Operational Eco-Efficiency'], 0.5536482334136963)","('NON-ESG', 0.19796325266361237)","('NON-ESG', 0.05232532322406769)"
Line 457,"We recognize our responsibility to further respond to  climate change, and are working towards implementing  recommendations by the Task Force on Climate-Related  Financial Disclosures (TCFD).Reducing our  environmental impact We were one of the first medical device manufacturers  to pledge to achieve carbon neutrality by 2030 in all  manufacturing and key distribution sites, and we are  on track to meet this goal.
","('Physical_Impacts_Of_Climate_Change', 0.945745050907135)","('GHG_Emissions', 0.009295681491494179)","('Business_Model_Resilience', 0.009258094243705273)","(['Climate Change'], 0.945745050907135)","('NON-ESG', 0.009295681491494179)","('NON-ESG', 0.009258094243705273)"
Line 458,"In 2021, Boston Scientific  expanded our climate action goals by joining the United  Nations Race to Zero and Science Based Targets initiative  (SBTi) Business Ambition for 1.5°C campaign.
","('Physical_Impacts_Of_Climate_Change', 0.8867583274841309)","('GHG_Emissions', 0.030921632423996925)","('Business_Model_Resilience', 0.019663576036691666)","(['Climate Change'], 0.8867583274841309)","('NON-ESG', 0.030921632423996925)","('NON-ESG', 0.019663576036691666)"
Line 459,"By making  this commitment, we build on our strong foundation and  begin to establish ambitious science-based targets that  will set us on a path toward net-zero carbon emissions  across our entire value chain by 2050.
","('GHG_Emissions', 0.8666265606880188)","('Air_Quality', 0.032398711889982224)","('Energy_Management', 0.027196276932954788)","(['Climate Change'], 0.8666265606880188)","('NON-ESG', 0.032398711889982224)","('NON-ESG', 0.027196276932954788)"
Line 460,"We will share our  targets following the SBTi process and regularly report on  our progress.2021 progress against our   interim goals 73% of electricity consumed generated  from renewable sources, surpassing  our interim goal of 50% by 20211, 38% of all energy used at Boston Scientific  facilities from renewable sources, on  track to meet our interim goal of 90%  by 52% reduction in our carbon  footprint since 2017 (Scope 1   and 2), while increasing the  number of patients reached   by 20%1Our path to net-zero1  Inclusive of all manufacturing and key distribution sites only.
","('Energy_Management', 0.9783218502998352)","('Management_Of_Legal_And_Regulatory_Framework', 0.0030482334550470114)","('GHG_Emissions', 0.0016340973088517785)","(['Operational Eco-Efficiency'], 0.9783218502998352)","('NON-ESG', 0.0030482334550470114)","('NON-ESG', 0.0016340973088517785)"
Line 461,"We will share our  targets following the SBTi process and regularly report on  our progress.2021 progress against our   interim goals 73% of electricity consumed generated  from renewable sources, surpassing  our interim goal of 50% by 20211, 38% of all energy used at Boston Scientific  facilities from renewable sources, on  track to meet our interim goal of 90%  by 52% reduction in our carbon  footprint since 2017 (Scope 1   and 2), while increasing the  number of patients reached   by 20%1Our path to net-zero1  Inclusive of all manufacturing and key distribution sites only.
","('Supply_Chain_Management', 0.5711345076560974)","('Energy_Management', 0.07690561562776566)","('Product_Design_And_Lifecycle_Management', 0.06388654559850693)","(['Supply Chain Management'], 0.5711345076560974)","('NON-ESG', 0.07690561562776566)","('NON-ESG', 0.06388654559850693)"
Line 462,"2 Reflects adjustments to previously reported figure of 72% renewable electricity in our 2022 Annual Proxy Statement, based on subsequent internal audit.
","('Energy_Management', 0.7197604179382324)","('Management_Of_Legal_And_Regulatory_Framework', 0.20667418837547302)","('GHG_Emissions', 0.008425294421613216)","(['Operational Eco-Efficiency'], 0.7197604179382324)","('NON-ESG', 0.20667418837547302)","('NON-ESG', 0.008425294421613216)"
Line 463,"3 Trajectory to net-zero emissions defined by science-based targets.2024 2017 2021 2027 2030 2050100% Renewable electricity173% Renewable electricity, surpassing goal of 50%1,2One of the first medical device manufacturers to pledge to achieve carbon neutrality by 90% Renewable energy (all sources)Carbon neutrality (Scope 1 and 2)1CONet-zero emissions   (Scope 1, 2 and 3) 2021 Performance ReportIntroduction Transforming care Investing in   our people Accelerating   possibilities Protecting the  environment Overview and   2021 highlights Reducing our  environmental impact Managing climate risk Advancing product  stewardship Creating value  responsibly Appendix Key progress indicators definitions12017 2018 2019 2020 Carbon footprint (MT CO2eq)Total amount of Scope 1 and Scope 2 greenhouse gas emissions emitted into the  atmosphere from all manufacturing and key distribution sites.
","('GHG_Emissions', 0.3960244059562683)","('Energy_Management', 0.24198861420154572)","('Air_Quality', 0.12441128492355347)","('NON-ESG', 0.3960244059562683)","('NON-ESG', 0.24198861420154572)","('NON-ESG', 0.12441128492355347)"
Line 464,"3 Trajectory to net-zero emissions defined by science-based targets.2024 2017 2021 2027 2030 2050100% Renewable electricity173% Renewable electricity, surpassing goal of 50%1,2One of the first medical device manufacturers to pledge to achieve carbon neutrality by 90% Renewable energy (all sources)Carbon neutrality (Scope 1 and 2)1CONet-zero emissions   (Scope 1, 2 and 3) 2021 Performance ReportIntroduction Transforming care Investing in   our people Accelerating   possibilities Protecting the  environment Overview and   2021 highlights Reducing our  environmental impact Managing climate risk Advancing product  stewardship Creating value  responsibly Appendix Key progress indicators definitions12017 2018 2019 2020 Carbon footprint (MT CO2eq)Total amount of Scope 1 and Scope 2 greenhouse gas emissions emitted into the  atmosphere from all manufacturing and key distribution sites.
","('GHG_Emissions', 0.9558354616165161)","('Air_Quality', 0.00711342878639698)","('Physical_Impacts_Of_Climate_Change', 0.004909798968583345)","(['Climate Change'], 0.9558354616165161)","('NON-ESG', 0.00711342878639698)","('NON-ESG', 0.004909798968583345)"
Line 465,"Measured in metric  tons of carbon equivalent.94,946 85,127 84,778 53,730 52,Energy use (MWh)Total energy Boston Scientific consumes   annually to manufacture our products.Total MWh 364k 355k 368k 381k 397k Normalized MWh/  million $ revenue40 36 34 38 Green real estate (% of total)Percentage of Boston Scientific real estate that is independently certified for energy  efficiency by industry-leading bodies such as LEED for design and Energy Star or  ISO 50001:2018 for building operations.32% 32% 41% 42% 46% Renewable energy (% of total)Percentage of total energy consumed, generated  from renewable sources, with Boston Scientific  owning the renewable attributes.Electricity percent — 5% 11% 71% 73%All sources percent — 3% 6% 35% 38%GEMS key performance indicators Using the Boston Scientific Global Energy Management  System (GEMS), developed with the National University   of Ireland Galway, we are making measurable strides  toward carbon neutrality.
","('Energy_Management', 0.9783594012260437)","('Air_Quality', 0.0021849172189831734)","('Product_Design_And_Lifecycle_Management', 0.002107443753629923)","(['Operational Eco-Efficiency'], 0.9783594012260437)","('NON-ESG', 0.0021849172189831734)","('NON-ESG', 0.002107443753629923)"
Line 466,"Measured in metric  tons of carbon equivalent.94,946 85,127 84,778 53,730 52,Energy use (MWh)Total energy Boston Scientific consumes   annually to manufacture our products.Total MWh 364k 355k 368k 381k 397k Normalized MWh/  million $ revenue40 36 34 38 Green real estate (% of total)Percentage of Boston Scientific real estate that is independently certified for energy  efficiency by industry-leading bodies such as LEED for design and Energy Star or  ISO 50001:2018 for building operations.32% 32% 41% 42% 46% Renewable energy (% of total)Percentage of total energy consumed, generated  from renewable sources, with Boston Scientific  owning the renewable attributes.Electricity percent — 5% 11% 71% 73%All sources percent — 3% 6% 35% 38%GEMS key performance indicators Using the Boston Scientific Global Energy Management  System (GEMS), developed with the National University   of Ireland Galway, we are making measurable strides  toward carbon neutrality.
","('Energy_Management', 0.9785162210464478)","('Management_Of_Legal_And_Regulatory_Framework', 0.0027479329146444798)","('Air_Quality', 0.0017953822389245033)","(['Operational Eco-Efficiency'], 0.9785162210464478)","('NON-ESG', 0.0027479329146444798)","('NON-ESG', 0.0017953822389245033)"
Line 467,"Our Global Facilities Utility  Management (GFUM) Council benchmarks best practices,  monitors all metrics and publicly reports results using   four key performance indicators (KPIs) as indicated in   the chart below.“ We share and learn best practices  for energy management, adopting  practices that make sense for  Malaysia and align with our global  sustainability goals.” Valluvan Shanmugam manager,   Penang Facilities 2021 progress 68% reduction in greenhouse  gas emissions since 2009  (Scope 1 and 2)CO1 Inclusive of all manufacturing and key distribution sites only.
","('GHG_Emissions', 0.964669406414032)","('Air_Quality', 0.004581283312290907)","('Ecological_Impacts', 0.0032709590159356594)","(['Climate Change'], 0.964669406414032)","('NON-ESG', 0.004581283312290907)","('NON-ESG', 0.0032709590159356594)"
Line 468,"Our Global Facilities Utility  Management (GFUM) Council benchmarks best practices,  monitors all metrics and publicly reports results using   four key performance indicators (KPIs) as indicated in   the chart below.“ We share and learn best practices  for energy management, adopting  practices that make sense for  Malaysia and align with our global  sustainability goals.” Valluvan Shanmugam manager,   Penang Facilities 2021 progress 68% reduction in greenhouse  gas emissions since 2009  (Scope 1 and 2)CO1 Inclusive of all manufacturing and key distribution sites only.
","('Supply_Chain_Management', 0.5641420483589172)","('Product_Design_And_Lifecycle_Management', 0.11305629462003708)","('Energy_Management', 0.04988652095198631)","(['Supply Chain Management'], 0.5641420483589172)","('NON-ESG', 0.11305629462003708)","('NON-ESG', 0.04988652095198631)"
Line 469,"2 Reflects adjustments to previously reported figure of 72% renewable electricity and 53.7k metric tons CO2 in our 2022 Annual Proxy Statement, based on subsequent internal audit.
","('Energy_Management', 0.8632456660270691)","('Management_Of_Legal_And_Regulatory_Framework', 0.06663180887699127)","('GHG_Emissions', 0.016716906800866127)","(['Operational Eco-Efficiency'], 0.8632456660270691)","('NON-ESG', 0.06663180887699127)","('NON-ESG', 0.016716906800866127)"
Line 470,"2021 Performance ReportIntroduction Transforming care Investing in   our people Accelerating   possibilities Protecting the  environment Overview and   2021 highlights Reducing our  environmental impact Managing climate risk Advancing product  stewardship Creating value  responsibly Appendix Cutting energy use To ensure we’re investing in energy efficiency at  all sites and developing new construction that  meets the highest climate standards, we adhere  to the Leadership in Energy and Environmental  Design (LEED) framework and the International  Organization for Standardization (ISO) 50001:2018  energy management standard.Minimizing our carbon footprintA central component of our approach to carbon neutrality  is our C3 energy strategy: Cutting  energy use through continual  improvement  in energy  performance Converting to  renewable energy  sources instead of relying  on fossil fuelsCompensating  with carbon  credits and offset  projects for remaining  unavoidable emissions“ Across our operations, we  use science and innovation to  create a sustainable and flexible  footprint that accommodates  change, supports productivity  and protects the environment.” Paul Donhauser vice president, Global Real Estate,   Facilities Operations,   Environment, Health and SafetyConverting to renewable energy After investing in energy efficiency, converting  to renewable energy is the next step in our C3  strategy.
","('Energy_Management', 0.9118523001670837)","('Product_Design_And_Lifecycle_Management', 0.03321491554379463)","('Management_Of_Legal_And_Regulatory_Framework', 0.005653731059283018)","(['Operational Eco-Efficiency'], 0.9118523001670837)","('NON-ESG', 0.03321491554379463)","('NON-ESG', 0.005653731059283018)"
Line 471,"2021 Performance ReportIntroduction Transforming care Investing in   our people Accelerating   possibilities Protecting the  environment Overview and   2021 highlights Reducing our  environmental impact Managing climate risk Advancing product  stewardship Creating value  responsibly Appendix Cutting energy use To ensure we’re investing in energy efficiency at  all sites and developing new construction that  meets the highest climate standards, we adhere  to the Leadership in Energy and Environmental  Design (LEED) framework and the International  Organization for Standardization (ISO) 50001:2018  energy management standard.Minimizing our carbon footprintA central component of our approach to carbon neutrality  is our C3 energy strategy: Cutting  energy use through continual  improvement  in energy  performance Converting to  renewable energy  sources instead of relying  on fossil fuelsCompensating  with carbon  credits and offset  projects for remaining  unavoidable emissions“ Across our operations, we  use science and innovation to  create a sustainable and flexible  footprint that accommodates  change, supports productivity  and protects the environment.” Paul Donhauser vice president, Global Real Estate,   Facilities Operations,   Environment, Health and SafetyConverting to renewable energy After investing in energy efficiency, converting  to renewable energy is the next step in our C3  strategy.
","('Energy_Management', 0.9485350847244263)","('Management_Of_Legal_And_Regulatory_Framework', 0.012303786352276802)","('GHG_Emissions', 0.007136634085327387)","(['Operational Eco-Efficiency'], 0.9485350847244263)","('NON-ESG', 0.012303786352276802)","('NON-ESG', 0.007136634085327387)"
Line 472,"2021 Performance ReportIntroduction Transforming care Investing in   our people Accelerating   possibilities Protecting the  environment Overview and   2021 highlights Reducing our  environmental impact Managing climate risk Advancing product  stewardship Creating value  responsibly Appendix Cutting energy use To ensure we’re investing in energy efficiency at  all sites and developing new construction that  meets the highest climate standards, we adhere  to the Leadership in Energy and Environmental  Design (LEED) framework and the International  Organization for Standardization (ISO) 50001:2018  energy management standard.Minimizing our carbon footprintA central component of our approach to carbon neutrality  is our C3 energy strategy: Cutting  energy use through continual  improvement  in energy  performance Converting to  renewable energy  sources instead of relying  on fossil fuelsCompensating  with carbon  credits and offset  projects for remaining  unavoidable emissions“ Across our operations, we  use science and innovation to  create a sustainable and flexible  footprint that accommodates  change, supports productivity  and protects the environment.” Paul Donhauser vice president, Global Real Estate,   Facilities Operations,   Environment, Health and SafetyConverting to renewable energy After investing in energy efficiency, converting  to renewable energy is the next step in our C3  strategy.
","('Energy_Management', 0.9734709858894348)","('Product_Design_And_Lifecycle_Management', 0.0034924440551549196)","('Management_Of_Legal_And_Regulatory_Framework', 0.0033471938222646713)","(['Operational Eco-Efficiency'], 0.9734709858894348)","('NON-ESG', 0.0034924440551549196)","('NON-ESG', 0.0033471938222646713)"
Line 473,"We monitor the percentage of energy  generated from renewable sources, whether  produced onsite or purchased from outside  suppliers.
","('Energy_Management', 0.9779767394065857)","('Management_Of_Legal_And_Regulatory_Framework', 0.002542023081332445)","('Product_Design_And_Lifecycle_Management', 0.0020113911014050245)","(['Operational Eco-Efficiency'], 0.9779767394065857)","('NON-ESG', 0.002542023081332445)","('NON-ESG', 0.0020113911014050245)"
Line 474,"In 2021, we achieved 73% renewable  electricity, which exceeded our interim objective  of 50% for 2021 and keeps us on track to source or  generate 100% of our electricity from renewable  sources by 2024.1, 2 We are targeting, by 2027, 90%  of all energy used at Boston Scientific facilities be  from renewable sources.Compensating with carbon offsets While our primary focus is cutting energy use  and converting to clean energy sources, the third  part of our C3 strategy is to offset unavoidable  emissions for certified high quality carbon  removals.
","('Energy_Management', 0.9791103005409241)","('Management_Of_Legal_And_Regulatory_Framework', 0.0031227313447743654)","('Air_Quality', 0.0020103962160646915)","(['Operational Eco-Efficiency'], 0.9791103005409241)","('NON-ESG', 0.0031227313447743654)","('NON-ESG', 0.0020103962160646915)"
Line 475,"In 2021, we achieved 73% renewable  electricity, which exceeded our interim objective  of 50% for 2021 and keeps us on track to source or  generate 100% of our electricity from renewable  sources by 2024.1, 2 We are targeting, by 2027, 90%  of all energy used at Boston Scientific facilities be  from renewable sources.Compensating with carbon offsets While our primary focus is cutting energy use  and converting to clean energy sources, the third  part of our C3 strategy is to offset unavoidable  emissions for certified high quality carbon  removals.
","('GHG_Emissions', 0.2967946231365204)","('Waste_And_Hazardous_Materials_Management', 0.157377690076828)","('Water_And_Wastewater_Management', 0.10535335540771484)","('NON-ESG', 0.2967946231365204)","('NON-ESG', 0.157377690076828)","('NON-ESG', 0.10535335540771484)"
Line 476,"We assess potential projects to ensure  the results will balance our remaining emissions.
","('GHG_Emissions', 0.6858364343643188)","('Air_Quality', 0.14877980947494507)","('Energy_Management', 0.05326223745942116)","(['Climate Change'], 0.6858364343643188)","('NON-ESG', 0.14877980947494507)","('NON-ESG', 0.05326223745942116)"
Line 477,"1 Inclusive of all manufacturing and key distribution sites only.
","('Supply_Chain_Management', 0.6354331374168396)","('Product_Design_And_Lifecycle_Management', 0.08176569640636444)","('Energy_Management', 0.04781990498304367)","(['Supply Chain Management'], 0.6354331374168396)","('NON-ESG', 0.08176569640636444)","('NON-ESG', 0.04781990498304367)"
Line 478,"2  Reflects adjustments to previously reported figure of  72% renewable electricity in our 2022 Annual Proxy   Statement, based on subsequent internal audit.
","('Energy_Management', 0.7197604179382324)","('Management_Of_Legal_And_Regulatory_Framework', 0.20667418837547302)","('GHG_Emissions', 0.008425294421613216)","(['Operational Eco-Efficiency'], 0.7197604179382324)","('NON-ESG', 0.20667418837547302)","('NON-ESG', 0.008425294421613216)"
Line 479,"In 2021, Boston Scientific expanded operations in Galway.
","('Business_Model_Resilience', 0.2602204978466034)","('GHG_Emissions', 0.08569623529911041)","('Customer_Welfare', 0.07049005478620529)","('NON-ESG', 0.2602204978466034)","('NON-ESG', 0.08569623529911041)","('NON-ESG', 0.07049005478620529)"
Line 480,"The expansion includes more than 40,000 square feet of  manufacturing space that will be powered by renewable energy.
","('Energy_Management', 0.9562023282051086)","('Management_Of_Legal_And_Regulatory_Framework', 0.005930160637944937)","('Access_And_Affordability', 0.004452223423868418)","(['Operational Eco-Efficiency'], 0.9562023282051086)","('NON-ESG', 0.005930160637944937)","('NON-ESG', 0.004452223423868418)"
Line 481,"2021 Performance ReportIntroduction Transforming care Investing in   our people Accelerating   possibilities Protecting the  environment Overview and   2021 highlights Reducing our  environmental impact Managing climate risk Advancing product  stewardship Creating value  responsibly Appendix Transformation in Galway:   carbon neutral clean room At our Galway, Ireland manufacturing campus,  Boston Scientific teams re-engineered a computer  manufacturing facility that the company  purchased in 2016 into a carbon-neutral clean  room.
","('Product_Design_And_Lifecycle_Management', 0.9564689993858337)","('Product_Quality_And_Safety', 0.006697139702737331)","('Customer_Welfare', 0.004705245606601238)","(['Product Stewardship'], 0.9564689993858337)","('NON-ESG', 0.006697139702737331)","('NON-ESG', 0.004705245606601238)"
Line 482,"2021 Performance ReportIntroduction Transforming care Investing in   our people Accelerating   possibilities Protecting the  environment Overview and   2021 highlights Reducing our  environmental impact Managing climate risk Advancing product  stewardship Creating value  responsibly Appendix Transformation in Galway:   carbon neutral clean room At our Galway, Ireland manufacturing campus,  Boston Scientific teams re-engineered a computer  manufacturing facility that the company  purchased in 2016 into a carbon-neutral clean  room.
","('Waste_And_Hazardous_Materials_Management', 0.252352237701416)","('Product_Design_And_Lifecycle_Management', 0.23957838118076324)","('Water_And_Wastewater_Management', 0.1058119609951973)","('NON-ESG', 0.252352237701416)","('NON-ESG', 0.23957838118076324)","('NON-ESG', 0.1058119609951973)"
Line 483,"The team converted the facility into an  energy efficient space, powered by renewable  electricity, with fresh air handling units, air- source heat pumps and piped heat energy  recovery.
","('Air_Quality', 0.865727424621582)","('Energy_Management', 0.07054582983255386)","('Critical_Incident_Risk_Management', 0.007557059172540903)","(['Operational Eco-Efficiency'], 0.865727424621582)","('NON-ESG', 0.07054582983255386)","('NON-ESG', 0.007557059172540903)"
Line 484,"The facility, now certified ISO class 8,  requires approximately one-third the energy of a  conventional clean room of equivalent size.
","('Energy_Management', 0.8800183534622192)","('Product_Design_And_Lifecycle_Management', 0.013900745660066605)","('Supply_Chain_Management', 0.012933649122714996)","(['Operational Eco-Efficiency'], 0.8800183534622192)","('NON-ESG', 0.013900745660066605)","('NON-ESG', 0.012933649122714996)"
Line 485,"Patrick van der Meer senior engineer, Kerkrade Facilities“  Energy efficiency is not a project, but a journey of continual  improvement.
","('Energy_Management', 0.9796432852745056)","('Air_Quality', 0.002248072996735573)","('Product_Design_And_Lifecycle_Management', 0.0015695582842454314)","(['Operational Eco-Efficiency'], 0.9796432852745056)","('NON-ESG', 0.002248072996735573)","('NON-ESG', 0.0015695582842454314)"
Line 486,"As the company grows and changes, our efforts  to cut energy use and convert to renewable sources must work  together to ensure progress.”16  buildings adhere to LEED and all  newly constructed facilities are  designed to the LEED rating system46% of Boston Scientific real estate is  independently certified for energy  efficiency by industry-leading bodies  such as LEED for design and ISO  50001:2018 for building operations,  representing 4+ million square feetOur green real estate expands 2021 Performance ReportIntroduction Transforming care Investing in   our people Accelerating   possibilities Protecting the  environment Overview and   2021 highlights Reducing our  environmental impact Managing climate risk Advancing product  stewardship Creating value  responsibly Appendix Managing waste and water usage We use the ISO 14001:2015 environmental management  system to measure and reduce waste and water usage at  key manufacturing and distribution facilities.
","('Energy_Management', 0.9802323579788208)","('Air_Quality', 0.0018580707255750895)","('Access_And_Affordability', 0.0016829493688419461)","(['Operational Eco-Efficiency'], 0.9802323579788208)","('NON-ESG', 0.0018580707255750895)","('NON-ESG', 0.0016829493688419461)"
Line 487,"As the company grows and changes, our efforts  to cut energy use and convert to renewable sources must work  together to ensure progress.”16  buildings adhere to LEED and all  newly constructed facilities are  designed to the LEED rating system46% of Boston Scientific real estate is  independently certified for energy  efficiency by industry-leading bodies  such as LEED for design and ISO  50001:2018 for building operations,  representing 4+ million square feetOur green real estate expands 2021 Performance ReportIntroduction Transforming care Investing in   our people Accelerating   possibilities Protecting the  environment Overview and   2021 highlights Reducing our  environmental impact Managing climate risk Advancing product  stewardship Creating value  responsibly Appendix Managing waste and water usage We use the ISO 14001:2015 environmental management  system to measure and reduce waste and water usage at  key manufacturing and distribution facilities.
","('Waste_And_Hazardous_Materials_Management', 0.7601162791252136)","('Product_Design_And_Lifecycle_Management', 0.09748393297195435)","('Water_And_Wastewater_Management', 0.03654397651553154)","(['Operational Eco-Efficiency'], 0.7601162791252136)","('NON-ESG', 0.09748393297195435)","('NON-ESG', 0.03654397651553154)"
Line 488,"As of 2021,  we had 16 sites certified to this standard.
","('Product_Quality_And_Safety', 0.31412020325660706)","('Management_Of_Legal_And_Regulatory_Framework', 0.10486780852079391)","('Product_Design_And_Lifecycle_Management', 0.07471996545791626)","('NON-ESG', 0.31412020325660706)","('NON-ESG', 0.10486780852079391)","('NON-ESG', 0.07471996545791626)"
Line 489,"Managing non-hazardous waste To make progress toward our goal of diverting all waste  from landfills and incineration by 2030, Boston Scientific  is participating in the Total Resource Use and Efficiency  (TRUE) certification program at our manufacturing and major distribution centers.
","('Waste_And_Hazardous_Materials_Management', 0.9850466251373291)","('Water_And_Wastewater_Management', 0.001244676997885108)","('Data_Security', 0.0010951481526717544)","(['Operational Eco-Efficiency'], 0.9850466251373291)","('NON-ESG', 0.001244676997885108)","('NON-ESG', 0.0010951481526717544)"
Line 490,"This approach to resource use  and facility operations is helping us take the additional  steps necessary to achieve our zero-waste objective.
","('Waste_And_Hazardous_Materials_Management', 0.9754884839057922)","('Water_And_Wastewater_Management', 0.002553817117586732)","('Air_Quality', 0.0019910279661417007)","(['Operational Eco-Efficiency'], 0.9754884839057922)","('NON-ESG', 0.002553817117586732)","('NON-ESG', 0.0019910279661417007)"
Line 491,"Conserving water While our operations are not water intensive, we are  committed to minimizing usage and preparing for  environmental challenges such as water scarcity.
","('Water_And_Wastewater_Management', 0.9764268398284912)","('GHG_Emissions', 0.0027700746431946754)","('Ecological_Impacts', 0.0021377387456595898)","(['Operational Eco-Efficiency'], 0.9764268398284912)","('NON-ESG', 0.0027700746431946754)","('NON-ESG', 0.0021377387456595898)"
Line 492,"Water  usage at our manufacturing and major distribution  centers is predominantly associated with employees; 16%  of consumption is associated with production processes.
","('Water_And_Wastewater_Management', 0.9674795866012573)","('Energy_Management', 0.006157728377729654)","('GHG_Emissions', 0.002974055940285325)","(['Operational Eco-Efficiency'], 0.9674795866012573)","('NON-ESG', 0.006157728377729654)","('NON-ESG', 0.002974055940285325)"
Line 493,"2021 recycling and   waste management55% of hazardous and regulated waste  was recycled or recovered by the  company’s operations and primary  distribution sites 1,metric tons of solid waste were  diverted from landfills for total  landfill avoidance of 91% 8,metric tons – 74% of solid  waste – recycled • Heredia and Coyol, Costa Rica: Using electricity  predominantly from renewable sources, these  manufacturing sites have been certified as  carbon-neutral since 2016 — meeting the annual  requirements for certification (INTE B5:2016, INTE/ ISO 14064-1:2006) from the Institute of Technical  Standards of Costa Rica (INTECO).
","('Waste_And_Hazardous_Materials_Management', 0.9847997426986694)","('Water_And_Wastewater_Management', 0.0013467619428411126)","('Data_Security', 0.0011785362148657441)","(['Operational Eco-Efficiency'], 0.9847997426986694)","('NON-ESG', 0.0013467619428411126)","('NON-ESG', 0.0011785362148657441)"
Line 494,"2021 recycling and   waste management55% of hazardous and regulated waste  was recycled or recovered by the  company’s operations and primary  distribution sites 1,metric tons of solid waste were  diverted from landfills for total  landfill avoidance of 91% 8,metric tons – 74% of solid  waste – recycled • Heredia and Coyol, Costa Rica: Using electricity  predominantly from renewable sources, these  manufacturing sites have been certified as  carbon-neutral since 2016 — meeting the annual  requirements for certification (INTE B5:2016, INTE/ ISO 14064-1:2006) from the Institute of Technical  Standards of Costa Rica (INTECO).
","('Product_Quality_And_Safety', 0.38900765776634216)","('Management_Of_Legal_And_Regulatory_Framework', 0.20606335997581482)","('Product_Design_And_Lifecycle_Management', 0.06998328864574432)","('NON-ESG', 0.38900765776634216)","('NON-ESG', 0.20606335997581482)","('NON-ESG', 0.06998328864574432)"
Line 495,"• Clonmel, Cork and Galway, Ireland, and Kerkrade,  the Netherlands: Our facilities source only 100%  renewable electricity through our utility providers.
","('Energy_Management', 0.9661567807197571)","('Management_Of_Legal_And_Regulatory_Framework', 0.007330972235649824)","('Water_And_Wastewater_Management', 0.0031618874054402113)","(['Operational Eco-Efficiency'], 0.9661567807197571)","('NON-ESG', 0.007330972235649824)","('NON-ESG', 0.0031618874054402113)"
Line 496,"• Dorado, Puerto Rico: We completed solar  installations in 2021 that generated approximately  1.5 million kWh for the site.
","('Energy_Management', 0.9565898180007935)","('Management_Of_Legal_And_Regulatory_Framework', 0.0074174171313643456)","('GHG_Emissions', 0.004651855677366257)","(['Operational Eco-Efficiency'], 0.9565898180007935)","('NON-ESG', 0.0074174171313643456)","('NON-ESG', 0.004651855677366257)"
Line 497,"• Marlborough and Quincy, Massachusetts: Onsite  solar installations at our Marlborough headquarters  and Quincy distribution center generated  approximately 29% of onsite electricity needs   in 2021.Making progress toward environmental goals around the world Dorado, Puerto Rico solar installations were  completed in 2021.
","('Energy_Management', 0.9712689518928528)","('Management_Of_Legal_And_Regulatory_Framework', 0.005232013296335936)","('Air_Quality', 0.0026052261237055063)","(['Operational Eco-Efficiency'], 0.9712689518928528)","('NON-ESG', 0.005232013296335936)","('NON-ESG', 0.0026052261237055063)"
Line 498,"1 Inclusive of all manufacturing and key distribution sites only.
","('Supply_Chain_Management', 0.6354331374168396)","('Product_Design_And_Lifecycle_Management', 0.08176569640636444)","('Energy_Management', 0.04781990498304367)","(['Supply Chain Management'], 0.6354331374168396)","('NON-ESG', 0.08176569640636444)","('NON-ESG', 0.04781990498304367)"
Line 499,"2021 Performance ReportIntroduction Transforming care Investing in   our people Accelerating   possibilities Protecting the  environment Overview and   2021 highlights Reducing our  environmental impact Managing climate risk Advancing product  stewardship Creating value  responsibly Appendix Managing climate risk Climate change presents risks to the world around us  and our business.
","('Physical_Impacts_Of_Climate_Change', 0.9419980049133301)","('Business_Model_Resilience', 0.011987380683422089)","('Supply_Chain_Management', 0.004911541473120451)","(['Climate Change'], 0.9419980049133301)","('NON-ESG', 0.011987380683422089)","('NON-ESG', 0.004911541473120451)"
Line 500,"Natural disasters, extreme weather and  other climate-related conditions could adversely affect  our operations and supply chain, from the availability  of materials to energy supply and transportation.
","('Supply_Chain_Management', 0.9262620806694031)","('Physical_Impacts_Of_Climate_Change', 0.01628171093761921)","('Business_Model_Resilience', 0.005520447622984648)","(['Supply Chain Management'], 0.9262620806694031)","('NON-ESG', 0.01628171093761921)","('NON-ESG', 0.005520447622984648)"
Line 501,"As we  invest in protecting our business and customers from  climate-related disruption, we incorporate climate risk  into our modeling, planning and financial disclosures.
","('Physical_Impacts_Of_Climate_Change', 0.9482884407043457)","('Business_Model_Resilience', 0.010457533411681652)","('GHG_Emissions', 0.004591961856931448)","(['Climate Change'], 0.9482884407043457)","('NON-ESG', 0.010457533411681652)","('NON-ESG', 0.004591961856931448)"
Line 502,"To help identify and monitor the impacts of climate  change, we use risk management software to map our  sites against climate risk indices such as wildfire hazard,  drought hazard, heat stress and sea-level rise.
","('Physical_Impacts_Of_Climate_Change', 0.9486751556396484)","('Business_Model_Resilience', 0.011725789867341518)","('GHG_Emissions', 0.004974887240678072)","(['Climate Change'], 0.9486751556396484)","('NON-ESG', 0.011725789867341518)","('NON-ESG', 0.004974887240678072)"
Line 503,"Our climate risk management approach Oversight The Boston Scientific Board of Directors  oversees management of strategic, operational,  financial, legal and compliance risks, including  environmental and climate-related risks.
","('Physical_Impacts_Of_Climate_Change', 0.9460644721984863)","('Business_Model_Resilience', 0.013195174746215343)","('GHG_Emissions', 0.004450471606105566)","(['Climate Change'], 0.9460644721984863)","('NON-ESG', 0.013195174746215343)","('NON-ESG', 0.004450471606105566)"
Line 504,"Our  Enterprise Risk Management (ERM) program  supports the board in these activities.
","('Systemic_Risk_Management', 0.6005704998970032)","('Business_Model_Resilience', 0.21914540231227875)","('Physical_Impacts_Of_Climate_Change', 0.02195838652551174)","(['Risk & Crisis Management'], 0.6005704998970032)","('NON-ESG', 0.21914540231227875)","('NON-ESG', 0.02195838652551174)"
Line 505,"Risk assessment The ERM team analyzes climate risks so we can  manage potential challenges to meeting our  business objectives.
","('Physical_Impacts_Of_Climate_Change', 0.9440488815307617)","('Business_Model_Resilience', 0.01245442871004343)","('Supply_Chain_Management', 0.005962075665593147)","(['Climate Change'], 0.9440488815307617)","('NON-ESG', 0.01245442871004343)","('NON-ESG', 0.005962075665593147)"
Line 506,"They follow our climate- related controls and escalation procedures to  report potential material impacts to the board.
","('Physical_Impacts_Of_Climate_Change', 0.931756854057312)","('Business_Model_Resilience', 0.02069527842104435)","('GHG_Emissions', 0.007054897025227547)","(['Climate Change'], 0.931756854057312)","('NON-ESG', 0.02069527842104435)","('NON-ESG', 0.007054897025227547)"
Line 507,"Mitigation To mitigate climate risks, the company deploys  and diverts resources as needed to secure our  supply chain and limit operational disruption.
","('Supply_Chain_Management', 0.9482569098472595)","('Physical_Impacts_Of_Climate_Change', 0.007103416137397289)","('Systemic_Risk_Management', 0.0052494872361421585)","(['Supply Chain Management'], 0.9482569098472595)","('NON-ESG', 0.007103416137397289)","('NON-ESG', 0.0052494872361421585)"
Line 508,"In response to severe weather events, we engage  with potentially affected customers and external  partners to maintain business continuity.
","('Physical_Impacts_Of_Climate_Change', 0.7216511368751526)","('Business_Model_Resilience', 0.12672623991966248)","('Critical_Incident_Risk_Management', 0.02914133481681347)","(['Climate Change'], 0.7216511368751526)","('NON-ESG', 0.12672623991966248)","('NON-ESG', 0.02914133481681347)"
Line 509,"Measurement Using the CDP platform, we completed a  comprehensive assessment of the company’s  climate-related initiatives and received an  A- score.
","('Physical_Impacts_Of_Climate_Change', 0.8946951627731323)","('GHG_Emissions', 0.027362411841750145)","('Business_Model_Resilience', 0.018096186220645905)","(['Climate Change'], 0.8946951627731323)","('NON-ESG', 0.027362411841750145)","('NON-ESG', 0.018096186220645905)"
Line 510,"This result reflects strong progress  toward our climate-related disclosures, including  increased disclosures about our climate risks and  environmental practices.
","('Physical_Impacts_Of_Climate_Change', 0.953311026096344)","('Business_Model_Resilience', 0.009416413493454456)","('GHG_Emissions', 0.003872963134199381)","(['Climate Change'], 0.953311026096344)","('NON-ESG', 0.009416413493454456)","('NON-ESG', 0.003872963134199381)"
Line 511,"To learn more about business continuity and risk  management, see Creating value responsibly .
","('Business_Model_Resilience', 0.6464611887931824)","('Systemic_Risk_Management', 0.18865159153938293)","('Supply_Chain_Management', 0.0404244065284729)","(['Codes of Business Conduct'], 0.6464611887931824)","('NON-ESG', 0.18865159153938293)","('NON-ESG', 0.0404244065284729)"
Line 512,"2021 Performance ReportIntroduction Transforming care Investing in   our people Accelerating   possibilities Protecting the  environment Overview and   2021 highlights Reducing our  environmental impact Managing climate risk Advancing product  stewardship Creating value  responsibly Appendix Advancing product stewardship Good product stewardship requires a concerted effort to minimize the health, safety, environmental and social impacts  of our company’s products.
","('Product_Design_And_Lifecycle_Management', 0.8722241520881653)","('Product_Quality_And_Safety', 0.04854801669716835)","('Selling_Practices_And_Product_Labeling', 0.017119163647294044)","(['Product Stewardship'], 0.8722241520881653)","('NON-ESG', 0.04854801669716835)","('NON-ESG', 0.017119163647294044)"
Line 513,"We take this seriously and are examining the environmental footprint of our devices — from  design, sourcing, production and distribution to waste disposal or recycling.
","('Waste_And_Hazardous_Materials_Management', 0.9098445177078247)","('Product_Design_And_Lifecycle_Management', 0.029045535251498222)","('Supply_Chain_Management', 0.0073194424621760845)","(['Operational Eco-Efficiency'], 0.9098445177078247)","('NON-ESG', 0.029045535251498222)","('NON-ESG', 0.0073194424621760845)"
Line 514,"We have made measurable progress with  initiatives focused on packaging, labeling and device recycling and are focused on further reducing environmental  impacts of our technologies throughout the entire product life cycle.
","('Product_Design_And_Lifecycle_Management', 0.965252161026001)","('Selling_Practices_And_Product_Labeling', 0.003940322902053595)","('Product_Quality_And_Safety', 0.0036707641556859016)","(['Product Stewardship'], 0.965252161026001)","('NON-ESG', 0.003940322902053595)","('NON-ESG', 0.0036707641556859016)"
Line 515,"Reducing our footprint with improved  packaging and labeling Boston Scientific packaging practices require the  highest quality sterilization, distribution and storage  of our medical devices.
","('Product_Design_And_Lifecycle_Management', 0.7697720527648926)","('Selling_Practices_And_Product_Labeling', 0.07694876194000244)","('Product_Quality_And_Safety', 0.030173372477293015)","(['Product Stewardship'], 0.7697720527648926)","('NON-ESG', 0.07694876194000244)","('NON-ESG', 0.030173372477293015)"
Line 516,"We develop packaging and  labeling sustainability goals under the guidance of a  global steering committee and use processes that meet  international labeling regulations.
","('Selling_Practices_And_Product_Labeling', 0.8204665780067444)","('Customer_Welfare', 0.04952779412269592)","('Product_Quality_And_Safety', 0.02583366446197033)","(['Marketing Practices'], 0.8204665780067444)","('NON-ESG', 0.04952779412269592)","('NON-ESG', 0.02583366446197033)"
Line 517,"Our practices optimize design, reduce waste and limit  emissions from shipping.
","('Waste_And_Hazardous_Materials_Management', 0.9718469977378845)","('Air_Quality', 0.003255940740928054)","('Water_And_Wastewater_Management', 0.00294154928997159)","(['Operational Eco-Efficiency'], 0.9718469977378845)","('NON-ESG', 0.003255940740928054)","('NON-ESG', 0.00294154928997159)"
Line 518,"For example, we avoided more  than 41 metric tons of paper waste in 2021 by hosting  an eLabeling website where customers could download  Instructions for Use (IFU) as needed in multiple languages.
","('Waste_And_Hazardous_Materials_Management', 0.9808914065361023)","('Water_And_Wastewater_Management', 0.0021111133974045515)","('Air_Quality', 0.0017503012204542756)","(['Operational Eco-Efficiency'], 0.9808914065361023)","('NON-ESG', 0.0021111133974045515)","('NON-ESG', 0.0017503012204542756)"
Line 519,"We continue to advocate for eLabeling expansion into the  European Union through a MedTech Europe working group.Here are some examples of our 2021 packaging  and labeling sustainability advances and other  successful practices.
","('Product_Design_And_Lifecycle_Management', 0.4432259202003479)","('Selling_Practices_And_Product_Labeling', 0.25153571367263794)","('Product_Quality_And_Safety', 0.10160572081804276)","('NON-ESG', 0.4432259202003479)","('NON-ESG', 0.25153571367263794)","('NON-ESG', 0.10160572081804276)"
Line 520,"• Men’s health move to eLabeling.
","('Employee_Health_And_Safety', 0.45437368750572205)","('Access_And_Affordability', 0.1581188589334488)","('Employee_Engagement_Inclusion_And_Diversity', 0.07832327485084534)","('NON-ESG', 0.45437368750572205)","('NON-ESG', 0.1581188589334488)","('NON-ESG', 0.07832327485084534)"
Line 521,"We streamlined  product literature and used eLabeling to reduce  annual paper use by 3.9 metric tons and plastic waste  by 854 kg.
","('Waste_And_Hazardous_Materials_Management', 0.9758591055870056)","('Product_Design_And_Lifecycle_Management', 0.0032280003651976585)","('Water_And_Wastewater_Management', 0.001896367291919887)","(['Operational Eco-Efficiency'], 0.9758591055870056)","('NON-ESG', 0.0032280003651976585)","('NON-ESG', 0.001896367291919887)"
Line 522,"Minimizing the paper and plastic needed  for shipping enabled us to cut carbon emissions by  16.8 metric tons.
","('GHG_Emissions', 0.27305787801742554)","('Energy_Management', 0.2024538815021515)","('Product_Design_And_Lifecycle_Management', 0.0983264297246933)","('NON-ESG', 0.27305787801742554)","('NON-ESG', 0.2024538815021515)","('NON-ESG', 0.0983264297246933)"
Line 523,"• Sustainable packaging solutions.
","('Product_Design_And_Lifecycle_Management', 0.9342914819717407)","('Supply_Chain_Management', 0.00751163624227047)","('Energy_Management', 0.006424858700484037)","(['Product Stewardship'], 0.9342914819717407)","('NON-ESG', 0.00751163624227047)","('NON-ESG', 0.006424858700484037)"
Line 524,"In our Quincy,  Massachusetts and Kerkrade, the Netherlands  distribution centers, we use integrated packaging  machines for most of our orders.
","('Product_Design_And_Lifecycle_Management', 0.8143708109855652)","('Energy_Management', 0.029523007571697235)","('Customer_Welfare', 0.02573070116341114)","(['Product Stewardship'], 0.8143708109855652)","('NON-ESG', 0.029523007571697235)","('NON-ESG', 0.02573070116341114)"
Line 525,"These machines  better fit products into custom-sized boxes, reduce  empty space and require fewer cartons per order.
","('Product_Design_And_Lifecycle_Management', 0.9031281471252441)","('Customer_Welfare', 0.01702757738530636)","('Waste_And_Hazardous_Materials_Management', 0.011149963364005089)","(['Product Stewardship'], 0.9031281471252441)","('NON-ESG', 0.01702757738530636)","('NON-ESG', 0.011149963364005089)"
Line 526,"Since 2011, Boston Scientific has reduced packaging  during shipping by 30% in Kerkrade.
","('Product_Design_And_Lifecycle_Management', 0.8655121922492981)","('Selling_Practices_And_Product_Labeling', 0.02265729382634163)","('Waste_And_Hazardous_Materials_Management', 0.017879795283079147)","(['Product Stewardship'], 0.8655121922492981)","('NON-ESG', 0.02265729382634163)","('NON-ESG', 0.017879795283079147)"
Line 527,"In Quincy, we have  reduced packaging during shipping by 27% since 2020.
","('Product_Design_And_Lifecycle_Management', 0.8661642074584961)","('Selling_Practices_And_Product_Labeling', 0.020290732383728027)","('Energy_Management', 0.019703015685081482)","(['Product Stewardship'], 0.8661642074584961)","('NON-ESG', 0.020290732383728027)","('NON-ESG', 0.019703015685081482)"
Line 528,"• Healthcare Plastics Recycling Council (HPRC).
","('Waste_And_Hazardous_Materials_Management', 0.9319080710411072)","('Product_Design_And_Lifecycle_Management', 0.011730745434761047)","('Water_And_Wastewater_Management', 0.006873028818517923)","(['Operational Eco-Efficiency'], 0.9319080710411072)","('NON-ESG', 0.011730745434761047)","('NON-ESG', 0.006873028818517923)"
Line 529,"As a  member of HPRC, we collaborate with industry peers  to increase the recycling of plastics in clinical settings.
","('Product_Design_And_Lifecycle_Management', 0.5679057240486145)","('Waste_And_Hazardous_Materials_Management', 0.2079348862171173)","('Supply_Chain_Management', 0.03737659379839897)","(['Product Stewardship'], 0.5679057240486145)","('NON-ESG', 0.2079348862171173)","('NON-ESG', 0.03737659379839897)"
Line 530,"For instance, we supported the HPRC’s work in 2021 to  understand the guidelines for using advanced recycling  technologies for medical recycling that break down  plastic waste and require less sorting by facilities staff.2021 packaging   sustainability snapshot metric tons of packaging removed  from waste stream 33,products diverted from landfill  during development pallet shipments avoided 2021 Performance ReportIntroduction Transforming care Investing in   our people Accelerating   possibilities Protecting the  environment Overview and   2021 highlights Reducing our  environmental impact Managing climate risk Advancing product  stewardship Creating value  responsibly Appendix Collaborating to increase medical device recycling In the United States, we partner with industry leaders in medical recycling and waste management to offer sustainability  solutions for select single-use devices, such as systems for recycling entire devices and converting product waste to energy.
","('Waste_And_Hazardous_Materials_Management', 0.971373438835144)","('Product_Design_And_Lifecycle_Management', 0.0055365292355418205)","('Water_And_Wastewater_Management', 0.0019429032690823078)","(['Operational Eco-Efficiency'], 0.971373438835144)","('NON-ESG', 0.0055365292355418205)","('NON-ESG', 0.0019429032690823078)"
Line 531,"For instance, we supported the HPRC’s work in 2021 to  understand the guidelines for using advanced recycling  technologies for medical recycling that break down  plastic waste and require less sorting by facilities staff.2021 packaging   sustainability snapshot metric tons of packaging removed  from waste stream 33,products diverted from landfill  during development pallet shipments avoided 2021 Performance ReportIntroduction Transforming care Investing in   our people Accelerating   possibilities Protecting the  environment Overview and   2021 highlights Reducing our  environmental impact Managing climate risk Advancing product  stewardship Creating value  responsibly Appendix Collaborating to increase medical device recycling In the United States, we partner with industry leaders in medical recycling and waste management to offer sustainability  solutions for select single-use devices, such as systems for recycling entire devices and converting product waste to energy.
","('Product_Design_And_Lifecycle_Management', 0.46551162004470825)","('Waste_And_Hazardous_Materials_Management', 0.4004592299461365)","('Product_Quality_And_Safety', 0.02036242000758648)","('NON-ESG', 0.46551162004470825)","('NON-ESG', 0.4004592299461365)","('NON-ESG', 0.02036242000758648)"
Line 532,"For example, within participating customers, 65% of LithoVue™ systems and 39% of EXALT™ Model D systems were recycled  in the United States in 2021.
","('Product_Design_And_Lifecycle_Management', 0.4315032660961151)","('Energy_Management', 0.24601776897907257)","('Supply_Chain_Management', 0.04840387403964996)","('NON-ESG', 0.4315032660961151)","('NON-ESG', 0.24601776897907257)","('NON-ESG', 0.04840387403964996)"
Line 533,"We will continue to explore additional options in the future.A partnership to reduce  environmental impact In 2021, we expanded our collaboration with the  Liryc Electrophysiology and Heart Modeling Institute  to focus on reducing the environmental impact of  single-use electrophysiology (EP) catheters.
","('Access_And_Affordability', 0.1533699482679367)","('Energy_Management', 0.14495410025119781)","('Employee_Health_And_Safety', 0.13728827238082886)","('NON-ESG', 0.1533699482679367)","('NON-ESG', 0.14495410025119781)","('NON-ESG', 0.13728827238082886)"
Line 534,"Together  we worked with a group of cross-functional experts  to study catheter end-of-life practices such as  recycling.
","('Product_Design_And_Lifecycle_Management', 0.8876409530639648)","('Waste_And_Hazardous_Materials_Management', 0.016673460602760315)","('Energy_Management', 0.015106201171875)","(['Product Stewardship'], 0.8876409530639648)","('NON-ESG', 0.016673460602760315)","('NON-ESG', 0.015106201171875)"
Line 535,"We also supported a survey conducted by  Liryc, in partnership with the European Heart Rhythm  Association (EHRA), to identify physician practices and  opportunities to reduce the environmental impact of  EP catheters.
","('Access_And_Affordability', 0.2645065486431122)","('Employee_Health_And_Safety', 0.19014038145542145)","('Customer_Welfare', 0.06833183020353317)","('NON-ESG', 0.2645065486431122)","('NON-ESG', 0.19014038145542145)","('NON-ESG', 0.06833183020353317)"
Line 536,"2021 Performance ReportIntroduction Transforming care Investing in   our people Accelerating   possibilities Protecting the  environment Overview and   2021 highlights Reducing our  environmental impact Managing climate risk Advancing product  stewardship Creating value  responsibly Appendix Creating value  responsibly When we challenge ourselves to innovate with  integrity, we advance our contributions as global  corporate citizens.
","('Product_Design_And_Lifecycle_Management', 0.8473262786865234)","('Business_Model_Resilience', 0.04460171237587929)","('Supply_Chain_Management', 0.013650466687977314)","(['Product Stewardship'], 0.8473262786865234)","('NON-ESG', 0.04460171237587929)","('NON-ESG', 0.013650466687977314)"
Line 537,"At Boston Scientific, our teams are guided by strong ethics, core  values and respect for human life.
","('Business_Ethics', 0.8627830743789673)","('Human_Rights_And_Community_Relations', 0.023371022194623947)","('Competitive_Behavior', 0.0114270756021142)","(['Business Ethics'], 0.8627830743789673)","('NON-ESG', 0.023371022194623947)","('NON-ESG', 0.0114270756021142)"
Line 538,"We make products people  trust and work together across our global supply chain to deliver  solutions that change and save lives.
","('Supply_Chain_Management', 0.8965362310409546)","('Product_Design_And_Lifecycle_Management', 0.02472696639597416)","('Employee_Health_And_Safety', 0.006982829887419939)","(['Supply Chain Management'], 0.8965362310409546)","('NON-ESG', 0.02472696639597416)","('NON-ESG', 0.006982829887419939)"
Line 539,"2021 Performance ReportIntroduction Transforming care Investing in   our people Accelerating   possibilities Protecting the  environment Creating value  responsibly Overview and   2021 highlights Good governance   reflects our values  Compliance, ethics   and integrity Protecting human rights  across our company   and supply chain Keeping our supply chain  resilient and reliable Risk management   and global security Keeping our products   and patient data secure Appendix ~35 million products delivered$865+ million  spent on small and diverse suppliersOverview and   2021 highlights Meeting our responsibilities as a global company and  corporate citizen called for new levels of innovation and  resilience in 2021.
","('Supply_Chain_Management', 0.7988817095756531)","('Systemic_Risk_Management', 0.028144143521785736)","('Business_Model_Resilience', 0.026021664962172508)","(['Supply Chain Management'], 0.7988817095756531)","('NON-ESG', 0.028144143521785736)","('NON-ESG', 0.026021664962172508)"
Line 540,"2021 Performance ReportIntroduction Transforming care Investing in   our people Accelerating   possibilities Protecting the  environment Creating value  responsibly Overview and   2021 highlights Good governance   reflects our values  Compliance, ethics   and integrity Protecting human rights  across our company   and supply chain Keeping our supply chain  resilient and reliable Risk management   and global security Keeping our products   and patient data secure Appendix ~35 million products delivered$865+ million  spent on small and diverse suppliersOverview and   2021 highlights Meeting our responsibilities as a global company and  corporate citizen called for new levels of innovation and  resilience in 2021.
","('Business_Model_Resilience', 0.674723744392395)","('Supply_Chain_Management', 0.14044715464115143)","('Product_Design_And_Lifecycle_Management', 0.05760827660560608)","(['Codes of Business Conduct'], 0.674723744392395)","('NON-ESG', 0.14044715464115143)","('NON-ESG', 0.05760827660560608)"
Line 541,"Boston Scientific teams addressed  challenges and met our obligations to stakeholders amid  geopolitical conflicts, climate concerns and the continuing  COVID-19 pandemic.
","('Physical_Impacts_Of_Climate_Change', 0.9041255712509155)","('Business_Model_Resilience', 0.0320759192109108)","('GHG_Emissions', 0.009891724213957787)","(['Climate Change'], 0.9041255712509155)","('NON-ESG', 0.0320759192109108)","('NON-ESG', 0.009891724213957787)"
Line 542,"Risk and supply chain management  were among our top priorities as we reinforced product  and data security companywide.
","('Supply_Chain_Management', 0.9305523037910461)","('Product_Design_And_Lifecycle_Management', 0.010877369903028011)","('Employee_Health_And_Safety', 0.005898144096136093)","(['Supply Chain Management'], 0.9305523037910461)","('NON-ESG', 0.010877369903028011)","('NON-ESG', 0.005898144096136093)"
Line 543,"Good governance  reflects our values The Boston Scientific Board of Directors has adopted  Corporate Governance Guidelines and charters for each of  its standing committees (audit, executive compensation and  human resources, nominating and governance, and risk).
","('Management_Of_Legal_And_Regulatory_Framework', 0.3314332962036133)","('Director_Removal', 0.3194220960140228)","('Business_Ethics', 0.1360459327697754)","('NON-ESG', 0.3314332962036133)","('NON-ESG', 0.3194220960140228)","('NON-ESG', 0.1360459327697754)"
Line 544,"Global tax strategy and compliance In keeping with our commitment to social responsibility,  we comply with all applicable tax laws, regulations and  related disclosure requirements in every jurisdiction where  we operate.
","('Management_Of_Legal_And_Regulatory_Framework', 0.9735855460166931)","('Energy_Management', 0.002951087662950158)","('Director_Removal', 0.002012323820963502)","(['Corporate Governance'], 0.9735855460166931)","('NON-ESG', 0.002951087662950158)","('NON-ESG', 0.002012323820963502)"
Line 545,"Our tax professionals are committed to the  highest compliance standards and use processes based  on standardization and automation to minimize tax risk.
","('Management_Of_Legal_And_Regulatory_Framework', 0.7263100743293762)","('Business_Ethics', 0.1585942953824997)","('Product_Quality_And_Safety', 0.024505017325282097)","(['Corporate Governance'], 0.7263100743293762)","('NON-ESG', 0.1585942953824997)","('NON-ESG', 0.024505017325282097)"
Line 546,"In 2021, we published our global tax strategy outlining the  Boston Scientific approach to taxation.
","('Management_Of_Legal_And_Regulatory_Framework', 0.9677543640136719)","('Energy_Management', 0.0038870538119226694)","('Competitive_Behavior', 0.0032340690959244967)","(['Corporate Governance'], 0.9677543640136719)","('NON-ESG', 0.0038870538119226694)","('NON-ESG', 0.0032340690959244967)"
Line 547,"Political involvement for sound   public policy Boston Scientific supports public policies that promote  diversity, equity and inclusion and improve patient  health, our employees’ lives as well as the livelihoods  of the communities we serve.
","('Employee_Engagement_Inclusion_And_Diversity', 0.9684325456619263)","('Human_Rights_And_Community_Relations', 0.004131210036575794)","('Employee_Health_And_Safety', 0.0026056955102831125)","(['Human Capital Development'], 0.9684325456619263)","('NON-ESG', 0.004131210036575794)","('NON-ESG', 0.0026056955102831125)"
Line 548,"We advocate for policies  that increase access to care and provide annual updates  on political action committee (PAC) activity and other  contributions.
","('Access_And_Affordability', 0.921943187713623)","('Product_Quality_And_Safety', 0.008136178366839886)","('Management_Of_Legal_And_Regulatory_Framework', 0.007233216427266598)","(['Health Outcome Contribution'], 0.921943187713623)","('NON-ESG', 0.008136178366839886)","('NON-ESG', 0.007233216427266598)"
Line 549,"The Boston Scientific Corporation PAC  facilitates voluntary political contributions by eligible  employees and our board of directors to advance sound  public policy in accordance with federal law.
","('Management_Of_Legal_And_Regulatory_Framework', 0.8303828239440918)","('Director_Removal', 0.05840614438056946)","('Labor_Practices', 0.02294054627418518)","(['Corporate Governance'], 0.8303828239440918)","('NON-ESG', 0.05840614438056946)","('NON-ESG', 0.02294054627418518)"
Line 550,"Public-private partnership to improve  patient care and access Boston Scientific collaborates with trade associations  and regulatory bodies to share our quality standards and  stay informed about developments so we can be agile  in our response to regulatory updates.
","('Management_Of_Legal_And_Regulatory_Framework', 0.9120745062828064)","('Product_Quality_And_Safety', 0.01887233927845955)","('Business_Ethics', 0.00949525460600853)","(['Corporate Governance'], 0.9120745062828064)","('NON-ESG', 0.01887233927845955)","('NON-ESG', 0.00949525460600853)"
Line 551,"For example, we  work closely with the U.S. Food and Drug Administration  (FDA) through the Digital Health Software Precertification  Program to expedite patient access to safe and effective  software-based medical innovations.
","('Access_And_Affordability', 0.37100744247436523)","('Customer_Welfare', 0.13803885877132416)","('Product_Quality_And_Safety', 0.08543436229228973)","('NON-ESG', 0.37100744247436523)","('NON-ESG', 0.13803885877132416)","('NON-ESG', 0.08543436229228973)"
Line 552,"We are also part of  the Medical Device Innovation Consortium working with  the FDA to advance solutions that promote patient access  to innovative medical technologies.
","('Access_And_Affordability', 0.3678687810897827)","('Customer_Welfare', 0.15359647572040558)","('Product_Design_And_Lifecycle_Management', 0.09097738564014435)","('NON-ESG', 0.3678687810897827)","('NON-ESG', 0.15359647572040558)","('NON-ESG', 0.09097738564014435)"
Line 553,"To learn more about our political involvement,    visit our website .To learn more about expanding patient access   to care, go to Transforming care .Learn more about the policies and standards we  comply with in the Appendix.
","('Access_And_Affordability', 0.33339110016822815)","('Management_Of_Legal_And_Regulatory_Framework', 0.2923087179660797)","('Product_Quality_And_Safety', 0.08089948445558548)","('NON-ESG', 0.33339110016822815)","('NON-ESG', 0.2923087179660797)","('NON-ESG', 0.08089948445558548)"
Line 554,"2021 Performance ReportIntroduction Transforming care Investing in   our people Accelerating   possibilities Protecting the  environment Creating value  responsibly Overview and   2021 highlights Good governance   reflects our values  Compliance, ethics   and integrity Protecting human rights  across our company   and supply chain Keeping our supply chain  resilient and reliable Risk management   and global security Keeping our products   and patient data secure Appendix Compliance, ethics   and integrity Ethics and integrity govern how we work every day  including how we innovate, develop life-changing  products and collaborate with one another and  our partners.
","('Business_Ethics', 0.9407863616943359)","('Data_Security', 0.006071656011044979)","('Human_Rights_And_Community_Relations', 0.005202526226639748)","(['Business Ethics'], 0.9407863616943359)","('NON-ESG', 0.006071656011044979)","('NON-ESG', 0.005202526226639748)"
Line 555,"2021 Performance ReportIntroduction Transforming care Investing in   our people Accelerating   possibilities Protecting the  environment Creating value  responsibly Overview and   2021 highlights Good governance   reflects our values  Compliance, ethics   and integrity Protecting human rights  across our company   and supply chain Keeping our supply chain  resilient and reliable Risk management   and global security Keeping our products   and patient data secure Appendix Compliance, ethics   and integrity Ethics and integrity govern how we work every day  including how we innovate, develop life-changing  products and collaborate with one another and  our partners.
","('Product_Design_And_Lifecycle_Management', 0.9127064943313599)","('Business_Model_Resilience', 0.017852984368801117)","('Customer_Welfare', 0.007437058724462986)","(['Product Stewardship'], 0.9127064943313599)","('NON-ESG', 0.017852984368801117)","('NON-ESG', 0.007437058724462986)"
Line 556,"All Boston Scientific employees share a commitment to: • Act honestly and ethically in all company matters.
","('Business_Ethics', 0.8939372301101685)","('Human_Rights_And_Community_Relations', 0.011763437651097775)","('Labor_Practices', 0.010381910018622875)","(['Business Ethics'], 0.8939372301101685)","('NON-ESG', 0.011763437651097775)","('NON-ESG', 0.010381910018622875)"
Line 557,"• Protect the privacy of patients, customers  and employees.
","('Customer_Privacy', 0.8807308077812195)","('Data_Security', 0.040084827691316605)","('Business_Ethics', 0.0057404981926083565)","(['Privacy Protection'], 0.8807308077812195)","('NON-ESG', 0.040084827691316605)","('NON-ESG', 0.0057404981926083565)"
Line 558,"• Treat one another with respect and fairness.
","('Business_Ethics', 0.7380685806274414)","('Competitive_Behavior', 0.06550434231758118)","('Labor_Practices', 0.03221643343567848)","(['Business Ethics'], 0.7380685806274414)","('NON-ESG', 0.06550434231758118)","('NON-ESG', 0.03221643343567848)"
Line 559,"• Hold one another accountable for quality in everything  we do.
","('Business_Ethics', 0.25682371854782104)","('Systemic_Risk_Management', 0.11089885234832764)","('Competitive_Behavior', 0.08908779174089432)","('NON-ESG', 0.25682371854782104)","('NON-ESG', 0.11089885234832764)","('NON-ESG', 0.08908779174089432)"
Line 560,"Our Global Compliance team provides employees  with the resources and training they need to conduct  business responsibly, treat customers and suppliers  fairly and report ethics concerns if they arise.
","('Business_Ethics', 0.9648424983024597)","('Management_Of_Legal_And_Regulatory_Framework', 0.004099591169506311)","('Product_Quality_And_Safety', 0.004060947336256504)","(['Business Ethics'], 0.9648424983024597)","('NON-ESG', 0.004099591169506311)","('NON-ESG', 0.004060947336256504)"
Line 561,"The team,  led by our chief compliance officer, collaborates across  the company to monitor our activities and compliance  with applicable laws and company policies.
","('Management_Of_Legal_And_Regulatory_Framework', 0.9619406461715698)","('Human_Rights_And_Community_Relations', 0.004196924157440662)","('Business_Ethics', 0.0037611713632941246)","(['Corporate Governance'], 0.9619406461715698)","('NON-ESG', 0.004196924157440662)","('NON-ESG', 0.0037611713632941246)"
Line 562,"The chief  compliance officer reports to the Risk Committee of our  board of directors on an annual basis and to the Audit  Committee as needed.Marketing practices people can trust We promote our products honestly and accurately.
","('Selling_Practices_And_Product_Labeling', 0.46459856629371643)","('Product_Design_And_Lifecycle_Management', 0.23635248839855194)","('Customer_Welfare', 0.0939796045422554)","('NON-ESG', 0.46459856629371643)","('NON-ESG', 0.23635248839855194)","('NON-ESG', 0.0939796045422554)"
Line 563,"Our Code  of Conduct and other policies emphasize the importance of  fair and honest communications with patients, customers  and the public.
","('Business_Ethics', 0.8835263252258301)","('Management_Of_Legal_And_Regulatory_Framework', 0.017886793240904808)","('Competitive_Behavior', 0.013631037436425686)","(['Business Ethics'], 0.8835263252258301)","('NON-ESG', 0.017886793240904808)","('NON-ESG', 0.013631037436425686)"
Line 564,"All customer-facing employees receive  training on fair and honest marketing practices, interactions  with health care providers and public officials and respect  for intellectual property.
","('Business_Ethics', 0.7986557483673096)","('Competitive_Behavior', 0.10260523110628128)","('Management_Of_Legal_And_Regulatory_Framework', 0.017610855400562286)","(['Business Ethics'], 0.7986557483673096)","('NON-ESG', 0.10260523110628128)","('NON-ESG', 0.017610855400562286)"
Line 565,"The training also addresses how to  navigate actual and perceived conflicts of interest, which  includes guidance for managing off-label inquiries and  focusing marketing discussions on approved, on-label use   of our products.2021 sales and marketing training “Accelerating with Integrity”  campaign We regularly sponsor campaigns to promote  employee awareness of the Code of Conduct.
","('Selling_Practices_And_Product_Labeling', 0.7390337586402893)","('Customer_Welfare', 0.07672728598117828)","('Product_Quality_And_Safety', 0.05347411707043648)","(['Marketing Practices'], 0.7390337586402893)","('NON-ESG', 0.07672728598117828)","('NON-ESG', 0.05347411707043648)"
Line 566,"In 2021,  our companywide Integrity Week featured video  messages from senior leaders that emphasized the  importance of working ethically and reporting   ethics concerns.
","('Business_Ethics', 0.970005989074707)","('Product_Quality_And_Safety', 0.002498562913388014)","('Competitive_Behavior', 0.0023769123945385218)","(['Business Ethics'], 0.970005989074707)","('NON-ESG', 0.002498562913388014)","('NON-ESG', 0.0023769123945385218)"
Line 567,"10,000+ hours of compliance training for  customer-facing employees Mandatory training All employees complete annual training on  the Code of Conduct and take additional  mandatory training courses that reinforce  company policies, explain corruption- and  compliance-related risks and provide  resources for reporting concerns.
","('Business_Ethics', 0.940132200717926)","('Management_Of_Legal_And_Regulatory_Framework', 0.020087601616978645)","('Product_Quality_And_Safety', 0.004609840456396341)","(['Business Ethics'], 0.940132200717926)","('NON-ESG', 0.020087601616978645)","('NON-ESG', 0.004609840456396341)"
Line 568,"Advice line All employees are responsible for  immediately reporting any suspected  violation of the Code of Conduct or other  company policy.
","('Business_Ethics', 0.9101846218109131)","('Management_Of_Legal_And_Regulatory_Framework', 0.015134982764720917)","('Labor_Practices', 0.009276589378714561)","(['Business Ethics'], 0.9101846218109131)","('NON-ESG', 0.015134982764720917)","('NON-ESG', 0.009276589378714561)"
Line 569,"Ethics concerns may be  confidentially reported at any time through  the Boston Scientific advice line which is  operated by a third party.
","('Business_Ethics', 0.9485362768173218)","('Customer_Privacy', 0.0073708039708435535)","('Director_Removal', 0.005608502775430679)","(['Business Ethics'], 0.9485362768173218)","('NON-ESG', 0.0073708039708435535)","('NON-ESG', 0.005608502775430679)"
Line 570,"Non-retaliation policy The Boston Scientific Non-Retaliation Policy  prohibits any form of retaliation, direct or  indirect, against an individual who raises  a concern in good faith.
","('Business_Ethics', 0.9196712970733643)","('Management_Of_Legal_And_Regulatory_Framework', 0.013665561564266682)","('Competitive_Behavior', 0.009981718845665455)","(['Business Ethics'], 0.9196712970733643)","('NON-ESG', 0.013665561564266682)","('NON-ESG', 0.009981718845665455)"
Line 571,"This protection  extends to anyone who assists with, or  cooperates in, an investigation or report   of misconduct.
","('Business_Ethics', 0.9576123952865601)","('Management_Of_Legal_And_Regulatory_Framework', 0.004035518039017916)","('Employee_Health_And_Safety', 0.0038801205810159445)","(['Business Ethics'], 0.9576123952865601)","('NON-ESG', 0.004035518039017916)","('NON-ESG', 0.0038801205810159445)"
Line 572,"Learn more about our policies and practices   on our website .The Boston Scientific Code of Conduct Every Boston Scientific employee is required to read  and understand the Boston Scientific Code of Conduct,  the foundation for all of our business practices  and relationships.
","('Business_Ethics', 0.5993463397026062)","('Management_Of_Legal_And_Regulatory_Framework', 0.25162848830223083)","('Director_Removal', 0.020953407511115074)","(['Business Ethics'], 0.5993463397026062)","('NON-ESG', 0.25162848830223083)","('NON-ESG', 0.020953407511115074)"
Line 573,"2021 Performance ReportIntroduction Transforming care Investing in   our people Accelerating   possibilities Protecting the  environment Creating value  responsibly Overview and   2021 highlights Good governance   reflects our values  Compliance, ethics   and integrity Protecting human rights  across our company   and supply chain Keeping our supply chain  resilient and reliable Risk management   and global security Keeping our products   and patient data secure Appendix Protecting human rights across our company   and supply chain Businesses have a critical role to play in protecting human rights.
","('Human_Rights_And_Community_Relations', 0.6098890900611877)","('Supply_Chain_Management', 0.13403856754302979)","('Labor_Practices', 0.023671099916100502)","(['Community Relations'], 0.6098890900611877)","('NON-ESG', 0.13403856754302979)","('NON-ESG', 0.023671099916100502)"
Line 574,"2021 Performance ReportIntroduction Transforming care Investing in   our people Accelerating   possibilities Protecting the  environment Creating value  responsibly Overview and   2021 highlights Good governance   reflects our values  Compliance, ethics   and integrity Protecting human rights  across our company   and supply chain Keeping our supply chain  resilient and reliable Risk management   and global security Keeping our products   and patient data secure Appendix Protecting human rights across our company   and supply chain Businesses have a critical role to play in protecting human rights.
","('Human_Rights_And_Community_Relations', 0.8531838655471802)","('Supply_Chain_Management', 0.04023493826389313)","('Employee_Health_And_Safety', 0.011001372709870338)","(['Community Relations'], 0.8531838655471802)","('NON-ESG', 0.04023493826389313)","('NON-ESG', 0.011001372709870338)"
Line 575,"Boston Scientific respects and strictly adheres to  all labor and human rights laws, including those related to modern slavery, child labor, human trafficking, bribery,  discrimination, harassment and pay equity.
","('Labor_Practices', 0.9583157300949097)","('Employee_Engagement_Inclusion_And_Diversity', 0.005894635803997517)","('Employee_Health_And_Safety', 0.004505471792072058)","(['Labor Practice Indicators'], 0.9583157300949097)","('NON-ESG', 0.005894635803997517)","('NON-ESG', 0.004505471792072058)"
Line 576,"Our contractors, suppliers and business partners are required to conduct  their businesses legally and ethically as well.
","('Business_Ethics', 0.33619844913482666)","('Labor_Practices', 0.27780160307884216)","('Supply_Chain_Management', 0.09792433679103851)","('NON-ESG', 0.33619844913482666)","('NON-ESG', 0.27780160307884216)","('NON-ESG', 0.09792433679103851)"
Line 577,"Please refer to the Boston Scientific Human Rights Policy to learn more  about how we operate.Supporting transparency   and accountability We conduct business in a way that respects human rights  and the dignity of all people, and we require the same  of our contractors, vendors and suppliers.
","('Business_Ethics', 0.7743268013000488)","('Human_Rights_And_Community_Relations', 0.10071465373039246)","('Management_Of_Legal_And_Regulatory_Framework', 0.016385233029723167)","(['Business Ethics'], 0.7743268013000488)","('NON-ESG', 0.10071465373039246)","('NON-ESG', 0.016385233029723167)"
Line 578,"Our Human  Resources and Compliance teams have processes for  employees and external partners to discuss human rights  concerns, report suspected failures and take necessary  actions, up to termination.
","('Business_Ethics', 0.5333951711654663)","('Human_Rights_And_Community_Relations', 0.20529669523239136)","('Management_Of_Legal_And_Regulatory_Framework', 0.05497779697179794)","(['Business Ethics'], 0.5333951711654663)","('NON-ESG', 0.20529669523239136)","('NON-ESG', 0.05497779697179794)"
Line 579,"• Enrolling contractors, suppliers and partners.
","('Supply_Chain_Management', 0.835697591304779)","('Labor_Practices', 0.04223085939884186)","('Water_And_Wastewater_Management', 0.012353005819022655)","(['Supply Chain Management'], 0.835697591304779)","('NON-ESG', 0.04223085939884186)","('NON-ESG', 0.012353005819022655)"
Line 580,"Our  business agreements with partners around the world  require that they conduct their businesses legally and  ethically.
","('Business_Ethics', 0.8874894380569458)","('Management_Of_Legal_And_Regulatory_Framework', 0.02532651461660862)","('Competitive_Behavior', 0.021129060536623)","(['Business Ethics'], 0.8874894380569458)","('NON-ESG', 0.02532651461660862)","('NON-ESG', 0.021129060536623)"
Line 581,"Our Supplier Guidebook mandates adherence  to all human rights laws and labor standards and  requires safe and healthy working conditions at  all times.
","('Labor_Practices', 0.9696434140205383)","('Employee_Health_And_Safety', 0.005624944344162941)","('Supply_Chain_Management', 0.0026292388793081045)","(['Labor Practice Indicators'], 0.9696434140205383)","('NON-ESG', 0.005624944344162941)","('NON-ESG', 0.0026292388793081045)"
Line 582,"• Reporting concerns.
","('Management_Of_Legal_And_Regulatory_Framework', 0.530552089214325)","('Human_Rights_And_Community_Relations', 0.0700700581073761)","('Business_Ethics', 0.062482573091983795)","(['Corporate Governance'], 0.530552089214325)","('NON-ESG', 0.0700700581073761)","('NON-ESG', 0.062482573091983795)"
Line 583,"Our Global Compliance program  provides resources for employees and people outside  the company to ask questions, obtain guidance and  report human rights or Code of Conduct concerns.
","('Human_Rights_And_Community_Relations', 0.672705888748169)","('Business_Ethics', 0.09201603382825851)","('Management_Of_Legal_And_Regulatory_Framework', 0.04130449891090393)","(['Community Relations'], 0.672705888748169)","('NON-ESG', 0.09201603382825851)","('NON-ESG', 0.04130449891090393)"
Line 584,"2021 Performance ReportIntroduction Transforming care Investing in   our people Accelerating   possibilities Protecting the  environment Creating value  responsibly Overview and   2021 highlights Good governance   reflects our values  Compliance, ethics   and integrity Protecting human rights  across our company   and supply chain Keeping our supply chain  resilient and reliable Risk management   and global security Keeping our products   and patient data secure Appendix Keeping our supply chain resilient   and reliable The Boston Scientific Global Supply Chain team works tirelessly to lead our planning, sourcing, manufacturing  and distribution efforts worldwide.
","('Supply_Chain_Management', 0.9268752932548523)","('Business_Model_Resilience', 0.010456819087266922)","('Systemic_Risk_Management', 0.006899259518831968)","(['Supply Chain Management'], 0.9268752932548523)","('NON-ESG', 0.010456819087266922)","('NON-ESG', 0.006899259518831968)"
Line 585,"2021 Performance ReportIntroduction Transforming care Investing in   our people Accelerating   possibilities Protecting the  environment Creating value  responsibly Overview and   2021 highlights Good governance   reflects our values  Compliance, ethics   and integrity Protecting human rights  across our company   and supply chain Keeping our supply chain  resilient and reliable Risk management   and global security Keeping our products   and patient data secure Appendix Keeping our supply chain resilient   and reliable The Boston Scientific Global Supply Chain team works tirelessly to lead our planning, sourcing, manufacturing  and distribution efforts worldwide.
","('Supply_Chain_Management', 0.9467354416847229)","('Product_Design_And_Lifecycle_Management', 0.005770088639110327)","('Labor_Practices', 0.004219423979520798)","(['Supply Chain Management'], 0.9467354416847229)","('NON-ESG', 0.005770088639110327)","('NON-ESG', 0.004219423979520798)"
Line 586,"Our 18,000 team members partner with more than 10,000 active indirect and  direct suppliers to deliver ~35 million products annually.
","('Product_Design_And_Lifecycle_Management', 0.9553969502449036)","('Supply_Chain_Management', 0.005566152278333902)","('Product_Quality_And_Safety', 0.004327563103288412)","(['Product Stewardship'], 0.9553969502449036)","('NON-ESG', 0.005566152278333902)","('NON-ESG', 0.004327563103288412)"
Line 587,"They perform this mission-critical work while meeting the  highest benchmarks for quality, service, ethical conduct and regulatory compliance.
","('Business_Ethics', 0.92081218957901)","('Management_Of_Legal_And_Regulatory_Framework', 0.03640212491154671)","('Competitive_Behavior', 0.005905740894377232)","(['Business Ethics'], 0.92081218957901)","('NON-ESG', 0.03640212491154671)","('NON-ESG', 0.005905740894377232)"
Line 588,"We use a standardized supplier  performance tool to assess the integrity of potential suppliers’ business practices to help ensure that we responsibly  meet our commitments to our customers and their patients.
","('Supply_Chain_Management', 0.9406930804252625)","('Product_Design_And_Lifecycle_Management', 0.0072907558642327785)","('Labor_Practices', 0.005700761917978525)","(['Supply Chain Management'], 0.9406930804252625)","('NON-ESG', 0.0072907558642327785)","('NON-ESG', 0.005700761917978525)"
Line 589,"Our teams at our global manufacturing, distribution and customer care centers have worked with agility and persistence  to serve customers throughout the pandemic.
","('Customer_Welfare', 0.31109505891799927)","('Product_Design_And_Lifecycle_Management', 0.13537351787090302)","('Access_And_Affordability', 0.07356120645999908)","('NON-ESG', 0.31109505891799927)","('NON-ESG', 0.13537351787090302)","('NON-ESG', 0.07356120645999908)"
Line 590,"As markets recovered, they stayed ahead of challenges, kept inventory  stable and responded quickly.
","('Systemic_Risk_Management', 0.4813683032989502)","('Competitive_Behavior', 0.12853141129016876)","('Business_Model_Resilience', 0.09305889904499054)","('NON-ESG', 0.4813683032989502)","('NON-ESG', 0.12853141129016876)","('NON-ESG', 0.09305889904499054)"
Line 591,"In a year marked by global breakdowns in sourcing and supplies, Boston Scientific kept our  end-to-end global supply chain operating and delivered products to the customers and patients who count on them for  quality care and outcomes.Managing complexities   around the clock ~35 million products delivered 18,team members across  16 principal manufacturing  and distribution locations Brad Sorenson executive vice president,  Global Operations“ Our Global Supply Chain team consistently manages  uncertainty and disruption.
","('Supply_Chain_Management', 0.8116940259933472)","('Product_Design_And_Lifecycle_Management', 0.08056522160768509)","('Waste_And_Hazardous_Materials_Management', 0.009739765897393227)","(['Supply Chain Management'], 0.8116940259933472)","('NON-ESG', 0.08056522160768509)","('NON-ESG', 0.009739765897393227)"
Line 592,"In a year marked by global breakdowns in sourcing and supplies, Boston Scientific kept our  end-to-end global supply chain operating and delivered products to the customers and patients who count on them for  quality care and outcomes.Managing complexities   around the clock ~35 million products delivered 18,team members across  16 principal manufacturing  and distribution locations Brad Sorenson executive vice president,  Global Operations“ Our Global Supply Chain team consistently manages  uncertainty and disruption.
","('Data_Security', 0.5343596339225769)","('Systemic_Risk_Management', 0.0918312519788742)","('Critical_Incident_Risk_Management', 0.05015384033322334)","(['Information Security/Cybersecurity & System Availability'], 0.5343596339225769)","('NON-ESG', 0.0918312519788742)","('NON-ESG', 0.05015384033322334)"
Line 593,"We were tested in new  ways in 2021, and have delivered for the patients  who count on our products around the world.” 2021 Performance ReportIntroduction Transforming care Investing in   our people Accelerating   possibilities Protecting the  environment Creating value  responsibly Overview and   2021 highlights Good governance   reflects our values  Compliance, ethics   and integrity Protecting human rights  across our company   and supply chain Keeping our supply chain  resilient and reliable Risk management   and global security Keeping our products   and patient data secure Appendix Risk management and global security The Boston Scientific enterprise risk management team analyzes strategic, operational, financial, legal and compliance  risks so we can safely adapt to challenges, pursue opportunities and meet commitments to stakeholders.
","('Supply_Chain_Management', 0.9363265633583069)","('Product_Design_And_Lifecycle_Management', 0.01067406591027975)","('Business_Model_Resilience', 0.006237433757632971)","(['Supply Chain Management'], 0.9363265633583069)","('NON-ESG', 0.01067406591027975)","('NON-ESG', 0.006237433757632971)"
Line 594,"We were tested in new  ways in 2021, and have delivered for the patients  who count on our products around the world.” 2021 Performance ReportIntroduction Transforming care Investing in   our people Accelerating   possibilities Protecting the  environment Creating value  responsibly Overview and   2021 highlights Good governance   reflects our values  Compliance, ethics   and integrity Protecting human rights  across our company   and supply chain Keeping our supply chain  resilient and reliable Risk management   and global security Keeping our products   and patient data secure Appendix Risk management and global security The Boston Scientific enterprise risk management team analyzes strategic, operational, financial, legal and compliance  risks so we can safely adapt to challenges, pursue opportunities and meet commitments to stakeholders.
","('Data_Security', 0.9515143036842346)","('Business_Ethics', 0.007001511752605438)","('Systemic_Risk_Management', 0.005721807014197111)","(['Information Security/Cybersecurity & System Availability'], 0.9515143036842346)","('NON-ESG', 0.007001511752605438)","('NON-ESG', 0.005721807014197111)"
Line 595,"Enterprise risk  management is led by our vice president of global internal audit who reports any financial, operational or risk issues to the  board of directors and its relevant committees.
","('Systemic_Risk_Management', 0.7468937635421753)","('Business_Ethics', 0.09072162955999374)","('Management_Of_Legal_And_Regulatory_Framework', 0.03736467286944389)","(['Risk & Crisis Management'], 0.7468937635421753)","('NON-ESG', 0.09072162955999374)","('NON-ESG', 0.03736467286944389)"
Line 596,"Our global security and resiliency team works closely with enterprise risk  management to ensure we can sustain operations and secure our facilities in the event of a crisis.
","('Business_Model_Resilience', 0.7196936011314392)","('Physical_Impacts_Of_Climate_Change', 0.07171149551868439)","('Systemic_Risk_Management', 0.04488888755440712)","(['Codes of Business Conduct'], 0.7196936011314392)","('NON-ESG', 0.07171149551868439)","('NON-ESG', 0.04488888755440712)"
Line 597,"Business resiliency Working closely with our global operations team, our  global security and resiliency experts prepare for a range  of potential threats, including meteorologic, geologic,  geo-political and climate-related changes.
","('Business_Model_Resilience', 0.8424872159957886)","('Physical_Impacts_Of_Climate_Change', 0.04594507813453674)","('Systemic_Risk_Management', 0.01919001154601574)","(['Codes of Business Conduct'], 0.8424872159957886)","('NON-ESG', 0.04594507813453674)","('NON-ESG', 0.01919001154601574)"
Line 598,"They evaluate  our entire value chain to enable comprehensive impact  assessments in case of a disaster.
","('Critical_Incident_Risk_Management', 0.9709559679031372)","('Employee_Health_And_Safety', 0.0034914114512503147)","('Physical_Impacts_Of_Climate_Change', 0.0032421296928077936)","(['Risk & Crisis Management'], 0.9709559679031372)","('NON-ESG', 0.0034914114512503147)","('NON-ESG', 0.0032421296928077936)"
Line 599,"This includes identifying  and mitigating high-risk dependencies in an effort to  avoid events that could interfere with delivering our  products to customers or jeopardize the safety of our  people, suppliers and communities.
","('Product_Design_And_Lifecycle_Management', 0.47127899527549744)","('Product_Quality_And_Safety', 0.3678229749202728)","('Selling_Practices_And_Product_Labeling', 0.035928383469581604)","('NON-ESG', 0.47127899527549744)","('NON-ESG', 0.3678229749202728)","('NON-ESG', 0.035928383469581604)"
Line 600,"The team works  closely with our information technology (IT) disaster  recovery specialists to identify technology vulnerabilities  so we can make investments that maintain the security of  company operations.Protecting global assets Our global security and resiliency group protects our  people, enterprise assets and operations.
","('Data_Security', 0.862646222114563)","('Business_Model_Resilience', 0.024366216734051704)","('Systemic_Risk_Management', 0.01859389990568161)","(['Information Security/Cybersecurity & System Availability'], 0.862646222114563)","('NON-ESG', 0.024366216734051704)","('NON-ESG', 0.01859389990568161)"
Line 601,"The team  uses industry-standard protocols to run a 24/7 global  security operations center with support from a network of  partners specializing in cybersecurity, environment, health  and safety, supply chain, regulation and data privacy.
","('Data_Security', 0.9498835802078247)","('Systemic_Risk_Management', 0.006324113346636295)","('Supply_Chain_Management', 0.004374849144369364)","(['Information Security/Cybersecurity & System Availability'], 0.9498835802078247)","('NON-ESG', 0.006324113346636295)","('NON-ESG', 0.004374849144369364)"
Line 602,"In 2021, we strengthened our operations by expanding  the company’s digital infrastructure to include greater  detail about suppliers, contractors and our small business  partners.
","('Supply_Chain_Management', 0.9282851815223694)","('Product_Design_And_Lifecycle_Management', 0.006993104703724384)","('Labor_Practices', 0.0055731721222400665)","(['Supply Chain Management'], 0.9282851815223694)","('NON-ESG', 0.006993104703724384)","('NON-ESG', 0.0055731721222400665)"
Line 603,"In addition to maintaining operations without  significant disruption, we built a scalable system that  secures our capacity to do business responsibly as new  risks emerge.
","('Systemic_Risk_Management', 0.7840417623519897)","('Data_Security', 0.06108717992901802)","('Supply_Chain_Management', 0.028973126783967018)","(['Risk & Crisis Management'], 0.7840417623519897)","('NON-ESG', 0.06108717992901802)","('NON-ESG', 0.028973126783967018)"
Line 604,"For more on our climate risk management work, see the Protecting the environment section of this report.
","('Physical_Impacts_Of_Climate_Change', 0.8149278163909912)","('Ecological_Impacts', 0.04526592791080475)","('GHG_Emissions', 0.0416434220969677)","(['Climate Change'], 0.8149278163909912)","('NON-ESG', 0.04526592791080475)","('NON-ESG', 0.0416434220969677)"
Line 605,"Supporting supplier diversity Our approach to supplier selection builds  diversity, equity and inclusion throughout  the Boston Scientific supplier network.
","('Employee_Engagement_Inclusion_And_Diversity', 0.31707504391670227)","('Supply_Chain_Management', 0.2972252666950226)","('Labor_Practices', 0.12416600435972214)","('NON-ESG', 0.31707504391670227)","('NON-ESG', 0.2972252666950226)","('NON-ESG', 0.12416600435972214)"
Line 606,"In the  U.S., Boston Scientific prioritizes working with  certified companies that share our dedication  to improving customer and patient care,  including businesses that are: Pamela Nelson president and chief executive officer,  Bracane Company Inc.
","('Access_And_Affordability', 0.433743417263031)","('Customer_Welfare', 0.12051377445459366)","('Product_Design_And_Lifecycle_Management', 0.05673185735940933)","('NON-ESG', 0.433743417263031)","('NON-ESG', 0.12051377445459366)","('NON-ESG', 0.05673185735940933)"
Line 607,"and Boston Scientific supplier“ By investing in programs that support Black-owned suppliers, Boston Scientific  is doing its part to increase supplier diversity within the life sciences industry.”• Minority-owned • Women-owned • Small or  disadvantaged• Service-disabled • Veteran-owned • LGBTQ-owned • Disability-owned 3,small and diverse  suppliers engaged $865+ million spent on small and   diverse suppliers 2021 Performance ReportIntroduction Transforming care Investing in   our people Accelerating   possibilities Protecting the  environment Creating value  responsibly Overview and   2021 highlights Good governance   reflects our values  Compliance, ethics   and integrity Protecting human rights  across our company   and supply chain Keeping our supply chain  resilient and reliable Risk management   and global security Keeping our products   and patient data secure Appendix Keeping our products and patient data secure Ensuring the safety and security of our products and the patients who rely on them is a top priority.
","('Employee_Engagement_Inclusion_And_Diversity', 0.8516311049461365)","('Labor_Practices', 0.028855862095952034)","('Supply_Chain_Management', 0.020372726023197174)","(['Human Capital Development'], 0.8516311049461365)","('NON-ESG', 0.028855862095952034)","('NON-ESG', 0.020372726023197174)"
Line 608,"and Boston Scientific supplier“ By investing in programs that support Black-owned suppliers, Boston Scientific  is doing its part to increase supplier diversity within the life sciences industry.”• Minority-owned • Women-owned • Small or  disadvantaged• Service-disabled • Veteran-owned • LGBTQ-owned • Disability-owned 3,small and diverse  suppliers engaged $865+ million spent on small and   diverse suppliers 2021 Performance ReportIntroduction Transforming care Investing in   our people Accelerating   possibilities Protecting the  environment Creating value  responsibly Overview and   2021 highlights Good governance   reflects our values  Compliance, ethics   and integrity Protecting human rights  across our company   and supply chain Keeping our supply chain  resilient and reliable Risk management   and global security Keeping our products   and patient data secure Appendix Keeping our products and patient data secure Ensuring the safety and security of our products and the patients who rely on them is a top priority.
","('Product_Design_And_Lifecycle_Management', 0.3388744592666626)","('Product_Quality_And_Safety', 0.3180566132068634)","('Data_Security', 0.051714543253183365)","('NON-ESG', 0.3388744592666626)","('NON-ESG', 0.3180566132068634)","('NON-ESG', 0.051714543253183365)"
Line 609,"and Boston Scientific supplier“ By investing in programs that support Black-owned suppliers, Boston Scientific  is doing its part to increase supplier diversity within the life sciences industry.”• Minority-owned • Women-owned • Small or  disadvantaged• Service-disabled • Veteran-owned • LGBTQ-owned • Disability-owned 3,small and diverse  suppliers engaged $865+ million spent on small and   diverse suppliers 2021 Performance ReportIntroduction Transforming care Investing in   our people Accelerating   possibilities Protecting the  environment Creating value  responsibly Overview and   2021 highlights Good governance   reflects our values  Compliance, ethics   and integrity Protecting human rights  across our company   and supply chain Keeping our supply chain  resilient and reliable Risk management   and global security Keeping our products   and patient data secure Appendix Keeping our products and patient data secure Ensuring the safety and security of our products and the patients who rely on them is a top priority.
","('Ecological_Impacts', 0.171805739402771)","('Access_And_Affordability', 0.13686832785606384)","('Systemic_Risk_Management', 0.06737437099218369)","('NON-ESG', 0.171805739402771)","('NON-ESG', 0.13686832785606384)","('NON-ESG', 0.06737437099218369)"
Line 610,"Boston Scientific has  global cybersecurity protocols that anticipate and address possible threats to product security and to patient information.
","('Data_Security', 0.9643582105636597)","('Director_Removal', 0.002855623373761773)","('Physical_Impacts_Of_Climate_Change', 0.0028482445050030947)","(['Information Security/Cybersecurity & System Availability'], 0.9643582105636597)","('NON-ESG', 0.002855623373761773)","('NON-ESG', 0.0028482445050030947)"
Line 611,"The company’s Remote Patient Management System that allows health care providers to remotely monitor Boston  Scientific implantable cardiac medical devices is certified by the International Organization for Standardization ISO/ IEC 27001:2013 and ISO/IEC27018:2014, and we conduct business in compliance with applicable international laws and  regulations governing product and data security.
","('Data_Security', 0.7619497179985046)","('Customer_Privacy', 0.09182654321193695)","('Business_Ethics', 0.014387417584657669)","(['Information Security/Cybersecurity & System Availability'], 0.7619497179985046)","('NON-ESG', 0.09182654321193695)","('NON-ESG', 0.014387417584657669)"
Line 612,"As a member of the Health Information Sharing and Analysis Center  (H-ISAC) community of private and public health organizations, we can access and share security best practices and threat  intelligence across the health care and public health sectors.
","('Data_Security', 0.9632387161254883)","('Customer_Privacy', 0.0035173490177839994)","('Systemic_Risk_Management', 0.0028720267582684755)","(['Information Security/Cybersecurity & System Availability'], 0.9632387161254883)","('NON-ESG', 0.0035173490177839994)","('NON-ESG', 0.0028720267582684755)"
Line 613,"Ensuring product security In 2021, we expanded our product security approach to  include multiple layers of risk analysis for every hardware  and software component, while using penetration testing  — a form of security testing used to better understand  potential weaknesses that could be exploited — to  identify vulnerabilities.
","('Data_Security', 0.9455487728118896)","('Systemic_Risk_Management', 0.007438029162585735)","('Business_Ethics', 0.005734192207455635)","(['Information Security/Cybersecurity & System Availability'], 0.9455487728118896)","('NON-ESG', 0.007438029162585735)","('NON-ESG', 0.005734192207455635)"
Line 614,"Our product lifecycle security  practices cover the design, sourcing, manufacturing and  support of all devices according to our cybersecurity  protocols that are incorporated into our global quality  system.
","('Data_Security', 0.8563077449798584)","('Product_Design_And_Lifecycle_Management', 0.01857759989798069)","('Systemic_Risk_Management', 0.01178320124745369)","(['Information Security/Cybersecurity & System Availability'], 0.8563077449798584)","('NON-ESG', 0.01857759989798069)","('NON-ESG', 0.01178320124745369)"
Line 615,"We also monitor various threat intelligence  feeds for high profile vulnerabilities that may impact our  products and post regular product vulnerability updates.
","('Data_Security', 0.9539522528648376)","('Systemic_Risk_Management', 0.005588548723608255)","('Customer_Privacy', 0.003754916600883007)","(['Information Security/Cybersecurity & System Availability'], 0.9539522528648376)","('NON-ESG', 0.005588548723608255)","('NON-ESG', 0.003754916600883007)"
Line 616,"Here are some of the actions we take to ensure  transparency:  • Open communication: Our external Boston  Scientific Product Security website communicates  with customers, patients and caregivers about  security findings.• Information sharing: We are an active member  of the Health Information Sharing and Analysis  Center (H-ISAC).
","('Data_Security', 0.9368008971214294)","('Customer_Privacy', 0.015320815145969391)","('Business_Ethics', 0.008012866601347923)","(['Information Security/Cybersecurity & System Availability'], 0.9368008971214294)","('NON-ESG', 0.015320815145969391)","('NON-ESG', 0.008012866601347923)"
Line 617,"We have a process in place for  coordinated vulnerability disclosures to ensure that  our customers and patients are notified of critical  security vulnerabilities and mitigations as needed in  coordination with researchers and the U.S. Department  of Homeland Security’s Cybersecurity & Infrastructure  Security Agency.
","('Data_Security', 0.9580265879631042)","('Systemic_Risk_Management', 0.005165102891623974)","('Physical_Impacts_Of_Climate_Change', 0.0037923071067780256)","(['Information Security/Cybersecurity & System Availability'], 0.9580265879631042)","('NON-ESG', 0.005165102891623974)","('NON-ESG', 0.0037923071067780256)"
Line 618,"Learn more about Boston Scientific product  security on our website .
","('Data_Security', 0.9261310696601868)","('Director_Removal', 0.007005883846431971)","('Business_Ethics', 0.006925356108695269)","(['Information Security/Cybersecurity & System Availability'], 0.9261310696601868)","('NON-ESG', 0.007005883846431971)","('NON-ESG', 0.006925356108695269)"
Line 619,"Protecting data security Boston Scientific products may hold and transmit  sensitive personal data.
","('Customer_Privacy', 0.485720694065094)","('Data_Security', 0.4257594645023346)","('Waste_And_Hazardous_Materials_Management', 0.008727340027689934)","('NON-ESG', 0.485720694065094)","('NON-ESG', 0.4257594645023346)","('NON-ESG', 0.008727340027689934)"
Line 620,"We protect this data with  protocols that honor provider and patient privacy.
","('Customer_Privacy', 0.7570462822914124)","('Data_Security', 0.16185328364372253)","('Waste_And_Hazardous_Materials_Management', 0.00641769589856267)","(['Privacy Protection'], 0.7570462822914124)","('NON-ESG', 0.16185328364372253)","('NON-ESG', 0.00641769589856267)"
Line 621,"Our teams uphold standards for data privacy with  industry-leading data protection practices that protect  confidential health care provider and patient information  from unauthorized disclosures.
","('Data_Security', 0.9109304547309875)","('Customer_Privacy', 0.03573901578783989)","('Business_Ethics', 0.006530608981847763)","(['Information Security/Cybersecurity & System Availability'], 0.9109304547309875)","('NON-ESG', 0.03573901578783989)","('NON-ESG', 0.006530608981847763)"
Line 622,"The company has data  security and incident response plans that address  potential threats to information privacy across all product  portfolios.
","('Data_Security', 0.9559692144393921)","('Customer_Privacy', 0.008082468993961811)","('Director_Removal', 0.003102160058915615)","(['Information Security/Cybersecurity & System Availability'], 0.9559692144393921)","('NON-ESG', 0.008082468993961811)","('NON-ESG', 0.003102160058915615)"
Line 623,"We regularly conduct awareness outreach with  employees and external health providers to educate them about various types of data, privacy and security best practices  and their role in protecting private information.
","('Data_Security', 0.8976934552192688)","('Customer_Privacy', 0.05158776044845581)","('Waste_And_Hazardous_Materials_Management', 0.004477743990719318)","(['Information Security/Cybersecurity & System Availability'], 0.8976934552192688)","('NON-ESG', 0.05158776044845581)","('NON-ESG', 0.004477743990719318)"
Line 624,"2021 regulatory and privacy objectives include: • Privacy impact assessments: We require all employees  to submit impact assessments for any products, processes  and initiatives that collect, use, manage or process personal  data as part of the company’s culture of ensuring privacy  by design and default.
","('Customer_Privacy', 0.897104799747467)","('Data_Security', 0.05151603743433952)","('Selling_Practices_And_Product_Labeling', 0.0038017062470316887)","(['Privacy Protection'], 0.897104799747467)","('NON-ESG', 0.05151603743433952)","('NON-ESG', 0.0038017062470316887)"
Line 625,"In 2021, the Global Privacy team  reviewed over 500 privacy impact assessments.
","('Data_Security', 0.8864786028862)","('Customer_Privacy', 0.03486912325024605)","('Business_Ethics', 0.006581802386790514)","(['Information Security/Cybersecurity & System Availability'], 0.8864786028862)","('NON-ESG', 0.03486912325024605)","('NON-ESG', 0.006581802386790514)"
Line 626,"• Protecting COVID data privacy: We introduced a COVID-19  vaccine tracking tool that complied with rapidly changing  government regulations and enabled employees access to  our sites and to customers.
","('Data_Security', 0.8288887143135071)","('Customer_Privacy', 0.0983402356505394)","('Business_Ethics', 0.006699121557176113)","(['Information Security/Cybersecurity & System Availability'], 0.8288887143135071)","('NON-ESG', 0.0983402356505394)","('NON-ESG', 0.006699121557176113)"
Line 627,"We protected employee and  visitor privacy according to each jurisdiction and ensured  that employees controlled their data for the purpose of  contact tracing.
","('Customer_Privacy', 0.9211306571960449)","('Data_Security', 0.03013772703707218)","('Labor_Practices', 0.0042125023901462555)","(['Privacy Protection'], 0.9211306571960449)","('NON-ESG', 0.03013772703707218)","('NON-ESG', 0.0042125023901462555)"
Line 628,"• Companywide data privacy training: We launched an  employee training program with content tailored to different  areas and functions, to make the training relevant to  employees’ day-to-day work.
","('Data_Security', 0.8307885527610779)","('Customer_Privacy', 0.08432900905609131)","('Business_Ethics', 0.013629342429339886)","(['Information Security/Cybersecurity & System Availability'], 0.8307885527610779)","('NON-ESG', 0.08432900905609131)","('NON-ESG', 0.013629342429339886)"
Line 629,"Different training scenarios  helped Boston Scientific employees who interact with  customers to understand the types of data they may  engage with and their responsibility to protect information  and report privacy concerns.
","('Customer_Privacy', 0.6359163522720337)","('Data_Security', 0.2813844084739685)","('Waste_And_Hazardous_Materials_Management', 0.007893897593021393)","(['Privacy Protection'], 0.6359163522720337)","('NON-ESG', 0.2813844084739685)","('NON-ESG', 0.007893897593021393)"
Line 630,"2021 Performance ReportIntroduction Transforming care Investing in   our people Accelerating   possibilities Protecting the  environment Creating value  responsibly Overview and   2021 highlights Good governance   reflects our values  Compliance, ethics   and integrity Protecting human rights  across our company   and supply chain Keeping our supply chain  resilient and reliable Risk management   and global security Keeping our products   and patient data secure Appendix Appendix 2021 Performance ReportIntroduction Transforming care Investing in   our people Accelerating   possibilities Protecting the  environment Creating value  responsibly Appendix Stakeholder engagement Metrics summary Global Reporting Initiative  (GRI) index Sustainability Accounting  Standards Board   (SASB) index United Nations  Sustainable Development  Goals (SDGs) Stakeholder Engagement Customers • Clinical trial management • Post-market surveillance • Customer care • Training and medical education• Business continuity and resiliency planning • Close the Gap  • Product and data security • Professional section of Bostonscientific.com • Performance Report Patients and patient  advocacy groups• Clinical trials • Close the Gap  • Product and data security• Customer service and complaint handling • Advocacy group engagement • Patients section of Bostonscientific.com Employees • Employee engagement surveys • Employee resource groups • Quarterly business updates • Business-specific town halls• Boston Scientific Intranet and Yammer • Weekly global newsletter and monthly CEO letter • Matching gift program and volunteering • Awards and recognition Individual shareholders   and institutional investors• Annual shareholder meeting and quarterly earnings calls • Investor section of Bostonscientific.com • Bi-annual investor day • Investor calls and meetings• Annual report on Form 10-K and quarterly reports on Form 10-Q • Annual Proxy Statement • Performance Report Government regulators and policymakers • Government affairs team • Trade associations• Boston Scientific Corporation Political Action Committee • Policy & Advocacy Nongovernmental organizations   and local communities• Boston Scientific Foundations • Grants, donations and exhibits • Employee volunteering• Scholarships and internships • Sponsorships, partnerships and collaborations Suppliers and distributors • Supplier diversity program • Global supplier guidebook and resource center• Supplier scorecards • Supplier quality and audit programsStakeholder engagement The following chart outlines our key stakeholders and describes the ways we regularly engage with them.
","('Supply_Chain_Management', 0.7047697901725769)","('Systemic_Risk_Management', 0.058470554649829865)","('Business_Model_Resilience', 0.04547354206442833)","(['Supply Chain Management'], 0.7047697901725769)","('NON-ESG', 0.058470554649829865)","('NON-ESG', 0.04547354206442833)"
Line 631,"2021 Performance ReportIntroduction Transforming care Investing in   our people Accelerating   possibilities Protecting the  environment Creating value  responsibly Overview and   2021 highlights Good governance   reflects our values  Compliance, ethics   and integrity Protecting human rights  across our company   and supply chain Keeping our supply chain  resilient and reliable Risk management   and global security Keeping our products   and patient data secure Appendix Appendix 2021 Performance ReportIntroduction Transforming care Investing in   our people Accelerating   possibilities Protecting the  environment Creating value  responsibly Appendix Stakeholder engagement Metrics summary Global Reporting Initiative  (GRI) index Sustainability Accounting  Standards Board   (SASB) index United Nations  Sustainable Development  Goals (SDGs) Stakeholder Engagement Customers • Clinical trial management • Post-market surveillance • Customer care • Training and medical education• Business continuity and resiliency planning • Close the Gap  • Product and data security • Professional section of Bostonscientific.com • Performance Report Patients and patient  advocacy groups• Clinical trials • Close the Gap  • Product and data security• Customer service and complaint handling • Advocacy group engagement • Patients section of Bostonscientific.com Employees • Employee engagement surveys • Employee resource groups • Quarterly business updates • Business-specific town halls• Boston Scientific Intranet and Yammer • Weekly global newsletter and monthly CEO letter • Matching gift program and volunteering • Awards and recognition Individual shareholders   and institutional investors• Annual shareholder meeting and quarterly earnings calls • Investor section of Bostonscientific.com • Bi-annual investor day • Investor calls and meetings• Annual report on Form 10-K and quarterly reports on Form 10-Q • Annual Proxy Statement • Performance Report Government regulators and policymakers • Government affairs team • Trade associations• Boston Scientific Corporation Political Action Committee • Policy & Advocacy Nongovernmental organizations   and local communities• Boston Scientific Foundations • Grants, donations and exhibits • Employee volunteering• Scholarships and internships • Sponsorships, partnerships and collaborations Suppliers and distributors • Supplier diversity program • Global supplier guidebook and resource center• Supplier scorecards • Supplier quality and audit programsStakeholder engagement The following chart outlines our key stakeholders and describes the ways we regularly engage with them.
","('Business_Model_Resilience', 0.8302777409553528)","('Employee_Engagement_Inclusion_And_Diversity', 0.02100900001823902)","('Product_Design_And_Lifecycle_Management', 0.0177044328302145)","(['Codes of Business Conduct'], 0.8302777409553528)","('NON-ESG', 0.02100900001823902)","('NON-ESG', 0.0177044328302145)"
Line 632,"2021 Performance ReportIntroduction Transforming care Investing in   our people Accelerating   possibilities Protecting the  environment Creating value  responsibly Overview and   2021 highlights Good governance   reflects our values  Compliance, ethics   and integrity Protecting human rights  across our company   and supply chain Keeping our supply chain  resilient and reliable Risk management   and global security Keeping our products   and patient data secure Appendix Appendix 2021 Performance ReportIntroduction Transforming care Investing in   our people Accelerating   possibilities Protecting the  environment Creating value  responsibly Appendix Stakeholder engagement Metrics summary Global Reporting Initiative  (GRI) index Sustainability Accounting  Standards Board   (SASB) index United Nations  Sustainable Development  Goals (SDGs) Stakeholder Engagement Customers • Clinical trial management • Post-market surveillance • Customer care • Training and medical education• Business continuity and resiliency planning • Close the Gap  • Product and data security • Professional section of Bostonscientific.com • Performance Report Patients and patient  advocacy groups• Clinical trials • Close the Gap  • Product and data security• Customer service and complaint handling • Advocacy group engagement • Patients section of Bostonscientific.com Employees • Employee engagement surveys • Employee resource groups • Quarterly business updates • Business-specific town halls• Boston Scientific Intranet and Yammer • Weekly global newsletter and monthly CEO letter • Matching gift program and volunteering • Awards and recognition Individual shareholders   and institutional investors• Annual shareholder meeting and quarterly earnings calls • Investor section of Bostonscientific.com • Bi-annual investor day • Investor calls and meetings• Annual report on Form 10-K and quarterly reports on Form 10-Q • Annual Proxy Statement • Performance Report Government regulators and policymakers • Government affairs team • Trade associations• Boston Scientific Corporation Political Action Committee • Policy & Advocacy Nongovernmental organizations   and local communities• Boston Scientific Foundations • Grants, donations and exhibits • Employee volunteering• Scholarships and internships • Sponsorships, partnerships and collaborations Suppliers and distributors • Supplier diversity program • Global supplier guidebook and resource center• Supplier scorecards • Supplier quality and audit programsStakeholder engagement The following chart outlines our key stakeholders and describes the ways we regularly engage with them.
","('Data_Security', 0.8900957107543945)","('Customer_Privacy', 0.03724875673651695)","('Business_Ethics', 0.011006202548742294)","(['Information Security/Cybersecurity & System Availability'], 0.8900957107543945)","('NON-ESG', 0.03724875673651695)","('NON-ESG', 0.011006202548742294)"
Line 633,"2021 Performance ReportIntroduction Transforming care Investing in   our people Accelerating   possibilities Protecting the  environment Creating value  responsibly Overview and   2021 highlights Good governance   reflects our values  Compliance, ethics   and integrity Protecting human rights  across our company   and supply chain Keeping our supply chain  resilient and reliable Risk management   and global security Keeping our products   and patient data secure Appendix Appendix 2021 Performance ReportIntroduction Transforming care Investing in   our people Accelerating   possibilities Protecting the  environment Creating value  responsibly Appendix Stakeholder engagement Metrics summary Global Reporting Initiative  (GRI) index Sustainability Accounting  Standards Board   (SASB) index United Nations  Sustainable Development  Goals (SDGs) Stakeholder Engagement Customers • Clinical trial management • Post-market surveillance • Customer care • Training and medical education• Business continuity and resiliency planning • Close the Gap  • Product and data security • Professional section of Bostonscientific.com • Performance Report Patients and patient  advocacy groups• Clinical trials • Close the Gap  • Product and data security• Customer service and complaint handling • Advocacy group engagement • Patients section of Bostonscientific.com Employees • Employee engagement surveys • Employee resource groups • Quarterly business updates • Business-specific town halls• Boston Scientific Intranet and Yammer • Weekly global newsletter and monthly CEO letter • Matching gift program and volunteering • Awards and recognition Individual shareholders   and institutional investors• Annual shareholder meeting and quarterly earnings calls • Investor section of Bostonscientific.com • Bi-annual investor day • Investor calls and meetings• Annual report on Form 10-K and quarterly reports on Form 10-Q • Annual Proxy Statement • Performance Report Government regulators and policymakers • Government affairs team • Trade associations• Boston Scientific Corporation Political Action Committee • Policy & Advocacy Nongovernmental organizations   and local communities• Boston Scientific Foundations • Grants, donations and exhibits • Employee volunteering• Scholarships and internships • Sponsorships, partnerships and collaborations Suppliers and distributors • Supplier diversity program • Global supplier guidebook and resource center• Supplier scorecards • Supplier quality and audit programsStakeholder engagement The following chart outlines our key stakeholders and describes the ways we regularly engage with them.
","('Management_Of_Legal_And_Regulatory_Framework', 0.9290759563446045)","('Director_Removal', 0.011286141350865364)","('Business_Ethics', 0.010008431039750576)","(['Corporate Governance'], 0.9290759563446045)","('NON-ESG', 0.011286141350865364)","('NON-ESG', 0.010008431039750576)"
Line 634,"2021 Performance ReportIntroduction Transforming care Investing in   our people Accelerating   possibilities Protecting the  environment Creating value  responsibly Overview and   2021 highlights Good governance   reflects our values  Compliance, ethics   and integrity Protecting human rights  across our company   and supply chain Keeping our supply chain  resilient and reliable Risk management   and global security Keeping our products   and patient data secure Appendix Appendix 2021 Performance ReportIntroduction Transforming care Investing in   our people Accelerating   possibilities Protecting the  environment Creating value  responsibly Appendix Stakeholder engagement Metrics summary Global Reporting Initiative  (GRI) index Sustainability Accounting  Standards Board   (SASB) index United Nations  Sustainable Development  Goals (SDGs) Stakeholder Engagement Customers • Clinical trial management • Post-market surveillance • Customer care • Training and medical education• Business continuity and resiliency planning • Close the Gap  • Product and data security • Professional section of Bostonscientific.com • Performance Report Patients and patient  advocacy groups• Clinical trials • Close the Gap  • Product and data security• Customer service and complaint handling • Advocacy group engagement • Patients section of Bostonscientific.com Employees • Employee engagement surveys • Employee resource groups • Quarterly business updates • Business-specific town halls• Boston Scientific Intranet and Yammer • Weekly global newsletter and monthly CEO letter • Matching gift program and volunteering • Awards and recognition Individual shareholders   and institutional investors• Annual shareholder meeting and quarterly earnings calls • Investor section of Bostonscientific.com • Bi-annual investor day • Investor calls and meetings• Annual report on Form 10-K and quarterly reports on Form 10-Q • Annual Proxy Statement • Performance Report Government regulators and policymakers • Government affairs team • Trade associations• Boston Scientific Corporation Political Action Committee • Policy & Advocacy Nongovernmental organizations   and local communities• Boston Scientific Foundations • Grants, donations and exhibits • Employee volunteering• Scholarships and internships • Sponsorships, partnerships and collaborations Suppliers and distributors • Supplier diversity program • Global supplier guidebook and resource center• Supplier scorecards • Supplier quality and audit programsStakeholder engagement The following chart outlines our key stakeholders and describes the ways we regularly engage with them.
","('Supply_Chain_Management', 0.9111835360527039)","('Labor_Practices', 0.014270723797380924)","('Product_Design_And_Lifecycle_Management', 0.007030719891190529)","(['Supply Chain Management'], 0.9111835360527039)","('NON-ESG', 0.014270723797380924)","('NON-ESG', 0.007030719891190529)"
Line 635,"2021 Performance ReportIntroduction Transforming care Investing in   our people Accelerating   possibilities Protecting the  environment Creating value  responsibly Overview and   2021 highlights Good governance   reflects our values  Compliance, ethics   and integrity Protecting human rights  across our company   and supply chain Keeping our supply chain  resilient and reliable Risk management   and global security Keeping our products   and patient data secure Appendix Appendix 2021 Performance ReportIntroduction Transforming care Investing in   our people Accelerating   possibilities Protecting the  environment Creating value  responsibly Appendix Stakeholder engagement Metrics summary Global Reporting Initiative  (GRI) index Sustainability Accounting  Standards Board   (SASB) index United Nations  Sustainable Development  Goals (SDGs) Stakeholder Engagement Customers • Clinical trial management • Post-market surveillance • Customer care • Training and medical education• Business continuity and resiliency planning • Close the Gap  • Product and data security • Professional section of Bostonscientific.com • Performance Report Patients and patient  advocacy groups• Clinical trials • Close the Gap  • Product and data security• Customer service and complaint handling • Advocacy group engagement • Patients section of Bostonscientific.com Employees • Employee engagement surveys • Employee resource groups • Quarterly business updates • Business-specific town halls• Boston Scientific Intranet and Yammer • Weekly global newsletter and monthly CEO letter • Matching gift program and volunteering • Awards and recognition Individual shareholders   and institutional investors• Annual shareholder meeting and quarterly earnings calls • Investor section of Bostonscientific.com • Bi-annual investor day • Investor calls and meetings• Annual report on Form 10-K and quarterly reports on Form 10-Q • Annual Proxy Statement • Performance Report Government regulators and policymakers • Government affairs team • Trade associations• Boston Scientific Corporation Political Action Committee • Policy & Advocacy Nongovernmental organizations   and local communities• Boston Scientific Foundations • Grants, donations and exhibits • Employee volunteering• Scholarships and internships • Sponsorships, partnerships and collaborations Suppliers and distributors • Supplier diversity program • Global supplier guidebook and resource center• Supplier scorecards • Supplier quality and audit programsStakeholder engagement The following chart outlines our key stakeholders and describes the ways we regularly engage with them.
","('Human_Rights_And_Community_Relations', 0.7242307662963867)","('Management_Of_Legal_And_Regulatory_Framework', 0.036362722516059875)","('Business_Model_Resilience', 0.03160302713513374)","(['Community Relations'], 0.7242307662963867)","('NON-ESG', 0.036362722516059875)","('NON-ESG', 0.03160302713513374)"
Line 636,"2021 Performance ReportIntroduction Transforming care Investing in   our people Accelerating   possibilities Protecting the  environment Creating value  responsibly Appendix Stakeholder engagement Metrics summary Global Reporting Initiative  (GRI) index Sustainability Accounting  Standards Board   (SASB) index United Nations  Sustainable Development  Goals (SDGs) Product quality and safety Unit 2018 2019 2020 Class I recalls # 0 0 3 Value of Class I recalled products1USD millions 0 0 77.09 120.Class II recalls # 5 7 15 Value of Class II recalled products1USD millions 1.22 9.60 59.01 8.Regulatory inspections # 76 87 85 Form 483 observations # 7 0 0 Annual revenues from 483 affected facilities USD millions 107 0 0 Annual revenues impacted by production stoppages USD millions 0 0 0 FDA warning letters Yes/No No No No No Innovation Unit 2018 2019 2020 Research & Development (R&D) spend USD millions 1,113 1,174 1,143 1,R&D spend as a percent of sales Percent 11.3 10.9 11.5 10.Number of R&D positions FTE 1,453 2,040 2,114 2,136Transforming careMetrics summary Our metrics summary provides key performance data organized under five pillars that align to leading Environmental, Social and Governance (ESG) ratings and inclusion   within sustainability indices.
","('Product_Quality_And_Safety', 0.773606538772583)","('Product_Design_And_Lifecycle_Management', 0.11605310440063477)","('Employee_Health_And_Safety', 0.014868730679154396)","(['Product Quality & Recall Management'], 0.773606538772583)","('NON-ESG', 0.11605310440063477)","('NON-ESG', 0.014868730679154396)"
Line 637,"2021 Performance ReportIntroduction Transforming care Investing in   our people Accelerating   possibilities Protecting the  environment Creating value  responsibly Appendix Stakeholder engagement Metrics summary Global Reporting Initiative  (GRI) index Sustainability Accounting  Standards Board   (SASB) index United Nations  Sustainable Development  Goals (SDGs) Product quality and safety Unit 2018 2019 2020 Class I recalls # 0 0 3 Value of Class I recalled products1USD millions 0 0 77.09 120.Class II recalls # 5 7 15 Value of Class II recalled products1USD millions 1.22 9.60 59.01 8.Regulatory inspections # 76 87 85 Form 483 observations # 7 0 0 Annual revenues from 483 affected facilities USD millions 107 0 0 Annual revenues impacted by production stoppages USD millions 0 0 0 FDA warning letters Yes/No No No No No Innovation Unit 2018 2019 2020 Research & Development (R&D) spend USD millions 1,113 1,174 1,143 1,R&D spend as a percent of sales Percent 11.3 10.9 11.5 10.Number of R&D positions FTE 1,453 2,040 2,114 2,136Transforming careMetrics summary Our metrics summary provides key performance data organized under five pillars that align to leading Environmental, Social and Governance (ESG) ratings and inclusion   within sustainability indices.
","('Management_Of_Legal_And_Regulatory_Framework', 0.6780791878700256)","('Competitive_Behavior', 0.06077057123184204)","('Business_Ethics', 0.05128942430019379)","(['Corporate Governance'], 0.6780791878700256)","('NON-ESG', 0.06077057123184204)","('NON-ESG', 0.05128942430019379)"
Line 638,"2021 Performance ReportIntroduction Transforming care Investing in   our people Accelerating   possibilities Protecting the  environment Creating value  responsibly Appendix Stakeholder engagement Metrics summary Global Reporting Initiative  (GRI) index Sustainability Accounting  Standards Board   (SASB) index United Nations  Sustainable Development  Goals (SDGs) Product quality and safety Unit 2018 2019 2020 Class I recalls # 0 0 3 Value of Class I recalled products1USD millions 0 0 77.09 120.Class II recalls # 5 7 15 Value of Class II recalled products1USD millions 1.22 9.60 59.01 8.Regulatory inspections # 76 87 85 Form 483 observations # 7 0 0 Annual revenues from 483 affected facilities USD millions 107 0 0 Annual revenues impacted by production stoppages USD millions 0 0 0 FDA warning letters Yes/No No No No No Innovation Unit 2018 2019 2020 Research & Development (R&D) spend USD millions 1,113 1,174 1,143 1,R&D spend as a percent of sales Percent 11.3 10.9 11.5 10.Number of R&D positions FTE 1,453 2,040 2,114 2,136Transforming careMetrics summary Our metrics summary provides key performance data organized under five pillars that align to leading Environmental, Social and Governance (ESG) ratings and inclusion   within sustainability indices.
","('Business_Model_Resilience', 0.377463161945343)","('Human_Rights_And_Community_Relations', 0.15684457123279572)","('Management_Of_Legal_And_Regulatory_Framework', 0.07027123868465424)","('NON-ESG', 0.377463161945343)","('NON-ESG', 0.15684457123279572)","('NON-ESG', 0.07027123868465424)"
Line 639,"1 Of the recalls classified in the year, value is determined by recall quantity multiplied by cost to manufacture.
","('Product_Quality_And_Safety', 0.3170119822025299)","('Selling_Practices_And_Product_Labeling', 0.09859651327133179)","('Critical_Incident_Risk_Management', 0.07260174304246902)","('NON-ESG', 0.3170119822025299)","('NON-ESG', 0.09859651327133179)","('NON-ESG', 0.07260174304246902)"
Line 640,"2021 Performance ReportIntroduction Transforming care Investing in   our people Accelerating   possibilities Protecting the  environment Creating value  responsibly Appendix Stakeholder engagement Metrics summary Global Reporting Initiative  (GRI) index Sustainability Accounting  Standards Board   (SASB) index United Nations  Sustainable Development  Goals (SDGs) Diversity and inclusion Unit 2018 2019 2020 Supervisors and managersSupervisors and managers — women2Percent 38.4 38.1 39.9 41.Supervisors and managers — multicultural talent3Percent 19.6 20.8 21.4 21.Total workforce (all levels)  Share of total workforce — women Percent 46.5 47.0 47.4 48.Share of total workforce — multicultural talent Percent 31.7 33.2 34.0 35.Representation of women (globally)    Board of directors — women Percent 30.0 30.0 30.0 30.Executive officers — women4Percent 18.8425.0425.0 18.Senior management — women5Percent 29.5 31.0 33.2 34.Supervisors and managers — women Percent 38.4 38.1 39.9 41.Share of total field sales management positions — women Percent 22.0 21.3 22.9 24.1Investing in our people 1 Supervisors and managers: includes all levels that are supervisor, manager I and manager II.
","('Employee_Engagement_Inclusion_And_Diversity', 0.9710133671760559)","('Human_Rights_And_Community_Relations', 0.0026421446818858385)","('Employee_Health_And_Safety', 0.0024609477259218693)","(['Human Capital Development'], 0.9710133671760559)","('NON-ESG', 0.0026421446818858385)","('NON-ESG', 0.0024609477259218693)"
Line 641,"2021 Performance ReportIntroduction Transforming care Investing in   our people Accelerating   possibilities Protecting the  environment Creating value  responsibly Appendix Stakeholder engagement Metrics summary Global Reporting Initiative  (GRI) index Sustainability Accounting  Standards Board   (SASB) index United Nations  Sustainable Development  Goals (SDGs) Diversity and inclusion Unit 2018 2019 2020 Supervisors and managersSupervisors and managers — women2Percent 38.4 38.1 39.9 41.Supervisors and managers — multicultural talent3Percent 19.6 20.8 21.4 21.Total workforce (all levels)  Share of total workforce — women Percent 46.5 47.0 47.4 48.Share of total workforce — multicultural talent Percent 31.7 33.2 34.0 35.Representation of women (globally)    Board of directors — women Percent 30.0 30.0 30.0 30.Executive officers — women4Percent 18.8425.0425.0 18.Senior management — women5Percent 29.5 31.0 33.2 34.Supervisors and managers — women Percent 38.4 38.1 39.9 41.Share of total field sales management positions — women Percent 22.0 21.3 22.9 24.1Investing in our people 1 Supervisors and managers: includes all levels that are supervisor, manager I and manager II.
","('Employee_Engagement_Inclusion_And_Diversity', 0.9254576563835144)","('Director_Removal', 0.010359134525060654)","('Labor_Practices', 0.008874430321156979)","(['Human Capital Development'], 0.9254576563835144)","('NON-ESG', 0.010359134525060654)","('NON-ESG', 0.008874430321156979)"
Line 642,"2021 Performance ReportIntroduction Transforming care Investing in   our people Accelerating   possibilities Protecting the  environment Creating value  responsibly Appendix Stakeholder engagement Metrics summary Global Reporting Initiative  (GRI) index Sustainability Accounting  Standards Board   (SASB) index United Nations  Sustainable Development  Goals (SDGs) Diversity and inclusion Unit 2018 2019 2020 Supervisors and managersSupervisors and managers — women2Percent 38.4 38.1 39.9 41.Supervisors and managers — multicultural talent3Percent 19.6 20.8 21.4 21.Total workforce (all levels)  Share of total workforce — women Percent 46.5 47.0 47.4 48.Share of total workforce — multicultural talent Percent 31.7 33.2 34.0 35.Representation of women (globally)    Board of directors — women Percent 30.0 30.0 30.0 30.Executive officers — women4Percent 18.8425.0425.0 18.Senior management — women5Percent 29.5 31.0 33.2 34.Supervisors and managers — women Percent 38.4 38.1 39.9 41.Share of total field sales management positions — women Percent 22.0 21.3 22.9 24.1Investing in our people 1 Supervisors and managers: includes all levels that are supervisor, manager I and manager II.
","('Employee_Engagement_Inclusion_And_Diversity', 0.38482242822647095)","('Labor_Practices', 0.2054053395986557)","('Director_Removal', 0.11466126888990402)","('NON-ESG', 0.38482242822647095)","('NON-ESG', 0.2054053395986557)","('NON-ESG', 0.11466126888990402)"
Line 643,"2 Gender: includes all employees globally where gender is identified.
","('Employee_Engagement_Inclusion_And_Diversity', 0.8954712152481079)","('Labor_Practices', 0.03545735403895378)","('Employee_Health_And_Safety', 0.00857766717672348)","(['Human Capital Development'], 0.8954712152481079)","('NON-ESG', 0.03545735403895378)","('NON-ESG', 0.00857766717672348)"
Line 644,"Excludes any employees where gender is ""undeclared"" and ""unknown."" 3   Multicultural talent: in the U.S. and Puerto Rico, defined as African American/Black, Asian, Hispanic/Latino, American Indian/Alaska Native,   Native Hawaiian/Other Pacific Islander and two or more races.
","('Employee_Engagement_Inclusion_And_Diversity', 0.974311113357544)","('Labor_Practices', 0.002163951750844717)","('Employee_Health_And_Safety', 0.001972841564565897)","(['Human Capital Development'], 0.974311113357544)","('NON-ESG', 0.002163951750844717)","('NON-ESG', 0.001972841564565897)"
Line 645,"Excludes any employees who choose not to self-identify.
","('Employee_Engagement_Inclusion_And_Diversity', 0.9159753918647766)","('Customer_Privacy', 0.011959224008023739)","('Labor_Practices', 0.010157001204788685)","(['Human Capital Development'], 0.9159753918647766)","('NON-ESG', 0.011959224008023739)","('NON-ESG', 0.010157001204788685)"
Line 646,"4 Executive officers: includes all executive officers listed in the Annual Report.
","('Director_Removal', 0.7583106756210327)","('Business_Model_Resilience', 0.024742688983678818)","('Employee_Engagement_Inclusion_And_Diversity', 0.022825853899121284)","(['Anti-Crime Policy & Measures'], 0.7583106756210327)","('NON-ESG', 0.024742688983678818)","('NON-ESG', 0.022825853899121284)"
Line 647,"Figures for 2018-2019 have been restated to conform to this definition.
","('Management_Of_Legal_And_Regulatory_Framework', 0.5570366978645325)","('Systemic_Risk_Management', 0.08726480603218079)","('Physical_Impacts_Of_Climate_Change', 0.03601659834384918)","(['Corporate Governance'], 0.5570366978645325)","('NON-ESG', 0.08726480603218079)","('NON-ESG', 0.03601659834384918)"
Line 648,"5 Senior management: includes all levels that are director, vice president, senior vice president, executive vice president and CEO.
","('Director_Removal', 0.6298117637634277)","('Employee_Engagement_Inclusion_And_Diversity', 0.05980900675058365)","('Business_Model_Resilience', 0.047948796302080154)","(['Anti-Crime Policy & Measures'], 0.6298117637634277)","('NON-ESG', 0.05980900675058365)","('NON-ESG', 0.047948796302080154)"
Line 649,"2021 Performance ReportIntroduction Transforming care Investing in   our people Accelerating   possibilities Protecting the  environment Creating value  responsibly Appendix Stakeholder engagement Metrics summary Global Reporting Initiative  (GRI) index Sustainability Accounting  Standards Board   (SASB) index United Nations  Sustainable Development  Goals (SDGs) Diversity and inclusion Unit 2018 2019 2020 Representation of multicultural talent (U.S. and Puerto Rico)American Indian/Alaska Native Percent 0.3 0.3 0.3 0.Asian Percent 13.4 13.3 13.6 12.African American/Black Percent 6.5 7.2 7.9 9.Hispanic/Latino Percent 9.5 10.5 10.3 11.Two or more races Percent 1.6 1.6 1.7 1.Native Hawaiian/Other Pacific Islander Percent 0.3 0.3 0.3 0.Total Percent 31.6 33.2 34.1 35.Senior management Percent 13.1 13.6 14.4 16.Supervisors and managers Percent 19.6 20.8 21.4 21.Women by region United States and Puerto Rico Percent 44.3 45.0 45.3 46.Latin America Percent 57.7 56.1 55.7 55.Canada Percent 43.6 43.4 48.1 48.Europe, Middle East and Africa Percent 45.5 45.5 46.3 47.Asia Pacific Percent 43.3 46.4 46.9 46.5Investing in our people 1 Reflects Equal Employment Opportunity (EEO) race/ethnicity categories.Reflects Equal Employment  Opportunity (EEO) race/ethnicity  categories.
","('Employee_Engagement_Inclusion_And_Diversity', 0.9759082794189453)","('Human_Rights_And_Community_Relations', 0.00199737842194736)","('Employee_Health_And_Safety', 0.001675920095294714)","(['Human Capital Development'], 0.9759082794189453)","('NON-ESG', 0.00199737842194736)","('NON-ESG', 0.001675920095294714)"
Line 650,"2021 Performance ReportIntroduction Transforming care Investing in   our people Accelerating   possibilities Protecting the  environment Creating value  responsibly Appendix Stakeholder engagement Metrics summary Global Reporting Initiative  (GRI) index Sustainability Accounting  Standards Board   (SASB) index United Nations  Sustainable Development  Goals (SDGs) Diversity and inclusion Unit 2018 2019 2020 Representation of multicultural talent (U.S. and Puerto Rico)American Indian/Alaska Native Percent 0.3 0.3 0.3 0.Asian Percent 13.4 13.3 13.6 12.African American/Black Percent 6.5 7.2 7.9 9.Hispanic/Latino Percent 9.5 10.5 10.3 11.Two or more races Percent 1.6 1.6 1.7 1.Native Hawaiian/Other Pacific Islander Percent 0.3 0.3 0.3 0.Total Percent 31.6 33.2 34.1 35.Senior management Percent 13.1 13.6 14.4 16.Supervisors and managers Percent 19.6 20.8 21.4 21.Women by region United States and Puerto Rico Percent 44.3 45.0 45.3 46.Latin America Percent 57.7 56.1 55.7 55.Canada Percent 43.6 43.4 48.1 48.Europe, Middle East and Africa Percent 45.5 45.5 46.3 47.Asia Pacific Percent 43.3 46.4 46.9 46.5Investing in our people 1 Reflects Equal Employment Opportunity (EEO) race/ethnicity categories.Reflects Equal Employment  Opportunity (EEO) race/ethnicity  categories.
","('Employee_Engagement_Inclusion_And_Diversity', 0.9588102698326111)","('Business_Model_Resilience', 0.003094494342803955)","('Human_Rights_And_Community_Relations', 0.003027563448995352)","(['Human Capital Development'], 0.9588102698326111)","('NON-ESG', 0.003094494342803955)","('NON-ESG', 0.003027563448995352)"
Line 651,"2021 Performance ReportIntroduction Transforming care Investing in   our people Accelerating   possibilities Protecting the  environment Creating value  responsibly Appendix Stakeholder engagement Metrics summary Global Reporting Initiative  (GRI) index Sustainability Accounting  Standards Board   (SASB) index United Nations  Sustainable Development  Goals (SDGs) Diversity and inclusion Unit 2018 2019 2020 Representation of multicultural talent (U.S. and Puerto Rico)American Indian/Alaska Native Percent 0.3 0.3 0.3 0.Asian Percent 13.4 13.3 13.6 12.African American/Black Percent 6.5 7.2 7.9 9.Hispanic/Latino Percent 9.5 10.5 10.3 11.Two or more races Percent 1.6 1.6 1.7 1.Native Hawaiian/Other Pacific Islander Percent 0.3 0.3 0.3 0.Total Percent 31.6 33.2 34.1 35.Senior management Percent 13.1 13.6 14.4 16.Supervisors and managers Percent 19.6 20.8 21.4 21.Women by region United States and Puerto Rico Percent 44.3 45.0 45.3 46.Latin America Percent 57.7 56.1 55.7 55.Canada Percent 43.6 43.4 48.1 48.Europe, Middle East and Africa Percent 45.5 45.5 46.3 47.Asia Pacific Percent 43.3 46.4 46.9 46.5Investing in our people 1 Reflects Equal Employment Opportunity (EEO) race/ethnicity categories.Reflects Equal Employment  Opportunity (EEO) race/ethnicity  categories.
","('Employee_Engagement_Inclusion_And_Diversity', 0.9755088090896606)","('Human_Rights_And_Community_Relations', 0.0019837685395032167)","('Employee_Health_And_Safety', 0.0017972568748518825)","(['Human Capital Development'], 0.9755088090896606)","('NON-ESG', 0.0019837685395032167)","('NON-ESG', 0.0017972568748518825)"
Line 652,"2021 Performance ReportIntroduction Transforming care Investing in   our people Accelerating   possibilities Protecting the  environment Creating value  responsibly Appendix Stakeholder engagement Metrics summary Global Reporting Initiative  (GRI) index Sustainability Accounting  Standards Board   (SASB) index United Nations  Sustainable Development  Goals (SDGs) Diversity and inclusion Unit 2018 2019 2020 Expanding our pipeline (new hires) Multicultural talent Percent 46.2 43.5 42.5149.Women Percent 51.2 50.2 48.9151.Representation of employees by age group (U.S. and Puerto Rico) <30 Percent 11.1 14.0 16.1 18.30-50 Percent 58.3 57.8 57.6 56.>50 Percent 30.6 28.1 26.3 25.Representation of employees by age group (global) <30 Percent 14.6 18.3 21.5 24.30-50 Percent 63.0 61.1 59.8 58.>50 Percent 22.5 20.6 18.7 17.8Investing in our people 1 2020 figures restated.
","('Employee_Engagement_Inclusion_And_Diversity', 0.972065806388855)","('Human_Rights_And_Community_Relations', 0.0024637042079120874)","('Employee_Health_And_Safety', 0.0021650071721524)","(['Human Capital Development'], 0.972065806388855)","('NON-ESG', 0.0024637042079120874)","('NON-ESG', 0.0021650071721524)"
Line 653,"2021 Performance ReportIntroduction Transforming care Investing in   our people Accelerating   possibilities Protecting the  environment Creating value  responsibly Appendix Stakeholder engagement Metrics summary Global Reporting Initiative  (GRI) index Sustainability Accounting  Standards Board   (SASB) index United Nations  Sustainable Development  Goals (SDGs) Diversity and inclusion Unit 2018 2019 2020 Expanding our pipeline (new hires) Multicultural talent Percent 46.2 43.5 42.5149.Women Percent 51.2 50.2 48.9151.Representation of employees by age group (U.S. and Puerto Rico) <30 Percent 11.1 14.0 16.1 18.30-50 Percent 58.3 57.8 57.6 56.>50 Percent 30.6 28.1 26.3 25.Representation of employees by age group (global) <30 Percent 14.6 18.3 21.5 24.30-50 Percent 63.0 61.1 59.8 58.>50 Percent 22.5 20.6 18.7 17.8Investing in our people 1 2020 figures restated.
","('Employee_Engagement_Inclusion_And_Diversity', 0.953048050403595)","('Labor_Practices', 0.0062576280906796455)","('Employee_Health_And_Safety', 0.003832419402897358)","(['Human Capital Development'], 0.953048050403595)","('NON-ESG', 0.0062576280906796455)","('NON-ESG', 0.003832419402897358)"
Line 654,"2021 Performance ReportIntroduction Transforming care Investing in   our people Accelerating   possibilities Protecting the  environment Creating value  responsibly Appendix Stakeholder engagement Metrics summary Global Reporting Initiative  (GRI) index Sustainability Accounting  Standards Board   (SASB) index United Nations  Sustainable Development  Goals (SDGs) Career and culture Unit 2018 2019 2020 Total new hires 7,298 8,417 6,494 8,Employee turnover rate Percent total employees 11.9 12.0 10.3 15.Employee voluntary turnover rate Percent total employees 9.5 9.5 7.1 11.Pay equity global (gender) Global BSC 99%+ 99%+Analysis not  completed99%+Pay equity multicultural (U.S. and Puerto Rico) U.S. and Puerto Rico 99%+ 99%+Analysis not  completed99%+Open positions filled by internal candidates Percent 20.1 17.5220.5 22.Period that long-term incentives for employees are paid out after Years 4 4 Average learning hours/employee Hours — — 16.5418.64Investing in our people 1 We will be completing every other year.
","('Employee_Engagement_Inclusion_And_Diversity', 0.7402371168136597)","('Labor_Practices', 0.09578611701726913)","('Employee_Health_And_Safety', 0.035261429846286774)","(['Human Capital Development'], 0.7402371168136597)","('NON-ESG', 0.09578611701726913)","('NON-ESG', 0.035261429846286774)"
Line 655,"2021 Performance ReportIntroduction Transforming care Investing in   our people Accelerating   possibilities Protecting the  environment Creating value  responsibly Appendix Stakeholder engagement Metrics summary Global Reporting Initiative  (GRI) index Sustainability Accounting  Standards Board   (SASB) index United Nations  Sustainable Development  Goals (SDGs) Career and culture Unit 2018 2019 2020 Total new hires 7,298 8,417 6,494 8,Employee turnover rate Percent total employees 11.9 12.0 10.3 15.Employee voluntary turnover rate Percent total employees 9.5 9.5 7.1 11.Pay equity global (gender) Global BSC 99%+ 99%+Analysis not  completed99%+Pay equity multicultural (U.S. and Puerto Rico) U.S. and Puerto Rico 99%+ 99%+Analysis not  completed99%+Open positions filled by internal candidates Percent 20.1 17.5220.5 22.Period that long-term incentives for employees are paid out after Years 4 4 Average learning hours/employee Hours — — 16.5418.64Investing in our people 1 We will be completing every other year.
","('Labor_Practices', 0.8834145069122314)","('Employee_Engagement_Inclusion_And_Diversity', 0.041580285876989365)","('Employee_Health_And_Safety', 0.013583597727119923)","(['Labor Practice Indicators'], 0.8834145069122314)","('NON-ESG', 0.041580285876989365)","('NON-ESG', 0.013583597727119923)"
Line 656,"Next analysis scheduled for 2023.
","('Management_Of_Legal_And_Regulatory_Framework', 0.4277056157588959)","('Physical_Impacts_Of_Climate_Change', 0.06601756811141968)","('GHG_Emissions', 0.06443533301353455)","('NON-ESG', 0.4277056157588959)","('NON-ESG', 0.06601756811141968)","('NON-ESG', 0.06443533301353455)"
Line 657,"2 2019 number restated.
","('Data_Security', 0.1892126351594925)","('Customer_Privacy', 0.1204029992222786)","('Director_Removal', 0.10138624906539917)","('NON-ESG', 0.1892126351594925)","('NON-ESG', 0.1204029992222786)","('NON-ESG', 0.10138624906539917)"
Line 658,"3 Vesting for options and restricted units is four years (25% per year).
","('Management_Of_Legal_And_Regulatory_Framework', 0.614967942237854)","('Competitive_Behavior', 0.0818130224943161)","('Employee_Engagement_Inclusion_And_Diversity', 0.04145408049225807)","(['Corporate Governance'], 0.614967942237854)","('NON-ESG', 0.0818130224943161)","('NON-ESG', 0.04145408049225807)"
Line 659,"Boston Scientific changed from 5-year to 4-year award vesting beginning  with RSUs granted in FY 2019.
","('Management_Of_Legal_And_Regulatory_Framework', 0.718625545501709)","('Ecological_Impacts', 0.03321913257241249)","('Competitive_Behavior', 0.03243579715490341)","(['Corporate Governance'], 0.718625545501709)","('NON-ESG', 0.03321913257241249)","('NON-ESG', 0.03243579715490341)"
Line 660,"Half of the value delivered to executives is through performance share units which have a three-year cliff vest.
","('Business_Model_Resilience', 0.3565957248210907)","('Systemic_Risk_Management', 0.20552977919578552)","('Competitive_Behavior', 0.06526139378547668)","('NON-ESG', 0.3565957248210907)","('NON-ESG', 0.20552977919578552)","('NON-ESG', 0.06526139378547668)"
Line 661,"4 Inclusive of global indirect labor employees only.
","('Labor_Practices', 0.9739340543746948)","('Director_Removal', 0.0030360210221260786)","('Employee_Engagement_Inclusion_And_Diversity', 0.0024835693184286356)","(['Labor Practice Indicators'], 0.9739340543746948)","('NON-ESG', 0.0030360210221260786)","('NON-ESG', 0.0024835693184286356)"
Line 662,"2021 Performance ReportIntroduction Transforming care Investing in   our people Accelerating   possibilities Protecting the  environment Creating value  responsibly Appendix Stakeholder engagement Metrics summary Global Reporting Initiative  (GRI) index Sustainability Accounting  Standards Board   (SASB) index United Nations  Sustainable Development  Goals (SDGs) Employee health and safety Unit 2018 2019 2020 Work-related fatalities — employees # 0.0 0.0 0.0 0.Work-related fatalities — contractors # 0.0 0.0 0.0 0.Total Recordable Incident Rate (TRIR) Injuries per  100 employees0.5 0.5 0.5 0.Total Recordable Injury Frequency Rate (TRIFR) Injuries per 1 million   hours worked2.6 2.7 2.3 2.Lost Time Injury Frequency Rate (LTIFR) Lost time injuries per   1 million hours worked2.623.0 1.7 1.Occupational Lost Time Rate (OLTR) Lost time days per   100 employees5.235.9 4.7 4.TRIR, TRIFR, LTIFR and OLTR rate coverage Percent of employees 66.0 66.0 67.0 98.0Investing in our people 1 For 2021, Boston Scientific expanded the relevant headcount in scope for TRIR, TRIFR, LTIFR  and OLTR reporting to include 98% of our population.
","('Employee_Health_And_Safety', 0.9836573004722595)","('Employee_Engagement_Inclusion_And_Diversity', 0.0018404180882498622)","('Critical_Incident_Risk_Management', 0.0014467514120042324)","(['Operational Eco-Efficiency'], 0.9836573004722595)","('NON-ESG', 0.0018404180882498622)","('NON-ESG', 0.0014467514120042324)"
Line 663,"2021 Performance ReportIntroduction Transforming care Investing in   our people Accelerating   possibilities Protecting the  environment Creating value  responsibly Appendix Stakeholder engagement Metrics summary Global Reporting Initiative  (GRI) index Sustainability Accounting  Standards Board   (SASB) index United Nations  Sustainable Development  Goals (SDGs) Employee health and safety Unit 2018 2019 2020 Work-related fatalities — employees # 0.0 0.0 0.0 0.Work-related fatalities — contractors # 0.0 0.0 0.0 0.Total Recordable Incident Rate (TRIR) Injuries per  100 employees0.5 0.5 0.5 0.Total Recordable Injury Frequency Rate (TRIFR) Injuries per 1 million   hours worked2.6 2.7 2.3 2.Lost Time Injury Frequency Rate (LTIFR) Lost time injuries per   1 million hours worked2.623.0 1.7 1.Occupational Lost Time Rate (OLTR) Lost time days per   100 employees5.235.9 4.7 4.TRIR, TRIFR, LTIFR and OLTR rate coverage Percent of employees 66.0 66.0 67.0 98.0Investing in our people 1 For 2021, Boston Scientific expanded the relevant headcount in scope for TRIR, TRIFR, LTIFR  and OLTR reporting to include 98% of our population.
","('Employee_Health_And_Safety', 0.9829508662223816)","('Employee_Engagement_Inclusion_And_Diversity', 0.001994228921830654)","('Product_Design_And_Lifecycle_Management', 0.0012401138665154576)","(['Operational Eco-Efficiency'], 0.9829508662223816)","('NON-ESG', 0.001994228921830654)","('NON-ESG', 0.0012401138665154576)"
Line 664,"2021 Performance ReportIntroduction Transforming care Investing in   our people Accelerating   possibilities Protecting the  environment Creating value  responsibly Appendix Stakeholder engagement Metrics summary Global Reporting Initiative  (GRI) index Sustainability Accounting  Standards Board   (SASB) index United Nations  Sustainable Development  Goals (SDGs) Employee health and safety Unit 2018 2019 2020 Work-related fatalities — employees # 0.0 0.0 0.0 0.Work-related fatalities — contractors # 0.0 0.0 0.0 0.Total Recordable Incident Rate (TRIR) Injuries per  100 employees0.5 0.5 0.5 0.Total Recordable Injury Frequency Rate (TRIFR) Injuries per 1 million   hours worked2.6 2.7 2.3 2.Lost Time Injury Frequency Rate (LTIFR) Lost time injuries per   1 million hours worked2.623.0 1.7 1.Occupational Lost Time Rate (OLTR) Lost time days per   100 employees5.235.9 4.7 4.TRIR, TRIFR, LTIFR and OLTR rate coverage Percent of employees 66.0 66.0 67.0 98.0Investing in our people 1 For 2021, Boston Scientific expanded the relevant headcount in scope for TRIR, TRIFR, LTIFR  and OLTR reporting to include 98% of our population.
","('Management_Of_Legal_And_Regulatory_Framework', 0.3020455241203308)","('Access_And_Affordability', 0.12331649661064148)","('Systemic_Risk_Management', 0.08006176352500916)","('NON-ESG', 0.3020455241203308)","('NON-ESG', 0.12331649661064148)","('NON-ESG', 0.08006176352500916)"
Line 665,"2 OLTR figures include lost and restricted time injuries.
","('Employee_Health_And_Safety', 0.9787565469741821)","('Employee_Engagement_Inclusion_And_Diversity', 0.002130876062437892)","('Critical_Incident_Risk_Management', 0.0019323690794408321)","(['Operational Eco-Efficiency'], 0.9787565469741821)","('NON-ESG', 0.002130876062437892)","('NON-ESG', 0.0019323690794408321)"
Line 666,"3 LTIFR includes all injuries.
","('Employee_Health_And_Safety', 0.9751560091972351)","('Critical_Incident_Risk_Management', 0.003904770128428936)","('Employee_Engagement_Inclusion_And_Diversity', 0.001920421258546412)","(['Operational Eco-Efficiency'], 0.9751560091972351)","('NON-ESG', 0.003904770128428936)","('NON-ESG', 0.001920421258546412)"
Line 667,"2021 Performance ReportIntroduction Transforming care Investing in   our people Accelerating   possibilities Protecting the  environment Creating value  responsibly Appendix Stakeholder engagement Metrics summary Global Reporting Initiative  (GRI) index Sustainability Accounting  Standards Board   (SASB) index United Nations  Sustainable Development  Goals (SDGs) Community engagement Unit 2018 2019 2020 Monetary value of philanthropic cash contributions1  USD millions 8.90 8.14 9.04 7.Boston Scientific Foundation (U.S.) cash contributions USD millions 1.07 1.19 1.21 1.Employee volunteering hours Hours 43,000 41,000 23,000 51,Overhead costs for management of philanthropic activities USD millions 0.068 0.067 0.200¹ 0.Environmental impact3Unit 2018 2019 2020 Total municipal water consumed Million cubic meters 0.568 0.581 0.618 0.Total fresh water consumed Million cubic meters 0.121 0.109 0.119 0.Total process water discharged Million cubic meters 0.057 0.068 0.109 0.Total domestic water discharged Million cubic meters 0.412 0.430 0.511 0.Water intensity Cubic meters/  USD millions revenue70 64 74 Total non-hazardous and hazardous waste generated Metric tons 12,372 12,196 10,936 12,Total non-hazardous waste generated Metric tons 11,579 11,200 9,978 11,703Accelerating possibilities Protecting the environment 1 This includes donations to HCP and non-HCP charitable organizations and does not include any medical grant, research grant or fellowship funding.
","('Human_Rights_And_Community_Relations', 0.789872407913208)","('Access_And_Affordability', 0.04251058027148247)","('Management_Of_Legal_And_Regulatory_Framework', 0.03520740568637848)","(['Community Relations'], 0.789872407913208)","('NON-ESG', 0.04251058027148247)","('NON-ESG', 0.03520740568637848)"
Line 668,"2021 Performance ReportIntroduction Transforming care Investing in   our people Accelerating   possibilities Protecting the  environment Creating value  responsibly Appendix Stakeholder engagement Metrics summary Global Reporting Initiative  (GRI) index Sustainability Accounting  Standards Board   (SASB) index United Nations  Sustainable Development  Goals (SDGs) Community engagement Unit 2018 2019 2020 Monetary value of philanthropic cash contributions1  USD millions 8.90 8.14 9.04 7.Boston Scientific Foundation (U.S.) cash contributions USD millions 1.07 1.19 1.21 1.Employee volunteering hours Hours 43,000 41,000 23,000 51,Overhead costs for management of philanthropic activities USD millions 0.068 0.067 0.200¹ 0.Environmental impact3Unit 2018 2019 2020 Total municipal water consumed Million cubic meters 0.568 0.581 0.618 0.Total fresh water consumed Million cubic meters 0.121 0.109 0.119 0.Total process water discharged Million cubic meters 0.057 0.068 0.109 0.Total domestic water discharged Million cubic meters 0.412 0.430 0.511 0.Water intensity Cubic meters/  USD millions revenue70 64 74 Total non-hazardous and hazardous waste generated Metric tons 12,372 12,196 10,936 12,Total non-hazardous waste generated Metric tons 11,579 11,200 9,978 11,703Accelerating possibilities Protecting the environment 1 This includes donations to HCP and non-HCP charitable organizations and does not include any medical grant, research grant or fellowship funding.
","('Water_And_Wastewater_Management', 0.9765207171440125)","('Waste_And_Hazardous_Materials_Management', 0.002144333440810442)","('Energy_Management', 0.002001351909711957)","(['Operational Eco-Efficiency'], 0.9765207171440125)","('NON-ESG', 0.002144333440810442)","('NON-ESG', 0.002001351909711957)"
Line 669,"2021 Performance ReportIntroduction Transforming care Investing in   our people Accelerating   possibilities Protecting the  environment Creating value  responsibly Appendix Stakeholder engagement Metrics summary Global Reporting Initiative  (GRI) index Sustainability Accounting  Standards Board   (SASB) index United Nations  Sustainable Development  Goals (SDGs) Community engagement Unit 2018 2019 2020 Monetary value of philanthropic cash contributions1  USD millions 8.90 8.14 9.04 7.Boston Scientific Foundation (U.S.) cash contributions USD millions 1.07 1.19 1.21 1.Employee volunteering hours Hours 43,000 41,000 23,000 51,Overhead costs for management of philanthropic activities USD millions 0.068 0.067 0.200¹ 0.Environmental impact3Unit 2018 2019 2020 Total municipal water consumed Million cubic meters 0.568 0.581 0.618 0.Total fresh water consumed Million cubic meters 0.121 0.109 0.119 0.Total process water discharged Million cubic meters 0.057 0.068 0.109 0.Total domestic water discharged Million cubic meters 0.412 0.430 0.511 0.Water intensity Cubic meters/  USD millions revenue70 64 74 Total non-hazardous and hazardous waste generated Metric tons 12,372 12,196 10,936 12,Total non-hazardous waste generated Metric tons 11,579 11,200 9,978 11,703Accelerating possibilities Protecting the environment 1 This includes donations to HCP and non-HCP charitable organizations and does not include any medical grant, research grant or fellowship funding.
","('Waste_And_Hazardous_Materials_Management', 0.9848496913909912)","('Water_And_Wastewater_Management', 0.001204016269184649)","('Employee_Health_And_Safety', 0.001055180560797453)","(['Operational Eco-Efficiency'], 0.9848496913909912)","('NON-ESG', 0.001204016269184649)","('NON-ESG', 0.001055180560797453)"
Line 670,"2 2020 and 2021 data includes community engagement, sales charitable contributions committee costs and foundation consultant fees.
","('Management_Of_Legal_And_Regulatory_Framework', 0.5684521794319153)","('Human_Rights_And_Community_Relations', 0.13568267226219177)","('Access_And_Affordability', 0.05921727046370506)","(['Corporate Governance'], 0.5684521794319153)","('NON-ESG', 0.13568267226219177)","('NON-ESG', 0.05921727046370506)"
Line 671,"3 Environmental impact metrics coverage includes Scope 1 and 2 from our manufacturing and key distribution sites only, which represent greater than 75% of business revenues.
","('Supply_Chain_Management', 0.41601458191871643)","('Product_Design_And_Lifecycle_Management', 0.2721547484397888)","('Business_Model_Resilience', 0.09591858834028244)","('NON-ESG', 0.41601458191871643)","('NON-ESG', 0.2721547484397888)","('NON-ESG', 0.09591858834028244)"
Line 672,"2021 Performance ReportIntroduction Transforming care Investing in   our people Accelerating   possibilities Protecting the  environment Creating value  responsibly Appendix Stakeholder engagement Metrics summary Global Reporting Initiative  (GRI) index Sustainability Accounting  Standards Board   (SASB) index United Nations  Sustainable Development  Goals (SDGs) Environmental impact1Unit 2018 2019 2020 Total non-hazardous waste recycled Metric tons 9,667 8,943 7,843 8,Total non-hazardous waste energy recovered Metric tons 1,332 1,744 1,545 1,Total non-hazardous waste disposed to landfill Metric tons 581 514 591 1,Total hazardous waste generated Metric tons 792 996 958 1,Total hazardous waste recovered Metric tons 76 57 94 Total hazardous waste energy recovered Metric tons 310 362 376 Total hazardous waste treatment Metric tons 247 240 292 Total hazardous waste incinerated Metric tons 135 218 152 Total hazardous waste landfilled Metric tons 0 0 14 Total hazardous waste recycled Metric tons 24 119 29 Environmental notice of violation # 0 3 0 0Protecting the environment 1 Environmental impact metrics coverage includes Scope 1 and 2 from our manufacturing and key distribution sites only, which represent greater than 75% of business revenues.
","('Waste_And_Hazardous_Materials_Management', 0.983180582523346)","('Employee_Health_And_Safety', 0.0013368793297559023)","('Water_And_Wastewater_Management', 0.001286737504415214)","(['Operational Eco-Efficiency'], 0.983180582523346)","('NON-ESG', 0.0013368793297559023)","('NON-ESG', 0.001286737504415214)"
Line 673,"2021 Performance ReportIntroduction Transforming care Investing in   our people Accelerating   possibilities Protecting the  environment Creating value  responsibly Appendix Stakeholder engagement Metrics summary Global Reporting Initiative  (GRI) index Sustainability Accounting  Standards Board   (SASB) index United Nations  Sustainable Development  Goals (SDGs) Environmental impact1Unit 2018 2019 2020 Total non-hazardous waste recycled Metric tons 9,667 8,943 7,843 8,Total non-hazardous waste energy recovered Metric tons 1,332 1,744 1,545 1,Total non-hazardous waste disposed to landfill Metric tons 581 514 591 1,Total hazardous waste generated Metric tons 792 996 958 1,Total hazardous waste recovered Metric tons 76 57 94 Total hazardous waste energy recovered Metric tons 310 362 376 Total hazardous waste treatment Metric tons 247 240 292 Total hazardous waste incinerated Metric tons 135 218 152 Total hazardous waste landfilled Metric tons 0 0 14 Total hazardous waste recycled Metric tons 24 119 29 Environmental notice of violation # 0 3 0 0Protecting the environment 1 Environmental impact metrics coverage includes Scope 1 and 2 from our manufacturing and key distribution sites only, which represent greater than 75% of business revenues.
","('Waste_And_Hazardous_Materials_Management', 0.9848226308822632)","('Water_And_Wastewater_Management', 0.0011460129171609879)","('Air_Quality', 0.0010122376261278987)","(['Operational Eco-Efficiency'], 0.9848226308822632)","('NON-ESG', 0.0011460129171609879)","('NON-ESG', 0.0010122376261278987)"
Line 674,"2021 Performance ReportIntroduction Transforming care Investing in   our people Accelerating   possibilities Protecting the  environment Creating value  responsibly Appendix Stakeholder engagement Metrics summary Global Reporting Initiative  (GRI) index Sustainability Accounting  Standards Board   (SASB) index United Nations  Sustainable Development  Goals (SDGs) Environmental impact1Unit 2018 2019 2020 Total non-hazardous waste recycled Metric tons 9,667 8,943 7,843 8,Total non-hazardous waste energy recovered Metric tons 1,332 1,744 1,545 1,Total non-hazardous waste disposed to landfill Metric tons 581 514 591 1,Total hazardous waste generated Metric tons 792 996 958 1,Total hazardous waste recovered Metric tons 76 57 94 Total hazardous waste energy recovered Metric tons 310 362 376 Total hazardous waste treatment Metric tons 247 240 292 Total hazardous waste incinerated Metric tons 135 218 152 Total hazardous waste landfilled Metric tons 0 0 14 Total hazardous waste recycled Metric tons 24 119 29 Environmental notice of violation # 0 3 0 0Protecting the environment 1 Environmental impact metrics coverage includes Scope 1 and 2 from our manufacturing and key distribution sites only, which represent greater than 75% of business revenues.
","('Supply_Chain_Management', 0.2333769053220749)","('Business_Model_Resilience', 0.17357395589351654)","('Physical_Impacts_Of_Climate_Change', 0.1306707113981247)","('NON-ESG', 0.2333769053220749)","('NON-ESG', 0.17357395589351654)","('NON-ESG', 0.1306707113981247)"
Line 675,"2021 Performance ReportIntroduction Transforming care Investing in   our people Accelerating   possibilities Protecting the  environment Creating value  responsibly Appendix Stakeholder engagement Metrics summary Global Reporting Initiative  (GRI) index Sustainability Accounting  Standards Board   (SASB) index United Nations  Sustainable Development  Goals (SDGs) Climate change1Unit 2018 2019 2020 Total direct greenhouse gas emissions (Scope 1) CO2 equivalent metric tons 31,257 34,168 35,908 35,395  Total indirect greenhouse gas emissions (Scope 2) CO2 equivalent metric tons 53,870 50,611 17,823 16,Non-renewable fuels consumed mWh 170,495 186,393 191,645 192,Total electricity purchased mWh 181,587 187,736 185,329 205,Total renewable electricity purchased mWh 9,149 22,508 131,8962149,Total energy use gWh 355 368 381 Green real estate3Percent 32 41 42 Number of LEED certified / registered buildings # 13 13 15 Number of ISO 50001:2018 certified sites # 2 5 6 Number of ISO 14001:2015 certified sites # 15 15 16 Carbon footprint (Scopes 1 and 2) Metric tons 85,127 84,778 53,730 52,Renewable electricity purchased with renewable energy certificates Percent 5 11 71 Renewable energy (all sources) used with renewable energy certificates Percent 3 6 35 Energy intensity % MWh/  USD millions revenue36  34 38 33Protecting the environment 1 Climate change metrics coverage includes Scope 1 and 2 from our manufacturing and key distribution sites only, which represent greater than 75% of business revenues.
","('GHG_Emissions', 0.9512163996696472)","('Ecological_Impacts', 0.009733744896948338)","('Physical_Impacts_Of_Climate_Change', 0.007971876300871372)","(['Climate Change'], 0.9512163996696472)","('NON-ESG', 0.009733744896948338)","('NON-ESG', 0.007971876300871372)"
Line 676,"2021 Performance ReportIntroduction Transforming care Investing in   our people Accelerating   possibilities Protecting the  environment Creating value  responsibly Appendix Stakeholder engagement Metrics summary Global Reporting Initiative  (GRI) index Sustainability Accounting  Standards Board   (SASB) index United Nations  Sustainable Development  Goals (SDGs) Climate change1Unit 2018 2019 2020 Total direct greenhouse gas emissions (Scope 1) CO2 equivalent metric tons 31,257 34,168 35,908 35,395  Total indirect greenhouse gas emissions (Scope 2) CO2 equivalent metric tons 53,870 50,611 17,823 16,Non-renewable fuels consumed mWh 170,495 186,393 191,645 192,Total electricity purchased mWh 181,587 187,736 185,329 205,Total renewable electricity purchased mWh 9,149 22,508 131,8962149,Total energy use gWh 355 368 381 Green real estate3Percent 32 41 42 Number of LEED certified / registered buildings # 13 13 15 Number of ISO 50001:2018 certified sites # 2 5 6 Number of ISO 14001:2015 certified sites # 15 15 16 Carbon footprint (Scopes 1 and 2) Metric tons 85,127 84,778 53,730 52,Renewable electricity purchased with renewable energy certificates Percent 5 11 71 Renewable energy (all sources) used with renewable energy certificates Percent 3 6 35 Energy intensity % MWh/  USD millions revenue36  34 38 33Protecting the environment 1 Climate change metrics coverage includes Scope 1 and 2 from our manufacturing and key distribution sites only, which represent greater than 75% of business revenues.
","('GHG_Emissions', 0.9432047009468079)","('Management_Of_Legal_And_Regulatory_Framework', 0.008223804645240307)","('Ecological_Impacts', 0.006401737220585346)","(['Climate Change'], 0.9432047009468079)","('NON-ESG', 0.008223804645240307)","('NON-ESG', 0.006401737220585346)"
Line 677,"2021 Performance ReportIntroduction Transforming care Investing in   our people Accelerating   possibilities Protecting the  environment Creating value  responsibly Appendix Stakeholder engagement Metrics summary Global Reporting Initiative  (GRI) index Sustainability Accounting  Standards Board   (SASB) index United Nations  Sustainable Development  Goals (SDGs) Climate change1Unit 2018 2019 2020 Total direct greenhouse gas emissions (Scope 1) CO2 equivalent metric tons 31,257 34,168 35,908 35,395  Total indirect greenhouse gas emissions (Scope 2) CO2 equivalent metric tons 53,870 50,611 17,823 16,Non-renewable fuels consumed mWh 170,495 186,393 191,645 192,Total electricity purchased mWh 181,587 187,736 185,329 205,Total renewable electricity purchased mWh 9,149 22,508 131,8962149,Total energy use gWh 355 368 381 Green real estate3Percent 32 41 42 Number of LEED certified / registered buildings # 13 13 15 Number of ISO 50001:2018 certified sites # 2 5 6 Number of ISO 14001:2015 certified sites # 15 15 16 Carbon footprint (Scopes 1 and 2) Metric tons 85,127 84,778 53,730 52,Renewable electricity purchased with renewable energy certificates Percent 5 11 71 Renewable energy (all sources) used with renewable energy certificates Percent 3 6 35 Energy intensity % MWh/  USD millions revenue36  34 38 33Protecting the environment 1 Climate change metrics coverage includes Scope 1 and 2 from our manufacturing and key distribution sites only, which represent greater than 75% of business revenues.
","('Physical_Impacts_Of_Climate_Change', 0.9100667834281921)","('GHG_Emissions', 0.013007541187107563)","('Business_Model_Resilience', 0.012470233254134655)","(['Climate Change'], 0.9100667834281921)","('NON-ESG', 0.013007541187107563)","('NON-ESG', 0.012470233254134655)"
Line 678,"2 2020 figure restated.
","('Management_Of_Legal_And_Regulatory_Framework', 0.7305602431297302)","('Energy_Management', 0.04166737198829651)","('GHG_Emissions', 0.0356040857732296)","(['Corporate Governance'], 0.7305602431297302)","('NON-ESG', 0.04166737198829651)","('NON-ESG', 0.0356040857732296)"
Line 679,"3  Green real estate: percentage of Boston Scientific real estate that is independently certified for energy efficiency by industry-leading bodies such as LEED for design and Energy Star  or ISO 50001:2018 for building operations 4 Reflects adjustments to previously reported figure of 72% renewable electricity and 53.7k metric tons CO2 in our 2022 Annual Proxy Statement, based on subsequent internal audit.
","('Energy_Management', 0.979592502117157)","('Air_Quality', 0.0021469788625836372)","('Management_Of_Legal_And_Regulatory_Framework', 0.0017006781417876482)","(['Operational Eco-Efficiency'], 0.979592502117157)","('NON-ESG', 0.0021469788625836372)","('NON-ESG', 0.0017006781417876482)"
Line 680,"2021 Performance ReportIntroduction Transforming care Investing in   our people Accelerating   possibilities Protecting the  environment Creating value  responsibly Appendix Stakeholder engagement Metrics summary Global Reporting Initiative  (GRI) index Sustainability Accounting  Standards Board   (SASB) index United Nations  Sustainable Development  Goals (SDGs) Responsible supply chain Unit 2018 2019 2020 Total number of suppliers identified as Tier 1 # 1,498 1,650 1,489 1,Percentage of suppliers identified as Tier 1 Percent 100 100 100 Total number of Tier 1 suppliers identified as critical # 153 141 137 Percentage of Tier 1 suppliers identified as critical Percent 10.2 8.6 9.2 9.Supplier scorecard risk assessment — total number of Tier 1   suppliers assessed in last three years # 393 333 337 Supplier scorecard risk assessment — percentage of Tier 1   suppliers assessed in last three years Percent 26.3 20.2 22.6 23.Comprehensive assessment of critical (Tier 1 and Non-Tier 1) suppliers annually Percent 10.2 8.6 9.2 9.Comprehensive assessment of critical (Tier 1 and Non-Tier 1)   suppliers in the last three yearsPercent 26.2 20.2 22.6 23.Compliance Unit 2018 2019 2020 Anti-competitive practices fines Yes/No No No No No Corruption and bribery cases # 0 0 0 Earnings before tax USD millions 1,422 687 -79 1,Reported taxes USD millions -249 -4,013 2 Reported tax rate Percent -17.5 -584.0 2.9 3.Cash taxes paid USD millions 1,037 242 207 Upheld regulatory complaints concerning marketing and selling practices # 0 0 0 Upheld self-regulatory complaints concerning marketing and selling practices # 0 0 0 0Creating value responsibly 2021 Performance ReportIntroduction Transforming care Investing in   our people Accelerating   possibilities Protecting the  environment Creating value  responsibly Appendix Stakeholder engagement Metrics summary Global Reporting Initiative  (GRI) index Sustainability Accounting  Standards Board   (SASB) index United Nations  Sustainable Development  Goals (SDGs) Governance Unit 2018 2019 2020 Number of executive directors # 1 1 1 Number of independent directors # 9 9 9 Number of women executives # 3 3 4 Average tenure of independent board members (years) # 5 6 7 No. of non-executive/independent directors who sit on   four or less public company boards, including Boston Scientific# 9 9 8 No. of public company boards outside of Boston Scientific   on which non-executive/independent directors can sit¹# 3 3 3 Performance period covered by Executive Compensation Plan Years 3 3 3 Clawback provision for Executive Compensation Plan Yes/No Yes Yes Yes Yes Reporting rights per 1 share (based on Form 10-K) Number of votes 1,385,961,926 1,396,195,349 1,417,165,707 1,426,724,Total annual CEO compensation USD millions 13.97 15.76 13.77 16.Median annual compensation for all employees USD thousands 62.5 65.6 59.3 68.Lobbying USD millions 1.68 1.68 1.52 1.Lobbying — local, regional or national political campaigns USD millions 0.27 0.26 0.25 0.Lobbying — trade associations USD millions 0.14 0.14 0.13 0.21Creating value responsibly 1 Without the approval of the Nominating and Governance Committee, no director may sit on more than four public company boards (including the Company’s board).
","('Supply_Chain_Management', 0.9380099773406982)","('Product_Design_And_Lifecycle_Management', 0.009276863187551498)","('Labor_Practices', 0.0041717165149748325)","(['Supply Chain Management'], 0.9380099773406982)","('NON-ESG', 0.009276863187551498)","('NON-ESG', 0.0041717165149748325)"
Line 681,"2021 Performance ReportIntroduction Transforming care Investing in   our people Accelerating   possibilities Protecting the  environment Creating value  responsibly Appendix Stakeholder engagement Metrics summary Global Reporting Initiative  (GRI) index Sustainability Accounting  Standards Board   (SASB) index United Nations  Sustainable Development  Goals (SDGs) Responsible supply chain Unit 2018 2019 2020 Total number of suppliers identified as Tier 1 # 1,498 1,650 1,489 1,Percentage of suppliers identified as Tier 1 Percent 100 100 100 Total number of Tier 1 suppliers identified as critical # 153 141 137 Percentage of Tier 1 suppliers identified as critical Percent 10.2 8.6 9.2 9.Supplier scorecard risk assessment — total number of Tier 1   suppliers assessed in last three years # 393 333 337 Supplier scorecard risk assessment — percentage of Tier 1   suppliers assessed in last three years Percent 26.3 20.2 22.6 23.Comprehensive assessment of critical (Tier 1 and Non-Tier 1) suppliers annually Percent 10.2 8.6 9.2 9.Comprehensive assessment of critical (Tier 1 and Non-Tier 1)   suppliers in the last three yearsPercent 26.2 20.2 22.6 23.Compliance Unit 2018 2019 2020 Anti-competitive practices fines Yes/No No No No No Corruption and bribery cases # 0 0 0 Earnings before tax USD millions 1,422 687 -79 1,Reported taxes USD millions -249 -4,013 2 Reported tax rate Percent -17.5 -584.0 2.9 3.Cash taxes paid USD millions 1,037 242 207 Upheld regulatory complaints concerning marketing and selling practices # 0 0 0 Upheld self-regulatory complaints concerning marketing and selling practices # 0 0 0 0Creating value responsibly 2021 Performance ReportIntroduction Transforming care Investing in   our people Accelerating   possibilities Protecting the  environment Creating value  responsibly Appendix Stakeholder engagement Metrics summary Global Reporting Initiative  (GRI) index Sustainability Accounting  Standards Board   (SASB) index United Nations  Sustainable Development  Goals (SDGs) Governance Unit 2018 2019 2020 Number of executive directors # 1 1 1 Number of independent directors # 9 9 9 Number of women executives # 3 3 4 Average tenure of independent board members (years) # 5 6 7 No. of non-executive/independent directors who sit on   four or less public company boards, including Boston Scientific# 9 9 8 No. of public company boards outside of Boston Scientific   on which non-executive/independent directors can sit¹# 3 3 3 Performance period covered by Executive Compensation Plan Years 3 3 3 Clawback provision for Executive Compensation Plan Yes/No Yes Yes Yes Yes Reporting rights per 1 share (based on Form 10-K) Number of votes 1,385,961,926 1,396,195,349 1,417,165,707 1,426,724,Total annual CEO compensation USD millions 13.97 15.76 13.77 16.Median annual compensation for all employees USD thousands 62.5 65.6 59.3 68.Lobbying USD millions 1.68 1.68 1.52 1.Lobbying — local, regional or national political campaigns USD millions 0.27 0.26 0.25 0.Lobbying — trade associations USD millions 0.14 0.14 0.13 0.21Creating value responsibly 1 Without the approval of the Nominating and Governance Committee, no director may sit on more than four public company boards (including the Company’s board).
","('Supply_Chain_Management', 0.9425485730171204)","('Water_And_Wastewater_Management', 0.0048774536699056625)","('Employee_Health_And_Safety', 0.004715932533144951)","(['Supply Chain Management'], 0.9425485730171204)","('NON-ESG', 0.0048774536699056625)","('NON-ESG', 0.004715932533144951)"
Line 682,"2021 Performance ReportIntroduction Transforming care Investing in   our people Accelerating   possibilities Protecting the  environment Creating value  responsibly Appendix Stakeholder engagement Metrics summary Global Reporting Initiative  (GRI) index Sustainability Accounting  Standards Board   (SASB) index United Nations  Sustainable Development  Goals (SDGs) Responsible supply chain Unit 2018 2019 2020 Total number of suppliers identified as Tier 1 # 1,498 1,650 1,489 1,Percentage of suppliers identified as Tier 1 Percent 100 100 100 Total number of Tier 1 suppliers identified as critical # 153 141 137 Percentage of Tier 1 suppliers identified as critical Percent 10.2 8.6 9.2 9.Supplier scorecard risk assessment — total number of Tier 1   suppliers assessed in last three years # 393 333 337 Supplier scorecard risk assessment — percentage of Tier 1   suppliers assessed in last three years Percent 26.3 20.2 22.6 23.Comprehensive assessment of critical (Tier 1 and Non-Tier 1) suppliers annually Percent 10.2 8.6 9.2 9.Comprehensive assessment of critical (Tier 1 and Non-Tier 1)   suppliers in the last three yearsPercent 26.2 20.2 22.6 23.Compliance Unit 2018 2019 2020 Anti-competitive practices fines Yes/No No No No No Corruption and bribery cases # 0 0 0 Earnings before tax USD millions 1,422 687 -79 1,Reported taxes USD millions -249 -4,013 2 Reported tax rate Percent -17.5 -584.0 2.9 3.Cash taxes paid USD millions 1,037 242 207 Upheld regulatory complaints concerning marketing and selling practices # 0 0 0 Upheld self-regulatory complaints concerning marketing and selling practices # 0 0 0 0Creating value responsibly 2021 Performance ReportIntroduction Transforming care Investing in   our people Accelerating   possibilities Protecting the  environment Creating value  responsibly Appendix Stakeholder engagement Metrics summary Global Reporting Initiative  (GRI) index Sustainability Accounting  Standards Board   (SASB) index United Nations  Sustainable Development  Goals (SDGs) Governance Unit 2018 2019 2020 Number of executive directors # 1 1 1 Number of independent directors # 9 9 9 Number of women executives # 3 3 4 Average tenure of independent board members (years) # 5 6 7 No. of non-executive/independent directors who sit on   four or less public company boards, including Boston Scientific# 9 9 8 No. of public company boards outside of Boston Scientific   on which non-executive/independent directors can sit¹# 3 3 3 Performance period covered by Executive Compensation Plan Years 3 3 3 Clawback provision for Executive Compensation Plan Yes/No Yes Yes Yes Yes Reporting rights per 1 share (based on Form 10-K) Number of votes 1,385,961,926 1,396,195,349 1,417,165,707 1,426,724,Total annual CEO compensation USD millions 13.97 15.76 13.77 16.Median annual compensation for all employees USD thousands 62.5 65.6 59.3 68.Lobbying USD millions 1.68 1.68 1.52 1.Lobbying — local, regional or national political campaigns USD millions 0.27 0.26 0.25 0.Lobbying — trade associations USD millions 0.14 0.14 0.13 0.21Creating value responsibly 1 Without the approval of the Nominating and Governance Committee, no director may sit on more than four public company boards (including the Company’s board).
","('Business_Ethics', 0.9705772399902344)","('Management_Of_Legal_And_Regulatory_Framework', 0.005359813570976257)","('Competitive_Behavior', 0.002924340544268489)","(['Business Ethics'], 0.9705772399902344)","('NON-ESG', 0.005359813570976257)","('NON-ESG', 0.002924340544268489)"
Line 683,"2021 Performance ReportIntroduction Transforming care Investing in   our people Accelerating   possibilities Protecting the  environment Creating value  responsibly Appendix Stakeholder engagement Metrics summary Global Reporting Initiative  (GRI) index Sustainability Accounting  Standards Board   (SASB) index United Nations  Sustainable Development  Goals (SDGs) Responsible supply chain Unit 2018 2019 2020 Total number of suppliers identified as Tier 1 # 1,498 1,650 1,489 1,Percentage of suppliers identified as Tier 1 Percent 100 100 100 Total number of Tier 1 suppliers identified as critical # 153 141 137 Percentage of Tier 1 suppliers identified as critical Percent 10.2 8.6 9.2 9.Supplier scorecard risk assessment — total number of Tier 1   suppliers assessed in last three years # 393 333 337 Supplier scorecard risk assessment — percentage of Tier 1   suppliers assessed in last three years Percent 26.3 20.2 22.6 23.Comprehensive assessment of critical (Tier 1 and Non-Tier 1) suppliers annually Percent 10.2 8.6 9.2 9.Comprehensive assessment of critical (Tier 1 and Non-Tier 1)   suppliers in the last three yearsPercent 26.2 20.2 22.6 23.Compliance Unit 2018 2019 2020 Anti-competitive practices fines Yes/No No No No No Corruption and bribery cases # 0 0 0 Earnings before tax USD millions 1,422 687 -79 1,Reported taxes USD millions -249 -4,013 2 Reported tax rate Percent -17.5 -584.0 2.9 3.Cash taxes paid USD millions 1,037 242 207 Upheld regulatory complaints concerning marketing and selling practices # 0 0 0 Upheld self-regulatory complaints concerning marketing and selling practices # 0 0 0 0Creating value responsibly 2021 Performance ReportIntroduction Transforming care Investing in   our people Accelerating   possibilities Protecting the  environment Creating value  responsibly Appendix Stakeholder engagement Metrics summary Global Reporting Initiative  (GRI) index Sustainability Accounting  Standards Board   (SASB) index United Nations  Sustainable Development  Goals (SDGs) Governance Unit 2018 2019 2020 Number of executive directors # 1 1 1 Number of independent directors # 9 9 9 Number of women executives # 3 3 4 Average tenure of independent board members (years) # 5 6 7 No. of non-executive/independent directors who sit on   four or less public company boards, including Boston Scientific# 9 9 8 No. of public company boards outside of Boston Scientific   on which non-executive/independent directors can sit¹# 3 3 3 Performance period covered by Executive Compensation Plan Years 3 3 3 Clawback provision for Executive Compensation Plan Yes/No Yes Yes Yes Yes Reporting rights per 1 share (based on Form 10-K) Number of votes 1,385,961,926 1,396,195,349 1,417,165,707 1,426,724,Total annual CEO compensation USD millions 13.97 15.76 13.77 16.Median annual compensation for all employees USD thousands 62.5 65.6 59.3 68.Lobbying USD millions 1.68 1.68 1.52 1.Lobbying — local, regional or national political campaigns USD millions 0.27 0.26 0.25 0.Lobbying — trade associations USD millions 0.14 0.14 0.13 0.21Creating value responsibly 1 Without the approval of the Nominating and Governance Committee, no director may sit on more than four public company boards (including the Company’s board).
","('Management_Of_Legal_And_Regulatory_Framework', 0.8726322054862976)","('Business_Ethics', 0.02780023217201233)","('Competitive_Behavior', 0.011293641291558743)","(['Corporate Governance'], 0.8726322054862976)","('NON-ESG', 0.02780023217201233)","('NON-ESG', 0.011293641291558743)"
Line 684,"2021 Performance ReportIntroduction Transforming care Investing in   our people Accelerating   possibilities Protecting the  environment Creating value  responsibly Appendix Stakeholder engagement Metrics summary Global Reporting Initiative  (GRI) index Sustainability Accounting  Standards Board   (SASB) index United Nations  Sustainable Development  Goals (SDGs) Responsible supply chain Unit 2018 2019 2020 Total number of suppliers identified as Tier 1 # 1,498 1,650 1,489 1,Percentage of suppliers identified as Tier 1 Percent 100 100 100 Total number of Tier 1 suppliers identified as critical # 153 141 137 Percentage of Tier 1 suppliers identified as critical Percent 10.2 8.6 9.2 9.Supplier scorecard risk assessment — total number of Tier 1   suppliers assessed in last three years # 393 333 337 Supplier scorecard risk assessment — percentage of Tier 1   suppliers assessed in last three years Percent 26.3 20.2 22.6 23.Comprehensive assessment of critical (Tier 1 and Non-Tier 1) suppliers annually Percent 10.2 8.6 9.2 9.Comprehensive assessment of critical (Tier 1 and Non-Tier 1)   suppliers in the last three yearsPercent 26.2 20.2 22.6 23.Compliance Unit 2018 2019 2020 Anti-competitive practices fines Yes/No No No No No Corruption and bribery cases # 0 0 0 Earnings before tax USD millions 1,422 687 -79 1,Reported taxes USD millions -249 -4,013 2 Reported tax rate Percent -17.5 -584.0 2.9 3.Cash taxes paid USD millions 1,037 242 207 Upheld regulatory complaints concerning marketing and selling practices # 0 0 0 Upheld self-regulatory complaints concerning marketing and selling practices # 0 0 0 0Creating value responsibly 2021 Performance ReportIntroduction Transforming care Investing in   our people Accelerating   possibilities Protecting the  environment Creating value  responsibly Appendix Stakeholder engagement Metrics summary Global Reporting Initiative  (GRI) index Sustainability Accounting  Standards Board   (SASB) index United Nations  Sustainable Development  Goals (SDGs) Governance Unit 2018 2019 2020 Number of executive directors # 1 1 1 Number of independent directors # 9 9 9 Number of women executives # 3 3 4 Average tenure of independent board members (years) # 5 6 7 No. of non-executive/independent directors who sit on   four or less public company boards, including Boston Scientific# 9 9 8 No. of public company boards outside of Boston Scientific   on which non-executive/independent directors can sit¹# 3 3 3 Performance period covered by Executive Compensation Plan Years 3 3 3 Clawback provision for Executive Compensation Plan Yes/No Yes Yes Yes Yes Reporting rights per 1 share (based on Form 10-K) Number of votes 1,385,961,926 1,396,195,349 1,417,165,707 1,426,724,Total annual CEO compensation USD millions 13.97 15.76 13.77 16.Median annual compensation for all employees USD thousands 62.5 65.6 59.3 68.Lobbying USD millions 1.68 1.68 1.52 1.Lobbying — local, regional or national political campaigns USD millions 0.27 0.26 0.25 0.Lobbying — trade associations USD millions 0.14 0.14 0.13 0.21Creating value responsibly 1 Without the approval of the Nominating and Governance Committee, no director may sit on more than four public company boards (including the Company’s board).
","('Director_Removal', 0.7258578538894653)","('Labor_Practices', 0.060480181127786636)","('Employee_Engagement_Inclusion_And_Diversity', 0.027108237147331238)","(['Anti-Crime Policy & Measures'], 0.7258578538894653)","('NON-ESG', 0.060480181127786636)","('NON-ESG', 0.027108237147331238)"
Line 685,"2021 Performance ReportIntroduction Transforming care Investing in   our people Accelerating   possibilities Protecting the  environment Creating value  responsibly Appendix Stakeholder engagement Metrics summary Global Reporting Initiative  (GRI) index Sustainability Accounting  Standards Board   (SASB) index United Nations  Sustainable Development  Goals (SDGs) Responsible supply chain Unit 2018 2019 2020 Total number of suppliers identified as Tier 1 # 1,498 1,650 1,489 1,Percentage of suppliers identified as Tier 1 Percent 100 100 100 Total number of Tier 1 suppliers identified as critical # 153 141 137 Percentage of Tier 1 suppliers identified as critical Percent 10.2 8.6 9.2 9.Supplier scorecard risk assessment — total number of Tier 1   suppliers assessed in last three years # 393 333 337 Supplier scorecard risk assessment — percentage of Tier 1   suppliers assessed in last three years Percent 26.3 20.2 22.6 23.Comprehensive assessment of critical (Tier 1 and Non-Tier 1) suppliers annually Percent 10.2 8.6 9.2 9.Comprehensive assessment of critical (Tier 1 and Non-Tier 1)   suppliers in the last three yearsPercent 26.2 20.2 22.6 23.Compliance Unit 2018 2019 2020 Anti-competitive practices fines Yes/No No No No No Corruption and bribery cases # 0 0 0 Earnings before tax USD millions 1,422 687 -79 1,Reported taxes USD millions -249 -4,013 2 Reported tax rate Percent -17.5 -584.0 2.9 3.Cash taxes paid USD millions 1,037 242 207 Upheld regulatory complaints concerning marketing and selling practices # 0 0 0 Upheld self-regulatory complaints concerning marketing and selling practices # 0 0 0 0Creating value responsibly 2021 Performance ReportIntroduction Transforming care Investing in   our people Accelerating   possibilities Protecting the  environment Creating value  responsibly Appendix Stakeholder engagement Metrics summary Global Reporting Initiative  (GRI) index Sustainability Accounting  Standards Board   (SASB) index United Nations  Sustainable Development  Goals (SDGs) Governance Unit 2018 2019 2020 Number of executive directors # 1 1 1 Number of independent directors # 9 9 9 Number of women executives # 3 3 4 Average tenure of independent board members (years) # 5 6 7 No. of non-executive/independent directors who sit on   four or less public company boards, including Boston Scientific# 9 9 8 No. of public company boards outside of Boston Scientific   on which non-executive/independent directors can sit¹# 3 3 3 Performance period covered by Executive Compensation Plan Years 3 3 3 Clawback provision for Executive Compensation Plan Yes/No Yes Yes Yes Yes Reporting rights per 1 share (based on Form 10-K) Number of votes 1,385,961,926 1,396,195,349 1,417,165,707 1,426,724,Total annual CEO compensation USD millions 13.97 15.76 13.77 16.Median annual compensation for all employees USD thousands 62.5 65.6 59.3 68.Lobbying USD millions 1.68 1.68 1.52 1.Lobbying — local, regional or national political campaigns USD millions 0.27 0.26 0.25 0.Lobbying — trade associations USD millions 0.14 0.14 0.13 0.21Creating value responsibly 1 Without the approval of the Nominating and Governance Committee, no director may sit on more than four public company boards (including the Company’s board).
","('Labor_Practices', 0.7085054516792297)","('Business_Ethics', 0.054891690611839294)","('Management_Of_Legal_And_Regulatory_Framework', 0.040456388145685196)","(['Labor Practice Indicators'], 0.7085054516792297)","('NON-ESG', 0.054891690611839294)","('NON-ESG', 0.040456388145685196)"
Line 686,"2021 Performance ReportIntroduction Transforming care Investing in   our people Accelerating   possibilities Protecting the  environment Creating value  responsibly Appendix Stakeholder engagement Metrics summary Global Reporting Initiative  (GRI) index Sustainability Accounting  Standards Board   (SASB) index United Nations  Sustainable Development  Goals (SDGs) Responsible supply chain Unit 2018 2019 2020 Total number of suppliers identified as Tier 1 # 1,498 1,650 1,489 1,Percentage of suppliers identified as Tier 1 Percent 100 100 100 Total number of Tier 1 suppliers identified as critical # 153 141 137 Percentage of Tier 1 suppliers identified as critical Percent 10.2 8.6 9.2 9.Supplier scorecard risk assessment — total number of Tier 1   suppliers assessed in last three years # 393 333 337 Supplier scorecard risk assessment — percentage of Tier 1   suppliers assessed in last three years Percent 26.3 20.2 22.6 23.Comprehensive assessment of critical (Tier 1 and Non-Tier 1) suppliers annually Percent 10.2 8.6 9.2 9.Comprehensive assessment of critical (Tier 1 and Non-Tier 1)   suppliers in the last three yearsPercent 26.2 20.2 22.6 23.Compliance Unit 2018 2019 2020 Anti-competitive practices fines Yes/No No No No No Corruption and bribery cases # 0 0 0 Earnings before tax USD millions 1,422 687 -79 1,Reported taxes USD millions -249 -4,013 2 Reported tax rate Percent -17.5 -584.0 2.9 3.Cash taxes paid USD millions 1,037 242 207 Upheld regulatory complaints concerning marketing and selling practices # 0 0 0 Upheld self-regulatory complaints concerning marketing and selling practices # 0 0 0 0Creating value responsibly 2021 Performance ReportIntroduction Transforming care Investing in   our people Accelerating   possibilities Protecting the  environment Creating value  responsibly Appendix Stakeholder engagement Metrics summary Global Reporting Initiative  (GRI) index Sustainability Accounting  Standards Board   (SASB) index United Nations  Sustainable Development  Goals (SDGs) Governance Unit 2018 2019 2020 Number of executive directors # 1 1 1 Number of independent directors # 9 9 9 Number of women executives # 3 3 4 Average tenure of independent board members (years) # 5 6 7 No. of non-executive/independent directors who sit on   four or less public company boards, including Boston Scientific# 9 9 8 No. of public company boards outside of Boston Scientific   on which non-executive/independent directors can sit¹# 3 3 3 Performance period covered by Executive Compensation Plan Years 3 3 3 Clawback provision for Executive Compensation Plan Yes/No Yes Yes Yes Yes Reporting rights per 1 share (based on Form 10-K) Number of votes 1,385,961,926 1,396,195,349 1,417,165,707 1,426,724,Total annual CEO compensation USD millions 13.97 15.76 13.77 16.Median annual compensation for all employees USD thousands 62.5 65.6 59.3 68.Lobbying USD millions 1.68 1.68 1.52 1.Lobbying — local, regional or national political campaigns USD millions 0.27 0.26 0.25 0.Lobbying — trade associations USD millions 0.14 0.14 0.13 0.21Creating value responsibly 1 Without the approval of the Nominating and Governance Committee, no director may sit on more than four public company boards (including the Company’s board).
","('Director_Removal', 0.781380295753479)","('Management_Of_Legal_And_Regulatory_Framework', 0.05057654157280922)","('Business_Ethics', 0.0158537570387125)","(['Anti-Crime Policy & Measures'], 0.781380295753479)","('NON-ESG', 0.05057654157280922)","('NON-ESG', 0.0158537570387125)"
Line 687,"For more information, please review our Corporate Governance Guidelines.
","('Management_Of_Legal_And_Regulatory_Framework', 0.8822501301765442)","('Business_Ethics', 0.01898590847849846)","('Competitive_Behavior', 0.013148490339517593)","(['Corporate Governance'], 0.8822501301765442)","('NON-ESG', 0.01898590847849846)","('NON-ESG', 0.013148490339517593)"
Line 688,"2021 Performance ReportIntroduction Transforming care Investing in   our people Accelerating   possibilities Protecting the  environment Creating value  responsibly Appendix Stakeholder engagement Metrics summary Global Reporting Initiative  (GRI) index Sustainability Accounting  Standards Board   (SASB) index United Nations  Sustainable Development  Goals (SDGs) Indicator Description Response GRI 102-1 Name of the organization Boston Scientific Corporation 102-2 Activities, brands, products and services Form 10-K, Item 1.
","('Product_Design_And_Lifecycle_Management', 0.911820650100708)","('Product_Quality_And_Safety', 0.01372223999351263)","('Business_Model_Resilience', 0.010015450417995453)","(['Product Stewardship'], 0.911820650100708)","('NON-ESG', 0.01372223999351263)","('NON-ESG', 0.010015450417995453)"
Line 689,"2021 Performance ReportIntroduction Transforming care Investing in   our people Accelerating   possibilities Protecting the  environment Creating value  responsibly Appendix Stakeholder engagement Metrics summary Global Reporting Initiative  (GRI) index Sustainability Accounting  Standards Board   (SASB) index United Nations  Sustainable Development  Goals (SDGs) Indicator Description Response GRI 102-1 Name of the organization Boston Scientific Corporation 102-2 Activities, brands, products and services Form 10-K, Item 1.
","('Management_Of_Legal_And_Regulatory_Framework', 0.8662540316581726)","('Energy_Management', 0.016967620700597763)","('Labor_Practices', 0.010803074575960636)","(['Corporate Governance'], 0.8662540316581726)","('NON-ESG', 0.016967620700597763)","('NON-ESG', 0.010803074575960636)"
Line 690,"Business, Page 3  Performance Report, Boston Scientific: 2021 at a glance, Page 102-3 Location of headquarters 300 Boston Scientific Way, Marlborough, MA 01752-102-4 Location of operations Form 10-K, Item 1.
","('Business_Model_Resilience', 0.5970748662948608)","('Director_Removal', 0.052806880325078964)","('Systemic_Risk_Management', 0.041815273463726044)","(['Codes of Business Conduct'], 0.5970748662948608)","('NON-ESG', 0.052806880325078964)","('NON-ESG', 0.041815273463726044)"
Line 691,"International Operations, Page 10   Form 10-K, Item 2.
","('Business_Model_Resilience', 0.19830192625522614)","('Systemic_Risk_Management', 0.1509908139705658)","('Management_Of_Legal_And_Regulatory_Framework', 0.09161005169153214)","('NON-ESG', 0.19830192625522614)","('NON-ESG', 0.1509908139705658)","('NON-ESG', 0.09161005169153214)"
Line 692,"Properties, Page 102-5 Ownership and legal form Boston Scientific Corporation, publicly traded on New York Stock Exchange as BSX 102-6 Markets served Form 10-K, Item 1.
","('Management_Of_Legal_And_Regulatory_Framework', 0.5539057850837708)","('Competitive_Behavior', 0.13925983011722565)","('Systemic_Risk_Management', 0.07528913021087646)","(['Corporate Governance'], 0.5539057850837708)","('NON-ESG', 0.13925983011722565)","('NON-ESG', 0.07528913021087646)"
Line 693,"Marketing and Sales, Page 102-7 Scale of the organization Performance Report, Boston Scientific: 2021 at a glance, Page 7    Form 10-K, Item 1.
","('Competitive_Behavior', 0.24179813265800476)","('Customer_Welfare', 0.22793364524841309)","('Selling_Practices_And_Product_Labeling', 0.15097415447235107)","('NON-ESG', 0.24179813265800476)","('NON-ESG', 0.22793364524841309)","('NON-ESG', 0.15097415447235107)"
Line 694,"Business, Page 102-8 Information on employees and other workers Form 10-K, Item 1.
","('Labor_Practices', 0.9466620087623596)","('Employee_Engagement_Inclusion_And_Diversity', 0.008318771608173847)","('Employee_Health_And_Safety', 0.007178869564086199)","(['Labor Practice Indicators'], 0.9466620087623596)","('NON-ESG', 0.008318771608173847)","('NON-ESG', 0.007178869564086199)"
Line 695,"Human Capital, Page 14  Performance Report Appendix 102-9 Supply chain Form 10-K, Item 1.
","('Supply_Chain_Management', 0.9556519985198975)","('Labor_Practices', 0.0036445255391299725)","('Physical_Impacts_Of_Climate_Change', 0.003409967292100191)","(['Supply Chain Management'], 0.9556519985198975)","('NON-ESG', 0.0036445255391299725)","('NON-ESG', 0.003409967292100191)"
Line 696,"Manufacturing and Raw Materials, Page 11   Performance Report, Creating value responsibly, Page 102-10 Significant changes to the organization and its   supply chainForm 10-K, Item 7.
","('Supply_Chain_Management', 0.936641275882721)","('Product_Design_And_Lifecycle_Management', 0.013514962047338486)","('Business_Model_Resilience', 0.004475222900509834)","(['Supply Chain Management'], 0.936641275882721)","('NON-ESG', 0.013514962047338486)","('NON-ESG', 0.004475222900509834)"
Line 697,"Management’s Discussion and Analysis of Financial Condition   and Results of Operations, Page 40  102-11 Precautionary Principle or approach Form 10-K, Item 1.
","('Systemic_Risk_Management', 0.40466979146003723)","('Business_Model_Resilience', 0.3982948362827301)","('Physical_Impacts_Of_Climate_Change', 0.038686878979206085)","('NON-ESG', 0.40466979146003723)","('NON-ESG', 0.3982948362827301)","('NON-ESG', 0.038686878979206085)"
Line 698,"Business Strategy, Page 3  Performance Report, Our ESG strategy, Page 8Global Reporting Initiative (GRI) index The Global Reporting Initiative (GRI) Standards represent global best practices for reporting publicly on a range of ESG impacts.
","('Systemic_Risk_Management', 0.3426216244697571)","('Business_Model_Resilience', 0.3233388364315033)","('Management_Of_Legal_And_Regulatory_Framework', 0.04020605608820915)","('NON-ESG', 0.3426216244697571)","('NON-ESG', 0.3233388364315033)","('NON-ESG', 0.04020605608820915)"
Line 699,"We continue to expand the scope of our ESG metrics and  disclosures to topics material to our business and stakeholders.
","('Business_Model_Resilience', 0.5945519804954529)","('Systemic_Risk_Management', 0.10738413035869598)","('Supply_Chain_Management', 0.031083013862371445)","(['Codes of Business Conduct'], 0.5945519804954529)","('NON-ESG', 0.10738413035869598)","('NON-ESG', 0.031083013862371445)"
Line 700,"This report has been prepared in accordance with the GRI Standards: Core option.
","('Management_Of_Legal_And_Regulatory_Framework', 0.5812124013900757)","('Product_Quality_And_Safety', 0.16000381112098694)","('Human_Rights_And_Community_Relations', 0.03048824332654476)","(['Corporate Governance'], 0.5812124013900757)","('NON-ESG', 0.16000381112098694)","('NON-ESG', 0.03048824332654476)"
Line 701,"The following table includes references  to our 2021 performance report, 2021 Form 10-K, and other documents available on BostonScientific.com.
","('Management_Of_Legal_And_Regulatory_Framework', 0.8075028657913208)","('Access_And_Affordability', 0.02332071028649807)","('Human_Rights_And_Community_Relations', 0.021081671118736267)","(['Corporate Governance'], 0.8075028657913208)","('NON-ESG', 0.02332071028649807)","('NON-ESG', 0.021081671118736267)"
Line 702,"2021 Performance ReportIntroduction Transforming care Investing in   our people Accelerating   possibilities Protecting the  environment Creating value  responsibly Appendix Stakeholder engagement Metrics summary Global Reporting Initiative  (GRI) index Sustainability Accounting  Standards Board   (SASB) index United Nations  Sustainable Development  Goals (SDGs) Indicator Description Response 102-12 External initiatives Performance Report, Accelerating possibilities, Page 31   Performance Report, Protecting the environment, Page 39  Performance Report, Creating value responsibly, Page 48  Respecting Human Rights 102-13 Memberships of associations Trade Association Memberships 102-14 Statement from senior decision-maker Performance Report, A Message from our Chairman and Chief Executive Officer, Page 102-15 Key impacts, risks and opportunities Form 10-K, Item 1A.
","('Human_Rights_And_Community_Relations', 0.42600226402282715)","('Management_Of_Legal_And_Regulatory_Framework', 0.08914300799369812)","('Access_And_Affordability', 0.08908753842115402)","('NON-ESG', 0.42600226402282715)","('NON-ESG', 0.08914300799369812)","('NON-ESG', 0.08908753842115402)"
Line 703,"2021 Performance ReportIntroduction Transforming care Investing in   our people Accelerating   possibilities Protecting the  environment Creating value  responsibly Appendix Stakeholder engagement Metrics summary Global Reporting Initiative  (GRI) index Sustainability Accounting  Standards Board   (SASB) index United Nations  Sustainable Development  Goals (SDGs) Indicator Description Response 102-12 External initiatives Performance Report, Accelerating possibilities, Page 31   Performance Report, Protecting the environment, Page 39  Performance Report, Creating value responsibly, Page 48  Respecting Human Rights 102-13 Memberships of associations Trade Association Memberships 102-14 Statement from senior decision-maker Performance Report, A Message from our Chairman and Chief Executive Officer, Page 102-15 Key impacts, risks and opportunities Form 10-K, Item 1A.
","('Human_Rights_And_Community_Relations', 0.9160290956497192)","('Access_And_Affordability', 0.007528100162744522)","('Employee_Health_And_Safety', 0.006495020817965269)","(['Community Relations'], 0.9160290956497192)","('NON-ESG', 0.007528100162744522)","('NON-ESG', 0.006495020817965269)"
Line 704,"Risk Factors, Page 102-16 Values, principles, standards and norms of behavior Performance Report, Our mission and values, Page 6  Code of Conduct 102-17 Mechanisms for advice and concerns about ethics Advice Line 102-18 Governance structure Proxy Statement   Governance overview 102-19 Delegating authority Proxy Statement 102-20 Executive-level responsibility for economic, environmental  and social topicsPerformance Report, Our ESG strategy, Page 8   Proxy Statement 102-21 Consulting stakeholders on economic, environmental   and social topicsPerformance Report, Our ESG strategy, Page 8   Performance Report Appendix, Stakeholder engagement, Page 102-22 Composition of the highest governance body   and its committeesProxy Statement 102-23 Chair of the highest governance body Proxy Statement 102-24 Nominating and selecting the highest governance body Proxy Statement 102-25 Conflicts of interest Code of Conduct 102-26 Role of highest governance body in setting  purpose,  values and strategyProxy Statement 102-27 Collective knowledge of highest governance body Proxy Statement 102-28 Evaluating the highest governance body’s performance Proxy Statement 2021 Performance ReportIntroduction Transforming care Investing in   our people Accelerating   possibilities Protecting the  environment Creating value  responsibly Appendix Stakeholder engagement Metrics summary Global Reporting Initiative  (GRI) index Sustainability Accounting  Standards Board   (SASB) index United Nations  Sustainable Development  Goals (SDGs) Indicator Description Response 102-29 Identifying and managing economic, environmental   and social impactsForm 10-K, Item 1.
","('Business_Ethics', 0.9506068229675293)","('Management_Of_Legal_And_Regulatory_Framework', 0.010393612086772919)","('Systemic_Risk_Management', 0.004552734550088644)","(['Business Ethics'], 0.9506068229675293)","('NON-ESG', 0.010393612086772919)","('NON-ESG', 0.004552734550088644)"
Line 705,"Risk Factors, Page 102-16 Values, principles, standards and norms of behavior Performance Report, Our mission and values, Page 6  Code of Conduct 102-17 Mechanisms for advice and concerns about ethics Advice Line 102-18 Governance structure Proxy Statement   Governance overview 102-19 Delegating authority Proxy Statement 102-20 Executive-level responsibility for economic, environmental  and social topicsPerformance Report, Our ESG strategy, Page 8   Proxy Statement 102-21 Consulting stakeholders on economic, environmental   and social topicsPerformance Report, Our ESG strategy, Page 8   Performance Report Appendix, Stakeholder engagement, Page 102-22 Composition of the highest governance body   and its committeesProxy Statement 102-23 Chair of the highest governance body Proxy Statement 102-24 Nominating and selecting the highest governance body Proxy Statement 102-25 Conflicts of interest Code of Conduct 102-26 Role of highest governance body in setting  purpose,  values and strategyProxy Statement 102-27 Collective knowledge of highest governance body Proxy Statement 102-28 Evaluating the highest governance body’s performance Proxy Statement 2021 Performance ReportIntroduction Transforming care Investing in   our people Accelerating   possibilities Protecting the  environment Creating value  responsibly Appendix Stakeholder engagement Metrics summary Global Reporting Initiative  (GRI) index Sustainability Accounting  Standards Board   (SASB) index United Nations  Sustainable Development  Goals (SDGs) Indicator Description Response 102-29 Identifying and managing economic, environmental   and social impactsForm 10-K, Item 1.
","('Human_Rights_And_Community_Relations', 0.3142920136451721)","('Business_Model_Resilience', 0.19062966108322144)","('Management_Of_Legal_And_Regulatory_Framework', 0.12413457781076431)","('NON-ESG', 0.3142920136451721)","('NON-ESG', 0.19062966108322144)","('NON-ESG', 0.12413457781076431)"
Line 706,"Risk Factors, Page 102-16 Values, principles, standards and norms of behavior Performance Report, Our mission and values, Page 6  Code of Conduct 102-17 Mechanisms for advice and concerns about ethics Advice Line 102-18 Governance structure Proxy Statement   Governance overview 102-19 Delegating authority Proxy Statement 102-20 Executive-level responsibility for economic, environmental  and social topicsPerformance Report, Our ESG strategy, Page 8   Proxy Statement 102-21 Consulting stakeholders on economic, environmental   and social topicsPerformance Report, Our ESG strategy, Page 8   Performance Report Appendix, Stakeholder engagement, Page 102-22 Composition of the highest governance body   and its committeesProxy Statement 102-23 Chair of the highest governance body Proxy Statement 102-24 Nominating and selecting the highest governance body Proxy Statement 102-25 Conflicts of interest Code of Conduct 102-26 Role of highest governance body in setting  purpose,  values and strategyProxy Statement 102-27 Collective knowledge of highest governance body Proxy Statement 102-28 Evaluating the highest governance body’s performance Proxy Statement 2021 Performance ReportIntroduction Transforming care Investing in   our people Accelerating   possibilities Protecting the  environment Creating value  responsibly Appendix Stakeholder engagement Metrics summary Global Reporting Initiative  (GRI) index Sustainability Accounting  Standards Board   (SASB) index United Nations  Sustainable Development  Goals (SDGs) Indicator Description Response 102-29 Identifying and managing economic, environmental   and social impactsForm 10-K, Item 1.
","('Management_Of_Legal_And_Regulatory_Framework', 0.4319002628326416)","('Business_Model_Resilience', 0.14752760529518127)","('Human_Rights_And_Community_Relations', 0.14247854053974152)","('NON-ESG', 0.4319002628326416)","('NON-ESG', 0.14752760529518127)","('NON-ESG', 0.14247854053974152)"
Line 707,"Risk Factors, Page 102-16 Values, principles, standards and norms of behavior Performance Report, Our mission and values, Page 6  Code of Conduct 102-17 Mechanisms for advice and concerns about ethics Advice Line 102-18 Governance structure Proxy Statement   Governance overview 102-19 Delegating authority Proxy Statement 102-20 Executive-level responsibility for economic, environmental  and social topicsPerformance Report, Our ESG strategy, Page 8   Proxy Statement 102-21 Consulting stakeholders on economic, environmental   and social topicsPerformance Report, Our ESG strategy, Page 8   Performance Report Appendix, Stakeholder engagement, Page 102-22 Composition of the highest governance body   and its committeesProxy Statement 102-23 Chair of the highest governance body Proxy Statement 102-24 Nominating and selecting the highest governance body Proxy Statement 102-25 Conflicts of interest Code of Conduct 102-26 Role of highest governance body in setting  purpose,  values and strategyProxy Statement 102-27 Collective knowledge of highest governance body Proxy Statement 102-28 Evaluating the highest governance body’s performance Proxy Statement 2021 Performance ReportIntroduction Transforming care Investing in   our people Accelerating   possibilities Protecting the  environment Creating value  responsibly Appendix Stakeholder engagement Metrics summary Global Reporting Initiative  (GRI) index Sustainability Accounting  Standards Board   (SASB) index United Nations  Sustainable Development  Goals (SDGs) Indicator Description Response 102-29 Identifying and managing economic, environmental   and social impactsForm 10-K, Item 1.
","('Human_Rights_And_Community_Relations', 0.8211347460746765)","('Ecological_Impacts', 0.03430331125855446)","('Business_Model_Resilience', 0.02589997462928295)","(['Community Relations'], 0.8211347460746765)","('NON-ESG', 0.03430331125855446)","('NON-ESG', 0.02589997462928295)"
Line 708,"Business, Page 3  Performance Report, Our ESG strategy, Page 8  102-30 Effectiveness of risk management processes Proxy Statement  Performance Report, Risk management and global security, Page 53  102-31 Review of economic, environmental and social topics See 102-102-32 Highest governance body’s role in sustainability reporting Proxy Statement 102-33 Communicating critical concerns Proxy Statement 102-34 Nature and total number of critical concerns Form 10-K, Item 1A.
","('Systemic_Risk_Management', 0.5218144059181213)","('Business_Model_Resilience', 0.15168100595474243)","('Business_Ethics', 0.04758867248892784)","(['Risk & Crisis Management'], 0.5218144059181213)","('NON-ESG', 0.15168100595474243)","('NON-ESG', 0.04758867248892784)"
Line 709,"Risk Factors, Page 102-35 Remuneration policies Proxy Statement 102-36 Process for determining remuneration Proxy Statement 102-37 Stakeholders’ involvement in remuneration Proxy Statement 102-38 Annual total compensation ratio Proxy Statement 102-39 Percentage increase in annual total compensation ratio Proxy Statement 102-40 List of stakeholder groups See 102-102-41 Collective bargaining agreements Human Rights, Collective Bargaining 102-42 Identifying and selecting stakeholders See 102-102-43 Approach to stakeholder engagement See 102-102-44 Key topics and concerns raised Performance Report, Our ESG strategy, Page 8  102-45 Entities included in the consolidated financial statements Form 10-K, Exhibit 102-46 Defining report content and topic boundaries Performance Report, Table of contents, Page 3  102-47 List of material topics Performance Report, Our ESG strategy, Page 8  102-48 Restatements of information Throughout Performance Report and Performance Report Appendix 102-49 Changes in reporting Throughout Performance Report and Performance Report Appendix 102-50 Reporting period Data in the Performance Report covers the period between January 1, 2020,   and December 31, 2020, unless otherwise indicated  2021 Performance ReportIntroduction Transforming care Investing in   our people Accelerating   possibilities Protecting the  environment Creating value  responsibly Appendix Stakeholder engagement Metrics summary Global Reporting Initiative  (GRI) index Sustainability Accounting  Standards Board   (SASB) index United Nations  Sustainable Development  Goals (SDGs) Indicator Description Response 102-51 Date of most recent report 4/15/2021  2020 Annual Performance Report 102-52 Reporting cycle Annual 102-53 Contact point for questions regarding the report Investor Relations 102-54 Claims of reporting in accordance with the GRI Standards Performance Report, Table of contents, Page 3  102-55 GRI content index Performance Report Appendix 102-56 External assurance This report has not been independently verified.
","('Labor_Practices', 0.977400004863739)","('Director_Removal', 0.002185620367527008)","('Employee_Engagement_Inclusion_And_Diversity', 0.0018456425750628114)","(['Labor Practice Indicators'], 0.977400004863739)","('NON-ESG', 0.002185620367527008)","('NON-ESG', 0.0018456425750628114)"
Line 710,"Risk Factors, Page 102-35 Remuneration policies Proxy Statement 102-36 Process for determining remuneration Proxy Statement 102-37 Stakeholders’ involvement in remuneration Proxy Statement 102-38 Annual total compensation ratio Proxy Statement 102-39 Percentage increase in annual total compensation ratio Proxy Statement 102-40 List of stakeholder groups See 102-102-41 Collective bargaining agreements Human Rights, Collective Bargaining 102-42 Identifying and selecting stakeholders See 102-102-43 Approach to stakeholder engagement See 102-102-44 Key topics and concerns raised Performance Report, Our ESG strategy, Page 8  102-45 Entities included in the consolidated financial statements Form 10-K, Exhibit 102-46 Defining report content and topic boundaries Performance Report, Table of contents, Page 3  102-47 List of material topics Performance Report, Our ESG strategy, Page 8  102-48 Restatements of information Throughout Performance Report and Performance Report Appendix 102-49 Changes in reporting Throughout Performance Report and Performance Report Appendix 102-50 Reporting period Data in the Performance Report covers the period between January 1, 2020,   and December 31, 2020, unless otherwise indicated  2021 Performance ReportIntroduction Transforming care Investing in   our people Accelerating   possibilities Protecting the  environment Creating value  responsibly Appendix Stakeholder engagement Metrics summary Global Reporting Initiative  (GRI) index Sustainability Accounting  Standards Board   (SASB) index United Nations  Sustainable Development  Goals (SDGs) Indicator Description Response 102-51 Date of most recent report 4/15/2021  2020 Annual Performance Report 102-52 Reporting cycle Annual 102-53 Contact point for questions regarding the report Investor Relations 102-54 Claims of reporting in accordance with the GRI Standards Performance Report, Table of contents, Page 3  102-55 GRI content index Performance Report Appendix 102-56 External assurance This report has not been independently verified.
","('Business_Model_Resilience', 0.5930076241493225)","('Human_Rights_And_Community_Relations', 0.059062160551548004)","('Systemic_Risk_Management', 0.05334771052002907)","(['Codes of Business Conduct'], 0.5930076241493225)","('NON-ESG', 0.059062160551548004)","('NON-ESG', 0.05334771052002907)"
Line 711,"Risk Factors, Page 102-35 Remuneration policies Proxy Statement 102-36 Process for determining remuneration Proxy Statement 102-37 Stakeholders’ involvement in remuneration Proxy Statement 102-38 Annual total compensation ratio Proxy Statement 102-39 Percentage increase in annual total compensation ratio Proxy Statement 102-40 List of stakeholder groups See 102-102-41 Collective bargaining agreements Human Rights, Collective Bargaining 102-42 Identifying and selecting stakeholders See 102-102-43 Approach to stakeholder engagement See 102-102-44 Key topics and concerns raised Performance Report, Our ESG strategy, Page 8  102-45 Entities included in the consolidated financial statements Form 10-K, Exhibit 102-46 Defining report content and topic boundaries Performance Report, Table of contents, Page 3  102-47 List of material topics Performance Report, Our ESG strategy, Page 8  102-48 Restatements of information Throughout Performance Report and Performance Report Appendix 102-49 Changes in reporting Throughout Performance Report and Performance Report Appendix 102-50 Reporting period Data in the Performance Report covers the period between January 1, 2020,   and December 31, 2020, unless otherwise indicated  2021 Performance ReportIntroduction Transforming care Investing in   our people Accelerating   possibilities Protecting the  environment Creating value  responsibly Appendix Stakeholder engagement Metrics summary Global Reporting Initiative  (GRI) index Sustainability Accounting  Standards Board   (SASB) index United Nations  Sustainable Development  Goals (SDGs) Indicator Description Response 102-51 Date of most recent report 4/15/2021  2020 Annual Performance Report 102-52 Reporting cycle Annual 102-53 Contact point for questions regarding the report Investor Relations 102-54 Claims of reporting in accordance with the GRI Standards Performance Report, Table of contents, Page 3  102-55 GRI content index Performance Report Appendix 102-56 External assurance This report has not been independently verified.
","('Business_Model_Resilience', 0.2595061957836151)","('Human_Rights_And_Community_Relations', 0.19634784758090973)","('Management_Of_Legal_And_Regulatory_Framework', 0.17371678352355957)","('NON-ESG', 0.2595061957836151)","('NON-ESG', 0.19634784758090973)","('NON-ESG', 0.17371678352355957)"
Line 712,"Risk Factors, Page 102-35 Remuneration policies Proxy Statement 102-36 Process for determining remuneration Proxy Statement 102-37 Stakeholders’ involvement in remuneration Proxy Statement 102-38 Annual total compensation ratio Proxy Statement 102-39 Percentage increase in annual total compensation ratio Proxy Statement 102-40 List of stakeholder groups See 102-102-41 Collective bargaining agreements Human Rights, Collective Bargaining 102-42 Identifying and selecting stakeholders See 102-102-43 Approach to stakeholder engagement See 102-102-44 Key topics and concerns raised Performance Report, Our ESG strategy, Page 8  102-45 Entities included in the consolidated financial statements Form 10-K, Exhibit 102-46 Defining report content and topic boundaries Performance Report, Table of contents, Page 3  102-47 List of material topics Performance Report, Our ESG strategy, Page 8  102-48 Restatements of information Throughout Performance Report and Performance Report Appendix 102-49 Changes in reporting Throughout Performance Report and Performance Report Appendix 102-50 Reporting period Data in the Performance Report covers the period between January 1, 2020,   and December 31, 2020, unless otherwise indicated  2021 Performance ReportIntroduction Transforming care Investing in   our people Accelerating   possibilities Protecting the  environment Creating value  responsibly Appendix Stakeholder engagement Metrics summary Global Reporting Initiative  (GRI) index Sustainability Accounting  Standards Board   (SASB) index United Nations  Sustainable Development  Goals (SDGs) Indicator Description Response 102-51 Date of most recent report 4/15/2021  2020 Annual Performance Report 102-52 Reporting cycle Annual 102-53 Contact point for questions regarding the report Investor Relations 102-54 Claims of reporting in accordance with the GRI Standards Performance Report, Table of contents, Page 3  102-55 GRI content index Performance Report Appendix 102-56 External assurance This report has not been independently verified.
","('Management_Of_Legal_And_Regulatory_Framework', 0.384177565574646)","('Human_Rights_And_Community_Relations', 0.14143933355808258)","('Business_Model_Resilience', 0.13050173223018646)","('NON-ESG', 0.384177565574646)","('NON-ESG', 0.14143933355808258)","('NON-ESG', 0.13050173223018646)"
Line 713,"GRI 201-1 Direct economic value generated and distributed Form 10-K, Item 8.
","('Energy_Management', 0.2516324818134308)","('Management_Of_Legal_And_Regulatory_Framework', 0.2181617021560669)","('Systemic_Risk_Management', 0.0752687007188797)","('NON-ESG', 0.2516324818134308)","('NON-ESG', 0.2181617021560669)","('NON-ESG', 0.0752687007188797)"
Line 714,"Financial Statements & Supplementary Data, Page 70  Performance Report, Boston Scientific: 2021 at a glance, Page 201-2 Financial implications and other risks and opportunities  due to climate changeForm 10-K, Item 1A.
","('Physical_Impacts_Of_Climate_Change', 0.9527279734611511)","('Business_Model_Resilience', 0.011160597205162048)","('Systemic_Risk_Management', 0.0036882255226373672)","(['Climate Change'], 0.9527279734611511)","('NON-ESG', 0.011160597205162048)","('NON-ESG', 0.0036882255226373672)"
Line 715,"Risk Factors, Page 35  Performance Report, Managing climate risk, Page 201-3 Defined benefit plan obligations and other   retirement plansForm 10-K, Item 15.
","('Physical_Impacts_Of_Climate_Change', 0.8269622325897217)","('Systemic_Risk_Management', 0.054157257080078125)","('Business_Model_Resilience', 0.04693231359124184)","(['Climate Change'], 0.8269622325897217)","('NON-ESG', 0.054157257080078125)","('NON-ESG', 0.04693231359124184)"
Line 716,"Exhibits and Financial Statement Schedules Note S, Page 202-1 Ratios of standard entry level wage by gender compared  to local minimum wageLabor and Human Rights, Commitment to Labor Initiatives or Standards  203-1 Infrastructure investments and services supported Form 10-K, Item 1.
","('Labor_Practices', 0.9771724343299866)","('Director_Removal', 0.0022356449626386166)","('Management_Of_Legal_And_Regulatory_Framework', 0.0017850243020802736)","(['Labor Practice Indicators'], 0.9771724343299866)","('NON-ESG', 0.0022356449626386166)","('NON-ESG', 0.0017850243020802736)"
Line 717,"Marketing and Sales, Page 203-2 Significant indirect economic impacts Performance Report, Transforming care, Page 13   Performance Report, Investing in our people, Page 20   Performance Report, Accelerating possibilities, Page 31   Performance Report, Protecting the environment, Page 39   Performance Report, Creating value responsibly, Page 204-1 Proportion of spending on local suppliers Performance Report, Keeping our supply chain resilient and reliable, Page 205-1 Operations assessed for risks related to corruption Anti-Corruption & Governance 205-2 Communication and training about anti-corruption policies  and proceduresPerformance Report, Compliance, ethics and integrity, Page 206-1 Legal actions for anti-competitive behavior, anti-trust   and monopoly practicesForm 10-K, Note K.
","('Supply_Chain_Management', 0.9196790456771851)","('Product_Design_And_Lifecycle_Management', 0.016056114807724953)","('Business_Model_Resilience', 0.014093926176428795)","(['Supply Chain Management'], 0.9196790456771851)","('NON-ESG', 0.016056114807724953)","('NON-ESG', 0.014093926176428795)"
Line 718,"Marketing and Sales, Page 203-2 Significant indirect economic impacts Performance Report, Transforming care, Page 13   Performance Report, Investing in our people, Page 20   Performance Report, Accelerating possibilities, Page 31   Performance Report, Protecting the environment, Page 39   Performance Report, Creating value responsibly, Page 204-1 Proportion of spending on local suppliers Performance Report, Keeping our supply chain resilient and reliable, Page 205-1 Operations assessed for risks related to corruption Anti-Corruption & Governance 205-2 Communication and training about anti-corruption policies  and proceduresPerformance Report, Compliance, ethics and integrity, Page 206-1 Legal actions for anti-competitive behavior, anti-trust   and monopoly practicesForm 10-K, Note K.
","('Business_Ethics', 0.9754312038421631)","('Competitive_Behavior', 0.0025235777720808983)","('Management_Of_Legal_And_Regulatory_Framework', 0.0022185479756444693)","(['Business Ethics'], 0.9754312038421631)","('NON-ESG', 0.0025235777720808983)","('NON-ESG', 0.0022185479756444693)"
Line 719,"Commitments and Contingencies, Page 2021 Performance ReportIntroduction Transforming care Investing in   our people Accelerating   possibilities Protecting the  environment Creating value  responsibly Appendix Stakeholder engagement Metrics summary Global Reporting Initiative  (GRI) index Sustainability Accounting  Standards Board   (SASB) index United Nations  Sustainable Development  Goals (SDGs) Indicator Description Response GRI 302-1 Energy consumption within the organization Performance Report, GEMS KPIs, Page 41  Performance Report Appendix, Metrics summary 302-3 Energy intensity Performance Report, GEMS KPIs, Page 41  Performance Report Appendix, Metrics summary 302-4 Reduction of energy consumption Performance Report, GEMS KPIs, Page 41  Performance Report Appendix, Metrics summary 302-5 Reductions in energy requirements of products   and servicesPerformance Report, GEMS KPIs, Page 41  Performance Report, Advancing product stewardship, Page 46  Performance Report Appendix, Metrics summary 303-1 Water withdrawal Performance Report Appendix, Metrics summary 303-2 Water discharge Performance Report Appendix, Metrics summary 303-3 Water consumption Performance Report Appendix, Metrics summary 305-1 Direct (Scope 1) GHG emissions Performance Report Appendix, Metrics summary 305-2 Energy indirect (Scope 2) GHG emissions Performance Report Appendix, Metrics summary 305-5 Reduction of GHG emissions Performance Report, Protecting the environment, Page 39   Performance Report Appendix, Metrics summary 306-1 Water discharge by quality and destination Performance Report Appendix, Metrics summary 306-2 Waste by type and disposal method Performance Report Appendix, Metrics summary 306-3 Significant spills No significant spills for 306-4 Transport of hazardous waste Performance Report Appendix, Metrics summary 307-1 Non-compliance with environmental laws and regulation Performance Report Appendix, Metrics summary 308-1 New suppliers that were screened using   environmental criteriaPerformance Report, Creating value responsibly, Page 48  2021 Performance ReportIntroduction Transforming care Investing in   our people Accelerating   possibilities Protecting the  environment Creating value  responsibly Appendix Stakeholder engagement Metrics summary Global Reporting Initiative  (GRI) index Sustainability Accounting  Standards Board   (SASB) index United Nations  Sustainable Development  Goals (SDGs) Indicator Description Response GRI 401-1 New employee hires and employee turnover Performance Report Appendix, Metrics summary 401-2 Benefits provided to full-time employees that are not  provided to temporary or part-time employeesBenefits 401-3 Parental leave Benefits 403-2 Types of injury and rates of injury, occupational   diseases, lost days, and absenteeism and number   of work-related fatalitiesPerformance Report Appendix, Metrics summary 404-1 Average hours of training per year per employee Performance Report Appendix, Metrics summary 404-2 Programs for upgrading employee skills and transition  assistance programsPerformance Report, Investing in our people, Page 404-3 Percentage of employees receiving regular performance  and career development reviewsPerformance Report, Investing in our people, Page 20  405-1 Diversity of governance bodies and employees Proxy Statement  Performance Appendix, Metrics summary 405-2 Ratio of basic salary and remuneration of women to men Performance Report, Investing in our people, Page 20  Equal Pay for Equal Work 406-1 Incidents of discrimination and corrective actions taken Compliance and Ethics  407-1 Operations and suppliers in which the right to freedom   of association and collective bargaining may be at riskHuman Rights 408-1 Operations and suppliers at significant risk for incidence   of child laborHuman Rights 409-1 Operations and suppliers at significant risk for incidence   of forced or compulsory laborHuman Rights 411-1 Incidents of violations involving rights of   indigenous peoplesHuman Rights 2021 Performance ReportIntroduction Transforming care Investing in   our people Accelerating   possibilities Protecting the  environment Creating value  responsibly Appendix Stakeholder engagement Metrics summary Global Reporting Initiative  (GRI) index Sustainability Accounting  Standards Board   (SASB) index United Nations  Sustainable Development  Goals (SDGs) Indicator Description Response 412-1 Operations that have been subject to human rights reviews  or impact assessmentsHuman Rights 412-2 Employee training on human rights policies or procedures Human Rights 413-1 Operations with local community engagement, impact  assessments and development programsPerformance Report, Supporting our communities, Page 36   Community Engagement 414-1 New suppliers that were screened using social criteria Performance Report, Creating value responsibly, Page 48  415-1 Political contributions Political Contributions 416-1 Assessment of the health and safety impacts of product  and service categoriesPerformance Report, Ensuring quality, health and safety, Page 416-2 Incidents of non-compliance concerning the health   and safety impacts of products and servicesPerformance Report, Ensuring quality, health and safety, Page 17  417-1 Requirements for product and service information   and labelingPerformance Report, Ensuring quality, health and safety, Page 17  Performance Report, Advancing product stewardship, Page 419-1 Non-compliance with laws and regulations in the social  and economic areaBoston Scientific adheres to all compliance requirements, see compliance references  throughout the Performance Report and BostonScientific.com   2021 Performance ReportIntroduction Transforming care Investing in   our people Accelerating   possibilities Protecting the  environment Creating value  responsibly Appendix Stakeholder engagement Metrics summary Global Reporting Initiative  (GRI) index Sustainability Accounting  Standards Board   (SASB) index United Nations  Sustainable Development  Goals (SDGs) Topic Accounting metric Code Response Affordability   and pricingRatio of weighted average rate of net price increases  (for all products) to the annual increase in the U.S.  Consumer Price IndexHC-MS-240a.1 Not currently disclosed Description of how price information for each product  is disclosed to customers or to their agentsHC-MS-240a.2 Form 10-K, Health Care Policies and Reimbursement, Pages 13-Product safety Number of recalls issued, total units recalled HC-MS-250a.1 Class I recalls: 3  Class II recalls: 8  Total units recalled: 47,List of products listed in the FDA's MedWatch  Safety Alerts for Human Medical Products databaseHC-MS-250a.2 FDA's MedWatch Safety Alerts for Human Medical Products database Number of fatalities related to products as reported  in the FDA Manufacturer and User Facility Device  ExperienceHC-MS-250a.3 FDA Manufacturer and User Facility Device Experience (MAUDE) database Number of FDA enforcement actions taken in  response to violations of current Good Manufacturing  Practices (cGMP), by typeHC-MS-250a.4 0 in Ethical marketing Total amount of monetary losses as a result of legal  proceedings associated with false marketing claimsHC-MS-270a.1 $0 in Description of code of ethics governing promotion  of off-label use of productsHC-MS-270a.2 Code of Conduct, Page 40;   Performance Report, Creating value responsibly, Page 48Sustainability Accounting Standards Board (SASB) index SASB is an independent standards-setting organization dedicated to improving the effectiveness and comparability of corporate disclosure on ESG factors.
","('Energy_Management', 0.9742574691772461)","('Access_And_Affordability', 0.003015894675627351)","('Air_Quality', 0.002403175225481391)","(['Operational Eco-Efficiency'], 0.9742574691772461)","('NON-ESG', 0.003015894675627351)","('NON-ESG', 0.002403175225481391)"
Line 720,"Commitments and Contingencies, Page 2021 Performance ReportIntroduction Transforming care Investing in   our people Accelerating   possibilities Protecting the  environment Creating value  responsibly Appendix Stakeholder engagement Metrics summary Global Reporting Initiative  (GRI) index Sustainability Accounting  Standards Board   (SASB) index United Nations  Sustainable Development  Goals (SDGs) Indicator Description Response GRI 302-1 Energy consumption within the organization Performance Report, GEMS KPIs, Page 41  Performance Report Appendix, Metrics summary 302-3 Energy intensity Performance Report, GEMS KPIs, Page 41  Performance Report Appendix, Metrics summary 302-4 Reduction of energy consumption Performance Report, GEMS KPIs, Page 41  Performance Report Appendix, Metrics summary 302-5 Reductions in energy requirements of products   and servicesPerformance Report, GEMS KPIs, Page 41  Performance Report, Advancing product stewardship, Page 46  Performance Report Appendix, Metrics summary 303-1 Water withdrawal Performance Report Appendix, Metrics summary 303-2 Water discharge Performance Report Appendix, Metrics summary 303-3 Water consumption Performance Report Appendix, Metrics summary 305-1 Direct (Scope 1) GHG emissions Performance Report Appendix, Metrics summary 305-2 Energy indirect (Scope 2) GHG emissions Performance Report Appendix, Metrics summary 305-5 Reduction of GHG emissions Performance Report, Protecting the environment, Page 39   Performance Report Appendix, Metrics summary 306-1 Water discharge by quality and destination Performance Report Appendix, Metrics summary 306-2 Waste by type and disposal method Performance Report Appendix, Metrics summary 306-3 Significant spills No significant spills for 306-4 Transport of hazardous waste Performance Report Appendix, Metrics summary 307-1 Non-compliance with environmental laws and regulation Performance Report Appendix, Metrics summary 308-1 New suppliers that were screened using   environmental criteriaPerformance Report, Creating value responsibly, Page 48  2021 Performance ReportIntroduction Transforming care Investing in   our people Accelerating   possibilities Protecting the  environment Creating value  responsibly Appendix Stakeholder engagement Metrics summary Global Reporting Initiative  (GRI) index Sustainability Accounting  Standards Board   (SASB) index United Nations  Sustainable Development  Goals (SDGs) Indicator Description Response GRI 401-1 New employee hires and employee turnover Performance Report Appendix, Metrics summary 401-2 Benefits provided to full-time employees that are not  provided to temporary or part-time employeesBenefits 401-3 Parental leave Benefits 403-2 Types of injury and rates of injury, occupational   diseases, lost days, and absenteeism and number   of work-related fatalitiesPerformance Report Appendix, Metrics summary 404-1 Average hours of training per year per employee Performance Report Appendix, Metrics summary 404-2 Programs for upgrading employee skills and transition  assistance programsPerformance Report, Investing in our people, Page 404-3 Percentage of employees receiving regular performance  and career development reviewsPerformance Report, Investing in our people, Page 20  405-1 Diversity of governance bodies and employees Proxy Statement  Performance Appendix, Metrics summary 405-2 Ratio of basic salary and remuneration of women to men Performance Report, Investing in our people, Page 20  Equal Pay for Equal Work 406-1 Incidents of discrimination and corrective actions taken Compliance and Ethics  407-1 Operations and suppliers in which the right to freedom   of association and collective bargaining may be at riskHuman Rights 408-1 Operations and suppliers at significant risk for incidence   of child laborHuman Rights 409-1 Operations and suppliers at significant risk for incidence   of forced or compulsory laborHuman Rights 411-1 Incidents of violations involving rights of   indigenous peoplesHuman Rights 2021 Performance ReportIntroduction Transforming care Investing in   our people Accelerating   possibilities Protecting the  environment Creating value  responsibly Appendix Stakeholder engagement Metrics summary Global Reporting Initiative  (GRI) index Sustainability Accounting  Standards Board   (SASB) index United Nations  Sustainable Development  Goals (SDGs) Indicator Description Response 412-1 Operations that have been subject to human rights reviews  or impact assessmentsHuman Rights 412-2 Employee training on human rights policies or procedures Human Rights 413-1 Operations with local community engagement, impact  assessments and development programsPerformance Report, Supporting our communities, Page 36   Community Engagement 414-1 New suppliers that were screened using social criteria Performance Report, Creating value responsibly, Page 48  415-1 Political contributions Political Contributions 416-1 Assessment of the health and safety impacts of product  and service categoriesPerformance Report, Ensuring quality, health and safety, Page 416-2 Incidents of non-compliance concerning the health   and safety impacts of products and servicesPerformance Report, Ensuring quality, health and safety, Page 17  417-1 Requirements for product and service information   and labelingPerformance Report, Ensuring quality, health and safety, Page 17  Performance Report, Advancing product stewardship, Page 419-1 Non-compliance with laws and regulations in the social  and economic areaBoston Scientific adheres to all compliance requirements, see compliance references  throughout the Performance Report and BostonScientific.com   2021 Performance ReportIntroduction Transforming care Investing in   our people Accelerating   possibilities Protecting the  environment Creating value  responsibly Appendix Stakeholder engagement Metrics summary Global Reporting Initiative  (GRI) index Sustainability Accounting  Standards Board   (SASB) index United Nations  Sustainable Development  Goals (SDGs) Topic Accounting metric Code Response Affordability   and pricingRatio of weighted average rate of net price increases  (for all products) to the annual increase in the U.S.  Consumer Price IndexHC-MS-240a.1 Not currently disclosed Description of how price information for each product  is disclosed to customers or to their agentsHC-MS-240a.2 Form 10-K, Health Care Policies and Reimbursement, Pages 13-Product safety Number of recalls issued, total units recalled HC-MS-250a.1 Class I recalls: 3  Class II recalls: 8  Total units recalled: 47,List of products listed in the FDA's MedWatch  Safety Alerts for Human Medical Products databaseHC-MS-250a.2 FDA's MedWatch Safety Alerts for Human Medical Products database Number of fatalities related to products as reported  in the FDA Manufacturer and User Facility Device  ExperienceHC-MS-250a.3 FDA Manufacturer and User Facility Device Experience (MAUDE) database Number of FDA enforcement actions taken in  response to violations of current Good Manufacturing  Practices (cGMP), by typeHC-MS-250a.4 0 in Ethical marketing Total amount of monetary losses as a result of legal  proceedings associated with false marketing claimsHC-MS-270a.1 $0 in Description of code of ethics governing promotion  of off-label use of productsHC-MS-270a.2 Code of Conduct, Page 40;   Performance Report, Creating value responsibly, Page 48Sustainability Accounting Standards Board (SASB) index SASB is an independent standards-setting organization dedicated to improving the effectiveness and comparability of corporate disclosure on ESG factors.
","('Energy_Management', 0.7526710033416748)","('Product_Design_And_Lifecycle_Management', 0.15844383835792542)","('Product_Quality_And_Safety', 0.011055261828005314)","(['Operational Eco-Efficiency'], 0.7526710033416748)","('NON-ESG', 0.15844383835792542)","('NON-ESG', 0.011055261828005314)"
Line 721,"Commitments and Contingencies, Page 2021 Performance ReportIntroduction Transforming care Investing in   our people Accelerating   possibilities Protecting the  environment Creating value  responsibly Appendix Stakeholder engagement Metrics summary Global Reporting Initiative  (GRI) index Sustainability Accounting  Standards Board   (SASB) index United Nations  Sustainable Development  Goals (SDGs) Indicator Description Response GRI 302-1 Energy consumption within the organization Performance Report, GEMS KPIs, Page 41  Performance Report Appendix, Metrics summary 302-3 Energy intensity Performance Report, GEMS KPIs, Page 41  Performance Report Appendix, Metrics summary 302-4 Reduction of energy consumption Performance Report, GEMS KPIs, Page 41  Performance Report Appendix, Metrics summary 302-5 Reductions in energy requirements of products   and servicesPerformance Report, GEMS KPIs, Page 41  Performance Report, Advancing product stewardship, Page 46  Performance Report Appendix, Metrics summary 303-1 Water withdrawal Performance Report Appendix, Metrics summary 303-2 Water discharge Performance Report Appendix, Metrics summary 303-3 Water consumption Performance Report Appendix, Metrics summary 305-1 Direct (Scope 1) GHG emissions Performance Report Appendix, Metrics summary 305-2 Energy indirect (Scope 2) GHG emissions Performance Report Appendix, Metrics summary 305-5 Reduction of GHG emissions Performance Report, Protecting the environment, Page 39   Performance Report Appendix, Metrics summary 306-1 Water discharge by quality and destination Performance Report Appendix, Metrics summary 306-2 Waste by type and disposal method Performance Report Appendix, Metrics summary 306-3 Significant spills No significant spills for 306-4 Transport of hazardous waste Performance Report Appendix, Metrics summary 307-1 Non-compliance with environmental laws and regulation Performance Report Appendix, Metrics summary 308-1 New suppliers that were screened using   environmental criteriaPerformance Report, Creating value responsibly, Page 48  2021 Performance ReportIntroduction Transforming care Investing in   our people Accelerating   possibilities Protecting the  environment Creating value  responsibly Appendix Stakeholder engagement Metrics summary Global Reporting Initiative  (GRI) index Sustainability Accounting  Standards Board   (SASB) index United Nations  Sustainable Development  Goals (SDGs) Indicator Description Response GRI 401-1 New employee hires and employee turnover Performance Report Appendix, Metrics summary 401-2 Benefits provided to full-time employees that are not  provided to temporary or part-time employeesBenefits 401-3 Parental leave Benefits 403-2 Types of injury and rates of injury, occupational   diseases, lost days, and absenteeism and number   of work-related fatalitiesPerformance Report Appendix, Metrics summary 404-1 Average hours of training per year per employee Performance Report Appendix, Metrics summary 404-2 Programs for upgrading employee skills and transition  assistance programsPerformance Report, Investing in our people, Page 404-3 Percentage of employees receiving regular performance  and career development reviewsPerformance Report, Investing in our people, Page 20  405-1 Diversity of governance bodies and employees Proxy Statement  Performance Appendix, Metrics summary 405-2 Ratio of basic salary and remuneration of women to men Performance Report, Investing in our people, Page 20  Equal Pay for Equal Work 406-1 Incidents of discrimination and corrective actions taken Compliance and Ethics  407-1 Operations and suppliers in which the right to freedom   of association and collective bargaining may be at riskHuman Rights 408-1 Operations and suppliers at significant risk for incidence   of child laborHuman Rights 409-1 Operations and suppliers at significant risk for incidence   of forced or compulsory laborHuman Rights 411-1 Incidents of violations involving rights of   indigenous peoplesHuman Rights 2021 Performance ReportIntroduction Transforming care Investing in   our people Accelerating   possibilities Protecting the  environment Creating value  responsibly Appendix Stakeholder engagement Metrics summary Global Reporting Initiative  (GRI) index Sustainability Accounting  Standards Board   (SASB) index United Nations  Sustainable Development  Goals (SDGs) Indicator Description Response 412-1 Operations that have been subject to human rights reviews  or impact assessmentsHuman Rights 412-2 Employee training on human rights policies or procedures Human Rights 413-1 Operations with local community engagement, impact  assessments and development programsPerformance Report, Supporting our communities, Page 36   Community Engagement 414-1 New suppliers that were screened using social criteria Performance Report, Creating value responsibly, Page 48  415-1 Political contributions Political Contributions 416-1 Assessment of the health and safety impacts of product  and service categoriesPerformance Report, Ensuring quality, health and safety, Page 416-2 Incidents of non-compliance concerning the health   and safety impacts of products and servicesPerformance Report, Ensuring quality, health and safety, Page 17  417-1 Requirements for product and service information   and labelingPerformance Report, Ensuring quality, health and safety, Page 17  Performance Report, Advancing product stewardship, Page 419-1 Non-compliance with laws and regulations in the social  and economic areaBoston Scientific adheres to all compliance requirements, see compliance references  throughout the Performance Report and BostonScientific.com   2021 Performance ReportIntroduction Transforming care Investing in   our people Accelerating   possibilities Protecting the  environment Creating value  responsibly Appendix Stakeholder engagement Metrics summary Global Reporting Initiative  (GRI) index Sustainability Accounting  Standards Board   (SASB) index United Nations  Sustainable Development  Goals (SDGs) Topic Accounting metric Code Response Affordability   and pricingRatio of weighted average rate of net price increases  (for all products) to the annual increase in the U.S.  Consumer Price IndexHC-MS-240a.1 Not currently disclosed Description of how price information for each product  is disclosed to customers or to their agentsHC-MS-240a.2 Form 10-K, Health Care Policies and Reimbursement, Pages 13-Product safety Number of recalls issued, total units recalled HC-MS-250a.1 Class I recalls: 3  Class II recalls: 8  Total units recalled: 47,List of products listed in the FDA's MedWatch  Safety Alerts for Human Medical Products databaseHC-MS-250a.2 FDA's MedWatch Safety Alerts for Human Medical Products database Number of fatalities related to products as reported  in the FDA Manufacturer and User Facility Device  ExperienceHC-MS-250a.3 FDA Manufacturer and User Facility Device Experience (MAUDE) database Number of FDA enforcement actions taken in  response to violations of current Good Manufacturing  Practices (cGMP), by typeHC-MS-250a.4 0 in Ethical marketing Total amount of monetary losses as a result of legal  proceedings associated with false marketing claimsHC-MS-270a.1 $0 in Description of code of ethics governing promotion  of off-label use of productsHC-MS-270a.2 Code of Conduct, Page 40;   Performance Report, Creating value responsibly, Page 48Sustainability Accounting Standards Board (SASB) index SASB is an independent standards-setting organization dedicated to improving the effectiveness and comparability of corporate disclosure on ESG factors.
","('GHG_Emissions', 0.9684056043624878)","('Air_Quality', 0.00426101079210639)","('Ecological_Impacts', 0.0033190862741321325)","(['Climate Change'], 0.9684056043624878)","('NON-ESG', 0.00426101079210639)","('NON-ESG', 0.0033190862741321325)"
Line 722,"Commitments and Contingencies, Page 2021 Performance ReportIntroduction Transforming care Investing in   our people Accelerating   possibilities Protecting the  environment Creating value  responsibly Appendix Stakeholder engagement Metrics summary Global Reporting Initiative  (GRI) index Sustainability Accounting  Standards Board   (SASB) index United Nations  Sustainable Development  Goals (SDGs) Indicator Description Response GRI 302-1 Energy consumption within the organization Performance Report, GEMS KPIs, Page 41  Performance Report Appendix, Metrics summary 302-3 Energy intensity Performance Report, GEMS KPIs, Page 41  Performance Report Appendix, Metrics summary 302-4 Reduction of energy consumption Performance Report, GEMS KPIs, Page 41  Performance Report Appendix, Metrics summary 302-5 Reductions in energy requirements of products   and servicesPerformance Report, GEMS KPIs, Page 41  Performance Report, Advancing product stewardship, Page 46  Performance Report Appendix, Metrics summary 303-1 Water withdrawal Performance Report Appendix, Metrics summary 303-2 Water discharge Performance Report Appendix, Metrics summary 303-3 Water consumption Performance Report Appendix, Metrics summary 305-1 Direct (Scope 1) GHG emissions Performance Report Appendix, Metrics summary 305-2 Energy indirect (Scope 2) GHG emissions Performance Report Appendix, Metrics summary 305-5 Reduction of GHG emissions Performance Report, Protecting the environment, Page 39   Performance Report Appendix, Metrics summary 306-1 Water discharge by quality and destination Performance Report Appendix, Metrics summary 306-2 Waste by type and disposal method Performance Report Appendix, Metrics summary 306-3 Significant spills No significant spills for 306-4 Transport of hazardous waste Performance Report Appendix, Metrics summary 307-1 Non-compliance with environmental laws and regulation Performance Report Appendix, Metrics summary 308-1 New suppliers that were screened using   environmental criteriaPerformance Report, Creating value responsibly, Page 48  2021 Performance ReportIntroduction Transforming care Investing in   our people Accelerating   possibilities Protecting the  environment Creating value  responsibly Appendix Stakeholder engagement Metrics summary Global Reporting Initiative  (GRI) index Sustainability Accounting  Standards Board   (SASB) index United Nations  Sustainable Development  Goals (SDGs) Indicator Description Response GRI 401-1 New employee hires and employee turnover Performance Report Appendix, Metrics summary 401-2 Benefits provided to full-time employees that are not  provided to temporary or part-time employeesBenefits 401-3 Parental leave Benefits 403-2 Types of injury and rates of injury, occupational   diseases, lost days, and absenteeism and number   of work-related fatalitiesPerformance Report Appendix, Metrics summary 404-1 Average hours of training per year per employee Performance Report Appendix, Metrics summary 404-2 Programs for upgrading employee skills and transition  assistance programsPerformance Report, Investing in our people, Page 404-3 Percentage of employees receiving regular performance  and career development reviewsPerformance Report, Investing in our people, Page 20  405-1 Diversity of governance bodies and employees Proxy Statement  Performance Appendix, Metrics summary 405-2 Ratio of basic salary and remuneration of women to men Performance Report, Investing in our people, Page 20  Equal Pay for Equal Work 406-1 Incidents of discrimination and corrective actions taken Compliance and Ethics  407-1 Operations and suppliers in which the right to freedom   of association and collective bargaining may be at riskHuman Rights 408-1 Operations and suppliers at significant risk for incidence   of child laborHuman Rights 409-1 Operations and suppliers at significant risk for incidence   of forced or compulsory laborHuman Rights 411-1 Incidents of violations involving rights of   indigenous peoplesHuman Rights 2021 Performance ReportIntroduction Transforming care Investing in   our people Accelerating   possibilities Protecting the  environment Creating value  responsibly Appendix Stakeholder engagement Metrics summary Global Reporting Initiative  (GRI) index Sustainability Accounting  Standards Board   (SASB) index United Nations  Sustainable Development  Goals (SDGs) Indicator Description Response 412-1 Operations that have been subject to human rights reviews  or impact assessmentsHuman Rights 412-2 Employee training on human rights policies or procedures Human Rights 413-1 Operations with local community engagement, impact  assessments and development programsPerformance Report, Supporting our communities, Page 36   Community Engagement 414-1 New suppliers that were screened using social criteria Performance Report, Creating value responsibly, Page 48  415-1 Political contributions Political Contributions 416-1 Assessment of the health and safety impacts of product  and service categoriesPerformance Report, Ensuring quality, health and safety, Page 416-2 Incidents of non-compliance concerning the health   and safety impacts of products and servicesPerformance Report, Ensuring quality, health and safety, Page 17  417-1 Requirements for product and service information   and labelingPerformance Report, Ensuring quality, health and safety, Page 17  Performance Report, Advancing product stewardship, Page 419-1 Non-compliance with laws and regulations in the social  and economic areaBoston Scientific adheres to all compliance requirements, see compliance references  throughout the Performance Report and BostonScientific.com   2021 Performance ReportIntroduction Transforming care Investing in   our people Accelerating   possibilities Protecting the  environment Creating value  responsibly Appendix Stakeholder engagement Metrics summary Global Reporting Initiative  (GRI) index Sustainability Accounting  Standards Board   (SASB) index United Nations  Sustainable Development  Goals (SDGs) Topic Accounting metric Code Response Affordability   and pricingRatio of weighted average rate of net price increases  (for all products) to the annual increase in the U.S.  Consumer Price IndexHC-MS-240a.1 Not currently disclosed Description of how price information for each product  is disclosed to customers or to their agentsHC-MS-240a.2 Form 10-K, Health Care Policies and Reimbursement, Pages 13-Product safety Number of recalls issued, total units recalled HC-MS-250a.1 Class I recalls: 3  Class II recalls: 8  Total units recalled: 47,List of products listed in the FDA's MedWatch  Safety Alerts for Human Medical Products databaseHC-MS-250a.2 FDA's MedWatch Safety Alerts for Human Medical Products database Number of fatalities related to products as reported  in the FDA Manufacturer and User Facility Device  ExperienceHC-MS-250a.3 FDA Manufacturer and User Facility Device Experience (MAUDE) database Number of FDA enforcement actions taken in  response to violations of current Good Manufacturing  Practices (cGMP), by typeHC-MS-250a.4 0 in Ethical marketing Total amount of monetary losses as a result of legal  proceedings associated with false marketing claimsHC-MS-270a.1 $0 in Description of code of ethics governing promotion  of off-label use of productsHC-MS-270a.2 Code of Conduct, Page 40;   Performance Report, Creating value responsibly, Page 48Sustainability Accounting Standards Board (SASB) index SASB is an independent standards-setting organization dedicated to improving the effectiveness and comparability of corporate disclosure on ESG factors.
","('Waste_And_Hazardous_Materials_Management', 0.9800598621368408)","('Water_And_Wastewater_Management', 0.0017031632596626878)","('Air_Quality', 0.0015571743715554476)","(['Operational Eco-Efficiency'], 0.9800598621368408)","('NON-ESG', 0.0017031632596626878)","('NON-ESG', 0.0015571743715554476)"
Line 723,"Commitments and Contingencies, Page 2021 Performance ReportIntroduction Transforming care Investing in   our people Accelerating   possibilities Protecting the  environment Creating value  responsibly Appendix Stakeholder engagement Metrics summary Global Reporting Initiative  (GRI) index Sustainability Accounting  Standards Board   (SASB) index United Nations  Sustainable Development  Goals (SDGs) Indicator Description Response GRI 302-1 Energy consumption within the organization Performance Report, GEMS KPIs, Page 41  Performance Report Appendix, Metrics summary 302-3 Energy intensity Performance Report, GEMS KPIs, Page 41  Performance Report Appendix, Metrics summary 302-4 Reduction of energy consumption Performance Report, GEMS KPIs, Page 41  Performance Report Appendix, Metrics summary 302-5 Reductions in energy requirements of products   and servicesPerformance Report, GEMS KPIs, Page 41  Performance Report, Advancing product stewardship, Page 46  Performance Report Appendix, Metrics summary 303-1 Water withdrawal Performance Report Appendix, Metrics summary 303-2 Water discharge Performance Report Appendix, Metrics summary 303-3 Water consumption Performance Report Appendix, Metrics summary 305-1 Direct (Scope 1) GHG emissions Performance Report Appendix, Metrics summary 305-2 Energy indirect (Scope 2) GHG emissions Performance Report Appendix, Metrics summary 305-5 Reduction of GHG emissions Performance Report, Protecting the environment, Page 39   Performance Report Appendix, Metrics summary 306-1 Water discharge by quality and destination Performance Report Appendix, Metrics summary 306-2 Waste by type and disposal method Performance Report Appendix, Metrics summary 306-3 Significant spills No significant spills for 306-4 Transport of hazardous waste Performance Report Appendix, Metrics summary 307-1 Non-compliance with environmental laws and regulation Performance Report Appendix, Metrics summary 308-1 New suppliers that were screened using   environmental criteriaPerformance Report, Creating value responsibly, Page 48  2021 Performance ReportIntroduction Transforming care Investing in   our people Accelerating   possibilities Protecting the  environment Creating value  responsibly Appendix Stakeholder engagement Metrics summary Global Reporting Initiative  (GRI) index Sustainability Accounting  Standards Board   (SASB) index United Nations  Sustainable Development  Goals (SDGs) Indicator Description Response GRI 401-1 New employee hires and employee turnover Performance Report Appendix, Metrics summary 401-2 Benefits provided to full-time employees that are not  provided to temporary or part-time employeesBenefits 401-3 Parental leave Benefits 403-2 Types of injury and rates of injury, occupational   diseases, lost days, and absenteeism and number   of work-related fatalitiesPerformance Report Appendix, Metrics summary 404-1 Average hours of training per year per employee Performance Report Appendix, Metrics summary 404-2 Programs for upgrading employee skills and transition  assistance programsPerformance Report, Investing in our people, Page 404-3 Percentage of employees receiving regular performance  and career development reviewsPerformance Report, Investing in our people, Page 20  405-1 Diversity of governance bodies and employees Proxy Statement  Performance Appendix, Metrics summary 405-2 Ratio of basic salary and remuneration of women to men Performance Report, Investing in our people, Page 20  Equal Pay for Equal Work 406-1 Incidents of discrimination and corrective actions taken Compliance and Ethics  407-1 Operations and suppliers in which the right to freedom   of association and collective bargaining may be at riskHuman Rights 408-1 Operations and suppliers at significant risk for incidence   of child laborHuman Rights 409-1 Operations and suppliers at significant risk for incidence   of forced or compulsory laborHuman Rights 411-1 Incidents of violations involving rights of   indigenous peoplesHuman Rights 2021 Performance ReportIntroduction Transforming care Investing in   our people Accelerating   possibilities Protecting the  environment Creating value  responsibly Appendix Stakeholder engagement Metrics summary Global Reporting Initiative  (GRI) index Sustainability Accounting  Standards Board   (SASB) index United Nations  Sustainable Development  Goals (SDGs) Indicator Description Response 412-1 Operations that have been subject to human rights reviews  or impact assessmentsHuman Rights 412-2 Employee training on human rights policies or procedures Human Rights 413-1 Operations with local community engagement, impact  assessments and development programsPerformance Report, Supporting our communities, Page 36   Community Engagement 414-1 New suppliers that were screened using social criteria Performance Report, Creating value responsibly, Page 48  415-1 Political contributions Political Contributions 416-1 Assessment of the health and safety impacts of product  and service categoriesPerformance Report, Ensuring quality, health and safety, Page 416-2 Incidents of non-compliance concerning the health   and safety impacts of products and servicesPerformance Report, Ensuring quality, health and safety, Page 17  417-1 Requirements for product and service information   and labelingPerformance Report, Ensuring quality, health and safety, Page 17  Performance Report, Advancing product stewardship, Page 419-1 Non-compliance with laws and regulations in the social  and economic areaBoston Scientific adheres to all compliance requirements, see compliance references  throughout the Performance Report and BostonScientific.com   2021 Performance ReportIntroduction Transforming care Investing in   our people Accelerating   possibilities Protecting the  environment Creating value  responsibly Appendix Stakeholder engagement Metrics summary Global Reporting Initiative  (GRI) index Sustainability Accounting  Standards Board   (SASB) index United Nations  Sustainable Development  Goals (SDGs) Topic Accounting metric Code Response Affordability   and pricingRatio of weighted average rate of net price increases  (for all products) to the annual increase in the U.S.  Consumer Price IndexHC-MS-240a.1 Not currently disclosed Description of how price information for each product  is disclosed to customers or to their agentsHC-MS-240a.2 Form 10-K, Health Care Policies and Reimbursement, Pages 13-Product safety Number of recalls issued, total units recalled HC-MS-250a.1 Class I recalls: 3  Class II recalls: 8  Total units recalled: 47,List of products listed in the FDA's MedWatch  Safety Alerts for Human Medical Products databaseHC-MS-250a.2 FDA's MedWatch Safety Alerts for Human Medical Products database Number of fatalities related to products as reported  in the FDA Manufacturer and User Facility Device  ExperienceHC-MS-250a.3 FDA Manufacturer and User Facility Device Experience (MAUDE) database Number of FDA enforcement actions taken in  response to violations of current Good Manufacturing  Practices (cGMP), by typeHC-MS-250a.4 0 in Ethical marketing Total amount of monetary losses as a result of legal  proceedings associated with false marketing claimsHC-MS-270a.1 $0 in Description of code of ethics governing promotion  of off-label use of productsHC-MS-270a.2 Code of Conduct, Page 40;   Performance Report, Creating value responsibly, Page 48Sustainability Accounting Standards Board (SASB) index SASB is an independent standards-setting organization dedicated to improving the effectiveness and comparability of corporate disclosure on ESG factors.
","('Employee_Engagement_Inclusion_And_Diversity', 0.6442937254905701)","('Labor_Practices', 0.129219189286232)","('Employee_Health_And_Safety', 0.07361860573291779)","(['Human Capital Development'], 0.6442937254905701)","('NON-ESG', 0.129219189286232)","('NON-ESG', 0.07361860573291779)"
Line 724,"Commitments and Contingencies, Page 2021 Performance ReportIntroduction Transforming care Investing in   our people Accelerating   possibilities Protecting the  environment Creating value  responsibly Appendix Stakeholder engagement Metrics summary Global Reporting Initiative  (GRI) index Sustainability Accounting  Standards Board   (SASB) index United Nations  Sustainable Development  Goals (SDGs) Indicator Description Response GRI 302-1 Energy consumption within the organization Performance Report, GEMS KPIs, Page 41  Performance Report Appendix, Metrics summary 302-3 Energy intensity Performance Report, GEMS KPIs, Page 41  Performance Report Appendix, Metrics summary 302-4 Reduction of energy consumption Performance Report, GEMS KPIs, Page 41  Performance Report Appendix, Metrics summary 302-5 Reductions in energy requirements of products   and servicesPerformance Report, GEMS KPIs, Page 41  Performance Report, Advancing product stewardship, Page 46  Performance Report Appendix, Metrics summary 303-1 Water withdrawal Performance Report Appendix, Metrics summary 303-2 Water discharge Performance Report Appendix, Metrics summary 303-3 Water consumption Performance Report Appendix, Metrics summary 305-1 Direct (Scope 1) GHG emissions Performance Report Appendix, Metrics summary 305-2 Energy indirect (Scope 2) GHG emissions Performance Report Appendix, Metrics summary 305-5 Reduction of GHG emissions Performance Report, Protecting the environment, Page 39   Performance Report Appendix, Metrics summary 306-1 Water discharge by quality and destination Performance Report Appendix, Metrics summary 306-2 Waste by type and disposal method Performance Report Appendix, Metrics summary 306-3 Significant spills No significant spills for 306-4 Transport of hazardous waste Performance Report Appendix, Metrics summary 307-1 Non-compliance with environmental laws and regulation Performance Report Appendix, Metrics summary 308-1 New suppliers that were screened using   environmental criteriaPerformance Report, Creating value responsibly, Page 48  2021 Performance ReportIntroduction Transforming care Investing in   our people Accelerating   possibilities Protecting the  environment Creating value  responsibly Appendix Stakeholder engagement Metrics summary Global Reporting Initiative  (GRI) index Sustainability Accounting  Standards Board   (SASB) index United Nations  Sustainable Development  Goals (SDGs) Indicator Description Response GRI 401-1 New employee hires and employee turnover Performance Report Appendix, Metrics summary 401-2 Benefits provided to full-time employees that are not  provided to temporary or part-time employeesBenefits 401-3 Parental leave Benefits 403-2 Types of injury and rates of injury, occupational   diseases, lost days, and absenteeism and number   of work-related fatalitiesPerformance Report Appendix, Metrics summary 404-1 Average hours of training per year per employee Performance Report Appendix, Metrics summary 404-2 Programs for upgrading employee skills and transition  assistance programsPerformance Report, Investing in our people, Page 404-3 Percentage of employees receiving regular performance  and career development reviewsPerformance Report, Investing in our people, Page 20  405-1 Diversity of governance bodies and employees Proxy Statement  Performance Appendix, Metrics summary 405-2 Ratio of basic salary and remuneration of women to men Performance Report, Investing in our people, Page 20  Equal Pay for Equal Work 406-1 Incidents of discrimination and corrective actions taken Compliance and Ethics  407-1 Operations and suppliers in which the right to freedom   of association and collective bargaining may be at riskHuman Rights 408-1 Operations and suppliers at significant risk for incidence   of child laborHuman Rights 409-1 Operations and suppliers at significant risk for incidence   of forced or compulsory laborHuman Rights 411-1 Incidents of violations involving rights of   indigenous peoplesHuman Rights 2021 Performance ReportIntroduction Transforming care Investing in   our people Accelerating   possibilities Protecting the  environment Creating value  responsibly Appendix Stakeholder engagement Metrics summary Global Reporting Initiative  (GRI) index Sustainability Accounting  Standards Board   (SASB) index United Nations  Sustainable Development  Goals (SDGs) Indicator Description Response 412-1 Operations that have been subject to human rights reviews  or impact assessmentsHuman Rights 412-2 Employee training on human rights policies or procedures Human Rights 413-1 Operations with local community engagement, impact  assessments and development programsPerformance Report, Supporting our communities, Page 36   Community Engagement 414-1 New suppliers that were screened using social criteria Performance Report, Creating value responsibly, Page 48  415-1 Political contributions Political Contributions 416-1 Assessment of the health and safety impacts of product  and service categoriesPerformance Report, Ensuring quality, health and safety, Page 416-2 Incidents of non-compliance concerning the health   and safety impacts of products and servicesPerformance Report, Ensuring quality, health and safety, Page 17  417-1 Requirements for product and service information   and labelingPerformance Report, Ensuring quality, health and safety, Page 17  Performance Report, Advancing product stewardship, Page 419-1 Non-compliance with laws and regulations in the social  and economic areaBoston Scientific adheres to all compliance requirements, see compliance references  throughout the Performance Report and BostonScientific.com   2021 Performance ReportIntroduction Transforming care Investing in   our people Accelerating   possibilities Protecting the  environment Creating value  responsibly Appendix Stakeholder engagement Metrics summary Global Reporting Initiative  (GRI) index Sustainability Accounting  Standards Board   (SASB) index United Nations  Sustainable Development  Goals (SDGs) Topic Accounting metric Code Response Affordability   and pricingRatio of weighted average rate of net price increases  (for all products) to the annual increase in the U.S.  Consumer Price IndexHC-MS-240a.1 Not currently disclosed Description of how price information for each product  is disclosed to customers or to their agentsHC-MS-240a.2 Form 10-K, Health Care Policies and Reimbursement, Pages 13-Product safety Number of recalls issued, total units recalled HC-MS-250a.1 Class I recalls: 3  Class II recalls: 8  Total units recalled: 47,List of products listed in the FDA's MedWatch  Safety Alerts for Human Medical Products databaseHC-MS-250a.2 FDA's MedWatch Safety Alerts for Human Medical Products database Number of fatalities related to products as reported  in the FDA Manufacturer and User Facility Device  ExperienceHC-MS-250a.3 FDA Manufacturer and User Facility Device Experience (MAUDE) database Number of FDA enforcement actions taken in  response to violations of current Good Manufacturing  Practices (cGMP), by typeHC-MS-250a.4 0 in Ethical marketing Total amount of monetary losses as a result of legal  proceedings associated with false marketing claimsHC-MS-270a.1 $0 in Description of code of ethics governing promotion  of off-label use of productsHC-MS-270a.2 Code of Conduct, Page 40;   Performance Report, Creating value responsibly, Page 48Sustainability Accounting Standards Board (SASB) index SASB is an independent standards-setting organization dedicated to improving the effectiveness and comparability of corporate disclosure on ESG factors.
","('Employee_Health_And_Safety', 0.9172723889350891)","('Labor_Practices', 0.026772448793053627)","('Employee_Engagement_Inclusion_And_Diversity', 0.016872111707925797)","(['Operational Eco-Efficiency'], 0.9172723889350891)","('NON-ESG', 0.026772448793053627)","('NON-ESG', 0.016872111707925797)"
Line 725,"Commitments and Contingencies, Page 2021 Performance ReportIntroduction Transforming care Investing in   our people Accelerating   possibilities Protecting the  environment Creating value  responsibly Appendix Stakeholder engagement Metrics summary Global Reporting Initiative  (GRI) index Sustainability Accounting  Standards Board   (SASB) index United Nations  Sustainable Development  Goals (SDGs) Indicator Description Response GRI 302-1 Energy consumption within the organization Performance Report, GEMS KPIs, Page 41  Performance Report Appendix, Metrics summary 302-3 Energy intensity Performance Report, GEMS KPIs, Page 41  Performance Report Appendix, Metrics summary 302-4 Reduction of energy consumption Performance Report, GEMS KPIs, Page 41  Performance Report Appendix, Metrics summary 302-5 Reductions in energy requirements of products   and servicesPerformance Report, GEMS KPIs, Page 41  Performance Report, Advancing product stewardship, Page 46  Performance Report Appendix, Metrics summary 303-1 Water withdrawal Performance Report Appendix, Metrics summary 303-2 Water discharge Performance Report Appendix, Metrics summary 303-3 Water consumption Performance Report Appendix, Metrics summary 305-1 Direct (Scope 1) GHG emissions Performance Report Appendix, Metrics summary 305-2 Energy indirect (Scope 2) GHG emissions Performance Report Appendix, Metrics summary 305-5 Reduction of GHG emissions Performance Report, Protecting the environment, Page 39   Performance Report Appendix, Metrics summary 306-1 Water discharge by quality and destination Performance Report Appendix, Metrics summary 306-2 Waste by type and disposal method Performance Report Appendix, Metrics summary 306-3 Significant spills No significant spills for 306-4 Transport of hazardous waste Performance Report Appendix, Metrics summary 307-1 Non-compliance with environmental laws and regulation Performance Report Appendix, Metrics summary 308-1 New suppliers that were screened using   environmental criteriaPerformance Report, Creating value responsibly, Page 48  2021 Performance ReportIntroduction Transforming care Investing in   our people Accelerating   possibilities Protecting the  environment Creating value  responsibly Appendix Stakeholder engagement Metrics summary Global Reporting Initiative  (GRI) index Sustainability Accounting  Standards Board   (SASB) index United Nations  Sustainable Development  Goals (SDGs) Indicator Description Response GRI 401-1 New employee hires and employee turnover Performance Report Appendix, Metrics summary 401-2 Benefits provided to full-time employees that are not  provided to temporary or part-time employeesBenefits 401-3 Parental leave Benefits 403-2 Types of injury and rates of injury, occupational   diseases, lost days, and absenteeism and number   of work-related fatalitiesPerformance Report Appendix, Metrics summary 404-1 Average hours of training per year per employee Performance Report Appendix, Metrics summary 404-2 Programs for upgrading employee skills and transition  assistance programsPerformance Report, Investing in our people, Page 404-3 Percentage of employees receiving regular performance  and career development reviewsPerformance Report, Investing in our people, Page 20  405-1 Diversity of governance bodies and employees Proxy Statement  Performance Appendix, Metrics summary 405-2 Ratio of basic salary and remuneration of women to men Performance Report, Investing in our people, Page 20  Equal Pay for Equal Work 406-1 Incidents of discrimination and corrective actions taken Compliance and Ethics  407-1 Operations and suppliers in which the right to freedom   of association and collective bargaining may be at riskHuman Rights 408-1 Operations and suppliers at significant risk for incidence   of child laborHuman Rights 409-1 Operations and suppliers at significant risk for incidence   of forced or compulsory laborHuman Rights 411-1 Incidents of violations involving rights of   indigenous peoplesHuman Rights 2021 Performance ReportIntroduction Transforming care Investing in   our people Accelerating   possibilities Protecting the  environment Creating value  responsibly Appendix Stakeholder engagement Metrics summary Global Reporting Initiative  (GRI) index Sustainability Accounting  Standards Board   (SASB) index United Nations  Sustainable Development  Goals (SDGs) Indicator Description Response 412-1 Operations that have been subject to human rights reviews  or impact assessmentsHuman Rights 412-2 Employee training on human rights policies or procedures Human Rights 413-1 Operations with local community engagement, impact  assessments and development programsPerformance Report, Supporting our communities, Page 36   Community Engagement 414-1 New suppliers that were screened using social criteria Performance Report, Creating value responsibly, Page 48  415-1 Political contributions Political Contributions 416-1 Assessment of the health and safety impacts of product  and service categoriesPerformance Report, Ensuring quality, health and safety, Page 416-2 Incidents of non-compliance concerning the health   and safety impacts of products and servicesPerformance Report, Ensuring quality, health and safety, Page 17  417-1 Requirements for product and service information   and labelingPerformance Report, Ensuring quality, health and safety, Page 17  Performance Report, Advancing product stewardship, Page 419-1 Non-compliance with laws and regulations in the social  and economic areaBoston Scientific adheres to all compliance requirements, see compliance references  throughout the Performance Report and BostonScientific.com   2021 Performance ReportIntroduction Transforming care Investing in   our people Accelerating   possibilities Protecting the  environment Creating value  responsibly Appendix Stakeholder engagement Metrics summary Global Reporting Initiative  (GRI) index Sustainability Accounting  Standards Board   (SASB) index United Nations  Sustainable Development  Goals (SDGs) Topic Accounting metric Code Response Affordability   and pricingRatio of weighted average rate of net price increases  (for all products) to the annual increase in the U.S.  Consumer Price IndexHC-MS-240a.1 Not currently disclosed Description of how price information for each product  is disclosed to customers or to their agentsHC-MS-240a.2 Form 10-K, Health Care Policies and Reimbursement, Pages 13-Product safety Number of recalls issued, total units recalled HC-MS-250a.1 Class I recalls: 3  Class II recalls: 8  Total units recalled: 47,List of products listed in the FDA's MedWatch  Safety Alerts for Human Medical Products databaseHC-MS-250a.2 FDA's MedWatch Safety Alerts for Human Medical Products database Number of fatalities related to products as reported  in the FDA Manufacturer and User Facility Device  ExperienceHC-MS-250a.3 FDA Manufacturer and User Facility Device Experience (MAUDE) database Number of FDA enforcement actions taken in  response to violations of current Good Manufacturing  Practices (cGMP), by typeHC-MS-250a.4 0 in Ethical marketing Total amount of monetary losses as a result of legal  proceedings associated with false marketing claimsHC-MS-270a.1 $0 in Description of code of ethics governing promotion  of off-label use of productsHC-MS-270a.2 Code of Conduct, Page 40;   Performance Report, Creating value responsibly, Page 48Sustainability Accounting Standards Board (SASB) index SASB is an independent standards-setting organization dedicated to improving the effectiveness and comparability of corporate disclosure on ESG factors.
","('Employee_Engagement_Inclusion_And_Diversity', 0.9430774450302124)","('Labor_Practices', 0.017680255696177483)","('Employee_Health_And_Safety', 0.005049563944339752)","(['Human Capital Development'], 0.9430774450302124)","('NON-ESG', 0.017680255696177483)","('NON-ESG', 0.005049563944339752)"
Line 726,"Commitments and Contingencies, Page 2021 Performance ReportIntroduction Transforming care Investing in   our people Accelerating   possibilities Protecting the  environment Creating value  responsibly Appendix Stakeholder engagement Metrics summary Global Reporting Initiative  (GRI) index Sustainability Accounting  Standards Board   (SASB) index United Nations  Sustainable Development  Goals (SDGs) Indicator Description Response GRI 302-1 Energy consumption within the organization Performance Report, GEMS KPIs, Page 41  Performance Report Appendix, Metrics summary 302-3 Energy intensity Performance Report, GEMS KPIs, Page 41  Performance Report Appendix, Metrics summary 302-4 Reduction of energy consumption Performance Report, GEMS KPIs, Page 41  Performance Report Appendix, Metrics summary 302-5 Reductions in energy requirements of products   and servicesPerformance Report, GEMS KPIs, Page 41  Performance Report, Advancing product stewardship, Page 46  Performance Report Appendix, Metrics summary 303-1 Water withdrawal Performance Report Appendix, Metrics summary 303-2 Water discharge Performance Report Appendix, Metrics summary 303-3 Water consumption Performance Report Appendix, Metrics summary 305-1 Direct (Scope 1) GHG emissions Performance Report Appendix, Metrics summary 305-2 Energy indirect (Scope 2) GHG emissions Performance Report Appendix, Metrics summary 305-5 Reduction of GHG emissions Performance Report, Protecting the environment, Page 39   Performance Report Appendix, Metrics summary 306-1 Water discharge by quality and destination Performance Report Appendix, Metrics summary 306-2 Waste by type and disposal method Performance Report Appendix, Metrics summary 306-3 Significant spills No significant spills for 306-4 Transport of hazardous waste Performance Report Appendix, Metrics summary 307-1 Non-compliance with environmental laws and regulation Performance Report Appendix, Metrics summary 308-1 New suppliers that were screened using   environmental criteriaPerformance Report, Creating value responsibly, Page 48  2021 Performance ReportIntroduction Transforming care Investing in   our people Accelerating   possibilities Protecting the  environment Creating value  responsibly Appendix Stakeholder engagement Metrics summary Global Reporting Initiative  (GRI) index Sustainability Accounting  Standards Board   (SASB) index United Nations  Sustainable Development  Goals (SDGs) Indicator Description Response GRI 401-1 New employee hires and employee turnover Performance Report Appendix, Metrics summary 401-2 Benefits provided to full-time employees that are not  provided to temporary or part-time employeesBenefits 401-3 Parental leave Benefits 403-2 Types of injury and rates of injury, occupational   diseases, lost days, and absenteeism and number   of work-related fatalitiesPerformance Report Appendix, Metrics summary 404-1 Average hours of training per year per employee Performance Report Appendix, Metrics summary 404-2 Programs for upgrading employee skills and transition  assistance programsPerformance Report, Investing in our people, Page 404-3 Percentage of employees receiving regular performance  and career development reviewsPerformance Report, Investing in our people, Page 20  405-1 Diversity of governance bodies and employees Proxy Statement  Performance Appendix, Metrics summary 405-2 Ratio of basic salary and remuneration of women to men Performance Report, Investing in our people, Page 20  Equal Pay for Equal Work 406-1 Incidents of discrimination and corrective actions taken Compliance and Ethics  407-1 Operations and suppliers in which the right to freedom   of association and collective bargaining may be at riskHuman Rights 408-1 Operations and suppliers at significant risk for incidence   of child laborHuman Rights 409-1 Operations and suppliers at significant risk for incidence   of forced or compulsory laborHuman Rights 411-1 Incidents of violations involving rights of   indigenous peoplesHuman Rights 2021 Performance ReportIntroduction Transforming care Investing in   our people Accelerating   possibilities Protecting the  environment Creating value  responsibly Appendix Stakeholder engagement Metrics summary Global Reporting Initiative  (GRI) index Sustainability Accounting  Standards Board   (SASB) index United Nations  Sustainable Development  Goals (SDGs) Indicator Description Response 412-1 Operations that have been subject to human rights reviews  or impact assessmentsHuman Rights 412-2 Employee training on human rights policies or procedures Human Rights 413-1 Operations with local community engagement, impact  assessments and development programsPerformance Report, Supporting our communities, Page 36   Community Engagement 414-1 New suppliers that were screened using social criteria Performance Report, Creating value responsibly, Page 48  415-1 Political contributions Political Contributions 416-1 Assessment of the health and safety impacts of product  and service categoriesPerformance Report, Ensuring quality, health and safety, Page 416-2 Incidents of non-compliance concerning the health   and safety impacts of products and servicesPerformance Report, Ensuring quality, health and safety, Page 17  417-1 Requirements for product and service information   and labelingPerformance Report, Ensuring quality, health and safety, Page 17  Performance Report, Advancing product stewardship, Page 419-1 Non-compliance with laws and regulations in the social  and economic areaBoston Scientific adheres to all compliance requirements, see compliance references  throughout the Performance Report and BostonScientific.com   2021 Performance ReportIntroduction Transforming care Investing in   our people Accelerating   possibilities Protecting the  environment Creating value  responsibly Appendix Stakeholder engagement Metrics summary Global Reporting Initiative  (GRI) index Sustainability Accounting  Standards Board   (SASB) index United Nations  Sustainable Development  Goals (SDGs) Topic Accounting metric Code Response Affordability   and pricingRatio of weighted average rate of net price increases  (for all products) to the annual increase in the U.S.  Consumer Price IndexHC-MS-240a.1 Not currently disclosed Description of how price information for each product  is disclosed to customers or to their agentsHC-MS-240a.2 Form 10-K, Health Care Policies and Reimbursement, Pages 13-Product safety Number of recalls issued, total units recalled HC-MS-250a.1 Class I recalls: 3  Class II recalls: 8  Total units recalled: 47,List of products listed in the FDA's MedWatch  Safety Alerts for Human Medical Products databaseHC-MS-250a.2 FDA's MedWatch Safety Alerts for Human Medical Products database Number of fatalities related to products as reported  in the FDA Manufacturer and User Facility Device  ExperienceHC-MS-250a.3 FDA Manufacturer and User Facility Device Experience (MAUDE) database Number of FDA enforcement actions taken in  response to violations of current Good Manufacturing  Practices (cGMP), by typeHC-MS-250a.4 0 in Ethical marketing Total amount of monetary losses as a result of legal  proceedings associated with false marketing claimsHC-MS-270a.1 $0 in Description of code of ethics governing promotion  of off-label use of productsHC-MS-270a.2 Code of Conduct, Page 40;   Performance Report, Creating value responsibly, Page 48Sustainability Accounting Standards Board (SASB) index SASB is an independent standards-setting organization dedicated to improving the effectiveness and comparability of corporate disclosure on ESG factors.
","('Human_Rights_And_Community_Relations', 0.6752703189849854)","('Labor_Practices', 0.22538809478282928)","('Employee_Engagement_Inclusion_And_Diversity', 0.010667599737644196)","(['Community Relations'], 0.6752703189849854)","('NON-ESG', 0.22538809478282928)","('NON-ESG', 0.010667599737644196)"
Line 727,"Commitments and Contingencies, Page 2021 Performance ReportIntroduction Transforming care Investing in   our people Accelerating   possibilities Protecting the  environment Creating value  responsibly Appendix Stakeholder engagement Metrics summary Global Reporting Initiative  (GRI) index Sustainability Accounting  Standards Board   (SASB) index United Nations  Sustainable Development  Goals (SDGs) Indicator Description Response GRI 302-1 Energy consumption within the organization Performance Report, GEMS KPIs, Page 41  Performance Report Appendix, Metrics summary 302-3 Energy intensity Performance Report, GEMS KPIs, Page 41  Performance Report Appendix, Metrics summary 302-4 Reduction of energy consumption Performance Report, GEMS KPIs, Page 41  Performance Report Appendix, Metrics summary 302-5 Reductions in energy requirements of products   and servicesPerformance Report, GEMS KPIs, Page 41  Performance Report, Advancing product stewardship, Page 46  Performance Report Appendix, Metrics summary 303-1 Water withdrawal Performance Report Appendix, Metrics summary 303-2 Water discharge Performance Report Appendix, Metrics summary 303-3 Water consumption Performance Report Appendix, Metrics summary 305-1 Direct (Scope 1) GHG emissions Performance Report Appendix, Metrics summary 305-2 Energy indirect (Scope 2) GHG emissions Performance Report Appendix, Metrics summary 305-5 Reduction of GHG emissions Performance Report, Protecting the environment, Page 39   Performance Report Appendix, Metrics summary 306-1 Water discharge by quality and destination Performance Report Appendix, Metrics summary 306-2 Waste by type and disposal method Performance Report Appendix, Metrics summary 306-3 Significant spills No significant spills for 306-4 Transport of hazardous waste Performance Report Appendix, Metrics summary 307-1 Non-compliance with environmental laws and regulation Performance Report Appendix, Metrics summary 308-1 New suppliers that were screened using   environmental criteriaPerformance Report, Creating value responsibly, Page 48  2021 Performance ReportIntroduction Transforming care Investing in   our people Accelerating   possibilities Protecting the  environment Creating value  responsibly Appendix Stakeholder engagement Metrics summary Global Reporting Initiative  (GRI) index Sustainability Accounting  Standards Board   (SASB) index United Nations  Sustainable Development  Goals (SDGs) Indicator Description Response GRI 401-1 New employee hires and employee turnover Performance Report Appendix, Metrics summary 401-2 Benefits provided to full-time employees that are not  provided to temporary or part-time employeesBenefits 401-3 Parental leave Benefits 403-2 Types of injury and rates of injury, occupational   diseases, lost days, and absenteeism and number   of work-related fatalitiesPerformance Report Appendix, Metrics summary 404-1 Average hours of training per year per employee Performance Report Appendix, Metrics summary 404-2 Programs for upgrading employee skills and transition  assistance programsPerformance Report, Investing in our people, Page 404-3 Percentage of employees receiving regular performance  and career development reviewsPerformance Report, Investing in our people, Page 20  405-1 Diversity of governance bodies and employees Proxy Statement  Performance Appendix, Metrics summary 405-2 Ratio of basic salary and remuneration of women to men Performance Report, Investing in our people, Page 20  Equal Pay for Equal Work 406-1 Incidents of discrimination and corrective actions taken Compliance and Ethics  407-1 Operations and suppliers in which the right to freedom   of association and collective bargaining may be at riskHuman Rights 408-1 Operations and suppliers at significant risk for incidence   of child laborHuman Rights 409-1 Operations and suppliers at significant risk for incidence   of forced or compulsory laborHuman Rights 411-1 Incidents of violations involving rights of   indigenous peoplesHuman Rights 2021 Performance ReportIntroduction Transforming care Investing in   our people Accelerating   possibilities Protecting the  environment Creating value  responsibly Appendix Stakeholder engagement Metrics summary Global Reporting Initiative  (GRI) index Sustainability Accounting  Standards Board   (SASB) index United Nations  Sustainable Development  Goals (SDGs) Indicator Description Response 412-1 Operations that have been subject to human rights reviews  or impact assessmentsHuman Rights 412-2 Employee training on human rights policies or procedures Human Rights 413-1 Operations with local community engagement, impact  assessments and development programsPerformance Report, Supporting our communities, Page 36   Community Engagement 414-1 New suppliers that were screened using social criteria Performance Report, Creating value responsibly, Page 48  415-1 Political contributions Political Contributions 416-1 Assessment of the health and safety impacts of product  and service categoriesPerformance Report, Ensuring quality, health and safety, Page 416-2 Incidents of non-compliance concerning the health   and safety impacts of products and servicesPerformance Report, Ensuring quality, health and safety, Page 17  417-1 Requirements for product and service information   and labelingPerformance Report, Ensuring quality, health and safety, Page 17  Performance Report, Advancing product stewardship, Page 419-1 Non-compliance with laws and regulations in the social  and economic areaBoston Scientific adheres to all compliance requirements, see compliance references  throughout the Performance Report and BostonScientific.com   2021 Performance ReportIntroduction Transforming care Investing in   our people Accelerating   possibilities Protecting the  environment Creating value  responsibly Appendix Stakeholder engagement Metrics summary Global Reporting Initiative  (GRI) index Sustainability Accounting  Standards Board   (SASB) index United Nations  Sustainable Development  Goals (SDGs) Topic Accounting metric Code Response Affordability   and pricingRatio of weighted average rate of net price increases  (for all products) to the annual increase in the U.S.  Consumer Price IndexHC-MS-240a.1 Not currently disclosed Description of how price information for each product  is disclosed to customers or to their agentsHC-MS-240a.2 Form 10-K, Health Care Policies and Reimbursement, Pages 13-Product safety Number of recalls issued, total units recalled HC-MS-250a.1 Class I recalls: 3  Class II recalls: 8  Total units recalled: 47,List of products listed in the FDA's MedWatch  Safety Alerts for Human Medical Products databaseHC-MS-250a.2 FDA's MedWatch Safety Alerts for Human Medical Products database Number of fatalities related to products as reported  in the FDA Manufacturer and User Facility Device  ExperienceHC-MS-250a.3 FDA Manufacturer and User Facility Device Experience (MAUDE) database Number of FDA enforcement actions taken in  response to violations of current Good Manufacturing  Practices (cGMP), by typeHC-MS-250a.4 0 in Ethical marketing Total amount of monetary losses as a result of legal  proceedings associated with false marketing claimsHC-MS-270a.1 $0 in Description of code of ethics governing promotion  of off-label use of productsHC-MS-270a.2 Code of Conduct, Page 40;   Performance Report, Creating value responsibly, Page 48Sustainability Accounting Standards Board (SASB) index SASB is an independent standards-setting organization dedicated to improving the effectiveness and comparability of corporate disclosure on ESG factors.
","('Human_Rights_And_Community_Relations', 0.9631756544113159)","('Access_And_Affordability', 0.0030750331934541464)","('Labor_Practices', 0.0025492811109870672)","(['Community Relations'], 0.9631756544113159)","('NON-ESG', 0.0030750331934541464)","('NON-ESG', 0.0025492811109870672)"
Line 728,"Commitments and Contingencies, Page 2021 Performance ReportIntroduction Transforming care Investing in   our people Accelerating   possibilities Protecting the  environment Creating value  responsibly Appendix Stakeholder engagement Metrics summary Global Reporting Initiative  (GRI) index Sustainability Accounting  Standards Board   (SASB) index United Nations  Sustainable Development  Goals (SDGs) Indicator Description Response GRI 302-1 Energy consumption within the organization Performance Report, GEMS KPIs, Page 41  Performance Report Appendix, Metrics summary 302-3 Energy intensity Performance Report, GEMS KPIs, Page 41  Performance Report Appendix, Metrics summary 302-4 Reduction of energy consumption Performance Report, GEMS KPIs, Page 41  Performance Report Appendix, Metrics summary 302-5 Reductions in energy requirements of products   and servicesPerformance Report, GEMS KPIs, Page 41  Performance Report, Advancing product stewardship, Page 46  Performance Report Appendix, Metrics summary 303-1 Water withdrawal Performance Report Appendix, Metrics summary 303-2 Water discharge Performance Report Appendix, Metrics summary 303-3 Water consumption Performance Report Appendix, Metrics summary 305-1 Direct (Scope 1) GHG emissions Performance Report Appendix, Metrics summary 305-2 Energy indirect (Scope 2) GHG emissions Performance Report Appendix, Metrics summary 305-5 Reduction of GHG emissions Performance Report, Protecting the environment, Page 39   Performance Report Appendix, Metrics summary 306-1 Water discharge by quality and destination Performance Report Appendix, Metrics summary 306-2 Waste by type and disposal method Performance Report Appendix, Metrics summary 306-3 Significant spills No significant spills for 306-4 Transport of hazardous waste Performance Report Appendix, Metrics summary 307-1 Non-compliance with environmental laws and regulation Performance Report Appendix, Metrics summary 308-1 New suppliers that were screened using   environmental criteriaPerformance Report, Creating value responsibly, Page 48  2021 Performance ReportIntroduction Transforming care Investing in   our people Accelerating   possibilities Protecting the  environment Creating value  responsibly Appendix Stakeholder engagement Metrics summary Global Reporting Initiative  (GRI) index Sustainability Accounting  Standards Board   (SASB) index United Nations  Sustainable Development  Goals (SDGs) Indicator Description Response GRI 401-1 New employee hires and employee turnover Performance Report Appendix, Metrics summary 401-2 Benefits provided to full-time employees that are not  provided to temporary or part-time employeesBenefits 401-3 Parental leave Benefits 403-2 Types of injury and rates of injury, occupational   diseases, lost days, and absenteeism and number   of work-related fatalitiesPerformance Report Appendix, Metrics summary 404-1 Average hours of training per year per employee Performance Report Appendix, Metrics summary 404-2 Programs for upgrading employee skills and transition  assistance programsPerformance Report, Investing in our people, Page 404-3 Percentage of employees receiving regular performance  and career development reviewsPerformance Report, Investing in our people, Page 20  405-1 Diversity of governance bodies and employees Proxy Statement  Performance Appendix, Metrics summary 405-2 Ratio of basic salary and remuneration of women to men Performance Report, Investing in our people, Page 20  Equal Pay for Equal Work 406-1 Incidents of discrimination and corrective actions taken Compliance and Ethics  407-1 Operations and suppliers in which the right to freedom   of association and collective bargaining may be at riskHuman Rights 408-1 Operations and suppliers at significant risk for incidence   of child laborHuman Rights 409-1 Operations and suppliers at significant risk for incidence   of forced or compulsory laborHuman Rights 411-1 Incidents of violations involving rights of   indigenous peoplesHuman Rights 2021 Performance ReportIntroduction Transforming care Investing in   our people Accelerating   possibilities Protecting the  environment Creating value  responsibly Appendix Stakeholder engagement Metrics summary Global Reporting Initiative  (GRI) index Sustainability Accounting  Standards Board   (SASB) index United Nations  Sustainable Development  Goals (SDGs) Indicator Description Response 412-1 Operations that have been subject to human rights reviews  or impact assessmentsHuman Rights 412-2 Employee training on human rights policies or procedures Human Rights 413-1 Operations with local community engagement, impact  assessments and development programsPerformance Report, Supporting our communities, Page 36   Community Engagement 414-1 New suppliers that were screened using social criteria Performance Report, Creating value responsibly, Page 48  415-1 Political contributions Political Contributions 416-1 Assessment of the health and safety impacts of product  and service categoriesPerformance Report, Ensuring quality, health and safety, Page 416-2 Incidents of non-compliance concerning the health   and safety impacts of products and servicesPerformance Report, Ensuring quality, health and safety, Page 17  417-1 Requirements for product and service information   and labelingPerformance Report, Ensuring quality, health and safety, Page 17  Performance Report, Advancing product stewardship, Page 419-1 Non-compliance with laws and regulations in the social  and economic areaBoston Scientific adheres to all compliance requirements, see compliance references  throughout the Performance Report and BostonScientific.com   2021 Performance ReportIntroduction Transforming care Investing in   our people Accelerating   possibilities Protecting the  environment Creating value  responsibly Appendix Stakeholder engagement Metrics summary Global Reporting Initiative  (GRI) index Sustainability Accounting  Standards Board   (SASB) index United Nations  Sustainable Development  Goals (SDGs) Topic Accounting metric Code Response Affordability   and pricingRatio of weighted average rate of net price increases  (for all products) to the annual increase in the U.S.  Consumer Price IndexHC-MS-240a.1 Not currently disclosed Description of how price information for each product  is disclosed to customers or to their agentsHC-MS-240a.2 Form 10-K, Health Care Policies and Reimbursement, Pages 13-Product safety Number of recalls issued, total units recalled HC-MS-250a.1 Class I recalls: 3  Class II recalls: 8  Total units recalled: 47,List of products listed in the FDA's MedWatch  Safety Alerts for Human Medical Products databaseHC-MS-250a.2 FDA's MedWatch Safety Alerts for Human Medical Products database Number of fatalities related to products as reported  in the FDA Manufacturer and User Facility Device  ExperienceHC-MS-250a.3 FDA Manufacturer and User Facility Device Experience (MAUDE) database Number of FDA enforcement actions taken in  response to violations of current Good Manufacturing  Practices (cGMP), by typeHC-MS-250a.4 0 in Ethical marketing Total amount of monetary losses as a result of legal  proceedings associated with false marketing claimsHC-MS-270a.1 $0 in Description of code of ethics governing promotion  of off-label use of productsHC-MS-270a.2 Code of Conduct, Page 40;   Performance Report, Creating value responsibly, Page 48Sustainability Accounting Standards Board (SASB) index SASB is an independent standards-setting organization dedicated to improving the effectiveness and comparability of corporate disclosure on ESG factors.
","('Product_Quality_And_Safety', 0.7070406675338745)","('Product_Design_And_Lifecycle_Management', 0.1727248877286911)","('Selling_Practices_And_Product_Labeling', 0.017913106828927994)","(['Product Quality & Recall Management'], 0.7070406675338745)","('NON-ESG', 0.1727248877286911)","('NON-ESG', 0.017913106828927994)"
Line 729,"Commitments and Contingencies, Page 2021 Performance ReportIntroduction Transforming care Investing in   our people Accelerating   possibilities Protecting the  environment Creating value  responsibly Appendix Stakeholder engagement Metrics summary Global Reporting Initiative  (GRI) index Sustainability Accounting  Standards Board   (SASB) index United Nations  Sustainable Development  Goals (SDGs) Indicator Description Response GRI 302-1 Energy consumption within the organization Performance Report, GEMS KPIs, Page 41  Performance Report Appendix, Metrics summary 302-3 Energy intensity Performance Report, GEMS KPIs, Page 41  Performance Report Appendix, Metrics summary 302-4 Reduction of energy consumption Performance Report, GEMS KPIs, Page 41  Performance Report Appendix, Metrics summary 302-5 Reductions in energy requirements of products   and servicesPerformance Report, GEMS KPIs, Page 41  Performance Report, Advancing product stewardship, Page 46  Performance Report Appendix, Metrics summary 303-1 Water withdrawal Performance Report Appendix, Metrics summary 303-2 Water discharge Performance Report Appendix, Metrics summary 303-3 Water consumption Performance Report Appendix, Metrics summary 305-1 Direct (Scope 1) GHG emissions Performance Report Appendix, Metrics summary 305-2 Energy indirect (Scope 2) GHG emissions Performance Report Appendix, Metrics summary 305-5 Reduction of GHG emissions Performance Report, Protecting the environment, Page 39   Performance Report Appendix, Metrics summary 306-1 Water discharge by quality and destination Performance Report Appendix, Metrics summary 306-2 Waste by type and disposal method Performance Report Appendix, Metrics summary 306-3 Significant spills No significant spills for 306-4 Transport of hazardous waste Performance Report Appendix, Metrics summary 307-1 Non-compliance with environmental laws and regulation Performance Report Appendix, Metrics summary 308-1 New suppliers that were screened using   environmental criteriaPerformance Report, Creating value responsibly, Page 48  2021 Performance ReportIntroduction Transforming care Investing in   our people Accelerating   possibilities Protecting the  environment Creating value  responsibly Appendix Stakeholder engagement Metrics summary Global Reporting Initiative  (GRI) index Sustainability Accounting  Standards Board   (SASB) index United Nations  Sustainable Development  Goals (SDGs) Indicator Description Response GRI 401-1 New employee hires and employee turnover Performance Report Appendix, Metrics summary 401-2 Benefits provided to full-time employees that are not  provided to temporary or part-time employeesBenefits 401-3 Parental leave Benefits 403-2 Types of injury and rates of injury, occupational   diseases, lost days, and absenteeism and number   of work-related fatalitiesPerformance Report Appendix, Metrics summary 404-1 Average hours of training per year per employee Performance Report Appendix, Metrics summary 404-2 Programs for upgrading employee skills and transition  assistance programsPerformance Report, Investing in our people, Page 404-3 Percentage of employees receiving regular performance  and career development reviewsPerformance Report, Investing in our people, Page 20  405-1 Diversity of governance bodies and employees Proxy Statement  Performance Appendix, Metrics summary 405-2 Ratio of basic salary and remuneration of women to men Performance Report, Investing in our people, Page 20  Equal Pay for Equal Work 406-1 Incidents of discrimination and corrective actions taken Compliance and Ethics  407-1 Operations and suppliers in which the right to freedom   of association and collective bargaining may be at riskHuman Rights 408-1 Operations and suppliers at significant risk for incidence   of child laborHuman Rights 409-1 Operations and suppliers at significant risk for incidence   of forced or compulsory laborHuman Rights 411-1 Incidents of violations involving rights of   indigenous peoplesHuman Rights 2021 Performance ReportIntroduction Transforming care Investing in   our people Accelerating   possibilities Protecting the  environment Creating value  responsibly Appendix Stakeholder engagement Metrics summary Global Reporting Initiative  (GRI) index Sustainability Accounting  Standards Board   (SASB) index United Nations  Sustainable Development  Goals (SDGs) Indicator Description Response 412-1 Operations that have been subject to human rights reviews  or impact assessmentsHuman Rights 412-2 Employee training on human rights policies or procedures Human Rights 413-1 Operations with local community engagement, impact  assessments and development programsPerformance Report, Supporting our communities, Page 36   Community Engagement 414-1 New suppliers that were screened using social criteria Performance Report, Creating value responsibly, Page 48  415-1 Political contributions Political Contributions 416-1 Assessment of the health and safety impacts of product  and service categoriesPerformance Report, Ensuring quality, health and safety, Page 416-2 Incidents of non-compliance concerning the health   and safety impacts of products and servicesPerformance Report, Ensuring quality, health and safety, Page 17  417-1 Requirements for product and service information   and labelingPerformance Report, Ensuring quality, health and safety, Page 17  Performance Report, Advancing product stewardship, Page 419-1 Non-compliance with laws and regulations in the social  and economic areaBoston Scientific adheres to all compliance requirements, see compliance references  throughout the Performance Report and BostonScientific.com   2021 Performance ReportIntroduction Transforming care Investing in   our people Accelerating   possibilities Protecting the  environment Creating value  responsibly Appendix Stakeholder engagement Metrics summary Global Reporting Initiative  (GRI) index Sustainability Accounting  Standards Board   (SASB) index United Nations  Sustainable Development  Goals (SDGs) Topic Accounting metric Code Response Affordability   and pricingRatio of weighted average rate of net price increases  (for all products) to the annual increase in the U.S.  Consumer Price IndexHC-MS-240a.1 Not currently disclosed Description of how price information for each product  is disclosed to customers or to their agentsHC-MS-240a.2 Form 10-K, Health Care Policies and Reimbursement, Pages 13-Product safety Number of recalls issued, total units recalled HC-MS-250a.1 Class I recalls: 3  Class II recalls: 8  Total units recalled: 47,List of products listed in the FDA's MedWatch  Safety Alerts for Human Medical Products databaseHC-MS-250a.2 FDA's MedWatch Safety Alerts for Human Medical Products database Number of fatalities related to products as reported  in the FDA Manufacturer and User Facility Device  ExperienceHC-MS-250a.3 FDA Manufacturer and User Facility Device Experience (MAUDE) database Number of FDA enforcement actions taken in  response to violations of current Good Manufacturing  Practices (cGMP), by typeHC-MS-250a.4 0 in Ethical marketing Total amount of monetary losses as a result of legal  proceedings associated with false marketing claimsHC-MS-270a.1 $0 in Description of code of ethics governing promotion  of off-label use of productsHC-MS-270a.2 Code of Conduct, Page 40;   Performance Report, Creating value responsibly, Page 48Sustainability Accounting Standards Board (SASB) index SASB is an independent standards-setting organization dedicated to improving the effectiveness and comparability of corporate disclosure on ESG factors.
","('Product_Quality_And_Safety', 0.8772470355033875)","('Product_Design_And_Lifecycle_Management', 0.03052404336631298)","('Selling_Practices_And_Product_Labeling', 0.017703266814351082)","(['Product Quality & Recall Management'], 0.8772470355033875)","('NON-ESG', 0.03052404336631298)","('NON-ESG', 0.017703266814351082)"
Line 730,"Commitments and Contingencies, Page 2021 Performance ReportIntroduction Transforming care Investing in   our people Accelerating   possibilities Protecting the  environment Creating value  responsibly Appendix Stakeholder engagement Metrics summary Global Reporting Initiative  (GRI) index Sustainability Accounting  Standards Board   (SASB) index United Nations  Sustainable Development  Goals (SDGs) Indicator Description Response GRI 302-1 Energy consumption within the organization Performance Report, GEMS KPIs, Page 41  Performance Report Appendix, Metrics summary 302-3 Energy intensity Performance Report, GEMS KPIs, Page 41  Performance Report Appendix, Metrics summary 302-4 Reduction of energy consumption Performance Report, GEMS KPIs, Page 41  Performance Report Appendix, Metrics summary 302-5 Reductions in energy requirements of products   and servicesPerformance Report, GEMS KPIs, Page 41  Performance Report, Advancing product stewardship, Page 46  Performance Report Appendix, Metrics summary 303-1 Water withdrawal Performance Report Appendix, Metrics summary 303-2 Water discharge Performance Report Appendix, Metrics summary 303-3 Water consumption Performance Report Appendix, Metrics summary 305-1 Direct (Scope 1) GHG emissions Performance Report Appendix, Metrics summary 305-2 Energy indirect (Scope 2) GHG emissions Performance Report Appendix, Metrics summary 305-5 Reduction of GHG emissions Performance Report, Protecting the environment, Page 39   Performance Report Appendix, Metrics summary 306-1 Water discharge by quality and destination Performance Report Appendix, Metrics summary 306-2 Waste by type and disposal method Performance Report Appendix, Metrics summary 306-3 Significant spills No significant spills for 306-4 Transport of hazardous waste Performance Report Appendix, Metrics summary 307-1 Non-compliance with environmental laws and regulation Performance Report Appendix, Metrics summary 308-1 New suppliers that were screened using   environmental criteriaPerformance Report, Creating value responsibly, Page 48  2021 Performance ReportIntroduction Transforming care Investing in   our people Accelerating   possibilities Protecting the  environment Creating value  responsibly Appendix Stakeholder engagement Metrics summary Global Reporting Initiative  (GRI) index Sustainability Accounting  Standards Board   (SASB) index United Nations  Sustainable Development  Goals (SDGs) Indicator Description Response GRI 401-1 New employee hires and employee turnover Performance Report Appendix, Metrics summary 401-2 Benefits provided to full-time employees that are not  provided to temporary or part-time employeesBenefits 401-3 Parental leave Benefits 403-2 Types of injury and rates of injury, occupational   diseases, lost days, and absenteeism and number   of work-related fatalitiesPerformance Report Appendix, Metrics summary 404-1 Average hours of training per year per employee Performance Report Appendix, Metrics summary 404-2 Programs for upgrading employee skills and transition  assistance programsPerformance Report, Investing in our people, Page 404-3 Percentage of employees receiving regular performance  and career development reviewsPerformance Report, Investing in our people, Page 20  405-1 Diversity of governance bodies and employees Proxy Statement  Performance Appendix, Metrics summary 405-2 Ratio of basic salary and remuneration of women to men Performance Report, Investing in our people, Page 20  Equal Pay for Equal Work 406-1 Incidents of discrimination and corrective actions taken Compliance and Ethics  407-1 Operations and suppliers in which the right to freedom   of association and collective bargaining may be at riskHuman Rights 408-1 Operations and suppliers at significant risk for incidence   of child laborHuman Rights 409-1 Operations and suppliers at significant risk for incidence   of forced or compulsory laborHuman Rights 411-1 Incidents of violations involving rights of   indigenous peoplesHuman Rights 2021 Performance ReportIntroduction Transforming care Investing in   our people Accelerating   possibilities Protecting the  environment Creating value  responsibly Appendix Stakeholder engagement Metrics summary Global Reporting Initiative  (GRI) index Sustainability Accounting  Standards Board   (SASB) index United Nations  Sustainable Development  Goals (SDGs) Indicator Description Response 412-1 Operations that have been subject to human rights reviews  or impact assessmentsHuman Rights 412-2 Employee training on human rights policies or procedures Human Rights 413-1 Operations with local community engagement, impact  assessments and development programsPerformance Report, Supporting our communities, Page 36   Community Engagement 414-1 New suppliers that were screened using social criteria Performance Report, Creating value responsibly, Page 48  415-1 Political contributions Political Contributions 416-1 Assessment of the health and safety impacts of product  and service categoriesPerformance Report, Ensuring quality, health and safety, Page 416-2 Incidents of non-compliance concerning the health   and safety impacts of products and servicesPerformance Report, Ensuring quality, health and safety, Page 17  417-1 Requirements for product and service information   and labelingPerformance Report, Ensuring quality, health and safety, Page 17  Performance Report, Advancing product stewardship, Page 419-1 Non-compliance with laws and regulations in the social  and economic areaBoston Scientific adheres to all compliance requirements, see compliance references  throughout the Performance Report and BostonScientific.com   2021 Performance ReportIntroduction Transforming care Investing in   our people Accelerating   possibilities Protecting the  environment Creating value  responsibly Appendix Stakeholder engagement Metrics summary Global Reporting Initiative  (GRI) index Sustainability Accounting  Standards Board   (SASB) index United Nations  Sustainable Development  Goals (SDGs) Topic Accounting metric Code Response Affordability   and pricingRatio of weighted average rate of net price increases  (for all products) to the annual increase in the U.S.  Consumer Price IndexHC-MS-240a.1 Not currently disclosed Description of how price information for each product  is disclosed to customers or to their agentsHC-MS-240a.2 Form 10-K, Health Care Policies and Reimbursement, Pages 13-Product safety Number of recalls issued, total units recalled HC-MS-250a.1 Class I recalls: 3  Class II recalls: 8  Total units recalled: 47,List of products listed in the FDA's MedWatch  Safety Alerts for Human Medical Products databaseHC-MS-250a.2 FDA's MedWatch Safety Alerts for Human Medical Products database Number of fatalities related to products as reported  in the FDA Manufacturer and User Facility Device  ExperienceHC-MS-250a.3 FDA Manufacturer and User Facility Device Experience (MAUDE) database Number of FDA enforcement actions taken in  response to violations of current Good Manufacturing  Practices (cGMP), by typeHC-MS-250a.4 0 in Ethical marketing Total amount of monetary losses as a result of legal  proceedings associated with false marketing claimsHC-MS-270a.1 $0 in Description of code of ethics governing promotion  of off-label use of productsHC-MS-270a.2 Code of Conduct, Page 40;   Performance Report, Creating value responsibly, Page 48Sustainability Accounting Standards Board (SASB) index SASB is an independent standards-setting organization dedicated to improving the effectiveness and comparability of corporate disclosure on ESG factors.
","('Competitive_Behavior', 0.2897098660469055)","('Management_Of_Legal_And_Regulatory_Framework', 0.19068802893161774)","('Business_Model_Resilience', 0.08853402733802795)","('NON-ESG', 0.2897098660469055)","('NON-ESG', 0.19068802893161774)","('NON-ESG', 0.08853402733802795)"
Line 731,"Commitments and Contingencies, Page 2021 Performance ReportIntroduction Transforming care Investing in   our people Accelerating   possibilities Protecting the  environment Creating value  responsibly Appendix Stakeholder engagement Metrics summary Global Reporting Initiative  (GRI) index Sustainability Accounting  Standards Board   (SASB) index United Nations  Sustainable Development  Goals (SDGs) Indicator Description Response GRI 302-1 Energy consumption within the organization Performance Report, GEMS KPIs, Page 41  Performance Report Appendix, Metrics summary 302-3 Energy intensity Performance Report, GEMS KPIs, Page 41  Performance Report Appendix, Metrics summary 302-4 Reduction of energy consumption Performance Report, GEMS KPIs, Page 41  Performance Report Appendix, Metrics summary 302-5 Reductions in energy requirements of products   and servicesPerformance Report, GEMS KPIs, Page 41  Performance Report, Advancing product stewardship, Page 46  Performance Report Appendix, Metrics summary 303-1 Water withdrawal Performance Report Appendix, Metrics summary 303-2 Water discharge Performance Report Appendix, Metrics summary 303-3 Water consumption Performance Report Appendix, Metrics summary 305-1 Direct (Scope 1) GHG emissions Performance Report Appendix, Metrics summary 305-2 Energy indirect (Scope 2) GHG emissions Performance Report Appendix, Metrics summary 305-5 Reduction of GHG emissions Performance Report, Protecting the environment, Page 39   Performance Report Appendix, Metrics summary 306-1 Water discharge by quality and destination Performance Report Appendix, Metrics summary 306-2 Waste by type and disposal method Performance Report Appendix, Metrics summary 306-3 Significant spills No significant spills for 306-4 Transport of hazardous waste Performance Report Appendix, Metrics summary 307-1 Non-compliance with environmental laws and regulation Performance Report Appendix, Metrics summary 308-1 New suppliers that were screened using   environmental criteriaPerformance Report, Creating value responsibly, Page 48  2021 Performance ReportIntroduction Transforming care Investing in   our people Accelerating   possibilities Protecting the  environment Creating value  responsibly Appendix Stakeholder engagement Metrics summary Global Reporting Initiative  (GRI) index Sustainability Accounting  Standards Board   (SASB) index United Nations  Sustainable Development  Goals (SDGs) Indicator Description Response GRI 401-1 New employee hires and employee turnover Performance Report Appendix, Metrics summary 401-2 Benefits provided to full-time employees that are not  provided to temporary or part-time employeesBenefits 401-3 Parental leave Benefits 403-2 Types of injury and rates of injury, occupational   diseases, lost days, and absenteeism and number   of work-related fatalitiesPerformance Report Appendix, Metrics summary 404-1 Average hours of training per year per employee Performance Report Appendix, Metrics summary 404-2 Programs for upgrading employee skills and transition  assistance programsPerformance Report, Investing in our people, Page 404-3 Percentage of employees receiving regular performance  and career development reviewsPerformance Report, Investing in our people, Page 20  405-1 Diversity of governance bodies and employees Proxy Statement  Performance Appendix, Metrics summary 405-2 Ratio of basic salary and remuneration of women to men Performance Report, Investing in our people, Page 20  Equal Pay for Equal Work 406-1 Incidents of discrimination and corrective actions taken Compliance and Ethics  407-1 Operations and suppliers in which the right to freedom   of association and collective bargaining may be at riskHuman Rights 408-1 Operations and suppliers at significant risk for incidence   of child laborHuman Rights 409-1 Operations and suppliers at significant risk for incidence   of forced or compulsory laborHuman Rights 411-1 Incidents of violations involving rights of   indigenous peoplesHuman Rights 2021 Performance ReportIntroduction Transforming care Investing in   our people Accelerating   possibilities Protecting the  environment Creating value  responsibly Appendix Stakeholder engagement Metrics summary Global Reporting Initiative  (GRI) index Sustainability Accounting  Standards Board   (SASB) index United Nations  Sustainable Development  Goals (SDGs) Indicator Description Response 412-1 Operations that have been subject to human rights reviews  or impact assessmentsHuman Rights 412-2 Employee training on human rights policies or procedures Human Rights 413-1 Operations with local community engagement, impact  assessments and development programsPerformance Report, Supporting our communities, Page 36   Community Engagement 414-1 New suppliers that were screened using social criteria Performance Report, Creating value responsibly, Page 48  415-1 Political contributions Political Contributions 416-1 Assessment of the health and safety impacts of product  and service categoriesPerformance Report, Ensuring quality, health and safety, Page 416-2 Incidents of non-compliance concerning the health   and safety impacts of products and servicesPerformance Report, Ensuring quality, health and safety, Page 17  417-1 Requirements for product and service information   and labelingPerformance Report, Ensuring quality, health and safety, Page 17  Performance Report, Advancing product stewardship, Page 419-1 Non-compliance with laws and regulations in the social  and economic areaBoston Scientific adheres to all compliance requirements, see compliance references  throughout the Performance Report and BostonScientific.com   2021 Performance ReportIntroduction Transforming care Investing in   our people Accelerating   possibilities Protecting the  environment Creating value  responsibly Appendix Stakeholder engagement Metrics summary Global Reporting Initiative  (GRI) index Sustainability Accounting  Standards Board   (SASB) index United Nations  Sustainable Development  Goals (SDGs) Topic Accounting metric Code Response Affordability   and pricingRatio of weighted average rate of net price increases  (for all products) to the annual increase in the U.S.  Consumer Price IndexHC-MS-240a.1 Not currently disclosed Description of how price information for each product  is disclosed to customers or to their agentsHC-MS-240a.2 Form 10-K, Health Care Policies and Reimbursement, Pages 13-Product safety Number of recalls issued, total units recalled HC-MS-250a.1 Class I recalls: 3  Class II recalls: 8  Total units recalled: 47,List of products listed in the FDA's MedWatch  Safety Alerts for Human Medical Products databaseHC-MS-250a.2 FDA's MedWatch Safety Alerts for Human Medical Products database Number of fatalities related to products as reported  in the FDA Manufacturer and User Facility Device  ExperienceHC-MS-250a.3 FDA Manufacturer and User Facility Device Experience (MAUDE) database Number of FDA enforcement actions taken in  response to violations of current Good Manufacturing  Practices (cGMP), by typeHC-MS-250a.4 0 in Ethical marketing Total amount of monetary losses as a result of legal  proceedings associated with false marketing claimsHC-MS-270a.1 $0 in Description of code of ethics governing promotion  of off-label use of productsHC-MS-270a.2 Code of Conduct, Page 40;   Performance Report, Creating value responsibly, Page 48Sustainability Accounting Standards Board (SASB) index SASB is an independent standards-setting organization dedicated to improving the effectiveness and comparability of corporate disclosure on ESG factors.
","('Product_Quality_And_Safety', 0.834309458732605)","('Selling_Practices_And_Product_Labeling', 0.05115322768688202)","('Product_Design_And_Lifecycle_Management', 0.01250420231372118)","(['Product Quality & Recall Management'], 0.834309458732605)","('NON-ESG', 0.05115322768688202)","('NON-ESG', 0.01250420231372118)"
Line 732,"Commitments and Contingencies, Page 2021 Performance ReportIntroduction Transforming care Investing in   our people Accelerating   possibilities Protecting the  environment Creating value  responsibly Appendix Stakeholder engagement Metrics summary Global Reporting Initiative  (GRI) index Sustainability Accounting  Standards Board   (SASB) index United Nations  Sustainable Development  Goals (SDGs) Indicator Description Response GRI 302-1 Energy consumption within the organization Performance Report, GEMS KPIs, Page 41  Performance Report Appendix, Metrics summary 302-3 Energy intensity Performance Report, GEMS KPIs, Page 41  Performance Report Appendix, Metrics summary 302-4 Reduction of energy consumption Performance Report, GEMS KPIs, Page 41  Performance Report Appendix, Metrics summary 302-5 Reductions in energy requirements of products   and servicesPerformance Report, GEMS KPIs, Page 41  Performance Report, Advancing product stewardship, Page 46  Performance Report Appendix, Metrics summary 303-1 Water withdrawal Performance Report Appendix, Metrics summary 303-2 Water discharge Performance Report Appendix, Metrics summary 303-3 Water consumption Performance Report Appendix, Metrics summary 305-1 Direct (Scope 1) GHG emissions Performance Report Appendix, Metrics summary 305-2 Energy indirect (Scope 2) GHG emissions Performance Report Appendix, Metrics summary 305-5 Reduction of GHG emissions Performance Report, Protecting the environment, Page 39   Performance Report Appendix, Metrics summary 306-1 Water discharge by quality and destination Performance Report Appendix, Metrics summary 306-2 Waste by type and disposal method Performance Report Appendix, Metrics summary 306-3 Significant spills No significant spills for 306-4 Transport of hazardous waste Performance Report Appendix, Metrics summary 307-1 Non-compliance with environmental laws and regulation Performance Report Appendix, Metrics summary 308-1 New suppliers that were screened using   environmental criteriaPerformance Report, Creating value responsibly, Page 48  2021 Performance ReportIntroduction Transforming care Investing in   our people Accelerating   possibilities Protecting the  environment Creating value  responsibly Appendix Stakeholder engagement Metrics summary Global Reporting Initiative  (GRI) index Sustainability Accounting  Standards Board   (SASB) index United Nations  Sustainable Development  Goals (SDGs) Indicator Description Response GRI 401-1 New employee hires and employee turnover Performance Report Appendix, Metrics summary 401-2 Benefits provided to full-time employees that are not  provided to temporary or part-time employeesBenefits 401-3 Parental leave Benefits 403-2 Types of injury and rates of injury, occupational   diseases, lost days, and absenteeism and number   of work-related fatalitiesPerformance Report Appendix, Metrics summary 404-1 Average hours of training per year per employee Performance Report Appendix, Metrics summary 404-2 Programs for upgrading employee skills and transition  assistance programsPerformance Report, Investing in our people, Page 404-3 Percentage of employees receiving regular performance  and career development reviewsPerformance Report, Investing in our people, Page 20  405-1 Diversity of governance bodies and employees Proxy Statement  Performance Appendix, Metrics summary 405-2 Ratio of basic salary and remuneration of women to men Performance Report, Investing in our people, Page 20  Equal Pay for Equal Work 406-1 Incidents of discrimination and corrective actions taken Compliance and Ethics  407-1 Operations and suppliers in which the right to freedom   of association and collective bargaining may be at riskHuman Rights 408-1 Operations and suppliers at significant risk for incidence   of child laborHuman Rights 409-1 Operations and suppliers at significant risk for incidence   of forced or compulsory laborHuman Rights 411-1 Incidents of violations involving rights of   indigenous peoplesHuman Rights 2021 Performance ReportIntroduction Transforming care Investing in   our people Accelerating   possibilities Protecting the  environment Creating value  responsibly Appendix Stakeholder engagement Metrics summary Global Reporting Initiative  (GRI) index Sustainability Accounting  Standards Board   (SASB) index United Nations  Sustainable Development  Goals (SDGs) Indicator Description Response 412-1 Operations that have been subject to human rights reviews  or impact assessmentsHuman Rights 412-2 Employee training on human rights policies or procedures Human Rights 413-1 Operations with local community engagement, impact  assessments and development programsPerformance Report, Supporting our communities, Page 36   Community Engagement 414-1 New suppliers that were screened using social criteria Performance Report, Creating value responsibly, Page 48  415-1 Political contributions Political Contributions 416-1 Assessment of the health and safety impacts of product  and service categoriesPerformance Report, Ensuring quality, health and safety, Page 416-2 Incidents of non-compliance concerning the health   and safety impacts of products and servicesPerformance Report, Ensuring quality, health and safety, Page 17  417-1 Requirements for product and service information   and labelingPerformance Report, Ensuring quality, health and safety, Page 17  Performance Report, Advancing product stewardship, Page 419-1 Non-compliance with laws and regulations in the social  and economic areaBoston Scientific adheres to all compliance requirements, see compliance references  throughout the Performance Report and BostonScientific.com   2021 Performance ReportIntroduction Transforming care Investing in   our people Accelerating   possibilities Protecting the  environment Creating value  responsibly Appendix Stakeholder engagement Metrics summary Global Reporting Initiative  (GRI) index Sustainability Accounting  Standards Board   (SASB) index United Nations  Sustainable Development  Goals (SDGs) Topic Accounting metric Code Response Affordability   and pricingRatio of weighted average rate of net price increases  (for all products) to the annual increase in the U.S.  Consumer Price IndexHC-MS-240a.1 Not currently disclosed Description of how price information for each product  is disclosed to customers or to their agentsHC-MS-240a.2 Form 10-K, Health Care Policies and Reimbursement, Pages 13-Product safety Number of recalls issued, total units recalled HC-MS-250a.1 Class I recalls: 3  Class II recalls: 8  Total units recalled: 47,List of products listed in the FDA's MedWatch  Safety Alerts for Human Medical Products databaseHC-MS-250a.2 FDA's MedWatch Safety Alerts for Human Medical Products database Number of fatalities related to products as reported  in the FDA Manufacturer and User Facility Device  ExperienceHC-MS-250a.3 FDA Manufacturer and User Facility Device Experience (MAUDE) database Number of FDA enforcement actions taken in  response to violations of current Good Manufacturing  Practices (cGMP), by typeHC-MS-250a.4 0 in Ethical marketing Total amount of monetary losses as a result of legal  proceedings associated with false marketing claimsHC-MS-270a.1 $0 in Description of code of ethics governing promotion  of off-label use of productsHC-MS-270a.2 Code of Conduct, Page 40;   Performance Report, Creating value responsibly, Page 48Sustainability Accounting Standards Board (SASB) index SASB is an independent standards-setting organization dedicated to improving the effectiveness and comparability of corporate disclosure on ESG factors.
","('Product_Quality_And_Safety', 0.8972458243370056)","('Selling_Practices_And_Product_Labeling', 0.01852600648999214)","('Product_Design_And_Lifecycle_Management', 0.012155664153397083)","(['Product Quality & Recall Management'], 0.8972458243370056)","('NON-ESG', 0.01852600648999214)","('NON-ESG', 0.012155664153397083)"
Line 733,"Commitments and Contingencies, Page 2021 Performance ReportIntroduction Transforming care Investing in   our people Accelerating   possibilities Protecting the  environment Creating value  responsibly Appendix Stakeholder engagement Metrics summary Global Reporting Initiative  (GRI) index Sustainability Accounting  Standards Board   (SASB) index United Nations  Sustainable Development  Goals (SDGs) Indicator Description Response GRI 302-1 Energy consumption within the organization Performance Report, GEMS KPIs, Page 41  Performance Report Appendix, Metrics summary 302-3 Energy intensity Performance Report, GEMS KPIs, Page 41  Performance Report Appendix, Metrics summary 302-4 Reduction of energy consumption Performance Report, GEMS KPIs, Page 41  Performance Report Appendix, Metrics summary 302-5 Reductions in energy requirements of products   and servicesPerformance Report, GEMS KPIs, Page 41  Performance Report, Advancing product stewardship, Page 46  Performance Report Appendix, Metrics summary 303-1 Water withdrawal Performance Report Appendix, Metrics summary 303-2 Water discharge Performance Report Appendix, Metrics summary 303-3 Water consumption Performance Report Appendix, Metrics summary 305-1 Direct (Scope 1) GHG emissions Performance Report Appendix, Metrics summary 305-2 Energy indirect (Scope 2) GHG emissions Performance Report Appendix, Metrics summary 305-5 Reduction of GHG emissions Performance Report, Protecting the environment, Page 39   Performance Report Appendix, Metrics summary 306-1 Water discharge by quality and destination Performance Report Appendix, Metrics summary 306-2 Waste by type and disposal method Performance Report Appendix, Metrics summary 306-3 Significant spills No significant spills for 306-4 Transport of hazardous waste Performance Report Appendix, Metrics summary 307-1 Non-compliance with environmental laws and regulation Performance Report Appendix, Metrics summary 308-1 New suppliers that were screened using   environmental criteriaPerformance Report, Creating value responsibly, Page 48  2021 Performance ReportIntroduction Transforming care Investing in   our people Accelerating   possibilities Protecting the  environment Creating value  responsibly Appendix Stakeholder engagement Metrics summary Global Reporting Initiative  (GRI) index Sustainability Accounting  Standards Board   (SASB) index United Nations  Sustainable Development  Goals (SDGs) Indicator Description Response GRI 401-1 New employee hires and employee turnover Performance Report Appendix, Metrics summary 401-2 Benefits provided to full-time employees that are not  provided to temporary or part-time employeesBenefits 401-3 Parental leave Benefits 403-2 Types of injury and rates of injury, occupational   diseases, lost days, and absenteeism and number   of work-related fatalitiesPerformance Report Appendix, Metrics summary 404-1 Average hours of training per year per employee Performance Report Appendix, Metrics summary 404-2 Programs for upgrading employee skills and transition  assistance programsPerformance Report, Investing in our people, Page 404-3 Percentage of employees receiving regular performance  and career development reviewsPerformance Report, Investing in our people, Page 20  405-1 Diversity of governance bodies and employees Proxy Statement  Performance Appendix, Metrics summary 405-2 Ratio of basic salary and remuneration of women to men Performance Report, Investing in our people, Page 20  Equal Pay for Equal Work 406-1 Incidents of discrimination and corrective actions taken Compliance and Ethics  407-1 Operations and suppliers in which the right to freedom   of association and collective bargaining may be at riskHuman Rights 408-1 Operations and suppliers at significant risk for incidence   of child laborHuman Rights 409-1 Operations and suppliers at significant risk for incidence   of forced or compulsory laborHuman Rights 411-1 Incidents of violations involving rights of   indigenous peoplesHuman Rights 2021 Performance ReportIntroduction Transforming care Investing in   our people Accelerating   possibilities Protecting the  environment Creating value  responsibly Appendix Stakeholder engagement Metrics summary Global Reporting Initiative  (GRI) index Sustainability Accounting  Standards Board   (SASB) index United Nations  Sustainable Development  Goals (SDGs) Indicator Description Response 412-1 Operations that have been subject to human rights reviews  or impact assessmentsHuman Rights 412-2 Employee training on human rights policies or procedures Human Rights 413-1 Operations with local community engagement, impact  assessments and development programsPerformance Report, Supporting our communities, Page 36   Community Engagement 414-1 New suppliers that were screened using social criteria Performance Report, Creating value responsibly, Page 48  415-1 Political contributions Political Contributions 416-1 Assessment of the health and safety impacts of product  and service categoriesPerformance Report, Ensuring quality, health and safety, Page 416-2 Incidents of non-compliance concerning the health   and safety impacts of products and servicesPerformance Report, Ensuring quality, health and safety, Page 17  417-1 Requirements for product and service information   and labelingPerformance Report, Ensuring quality, health and safety, Page 17  Performance Report, Advancing product stewardship, Page 419-1 Non-compliance with laws and regulations in the social  and economic areaBoston Scientific adheres to all compliance requirements, see compliance references  throughout the Performance Report and BostonScientific.com   2021 Performance ReportIntroduction Transforming care Investing in   our people Accelerating   possibilities Protecting the  environment Creating value  responsibly Appendix Stakeholder engagement Metrics summary Global Reporting Initiative  (GRI) index Sustainability Accounting  Standards Board   (SASB) index United Nations  Sustainable Development  Goals (SDGs) Topic Accounting metric Code Response Affordability   and pricingRatio of weighted average rate of net price increases  (for all products) to the annual increase in the U.S.  Consumer Price IndexHC-MS-240a.1 Not currently disclosed Description of how price information for each product  is disclosed to customers or to their agentsHC-MS-240a.2 Form 10-K, Health Care Policies and Reimbursement, Pages 13-Product safety Number of recalls issued, total units recalled HC-MS-250a.1 Class I recalls: 3  Class II recalls: 8  Total units recalled: 47,List of products listed in the FDA's MedWatch  Safety Alerts for Human Medical Products databaseHC-MS-250a.2 FDA's MedWatch Safety Alerts for Human Medical Products database Number of fatalities related to products as reported  in the FDA Manufacturer and User Facility Device  ExperienceHC-MS-250a.3 FDA Manufacturer and User Facility Device Experience (MAUDE) database Number of FDA enforcement actions taken in  response to violations of current Good Manufacturing  Practices (cGMP), by typeHC-MS-250a.4 0 in Ethical marketing Total amount of monetary losses as a result of legal  proceedings associated with false marketing claimsHC-MS-270a.1 $0 in Description of code of ethics governing promotion  of off-label use of productsHC-MS-270a.2 Code of Conduct, Page 40;   Performance Report, Creating value responsibly, Page 48Sustainability Accounting Standards Board (SASB) index SASB is an independent standards-setting organization dedicated to improving the effectiveness and comparability of corporate disclosure on ESG factors.
","('Business_Ethics', 0.6241295337677002)","('Selling_Practices_And_Product_Labeling', 0.08457401394844055)","('Product_Quality_And_Safety', 0.07419154047966003)","(['Business Ethics'], 0.6241295337677002)","('NON-ESG', 0.08457401394844055)","('NON-ESG', 0.07419154047966003)"
Line 734,"The following table  summarizes how our existing reporting is guided by recommended disclosure topics and accounting metrics for the Medical Equipment and Supplies industry standard, and includes  references to our 2021 Performance Report, 2021 Form 10-K and other documents available on BostonScientific.com.
","('Supply_Chain_Management', 0.32005348801612854)","('Customer_Welfare', 0.08331144601106644)","('Product_Quality_And_Safety', 0.07005030661821365)","('NON-ESG', 0.32005348801612854)","('NON-ESG', 0.08331144601106644)","('NON-ESG', 0.07005030661821365)"
Line 735,"2021 Performance ReportIntroduction Transforming care Investing in   our people Accelerating   possibilities Protecting the  environment Creating value  responsibly Appendix Stakeholder engagement Metrics summary Global Reporting Initiative  (GRI) index Sustainability Accounting  Standards Board   (SASB) index United Nations  Sustainable Development  Goals (SDGs) Topic Accounting metric Code Response Product design and  lifecycle managementDiscussion of process to assess and manage  environmental and human health considerations  associated with chemicals in products, and meet  demand for sustainable productsHC-MS-410a.1 Boston Scientific’s commitment to innovation and patient health extends  beyond the surgical suite by managing the environmental and human health  impact of chemicals in our products through design, manufacture and use.
","('Product_Design_And_Lifecycle_Management', 0.9546405673027039)","('Product_Quality_And_Safety', 0.007554918061941862)","('Business_Model_Resilience', 0.00426354119554162)","(['Product Stewardship'], 0.9546405673027039)","('NON-ESG', 0.007554918061941862)","('NON-ESG', 0.00426354119554162)"
Line 736,"2021 Performance ReportIntroduction Transforming care Investing in   our people Accelerating   possibilities Protecting the  environment Creating value  responsibly Appendix Stakeholder engagement Metrics summary Global Reporting Initiative  (GRI) index Sustainability Accounting  Standards Board   (SASB) index United Nations  Sustainable Development  Goals (SDGs) Topic Accounting metric Code Response Product design and  lifecycle managementDiscussion of process to assess and manage  environmental and human health considerations  associated with chemicals in products, and meet  demand for sustainable productsHC-MS-410a.1 Boston Scientific’s commitment to innovation and patient health extends  beyond the surgical suite by managing the environmental and human health  impact of chemicals in our products through design, manufacture and use.
","('Product_Design_And_Lifecycle_Management', 0.8806547522544861)","('Product_Quality_And_Safety', 0.04265857860445976)","('Selling_Practices_And_Product_Labeling', 0.01049147266894579)","(['Product Stewardship'], 0.8806547522544861)","('NON-ESG', 0.04265857860445976)","('NON-ESG', 0.01049147266894579)"
Line 737,"Our design and supplier management processes assess and manage relevant  environmental and chemical requirements.
","('Supply_Chain_Management', 0.9379035830497742)","('Product_Design_And_Lifecycle_Management', 0.011332767084240913)","('Business_Model_Resilience', 0.004716428462415934)","(['Supply Chain Management'], 0.9379035830497742)","('NON-ESG', 0.011332767084240913)","('NON-ESG', 0.004716428462415934)"
Line 738,"We work with our suppliers to  ensure material compliance of all purchased goods and components, allowing  us to make responsible material and chemical choices for the design and  manufacture of our products.
","('Product_Design_And_Lifecycle_Management', 0.9642336368560791)","('Selling_Practices_And_Product_Labeling', 0.003756142221391201)","('Product_Quality_And_Safety', 0.003501765662804246)","(['Product Stewardship'], 0.9642336368560791)","('NON-ESG', 0.003756142221391201)","('NON-ESG', 0.003501765662804246)"
Line 739,"Performance Report, Advancing product stewardship, Page Total amount of products accepted for take-back  and reused, recycled or donated, broken down by: (1)  devices and equipment (2) suppliesHC-MS-410a.2 Within participating customers:  • 65% of LithoVue™ systems recycled in the United States in • 39% of EXALT™ Model D systems recycled in the United States in Performance Report, Advancing product stewardship, Page Supply chain  managementPercentage of (1) entity's facilities and (2) Tier I  suppliers' facilities participating in third-party audit  programs for manufacturing and product qualityHC-MS-430a.1 All Boston Scientific medical device manufacturing facilities are audited by  external regulators or applicable authorities.
","('Product_Design_And_Lifecycle_Management', 0.9593599438667297)","('Product_Quality_And_Safety', 0.005455466452986002)","('Selling_Practices_And_Product_Labeling', 0.003901126328855753)","(['Product Stewardship'], 0.9593599438667297)","('NON-ESG', 0.005455466452986002)","('NON-ESG', 0.003901126328855753)"
Line 740,"Performance Report, Advancing product stewardship, Page Total amount of products accepted for take-back  and reused, recycled or donated, broken down by: (1)  devices and equipment (2) suppliesHC-MS-410a.2 Within participating customers:  • 65% of LithoVue™ systems recycled in the United States in • 39% of EXALT™ Model D systems recycled in the United States in Performance Report, Advancing product stewardship, Page Supply chain  managementPercentage of (1) entity's facilities and (2) Tier I  suppliers' facilities participating in third-party audit  programs for manufacturing and product qualityHC-MS-430a.1 All Boston Scientific medical device manufacturing facilities are audited by  external regulators or applicable authorities.
","('Product_Quality_And_Safety', 0.6751760244369507)","('Product_Design_And_Lifecycle_Management', 0.15111187100410461)","('Management_Of_Legal_And_Regulatory_Framework', 0.015130729414522648)","(['Product Quality & Recall Management'], 0.6751760244369507)","('NON-ESG', 0.15111187100410461)","('NON-ESG', 0.015130729414522648)"
Line 741,"A majority of our direct suppliers are  ISO certified (for example ISO 9001 or ISO 13485), as applicable, and demonstrate  compliance and quality through certification audits.
","('Product_Quality_And_Safety', 0.3694263994693756)","('Product_Design_And_Lifecycle_Management', 0.16798126697540283)","('Supply_Chain_Management', 0.1482057273387909)","('NON-ESG', 0.3694263994693756)","('NON-ESG', 0.16798126697540283)","('NON-ESG', 0.1482057273387909)"
Line 742,"Form 10-K, Quality Assurance, Page Description of efforts to maintain traceability within  the distribution chainHC-MS-430a.2 Boston Scientific maintains traceability within the manufacturing and distribution  chain through either serial or batch control of finished products.
","('Product_Design_And_Lifecycle_Management', 0.9124481678009033)","('Product_Quality_And_Safety', 0.026072176173329353)","('Supply_Chain_Management', 0.007107796613126993)","(['Product Stewardship'], 0.9124481678009033)","('NON-ESG', 0.026072176173329353)","('NON-ESG', 0.007107796613126993)"
Line 743,"We: • Leverage product identification technologies, such as barcoding  identification to track the information of products • Utilize enterprise resource planning (ERP) solutions to support identification  and control of products once they leave manufacturing sites — including  supporting specific patient tracking if required.
","('Product_Design_And_Lifecycle_Management', 0.6949901580810547)","('Selling_Practices_And_Product_Labeling', 0.11149104684591293)","('Product_Quality_And_Safety', 0.052520815283060074)","(['Product Stewardship'], 0.6949901580810547)","('NON-ESG', 0.11149104684591293)","('NON-ESG', 0.052520815283060074)"
Line 744,"Our ERP solutions ensure  compliance with regularity, quality and customs control requirements Description of the management of risks associated  with the use of critical materialsHC-MS-430a.3 Form 10-K, Manufacturing and Raw Materials, page 11  Performance Report, Cr eating value responsibly, Page Business ethics Total amount of monetary losses as a result of legal  proceedings associated with bribery or corruptionHC-MS-510a.1 $0 in Description of code of ethics governing interactions  with health care professionalsHC-MS-510a.2 Code of Conduct, Page 32  Performance Report, Creating value responsibly, Page Activity metrics Code Response Number of units sold by product category HC-MS-000.A Not currently disclosed 2021 Performance ReportIntroduction Transforming care Investing in   our people Accelerating   possibilities Protecting the  environment Creating value  responsibly Appendix Stakeholder engagement Metrics summary Global Reporting Initiative  (GRI) index Sustainability Accounting  Standards Board   (SASB) index United Nations  Sustainable Development  Goals (SDGs) Transforming care          Investing in our people               Accelerating possibilities                    Protecting the environment                         Creating value responsibly                         United Nations Sustainable Development Goals (SDGs) The United Nations Sustainable Development Goals (SDGs) are a set of 17 global goals with the aim to end poverty, fight inequality and injustice and tackle climate change by 2030.
","('Business_Ethics', 0.9758720397949219)","('Management_Of_Legal_And_Regulatory_Framework', 0.0019034878350794315)","('Data_Security', 0.0017905938439071178)","(['Business Ethics'], 0.9758720397949219)","('NON-ESG', 0.0019034878350794315)","('NON-ESG', 0.0017905938439071178)"
Line 745,"Our ERP solutions ensure  compliance with regularity, quality and customs control requirements Description of the management of risks associated  with the use of critical materialsHC-MS-430a.3 Form 10-K, Manufacturing and Raw Materials, page 11  Performance Report, Cr eating value responsibly, Page Business ethics Total amount of monetary losses as a result of legal  proceedings associated with bribery or corruptionHC-MS-510a.1 $0 in Description of code of ethics governing interactions  with health care professionalsHC-MS-510a.2 Code of Conduct, Page 32  Performance Report, Creating value responsibly, Page Activity metrics Code Response Number of units sold by product category HC-MS-000.A Not currently disclosed 2021 Performance ReportIntroduction Transforming care Investing in   our people Accelerating   possibilities Protecting the  environment Creating value  responsibly Appendix Stakeholder engagement Metrics summary Global Reporting Initiative  (GRI) index Sustainability Accounting  Standards Board   (SASB) index United Nations  Sustainable Development  Goals (SDGs) Transforming care          Investing in our people               Accelerating possibilities                    Protecting the environment                         Creating value responsibly                         United Nations Sustainable Development Goals (SDGs) The United Nations Sustainable Development Goals (SDGs) are a set of 17 global goals with the aim to end poverty, fight inequality and injustice and tackle climate change by 2030.
","('Product_Design_And_Lifecycle_Management', 0.9277400374412537)","('Product_Quality_And_Safety', 0.010838127695024014)","('Customer_Welfare', 0.010238483548164368)","(['Product Stewardship'], 0.9277400374412537)","('NON-ESG', 0.010838127695024014)","('NON-ESG', 0.010238483548164368)"
Line 746,"Our ERP solutions ensure  compliance with regularity, quality and customs control requirements Description of the management of risks associated  with the use of critical materialsHC-MS-430a.3 Form 10-K, Manufacturing and Raw Materials, page 11  Performance Report, Cr eating value responsibly, Page Business ethics Total amount of monetary losses as a result of legal  proceedings associated with bribery or corruptionHC-MS-510a.1 $0 in Description of code of ethics governing interactions  with health care professionalsHC-MS-510a.2 Code of Conduct, Page 32  Performance Report, Creating value responsibly, Page Activity metrics Code Response Number of units sold by product category HC-MS-000.A Not currently disclosed 2021 Performance ReportIntroduction Transforming care Investing in   our people Accelerating   possibilities Protecting the  environment Creating value  responsibly Appendix Stakeholder engagement Metrics summary Global Reporting Initiative  (GRI) index Sustainability Accounting  Standards Board   (SASB) index United Nations  Sustainable Development  Goals (SDGs) Transforming care          Investing in our people               Accelerating possibilities                    Protecting the environment                         Creating value responsibly                         United Nations Sustainable Development Goals (SDGs) The United Nations Sustainable Development Goals (SDGs) are a set of 17 global goals with the aim to end poverty, fight inequality and injustice and tackle climate change by 2030.
","('Physical_Impacts_Of_Climate_Change', 0.7026882767677307)","('Human_Rights_And_Community_Relations', 0.07607948035001755)","('Business_Model_Resilience', 0.04046735540032387)","(['Climate Change'], 0.7026882767677307)","('NON-ESG', 0.07607948035001755)","('NON-ESG', 0.04046735540032387)"
Line 747,"The following table summarizes how our reporting aligns with the SDGs. More information on our priorities can also be found in Our ESG strategy .
","('Business_Model_Resilience', 0.6017662882804871)","('Physical_Impacts_Of_Climate_Change', 0.06570367515087128)","('Human_Rights_And_Community_Relations', 0.05820927023887634)","(['Codes of Business Conduct'], 0.6017662882804871)","('NON-ESG', 0.06570367515087128)","('NON-ESG', 0.05820927023887634)"
Line 748,"2021 Performance ReportIntroduction Transforming care Investing in   our people Accelerating   possibilities Protecting the  environment Creating value  responsibly Appendix Stakeholder engagement Metrics summary Global Reporting Initiative  (GRI) index Sustainability Accounting  Standards Board   (SASB) index United Nations  Sustainable Development  Goals (SDGs) Cautionary Statement Regarding Forward-Looking Statements This report contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the  Securities Exchange Act of 1934.
","('Human_Rights_And_Community_Relations', 0.4375717341899872)","('Management_Of_Legal_And_Regulatory_Framework', 0.12481379508972168)","('Ecological_Impacts', 0.1017364040017128)","('NON-ESG', 0.4375717341899872)","('NON-ESG', 0.12481379508972168)","('NON-ESG', 0.1017364040017128)"
Line 749,"2021 Performance ReportIntroduction Transforming care Investing in   our people Accelerating   possibilities Protecting the  environment Creating value  responsibly Appendix Stakeholder engagement Metrics summary Global Reporting Initiative  (GRI) index Sustainability Accounting  Standards Board   (SASB) index United Nations  Sustainable Development  Goals (SDGs) Cautionary Statement Regarding Forward-Looking Statements This report contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the  Securities Exchange Act of 1934.
","('Management_Of_Legal_And_Regulatory_Framework', 0.9463949203491211)","('Business_Ethics', 0.008014201186597347)","('Director_Removal', 0.00534368259832263)","(['Corporate Governance'], 0.9463949203491211)","('NON-ESG', 0.008014201186597347)","('NON-ESG', 0.00534368259832263)"
Line 750,"Forward-looking statements may be identified by words like “anticipate,” “expect,” “project,” “believe,”  “plan,” “may,” “estimate,” “intend” and similar words.
","('Business_Model_Resilience', 0.4340716302394867)","('Systemic_Risk_Management', 0.11703287810087204)","('Competitive_Behavior', 0.08317375928163528)","('NON-ESG', 0.4340716302394867)","('NON-ESG', 0.11703287810087204)","('NON-ESG', 0.08317375928163528)"
Line 751,"These forward-looking statements are based on our beliefs, assumptions and  estimates using information available to us at the time and are not intended to be guarantees of future events or performance.
","('Business_Model_Resilience', 0.28967079520225525)","('Management_Of_Legal_And_Regulatory_Framework', 0.27173030376434326)","('Systemic_Risk_Management', 0.05909991264343262)","('NON-ESG', 0.28967079520225525)","('NON-ESG', 0.27173030376434326)","('NON-ESG', 0.05909991264343262)"
Line 752,"These  forward-looking statements include, among other things, statements regarding our expected net sales; reported, operational and organic  revenue growth rates; reported and adjusted EPS for the second quarter and full year 2022; our financial performance; our business  and environmental, social and governance (ESG) plans, performance and goals; product performance; and the impact of the COVID-19  pandemic on the company’s results of operations.
","('Business_Model_Resilience', 0.8178431391716003)","('Systemic_Risk_Management', 0.022660382091999054)","('Product_Design_And_Lifecycle_Management', 0.01953705959022045)","(['Codes of Business Conduct'], 0.8178431391716003)","('NON-ESG', 0.022660382091999054)","('NON-ESG', 0.01953705959022045)"
Line 753,"If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties  materialize, actual results could vary materially from the expectations and projections expressed or implied by our forward-looking  statements.
","('Systemic_Risk_Management', 0.6236871480941772)","('Competitive_Behavior', 0.18210957944393158)","('Business_Ethics', 0.040553804486989975)","(['Risk & Crisis Management'], 0.6236871480941772)","('NON-ESG', 0.18210957944393158)","('NON-ESG', 0.040553804486989975)"
Line 754,"These factors, in some cases, have affected and in the future (together with other factors) could affect our ability to implement  our business strategy and may cause actual results to differ materially from those contemplated by the statements expressed in this report.
","('Business_Model_Resilience', 0.6809966564178467)","('Systemic_Risk_Management', 0.0751846432685852)","('Physical_Impacts_Of_Climate_Change', 0.06977609544992447)","(['Codes of Business Conduct'], 0.6809966564178467)","('NON-ESG', 0.0751846432685852)","('NON-ESG', 0.06977609544992447)"
Line 755,"As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements.
","('Management_Of_Legal_And_Regulatory_Framework', 0.4015488028526306)","('Business_Ethics', 0.16501758992671967)","('Competitive_Behavior', 0.07064835727214813)","('NON-ESG', 0.4015488028526306)","('NON-ESG', 0.16501758992671967)","('NON-ESG', 0.07064835727214813)"
Line 756,"Risks and uncertainties that may cause such differences include, among other things: the impact of the ongoing COVID-19 pandemic on  our operations and financial results; future U.S. and global economic, political, competitive, reimbursement and regulatory conditions;  manufacturing, distribution and supply chain disruptions and cost increases; disruptions caused by cybersecurity events; disruptions  caused by extreme weather or other climate change-related events; labor shortages and increases in labor costs; new product  introductions; expected procedural volumes; the closing and integration of acquisitions; demographic trends; intellectual property rights;  litigation; financial market conditions; the execution and effect of our business strategy, including our cost-savings and growth initiatives;  and future business decisions made by us and our competitors.
","('Supply_Chain_Management', 0.4366278648376465)","('Systemic_Risk_Management', 0.31069010496139526)","('Physical_Impacts_Of_Climate_Change', 0.04488801211118698)","('NON-ESG', 0.4366278648376465)","('NON-ESG', 0.31069010496139526)","('NON-ESG', 0.04488801211118698)"
Line 757,"Risks and uncertainties that may cause such differences include, among other things: the impact of the ongoing COVID-19 pandemic on  our operations and financial results; future U.S. and global economic, political, competitive, reimbursement and regulatory conditions;  manufacturing, distribution and supply chain disruptions and cost increases; disruptions caused by cybersecurity events; disruptions  caused by extreme weather or other climate change-related events; labor shortages and increases in labor costs; new product  introductions; expected procedural volumes; the closing and integration of acquisitions; demographic trends; intellectual property rights;  litigation; financial market conditions; the execution and effect of our business strategy, including our cost-savings and growth initiatives;  and future business decisions made by us and our competitors.
","('Competitive_Behavior', 0.3656737804412842)","('Business_Model_Resilience', 0.21878615021705627)","('Product_Design_And_Lifecycle_Management', 0.079105444252491)","('NON-ESG', 0.3656737804412842)","('NON-ESG', 0.21878615021705627)","('NON-ESG', 0.079105444252491)"
Line 758,"New risks and uncertainties may arise from time to time and are difficult  to predict, including those that have emerged or have increased in significance or likelihood as a result of the COVID-19 pandemic.
","('Systemic_Risk_Management', 0.6610082983970642)","('Physical_Impacts_Of_Climate_Change', 0.20519551634788513)","('Business_Model_Resilience', 0.031812019646167755)","(['Risk & Crisis Management'], 0.6610082983970642)","('NON-ESG', 0.20519551634788513)","('NON-ESG', 0.031812019646167755)"
Line 759,"All of  these factors are difficult or impossible to predict accurately and many of them are beyond our control.
","('Systemic_Risk_Management', 0.4666770100593567)","('Physical_Impacts_Of_Climate_Change', 0.12611275911331177)","('Business_Model_Resilience', 0.07712353765964508)","('NON-ESG', 0.4666770100593567)","('NON-ESG', 0.12611275911331177)","('NON-ESG', 0.07712353765964508)"
Line 760,"For a further list and description  of these and other important risks and uncertainties that may affect our future operations, see Part I, Item 1A — Risk Factors in our most  recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, which we may update in Part II, Item 1A — Risk  Factors in Quarterly Reports on Form 10-Q we have filed or will file hereafter.
","('Systemic_Risk_Management', 0.9347371459007263)","('Business_Model_Resilience', 0.013358918018639088)","('Physical_Impacts_Of_Climate_Change', 0.00775996595621109)","(['Risk & Crisis Management'], 0.9347371459007263)","('NON-ESG', 0.013358918018639088)","('NON-ESG', 0.00775996595621109)"
Line 761,"We disclaim any intention or obligation to publicly update or  revise any forward-looking statements to reflect any change in our expectations or in events, conditions or circumstances on which those  expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking  statements.
","('Business_Model_Resilience', 0.48404359817504883)","('Management_Of_Legal_And_Regulatory_Framework', 0.09915660321712494)","('Systemic_Risk_Management', 0.09667550772428513)","('NON-ESG', 0.48404359817504883)","('NON-ESG', 0.09915660321712494)","('NON-ESG', 0.09667550772428513)"
Line 762,"This cautionary statement is applicable to all forward-looking statements contained in this report.
","('Management_Of_Legal_And_Regulatory_Framework', 0.7264617085456848)","('Systemic_Risk_Management', 0.0328611321747303)","('Access_And_Affordability', 0.02800106443464756)","(['Corporate Governance'], 0.7264617085456848)","('NON-ESG', 0.0328611321747303)","('NON-ESG', 0.02800106443464756)"
Line 763,"All images are the property of Boston Scientific.
","('Energy_Management', 0.14891502261161804)","('Management_Of_Legal_And_Regulatory_Framework', 0.10434065014123917)","('Customer_Privacy', 0.102125383913517)","('NON-ESG', 0.14891502261161804)","('NON-ESG', 0.10434065014123917)","('NON-ESG', 0.102125383913517)"
Line 764,"All trademarks are the property of their respective owners.
","('Customer_Privacy', 0.36605626344680786)","('Competitive_Behavior', 0.15782864391803741)","('Business_Ethics', 0.06312255561351776)","('NON-ESG', 0.36605626344680786)","('NON-ESG', 0.15782864391803741)","('NON-ESG', 0.06312255561351776)"
Line 765,"© 2022 Boston Scientific Corporation or its affiliates.
","('Business_Model_Resilience', 0.1612825095653534)","('Management_Of_Legal_And_Regulatory_Framework', 0.12572811543941498)","('Competitive_Behavior', 0.0865609422326088)","('NON-ESG', 0.1612825095653534)","('NON-ESG', 0.12572811543941498)","('NON-ESG', 0.0865609422326088)"
Line 766,"All rights reserved.
","('Customer_Privacy', 0.18397872149944305)","('Human_Rights_And_Community_Relations', 0.07860073447227478)","('Waste_And_Hazardous_Materials_Management', 0.07202215492725372)","('NON-ESG', 0.18397872149944305)","('NON-ESG', 0.07860073447227478)","('NON-ESG', 0.07202215492725372)"
Line 767,PR2021,"('Management_Of_Legal_And_Regulatory_Framework', 0.5169652104377747)","('Human_Rights_And_Community_Relations', 0.09829217195510864)","('Physical_Impacts_Of_Climate_Change', 0.08570067584514618)","(['Corporate Governance'], 0.5169652104377747)","('NON-ESG', 0.09829217195510864)","('NON-ESG', 0.08570067584514618)"
